{"idx_source": 1, "tag": "div", "text_raw": "0000200406 12/28 2025 Q1 FALSE 33 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:EUR jnj:segment jnj:claimant jnj:cases 0000200406 2024-12-30 2025-03-30 0000200406 us-gaap:CommonStockMember 2024-12-30 2025-03-30 0000200406 jnj:A1.150NotesDueNovember2028Member 2024-12-30 2025-03-30 0000200406 jnj:A2.700NotesDueFebruary2029Member 2024-12-30 2025-03-30 0000200406 jnj:A3.20NotesDueJune2032Member 2024-12-30 2025-03-30 0000200406 jnj:A3.050NotesDueFebruary2033Member 2024-12-30 2025-03-30 0000200406 jnj:A1.650NotesDue2035Member 2024-12-30 2025-03-30 0000200406 jnj:A3.350NotesDueJune2036Member 2024-12-30 2025-03-30 0000200406 jnj:A3.350NotesDueFebruary2037Member 2024-12-30 2025-03-30 0000200406 jnj:A3.550NotesDueJune2044Member 2024-12-30 2025-03-30 0000200406 jnj:A3.600NotesDueFebruary2045Member 2024-12-30 2025-03-30 0000200406 jnj:A3.700NotesDueFebruary2055Member 2024-12-30 2025-03-30 0000200406 2025-04-18 0000200406 2025-03-30 0000200406 2024-12-29 0000200406 2024-01-01 2024-03-31 0000200406 us-gaap:RetainedEarningsMember 2024-12-29 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-29 0000200406 us-gaap:CommonStockMember 2024-12-29 0000200406 us-gaap:TreasuryStockCommonMember 2024-12-29 0000200406 us-gaap:RetainedEarningsMember 2024-12-30 2025-03-30 0000200406 us-gaap:TreasuryStockCommonMember 2024-12-30 2025-03-30 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-30 2025-03-30 0000200406 us-gaap:RetainedEarningsMember 2025-03-30 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-30 0000200406 us-gaap:CommonStockMember 2025-03-30 0000200406 us-gaap:TreasuryStockCommonMember 2025-03-30 0000200406 2023-12-31 0000200406 us-gaap:RetainedEarningsMember 2023-12-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000200406 us-gaap:CommonStockMember 2023-12-31 0000200406 us-gaap:TreasuryStockCommonMember 2023-12-31 0000200406 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000200406 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000200406 2024-03-31 0000200406 us-gaap:RetainedEarningsMember 2024-03-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000200406 us-gaap:CommonStockMember 2024-03-31 0000200406 us-gaap:TreasuryStockCommonMember 2024-03-31 0000200406 jnj:PatentsAndTrademarksMember 2025-03-30 0000200406 jnj:PatentsAndTrademarksMember 2024-12-29 0000200406 us-gaap:OtherIntangibleAssetsMember 2025-03-30 0000200406 us-gaap:OtherIntangibleAssetsMember 2024-12-29 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2025-03-30 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2024-12-29 0000200406 jnj:InnovativeMedicineMember 2024-12-29 0000200406 jnj:MedTechMember 2024-12-29 0000200406 jnj:InnovativeMedicineMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember 2025-03-30 0000200406 jnj:MedTechMember 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2025-03-30 0000200406 us-gaap:InterestRateSwapMember 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2024-12-29 0000200406 us-gaap:InterestRateSwapMember 2024-12-29 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-12-30 2025-03-30 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:SalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:CostOfSalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-12-30 2025-03-30 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember jnj:InterestIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember jnj:OtherIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:SalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember jnj:InterestIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-12-30 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:DesignatedAsHedgingInstrumentMember 2025-03-30 0000200406 us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-01-01 2024-03-31 0000200406 jnj:OtherIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2024-12-30 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2024-01-01 2024-03-31 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CrossCurrencyInterestRateContractMember 2024-12-30 2025-03-30 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CrossCurrencyInterestRateContractMember 2024-01-01 2024-03-31 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2024-12-29 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2024-12-30 2025-03-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2025-03-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2024-12-29 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2024-12-30 2025-03-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeContractMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeContractMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2024-12-29 0000200406 us-gaap:FairValueInputsLevel1Member us-gaap:InterestRateContractMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateContractMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel3Member us-gaap:InterestRateContractMember 2025-03-30 0000200406 us-gaap:InterestRateContractMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateContractMember 2024-12-29 0000200406 us-gaap:FairValueInputsLevel1Member 2025-03-30 0000200406 us-gaap:FairValueInputsLevel2Member 2025-03-30 0000200406 us-gaap:FairValueInputsLevel3Member 2025-03-30 0000200406 us-gaap:FairValueInputsLevel2Member 2024-12-29 0000200406 us-gaap:FairValueInputsLevel1Member 2024-12-29 0000200406 us-gaap:FairValueInputsLevel3Member 2024-12-29 0000200406 us-gaap:OtherNoncurrentLiabilitiesMember 2025-03-30 0000200406 us-gaap:OtherNoncurrentLiabilitiesMember 2024-12-29 0000200406 us-gaap:OtherCurrentLiabilitiesMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:CashMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:USGovernmentDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:SovereignDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:MoneyMarketFundsMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:BankTimeDepositsMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USTreasuryAndGovernmentMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USTreasuryAndGovernmentMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:SovereignDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:SovereignDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember 2025-03-30 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2.95Notesdue2027Member 2025-03-30 0000200406 jnj:A2.95Notesdue2027Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2.95Notesdue2027Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A095NotesDue2027Member 2025-03-30 0000200406 jnj:A095NotesDue2027Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A095NotesDue2027Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.50NotesDue2027Member 2025-03-30 0000200406 jnj:A4.50NotesDue2027Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.50NotesDue2027Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2.900Notesdue2028Member 2025-03-30 0000200406 jnj:A2.900Notesdue2028Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2.900Notesdue2028Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A1.150NotesDue2028Member 2025-03-30 0000200406 jnj:A1.150NotesDue2028Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A1.150NotesDue2028Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.55NotesDue2029Member 2025-03-30 0000200406 jnj:A4.55NotesDue2029Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.55NotesDue2029Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.80NotesDue2029Member 2025-03-30 0000200406 jnj:A4.80NotesDue2029Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.80NotesDue2029Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A6.95Notesdue2029Member 2025-03-30 0000200406 jnj:A6.95Notesdue2029Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A6.95Notesdue2029Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2.700NotesDueFebruary2029Member 2025-03-30 0000200406 jnj:A2.700NotesDueFebruary2029Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2.700NotesDueFebruary2029Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A1300NotesDue2030Member 2025-03-30 0000200406 jnj:A1300NotesDue2030Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A1300NotesDue2030Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.70NotesDue2030Member 2025-03-30 0000200406 jnj:A4.70NotesDue2030Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.70NotesDue2030Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.90NotesDue2031Member 2025-03-30 0000200406 jnj:A4.90NotesDue2031Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.90NotesDue2031Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.20NotesDue2032Member 2025-03-30 0000200406 jnj:A3.20NotesDue2032Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.20NotesDue2032Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.85NotesDue2032Member 2025-03-30 0000200406 jnj:A4.85NotesDue2032Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.85NotesDue2032Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.95Debenturesdue2033Member 2025-03-30 0000200406 jnj:A4.95Debenturesdue2033Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.95Debenturesdue2033Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.375Notesdue2033Member 2025-03-30 0000200406 jnj:A4.375Notesdue2033Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.375Notesdue2033Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.050NotesDueFebruary2033Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.050NotesDueFebruary2033Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.95NotesDue2034Member 2025-03-30 0000200406 jnj:A4.95NotesDue2034Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.95NotesDue2034Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A1.650NotesDue2035Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A1.650NotesDue2035Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.00NotesDue2035Member 2025-03-30 0000200406 jnj:A5.00NotesDue2035Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.00NotesDue2035Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.35NotesDue2036800MMEuro1.0721Member 2025-03-30 0000200406 jnj:A3.35NotesDue2036800MMEuro1.0721Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.35NotesDue2036800MMEuro1.0721Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.587NotesDue2036Member 2025-03-30 0000200406 jnj:A3.587NotesDue2036Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.587NotesDue2036Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.95Notesdue2037Member 2025-03-30 0000200406 jnj:A5.95Notesdue2037Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.95Notesdue2037Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.625Notesdue2037Member 2025-03-30 0000200406 jnj:A3.625Notesdue2037Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.625Notesdue2037Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.350NotesDueFebruary2037Member 2025-03-30 0000200406 jnj:A3.350NotesDueFebruary2037Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.350NotesDueFebruary2037Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.400Notesdue2038Member 2025-03-30 0000200406 jnj:A3.400Notesdue2038Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.400Notesdue2038Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.85Debenturesdue2038Member 2025-03-30 0000200406 jnj:A5.85Debenturesdue2038Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.85Debenturesdue2038Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.50Debenturesdue2040Member 2025-03-30 0000200406 jnj:A4.50Debenturesdue2040Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.50Debenturesdue2040Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A210NotesDue2040Member 2025-03-30 0000200406 jnj:A210NotesDue2040Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A210NotesDue2040Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.85Notesdue2041Member 2025-03-30 0000200406 jnj:A4.85Notesdue2041Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.85Notesdue2041Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.50Notesdue2043Member 2025-03-30 0000200406 jnj:A4.50Notesdue2043Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.50Notesdue2043Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.55NotesDue20441.0BEuro1.0721Member 2025-03-30 0000200406 jnj:A3.55NotesDue20441.0BEuro1.0721Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.55NotesDue20441.0BEuro1.0721Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.600NotesDueFebruary2045Member 2025-03-30 0000200406 jnj:A3.600NotesDueFebruary2045Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.600NotesDueFebruary2045Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.70Notesdue2046Member 2025-03-30 0000200406 jnj:A3.70Notesdue2046Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.70Notesdue2046Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.75Notesdue2047Member 2025-03-30 0000200406 jnj:A3.75Notesdue2047Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.75Notesdue2047Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.500Notesdue2048Member 2025-03-30 0000200406 jnj:A3.500Notesdue2048Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.500Notesdue2048Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2250NotesDue2050Member 2025-03-30 0000200406 jnj:A2250NotesDue2050Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2250NotesDue2050Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.25NotesDue2054Member 2025-03-30 0000200406 jnj:A5.25NotesDue2054Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.25NotesDue2054Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.700NotesDueFebruary2055Member 2025-03-30 0000200406 jnj:A3.700NotesDueFebruary2055Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.700NotesDueFebruary2055Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2450NotesDue2060Member 2025-03-30 0000200406 jnj:A2450NotesDue2060Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2450NotesDue2060Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:NotesDuePeriodFifteenMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:NotesDuePeriodFifteenMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 us-gaap:UnsecuredDebtMember 2025-03-30 0000200406 2024-01-01 2024-12-29 0000200406 us-gaap:CommercialPaperMember 2025-03-30 0000200406 us-gaap:CommercialPaperMember 2024-12-30 2025-03-30 0000200406 jnj:TalcMember jnj:ConsumerMember 2024-12-30 2025-03-30 0000200406 jnj:TalcMember jnj:ConsumerMember 2024-01-01 2024-03-31 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2024-12-30 2025-03-30 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-03-31 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-30 2025-03-30 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-01-01 2024-03-31 0000200406 country:US 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignPlanMember 2024-12-30 2025-03-30 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-29 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-12-29 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-29 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-29 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-30 2025-03-30 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-12-30 2025-03-30 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-30 2025-03-30 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-30 2025-03-30 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2025-03-30 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2025-03-30 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-03-30 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:ERLEADAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:ERLEADAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:ERLEADAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:ERLEADAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:ERLEADAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:ERLEADAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:RYBREVANTLAZCLUZEMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:RYBREVANTLAZCLUZEMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:RYBREVANTLAZCLUZEMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:RYBREVANTLAZCLUZEMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:RYBREVANTLAZCLUZEMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:RYBREVANTLAZCLUZEMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:TALVEYMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:TALVEYMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:TALVEYMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:TALVEYMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:TALVEYMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:TALVEYMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:TecvayliMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:TecvayliMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:TecvayliMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:TecvayliMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:TecvayliMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:TecvayliMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:UNITEDSTATESExportsMember jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:UNITEDSTATESExportsMember jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 country:US jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 country:US jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 country:US jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 country:US jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 country:US jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 country:US jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OPSUMITOPSYNVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OPSUMITOPSYNVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OPSUMITOPSYNVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OPSUMITOPSYNVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 jnj:OPSUMITOPSYNVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 jnj:OPSUMITOPSYNVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OtherMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OtherMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 jnj:OtherMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 jnj:OtherMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 country:US jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 country:US jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 country:US jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 country:US jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 country:US jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 country:US jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 country:US jnj:InnovativeMedicineMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:CardiovascularMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:CardiovascularMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:ElectrophysiologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:ElectrophysiologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:ElectrophysiologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:ElectrophysiologyMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:AbiomedMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:AbiomedMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:AbiomedMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:AbiomedMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:AbiomedMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:AbiomedMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:ShockwaveMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:ShockwaveMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:ShockwaveMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:ShockwaveMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:ShockwaveMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:ShockwaveMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:OtherCardiovascularMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:OtherCardiovascularMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:OtherCardiovascularMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:OtherCardiovascularMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:OtherCardiovascularMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:OtherCardiovascularMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 country:US jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 country:US jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 country:US jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 country:US jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 country:US jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 country:US jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 country:US jnj:SPINEOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 country:US jnj:SPINEOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:SPINEOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:SPINEOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 jnj:SPINEOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 jnj:SPINEOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 country:US jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 country:US jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 country:US jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 country:US jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember 2024-01-01 2024-03-31 0000200406 country:US 2024-12-30 2025-03-30 0000200406 country:US 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember 2024-01-01 2024-03-31 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2024-12-30 2025-03-30 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2024-01-01 2024-03-31 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2024-01-01 2024-03-31 0000200406 us-gaap:OperatingSegmentsMember 2024-12-30 2025-03-30 0000200406 us-gaap:OperatingSegmentsMember 2024-01-01 2024-03-31 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2025-03-30 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2025-03-30 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2024-12-29 0000200406 jnj:SegmentsTotalMember 2025-03-30 0000200406 jnj:SegmentsTotalMember 2024-12-29 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2025-03-30 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2024-12-29 0000200406 jnj:SegmentsTotalMember 2024-12-30 2025-03-30 0000200406 jnj:SegmentsTotalMember 2024-01-01 2024-03-31 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2024-12-30 2025-03-30 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2024-01-01 2024-03-31 0000200406 srt:EuropeMember 2024-12-30 2025-03-30 0000200406 srt:EuropeMember 2024-01-01 2024-03-31 0000200406 jnj:WesternHemisphereExcludingUSMember 2024-12-30 2025-03-30 0000200406 jnj:WesternHemisphereExcludingUSMember 2024-01-01 2024-03-31 0000200406 jnj:AsiaPacificAfricaMember 2024-12-30 2025-03-30 0000200406 jnj:AsiaPacificAfricaMember 2024-01-01 2024-03-31 0000200406 jnj:IntraCellularTherapiesInc.Member us-gaap:SubsequentEventMember 2025-04-02 0000200406 jnj:IntraCellularTherapiesInc.Member us-gaap:SubsequentEventMember 2025-04-02 2025-04-02 0000200406 jnj:ProteologixMember 2024-06-20 2024-06-20 0000200406 jnj:ProteologixMember 2024-06-20 0000200406 jnj:ProteologixMember 2024-12-30 2025-03-30 0000200406 jnj:ShockwaveMedicalInc.Member 2024-05-31 2024-05-31 0000200406 jnj:ShockwaveMedicalInc.Member 2024-05-31 0000200406 jnj:ShockwaveMedicalInc.Member 2024-12-30 2025-03-30 0000200406 jnj:AmbrxMember 2024-03-07 2024-03-07 0000200406 jnj:AmbrxMember 2024-03-07 0000200406 jnj:AmbrxMember 2024-12-30 2025-03-30 0000200406 jnj:InghamVsJohnsonJohnsonMember 2018-07-01 2018-07-31 0000200406 jnj:InghamVsJohnsonJohnsonMember 2020-06-01 2020-06-30 0000200406 jnj:InghamVsJohnsonJohnsonMember 2021-06-01 2021-06-30 0000200406 jnj:TalcMember 2024-05-01 2024-05-01 0000200406 jnj:TalcMember 2024-05-01 0000200406 jnj:TalcMember 2024-01-01 2024-12-29 0000200406 jnj:TalcMember 2024-12-29 0000200406 jnj:MesotheliomaAndStateClaimsMember 2024-12-30 2025-03-30 0000200406 jnj:TalcMember 2025-03-30 0000200406 jnj:OpioidMember 2025-03-30 0000200406 jnj:OpioidMember 2021-07-04 0000200406 jnj:VariousStateCourtsMember jnj:OpioidMember 2024-12-30 2025-03-30 0000200406 jnj:OhioMultiDistrictLitigationMember jnj:OpioidMember 2024-12-30 2025-03-30 0000200406 jnj:FederalCourtsMember jnj:OpioidMember 2024-12-30 2025-03-30 0000200406 jnj:TalcMember 2025-03-30 0000200406 jnj:AsrMember 2025-03-30 0000200406 jnj:PinnacleAcetabularCupSystemMember 2025-03-30 0000200406 jnj:PelvicMeshesMember 2025-03-30 0000200406 jnj:PhysiomeshMember 2025-03-30 0000200406 jnj:ElmironMember 2025-03-30 0000200406 jnj:DePuyASRU.S.Member us-gaap:SettledLitigationMember 2025-03-30 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2021-05-31 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2021-09-30 0000200406 jnj:OrthopaedicsRestructuringPlanMember 2025-03-30 0000200406 jnj:OrthopaedicsRestructuringPlanMember srt:MinimumMember 2025-03-30 0000200406 jnj:OrthopaedicsRestructuringPlanMember srt:MaximumMember 2025-03-30 0000200406 us-gaap:RestructuringChargesMember jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 jnj:CostsOfGoodsAndServicesSoldMember jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 us-gaap:OtherNonoperatingIncomeExpenseMember jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 us-gaap:RestructuringChargesMember jnj:MedTechMember 2024-01-01 2024-03-31 0000200406 jnj:CostsOfGoodsAndServicesSoldMember jnj:MedTechMember 2024-01-01 2024-03-31", "text": "0000200406 12/28 2025 Q1 FALSE 33 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:EUR jnj:segment jnj:claimant jnj:cases 0000200406 2024-12-30 2025-03-30 0000200406 us-gaap:CommonStockMember 2024-12-30 2025-03-30 0000200406 jnj:A1.150NotesDueNovember2028Member 2024-12-30 2025-03-30 0000200406 jnj:A2.700NotesDueFebruary2029Member 2024-12-30 2025-03-30 0000200406 jnj:A3.20NotesDueJune2032Member 2024-12-30 2025-03-30 0000200406 jnj:A3.050NotesDueFebruary2033Member 2024-12-30 2025-03-30 0000200406 jnj:A1.650NotesDue2035Member 2024-12-30 2025-03-30 0000200406 jnj:A3.350NotesDueJune2036Member 2024-12-30 2025-03-30 0000200406 jnj:A3.350NotesDueFebruary2037Member 2024-12-30 2025-03-30 0000200406 jnj:A3.550NotesDueJune2044Member 2024-12-30 2025-03-30 0000200406 jnj:A3.600NotesDueFebruary2045Member 2024-12-30 2025-03-30 0000200406 jnj:A3.700NotesDueFebruary2055Member 2024-12-30 2025-03-30 0000200406 2025-04-18 0000200406 2025-03-30 0000200406 2024-12-29 0000200406 2024-01-01 2024-03-31 0000200406 us-gaap:RetainedEarningsMember 2024-12-29 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-29 0000200406 us-gaap:CommonStockMember 2024-12-29 0000200406 us-gaap:TreasuryStockCommonMember 2024-12-29 0000200406 us-gaap:RetainedEarningsMember 2024-12-30 2025-03-30 0000200406 us-gaap:TreasuryStockCommonMember 2024-12-30 2025-03-30 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-30 2025-03-30 0000200406 us-gaap:RetainedEarningsMember 2025-03-30 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-30 0000200406 us-gaap:CommonStockMember 2025-03-30 0000200406 us-gaap:TreasuryStockCommonMember 2025-03-30 0000200406 2023-12-31 0000200406 us-gaap:RetainedEarningsMember 2023-12-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000200406 us-gaap:CommonStockMember 2023-12-31 0000200406 us-gaap:TreasuryStockCommonMember 2023-12-31 0000200406 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000200406 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000200406 2024-03-31 0000200406 us-gaap:RetainedEarningsMember 2024-03-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000200406 us-gaap:CommonStockMember 2024-03-31 0000200406 us-gaap:TreasuryStockCommonMember 2024-03-31 0000200406 jnj:PatentsAndTrademarksMember 2025-03-30 0000200406 jnj:PatentsAndTrademarksMember 2024-12-29 0000200406 us-gaap:OtherIntangibleAssetsMember 2025-03-30 0000200406 us-gaap:OtherIntangibleAssetsMember 2024-12-29 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2025-03-30 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2024-12-29 0000200406 jnj:InnovativeMedicineMember 2024-12-29 0000200406 jnj:MedTechMember 2024-12-29 0000200406 jnj:InnovativeMedicineMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember 2025-03-30 0000200406 jnj:MedTechMember 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2025-03-30 0000200406 us-gaap:InterestRateSwapMember 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2024-12-29 0000200406 us-gaap:InterestRateSwapMember 2024-12-29 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-12-30 2025-03-30 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:SalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:CostOfSalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-12-30 2025-03-30 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember jnj:InterestIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember jnj:OtherIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:SalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember jnj:InterestIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-12-30 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-12-30 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:DesignatedAsHedgingInstrumentMember 2025-03-30 0000200406 us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-01-01 2024-03-31 0000200406 jnj:OtherIncomeExpenseNetMember 2024-12-30 2025-03-30 0000200406 jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-03-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2024-12-30 2025-03-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2024-01-01 2024-03-31 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CrossCurrencyInterestRateContractMember 2024-12-30 2025-03-30 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CrossCurrencyInterestRateContractMember 2024-01-01 2024-03-31 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2024-12-29 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2024-12-30 2025-03-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2025-03-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2024-12-29 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2024-12-30 2025-03-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeContractMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeContractMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2024-12-29 0000200406 us-gaap:FairValueInputsLevel1Member us-gaap:InterestRateContractMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateContractMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel3Member us-gaap:InterestRateContractMember 2025-03-30 0000200406 us-gaap:InterestRateContractMember 2025-03-30 0000200406 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateContractMember 2024-12-29 0000200406 us-gaap:FairValueInputsLevel1Member 2025-03-30 0000200406 us-gaap:FairValueInputsLevel2Member 2025-03-30 0000200406 us-gaap:FairValueInputsLevel3Member 2025-03-30 0000200406 us-gaap:FairValueInputsLevel2Member 2024-12-29 0000200406 us-gaap:FairValueInputsLevel1Member 2024-12-29 0000200406 us-gaap:FairValueInputsLevel3Member 2024-12-29 0000200406 us-gaap:OtherNoncurrentLiabilitiesMember 2025-03-30 0000200406 us-gaap:OtherNoncurrentLiabilitiesMember 2024-12-29 0000200406 us-gaap:OtherCurrentLiabilitiesMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:CashMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:USGovernmentDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:SovereignDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:MoneyMarketFundsMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:BankTimeDepositsMember 2025-03-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USTreasuryAndGovernmentMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USTreasuryAndGovernmentMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:SovereignDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:SovereignDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2025-03-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember 2025-03-30 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2.95Notesdue2027Member 2025-03-30 0000200406 jnj:A2.95Notesdue2027Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2.95Notesdue2027Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A095NotesDue2027Member 2025-03-30 0000200406 jnj:A095NotesDue2027Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A095NotesDue2027Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.50NotesDue2027Member 2025-03-30 0000200406 jnj:A4.50NotesDue2027Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.50NotesDue2027Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2.900Notesdue2028Member 2025-03-30 0000200406 jnj:A2.900Notesdue2028Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2.900Notesdue2028Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A1.150NotesDue2028Member 2025-03-30 0000200406 jnj:A1.150NotesDue2028Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A1.150NotesDue2028Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.55NotesDue2029Member 2025-03-30 0000200406 jnj:A4.55NotesDue2029Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.55NotesDue2029Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.80NotesDue2029Member 2025-03-30 0000200406 jnj:A4.80NotesDue2029Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.80NotesDue2029Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A6.95Notesdue2029Member 2025-03-30 0000200406 jnj:A6.95Notesdue2029Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A6.95Notesdue2029Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2.700NotesDueFebruary2029Member 2025-03-30 0000200406 jnj:A2.700NotesDueFebruary2029Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2.700NotesDueFebruary2029Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A1300NotesDue2030Member 2025-03-30 0000200406 jnj:A1300NotesDue2030Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A1300NotesDue2030Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.70NotesDue2030Member 2025-03-30 0000200406 jnj:A4.70NotesDue2030Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.70NotesDue2030Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.90NotesDue2031Member 2025-03-30 0000200406 jnj:A4.90NotesDue2031Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.90NotesDue2031Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.20NotesDue2032Member 2025-03-30 0000200406 jnj:A3.20NotesDue2032Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.20NotesDue2032Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.85NotesDue2032Member 2025-03-30 0000200406 jnj:A4.85NotesDue2032Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.85NotesDue2032Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.95Debenturesdue2033Member 2025-03-30 0000200406 jnj:A4.95Debenturesdue2033Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.95Debenturesdue2033Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.375Notesdue2033Member 2025-03-30 0000200406 jnj:A4.375Notesdue2033Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.375Notesdue2033Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.050NotesDueFebruary2033Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.050NotesDueFebruary2033Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.95NotesDue2034Member 2025-03-30 0000200406 jnj:A4.95NotesDue2034Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.95NotesDue2034Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A1.650NotesDue2035Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A1.650NotesDue2035Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.00NotesDue2035Member 2025-03-30 0000200406 jnj:A5.00NotesDue2035Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.00NotesDue2035Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.35NotesDue2036800MMEuro1.0721Member 2025-03-30 0000200406 jnj:A3.35NotesDue2036800MMEuro1.0721Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.35NotesDue2036800MMEuro1.0721Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.587NotesDue2036Member 2025-03-30 0000200406 jnj:A3.587NotesDue2036Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.587NotesDue2036Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.95Notesdue2037Member 2025-03-30 0000200406 jnj:A5.95Notesdue2037Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.95Notesdue2037Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.625Notesdue2037Member 2025-03-30 0000200406 jnj:A3.625Notesdue2037Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.625Notesdue2037Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.350NotesDueFebruary2037Member 2025-03-30 0000200406 jnj:A3.350NotesDueFebruary2037Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.350NotesDueFebruary2037Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.400Notesdue2038Member 2025-03-30 0000200406 jnj:A3.400Notesdue2038Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.400Notesdue2038Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.85Debenturesdue2038Member 2025-03-30 0000200406 jnj:A5.85Debenturesdue2038Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.85Debenturesdue2038Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.50Debenturesdue2040Member 2025-03-30 0000200406 jnj:A4.50Debenturesdue2040Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.50Debenturesdue2040Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A210NotesDue2040Member 2025-03-30 0000200406 jnj:A210NotesDue2040Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A210NotesDue2040Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.85Notesdue2041Member 2025-03-30 0000200406 jnj:A4.85Notesdue2041Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.85Notesdue2041Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.50Notesdue2043Member 2025-03-30 0000200406 jnj:A4.50Notesdue2043Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A4.50Notesdue2043Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.55NotesDue20441.0BEuro1.0721Member 2025-03-30 0000200406 jnj:A3.55NotesDue20441.0BEuro1.0721Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.55NotesDue20441.0BEuro1.0721Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.600NotesDueFebruary2045Member 2025-03-30 0000200406 jnj:A3.600NotesDueFebruary2045Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.600NotesDueFebruary2045Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.70Notesdue2046Member 2025-03-30 0000200406 jnj:A3.70Notesdue2046Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.70Notesdue2046Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.75Notesdue2047Member 2025-03-30 0000200406 jnj:A3.75Notesdue2047Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.75Notesdue2047Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.500Notesdue2048Member 2025-03-30 0000200406 jnj:A3.500Notesdue2048Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.500Notesdue2048Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2250NotesDue2050Member 2025-03-30 0000200406 jnj:A2250NotesDue2050Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2250NotesDue2050Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.25NotesDue2054Member 2025-03-30 0000200406 jnj:A5.25NotesDue2054Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A5.25NotesDue2054Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.700NotesDueFebruary2055Member 2025-03-30 0000200406 jnj:A3.700NotesDueFebruary2055Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A3.700NotesDueFebruary2055Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2450NotesDue2060Member 2025-03-30 0000200406 jnj:A2450NotesDue2060Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:A2450NotesDue2060Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 jnj:NotesDuePeriodFifteenMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-30 0000200406 jnj:NotesDuePeriodFifteenMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-30 0000200406 us-gaap:UnsecuredDebtMember 2025-03-30 0000200406 2024-01-01 2024-12-29 0000200406 us-gaap:CommercialPaperMember 2025-03-30 0000200406 us-gaap:CommercialPaperMember 2024-12-30 2025-03-30 0000200406 jnj:TalcMember jnj:ConsumerMember 2024-12-30 2025-03-30 0000200406 jnj:TalcMember jnj:ConsumerMember 2024-01-01 2024-03-31 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2024-12-30 2025-03-30 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-03-31 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-30 2025-03-30 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-01-01 2024-03-31 0000200406 country:US 2024-12-30 2025-03-30 0000200406 us-gaap:ForeignPlanMember 2024-12-30 2025-03-30 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-29 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-12-29 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-29 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-29 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-30 2025-03-30 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-12-30 2025-03-30 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-30 2025-03-30 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-30 2025-03-30 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2025-03-30 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2025-03-30 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-03-30 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:ERLEADAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:ERLEADAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:ERLEADAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:ERLEADAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:ERLEADAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:ERLEADAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:RYBREVANTLAZCLUZEMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:RYBREVANTLAZCLUZEMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:RYBREVANTLAZCLUZEMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:RYBREVANTLAZCLUZEMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:RYBREVANTLAZCLUZEMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:RYBREVANTLAZCLUZEMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:TALVEYMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:TALVEYMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:TALVEYMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:TALVEYMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:TALVEYMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:TALVEYMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:TecvayliMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:TecvayliMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:TecvayliMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:TecvayliMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:TecvayliMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:TecvayliMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-12-30 2025-03-30 0000200406 jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:UNITEDSTATESExportsMember jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:UNITEDSTATESExportsMember jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-12-30 2025-03-30 0000200406 jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 country:US jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 country:US jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 country:US jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 country:US jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 country:US jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 country:US jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-12-30 2025-03-30 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-03-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OPSUMITOPSYNVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OPSUMITOPSYNVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OPSUMITOPSYNVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OPSUMITOPSYNVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 jnj:OPSUMITOPSYNVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 jnj:OPSUMITOPSYNVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OtherMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OtherMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 jnj:OtherMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-12-30 2025-03-30 0000200406 jnj:OtherMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 country:US jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 country:US jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 country:US jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 country:US jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-12-30 2025-03-30 0000200406 jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-03-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 country:US jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 country:US jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 country:US jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 country:US jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-12-30 2025-03-30 0000200406 jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-03-31 0000200406 country:US jnj:InnovativeMedicineMember 2024-12-30 2025-03-30 0000200406 country:US jnj:InnovativeMedicineMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:CardiovascularMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:CardiovascularMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:ElectrophysiologyMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:ElectrophysiologyMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:ElectrophysiologyMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:ElectrophysiologyMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:AbiomedMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:AbiomedMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:AbiomedMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:AbiomedMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:AbiomedMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:AbiomedMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:ShockwaveMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:ShockwaveMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:ShockwaveMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:ShockwaveMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:ShockwaveMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:ShockwaveMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:OtherCardiovascularMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:OtherCardiovascularMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:OtherCardiovascularMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:OtherCardiovascularMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:OtherCardiovascularMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:OtherCardiovascularMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 country:US jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 country:US jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 country:US jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 country:US jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 country:US jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 country:US jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 country:US jnj:SPINEOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 country:US jnj:SPINEOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:SPINEOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:SPINEOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 jnj:SPINEOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-12-30 2025-03-30 0000200406 jnj:SPINEOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 country:US jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 country:US jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 country:US jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 country:US jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2024-12-30 2025-03-30 0000200406 jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 country:US jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2024-12-30 2025-03-30 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-03-31 0000200406 country:US jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 country:US jnj:MedTechMember 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember jnj:MedTechMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember 2024-01-01 2024-03-31 0000200406 country:US 2024-12-30 2025-03-30 0000200406 country:US 2024-01-01 2024-03-31 0000200406 us-gaap:NonUsMember 2024-12-30 2025-03-30 0000200406 us-gaap:NonUsMember 2024-01-01 2024-03-31 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2024-12-30 2025-03-30 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2024-01-01 2024-03-31 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2024-01-01 2024-03-31 0000200406 us-gaap:OperatingSegmentsMember 2024-12-30 2025-03-30 0000200406 us-gaap:OperatingSegmentsMember 2024-01-01 2024-03-31 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2025-03-30 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2025-03-30 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2024-12-29 0000200406 jnj:SegmentsTotalMember 2025-03-30 0000200406 jnj:SegmentsTotalMember 2024-12-29 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2025-03-30 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2024-12-29 0000200406 jnj:SegmentsTotalMember 2024-12-30 2025-03-30 0000200406 jnj:SegmentsTotalMember 2024-01-01 2024-03-31 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2024-12-30 2025-03-30 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2024-01-01 2024-03-31 0000200406 srt:EuropeMember 2024-12-30 2025-03-30 0000200406 srt:EuropeMember 2024-01-01 2024-03-31 0000200406 jnj:WesternHemisphereExcludingUSMember 2024-12-30 2025-03-30 0000200406 jnj:WesternHemisphereExcludingUSMember 2024-01-01 2024-03-31 0000200406 jnj:AsiaPacificAfricaMember 2024-12-30 2025-03-30 0000200406 jnj:AsiaPacificAfricaMember 2024-01-01 2024-03-31 0000200406 jnj:IntraCellularTherapiesInc.Member us-gaap:SubsequentEventMember 2025-04-02 0000200406 jnj:IntraCellularTherapiesInc.Member us-gaap:SubsequentEventMember 2025-04-02 2025-04-02 0000200406 jnj:ProteologixMember 2024-06-20 2024-06-20 0000200406 jnj:ProteologixMember 2024-06-20 0000200406 jnj:ProteologixMember 2024-12-30 2025-03-30 0000200406 jnj:ShockwaveMedicalInc.Member 2024-05-31 2024-05-31 0000200406 jnj:ShockwaveMedicalInc.Member 2024-05-31 0000200406 jnj:ShockwaveMedicalInc.Member 2024-12-30 2025-03-30 0000200406 jnj:AmbrxMember 2024-03-07 2024-03-07 0000200406 jnj:AmbrxMember 2024-03-07 0000200406 jnj:AmbrxMember 2024-12-30 2025-03-30 0000200406 jnj:InghamVsJohnsonJohnsonMember 2018-07-01 2018-07-31 0000200406 jnj:InghamVsJohnsonJohnsonMember 2020-06-01 2020-06-30 0000200406 jnj:InghamVsJohnsonJohnsonMember 2021-06-01 2021-06-30 0000200406 jnj:TalcMember 2024-05-01 2024-05-01 0000200406 jnj:TalcMember 2024-05-01 0000200406 jnj:TalcMember 2024-01-01 2024-12-29 0000200406 jnj:TalcMember 2024-12-29 0000200406 jnj:MesotheliomaAndStateClaimsMember 2024-12-30 2025-03-30 0000200406 jnj:TalcMember 2025-03-30 0000200406 jnj:OpioidMember 2025-03-30 0000200406 jnj:OpioidMember 2021-07-04 0000200406 jnj:VariousStateCourtsMember jnj:OpioidMember 2024-12-30 2025-03-30 0000200406 jnj:OhioMultiDistrictLitigationMember jnj:OpioidMember 2024-12-30 2025-03-30 0000200406 jnj:FederalCourtsMember jnj:OpioidMember 2024-12-30 2025-03-30 0000200406 jnj:TalcMember 2025-03-30 0000200406 jnj:AsrMember 2025-03-30 0000200406 jnj:PinnacleAcetabularCupSystemMember 2025-03-30 0000200406 jnj:PelvicMeshesMember 2025-03-30 0000200406 jnj:PhysiomeshMember 2025-03-30 0000200406 jnj:ElmironMember 2025-03-30 0000200406 jnj:DePuyASRU.S.Member us-gaap:SettledLitigationMember 2025-03-30 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2021-05-31 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2021-09-30 0000200406 jnj:OrthopaedicsRestructuringPlanMember 2025-03-30 0000200406 jnj:OrthopaedicsRestructuringPlanMember srt:MinimumMember 2025-03-30 0000200406 jnj:OrthopaedicsRestructuringPlanMember srt:MaximumMember 2025-03-30 0000200406 us-gaap:RestructuringChargesMember jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 jnj:CostsOfGoodsAndServicesSoldMember jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 us-gaap:OtherNonoperatingIncomeExpenseMember jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 us-gaap:RestructuringChargesMember jnj:MedTechMember 2024-01-01 2024-03-31 0000200406 jnj:CostsOfGoodsAndServicesSoldMember jnj:MedTechMember 2024-01-01 2024-03-31", "length": 62629, "numbers_raw": ["000", "020", "040", "6", "12", "28", "202", "5", "1", "33", "421", "7", "421", "7", "421", "7", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "1.150", "202", "8M", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "2.700", "202", "9M", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "3.20", "203", "2M", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "3.050", "203", "3M", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "1.650", "203", "5M", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "3.350", "203", "6M", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "3.350", "203", "7M", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "3.550", "204", "4M", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "3.600", "204", "5M", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "3.700", "205", "5M", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "04", "18", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "3", "12", "31", "000", "020", "040", "6", "202", "3", "12", "31", "000", "020", "040", "6", "202", "3", "12", "31", "000", "020", "040", "6", "202", "3", "12", "31", "000", "020", "040", "6", "202", "3", "12", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "03", "31", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "1M", "202", "5", "03", "30", "000", "020", "040", "6", "2M", "202", "5", "03", "30", "000", "020", "040", "6", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "2M", "202", "4", "12", "29", "000", "020", "040", "6", "1M", "202", "5", "03", "30", "000", "020", "040", "6", "2M", "202", "5", "03", "30", "000", "020", "040", "6", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "2M", "202", "4", "12", "29", "000", "020", "040", "6", "1M", "202", "5", "03", "30", "000", "020", "040", "6", "2M", "202", "5", "03", "30", "000", "020", "040", "6", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "2M", "202", "4", "12", "29", "000", "020", "040", "6", "1M", "202", "4", "12", "29", "000", "020", "040", "6", "3M", "202", "4", "12", "29", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "2.95", "202", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "2.95", "202", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "2.95", "202", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "095", "202", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "095", "202", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "095", "202", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "4.50", "202", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "4.50", "202", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "4.50", "202", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "2.900", "202", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "2.900", "202", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "2.900", "202", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "1.150", "202", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "1.150", "202", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "1.150", "202", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "4.55", "202", "9M", "202", "5", "03", "30", "000", "020", "040", "6", "4.55", "202", "9M", "202", "5", "03", "30", "000", "020", "040", "6", "4.55", "202", "9M", "202", "5", "03", "30", "000", "020", "040", "6", "4.80", "202", "9M", "202", "5", "03", "30", "000", "020", "040", "6", "4.80", "202", "9M", "202", "5", "03", "30", "000", "020", "040", "6", "4.80", "202", "9M", "202", "5", "03", "30", "000", "020", "040", "6", "6.95", "202", "9M", "202", "5", "03", "30", "000", "020", "040", "6", "6.95", "202", "9M", "202", "5", "03", "30", "000", "020", "040", "6", "6.95", "202", "9M", "202", "5", "03", "30", "000", "020", "040", "6", "2.700", "202", "9M", "202", "5", "03", "30", "000", "020", "040", "6", "2.700", "202", "9M", "202", "5", "03", "30", "000", "020", "040", "6", "2.700", "202", "9M", "202", "5", "03", "30", "000", "020", "040", "6", "130", "0", "203", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "130", "0", "203", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "130", "0", "203", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "4.70", "203", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "4.70", "203", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "4.70", "203", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "4.90", "203", "1M", "202", "5", "03", "30", "000", "020", "040", "6", "4.90", "203", "1M", "202", "5", "03", "30", "000", "020", "040", "6", "4.90", "203", "1M", "202", "5", "03", "30", "000", "020", "040", "6", "3.20", "203", "2M", "202", "5", "03", "30", "000", "020", "040", "6", "3.20", "203", "2M", "202", "5", "03", "30", "000", "020", "040", "6", "3.20", "203", "2M", "202", "5", "03", "30", "000", "020", "040", "6", "4.85", "203", "2M", "202", "5", "03", "30", "000", "020", "040", "6", "4.85", "203", "2M", "202", "5", "03", "30", "000", "020", "040", "6", "4.85", "203", "2M", "202", "5", "03", "30", "000", "020", "040", "6", "4.95", "203", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "4.95", "203", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "4.95", "203", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "4.375", "203", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "4.375", "203", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "4.375", "203", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "3.050", "203", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "3.050", "203", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "4.95", "203", "4M", "202", "5", "03", "30", "000", "020", "040", "6", "4.95", "203", "4M", "202", "5", "03", "30", "000", "020", "040", "6", "4.95", "203", "4M", "202", "5", "03", "30", "000", "020", "040", "6", "1.650", "203", "5M", "202", "5", "03", "30", "000", "020", "040", "6", "1.650", "203", "5M", "202", "5", "03", "30", "000", "020", "040", "6", "5.00", "203", "5M", "202", "5", "03", "30", "000", "020", "040", "6", "5.00", "203", "5M", "202", "5", "03", "30", "000", "020", "040", "6", "5.00", "203", "5M", "202", "5", "03", "30", "000", "020", "040", "6", "3.35", "203", "680", "0M", "1.0721M", "202", "5", "03", "30", "000", "020", "040", "6", "3.35", "203", "680", "0M", "1.0721M", "202", "5", "03", "30", "000", "020", "040", "6", "3.35", "203", "680", "0M", "1.0721M", "202", "5", "03", "30", "000", "020", "040", "6", "3.587", "203", "6M", "202", "5", "03", "30", "000", "020", "040", "6", "3.587", "203", "6M", "202", "5", "03", "30", "000", "020", "040", "6", "3.587", "203", "6M", "202", "5", "03", "30", "000", "020", "040", "6", "5.95", "203", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "5.95", "203", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "5.95", "203", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "3.625", "203", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "3.625", "203", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "3.625", "203", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "3.350", "203", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "3.350", "203", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "3.350", "203", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "3.400", "203", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "3.400", "203", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "3.400", "203", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "5.85", "203", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "5.85", "203", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "5.85", "203", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "4.50", "204", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "4.50", "204", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "4.50", "204", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "210", "204", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "210", "204", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "210", "204", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "4.85", "204", "1M", "202", "5", "03", "30", "000", "020", "040", "6", "4.85", "204", "1M", "202", "5", "03", "30", "000", "020", "040", "6", "4.85", "204", "1M", "202", "5", "03", "30", "000", "020", "040", "6", "4.50", "204", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "4.50", "204", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "4.50", "204", "3M", "202", "5", "03", "30", "000", "020", "040", "6", "3.55", "204", "41.0", "1.0721M", "202", "5", "03", "30", "000", "020", "040", "6", "3.55", "204", "41.0", "1.0721M", "202", "5", "03", "30", "000", "020", "040", "6", "3.55", "204", "41.0", "1.0721M", "202", "5", "03", "30", "000", "020", "040", "6", "3.600", "204", "5M", "202", "5", "03", "30", "000", "020", "040", "6", "3.600", "204", "5M", "202", "5", "03", "30", "000", "020", "040", "6", "3.600", "204", "5M", "202", "5", "03", "30", "000", "020", "040", "6", "3.70", "204", "6M", "202", "5", "03", "30", "000", "020", "040", "6", "3.70", "204", "6M", "202", "5", "03", "30", "000", "020", "040", "6", "3.70", "204", "6M", "202", "5", "03", "30", "000", "020", "040", "6", "3.75", "204", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "3.75", "204", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "3.75", "204", "7M", "202", "5", "03", "30", "000", "020", "040", "6", "3.500", "204", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "3.500", "204", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "3.500", "204", "8M", "202", "5", "03", "30", "000", "020", "040", "6", "225", "0", "205", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "225", "0", "205", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "225", "0", "205", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "5.25", "205", "4M", "202", "5", "03", "30", "000", "020", "040", "6", "5.25", "205", "4M", "202", "5", "03", "30", "000", "020", "040", "6", "5.25", "205", "4M", "202", "5", "03", "30", "000", "020", "040", "6", "3.700", "205", "5M", "202", "5", "03", "30", "000", "020", "040", "6", "3.700", "205", "5M", "202", "5", "03", "30", "000", "020", "040", "6", "3.700", "205", "5M", "202", "5", "03", "30", "000", "020", "040", "6", "245", "0", "206", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "245", "0", "206", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "245", "0", "206", "0M", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "12", "29", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "5", "04", "02", "000", "020", "040", "6", "202", "5", "04", "02", "202", "5", "04", "02", "000", "020", "040", "6", "202", "4", "06", "20", "202", "4", "06", "20", "000", "020", "040", "6", "202", "4", "06", "20", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "05", "31", "202", "4", "05", "31", "000", "020", "040", "6", "202", "4", "05", "31", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "03", "07", "202", "4", "03", "07", "000", "020", "040", "6", "202", "4", "03", "07", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "201", "8", "07", "01", "201", "8", "07", "31", "000", "020", "040", "6", "202", "0", "06", "01", "202", "0", "06", "30", "000", "020", "040", "6", "202", "1", "06", "01", "202", "1", "06", "30", "000", "020", "040", "6", "202", "4", "05", "01", "202", "4", "05", "01", "000", "020", "040", "6", "202", "4", "05", "01", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "29", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "1", "07", "04", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "1", "05", "31", "000", "020", "040", "6", "202", "1", "09", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "12", "30", "202", "5", "03", "30", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31", "000", "020", "040", "6", "202", "4", "01", "01", "202", "4", "03", "31"], "numbers": [0.0, 20.0, 40.0, 6.0, 12.0, 28.0, 202.0, 5.0, 1.0, 33.0, 421.0, 7.0, 421.0, 7.0, 421.0, 7.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 1.15, 202.0, 8000000.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2.7, 202.0, 9000000.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.2, 203.0, 2000000.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.05, 203.0, 3000000.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 1.65, 203.0, 5000000.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.35, 203.0, 6000000.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.35, 203.0, 7000000.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.55, 204.0, 4000000.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.6, 204.0, 5000000.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.7, 205.0, 5000000.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 4.0, 18.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 12.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 12.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 12.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 12.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 12.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 1000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2000000.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 1000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2000000.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 1000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2000000.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 1000000.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 3000000.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2.95, 202.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2.95, 202.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2.95, 202.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 95.0, 202.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 95.0, 202.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 95.0, 202.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.5, 202.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.5, 202.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.5, 202.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2.9, 202.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2.9, 202.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2.9, 202.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 1.15, 202.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 1.15, 202.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 1.15, 202.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.55, 202.0, 9000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.55, 202.0, 9000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.55, 202.0, 9000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.8, 202.0, 9000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.8, 202.0, 9000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.8, 202.0, 9000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 6.95, 202.0, 9000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 6.95, 202.0, 9000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 6.95, 202.0, 9000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2.7, 202.0, 9000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2.7, 202.0, 9000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 2.7, 202.0, 9000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 130.0, 0.0, 203.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 130.0, 0.0, 203.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 130.0, 0.0, 203.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.7, 203.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.7, 203.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.7, 203.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.9, 203.0, 1000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.9, 203.0, 1000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.9, 203.0, 1000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.2, 203.0, 2000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.2, 203.0, 2000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.2, 203.0, 2000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.85, 203.0, 2000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.85, 203.0, 2000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.85, 203.0, 2000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.95, 203.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.95, 203.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.95, 203.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.375, 203.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.375, 203.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.375, 203.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.05, 203.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.05, 203.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.95, 203.0, 4000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.95, 203.0, 4000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.95, 203.0, 4000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 1.65, 203.0, 5000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 1.65, 203.0, 5000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 5.0, 203.0, 5000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 5.0, 203.0, 5000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 5.0, 203.0, 5000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.35, 203.0, 680.0, 0.0, 1072100.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.35, 203.0, 680.0, 0.0, 1072100.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.35, 203.0, 680.0, 0.0, 1072100.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.587, 203.0, 6000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.587, 203.0, 6000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.587, 203.0, 6000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 5.95, 203.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 5.95, 203.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 5.95, 203.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.625, 203.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.625, 203.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.625, 203.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.35, 203.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.35, 203.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.35, 203.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.4, 203.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.4, 203.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.4, 203.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 5.85, 203.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 5.85, 203.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 5.85, 203.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.5, 204.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.5, 204.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.5, 204.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 210.0, 204.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 210.0, 204.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 210.0, 204.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.85, 204.0, 1000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.85, 204.0, 1000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.85, 204.0, 1000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.5, 204.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.5, 204.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 4.5, 204.0, 3000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.55, 204.0, 41.0, 1072100.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.55, 204.0, 41.0, 1072100.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.55, 204.0, 41.0, 1072100.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.6, 204.0, 5000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.6, 204.0, 5000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.6, 204.0, 5000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.7, 204.0, 6000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.7, 204.0, 6000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.7, 204.0, 6000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.75, 204.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.75, 204.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.75, 204.0, 7000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.5, 204.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.5, 204.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.5, 204.0, 8000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 225.0, 0.0, 205.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 225.0, 0.0, 205.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 225.0, 0.0, 205.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 5.25, 205.0, 4000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 5.25, 205.0, 4000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 5.25, 205.0, 4000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.7, 205.0, 5000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.7, 205.0, 5000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 3.7, 205.0, 5000000.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 245.0, 0.0, 206.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 245.0, 0.0, 206.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 245.0, 0.0, 206.0, 0.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 4.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 4.0, 2.0, 202.0, 5.0, 4.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 6.0, 20.0, 202.0, 4.0, 6.0, 20.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 6.0, 20.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 5.0, 31.0, 202.0, 4.0, 5.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 5.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 3.0, 7.0, 202.0, 4.0, 3.0, 7.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 3.0, 7.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 201.0, 8.0, 7.0, 1.0, 201.0, 8.0, 7.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 0.0, 6.0, 1.0, 202.0, 0.0, 6.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 1.0, 6.0, 1.0, 202.0, 1.0, 6.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 5.0, 1.0, 202.0, 4.0, 5.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 5.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 29.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 1.0, 7.0, 4.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 1.0, 5.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 1.0, 9.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 12.0, 30.0, 202.0, 5.0, 3.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 4.0, 1.0, 1.0, 202.0, 4.0, 3.0, 31.0], "percents_raw": [], "percents": [], "currencies": ["EUR", "USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 9, "tag": "div", "text_raw": "Washington, D.C. 20549", "text": "20549", "length": 5, "numbers_raw": ["205", "49"], "numbers": [205.0, 49.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 11, "tag": "div", "text_raw": "FORM 10-Q", "text": "FORM 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 12, "tag": "div", "text_raw": " Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934", "text": " Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934", "length": 89, "numbers_raw": ["13", "15", "193", "4"], "numbers": [13.0, 15.0, 193.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 13, "tag": "div", "text_raw": "for the quarterly period ended March 30, 2025", "text": "for the quarterly period ended March 30, 2025", "length": 45, "numbers_raw": ["30", "202", "5"], "numbers": [30.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 16, "tag": "div", "text_raw": " Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to", "text": " Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to", "length": 124, "numbers_raw": ["13", "15", "193", "4"], "numbers": [13.0, 15.0, 193.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 17, "tag": "div", "text_raw": "Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934", "text": "Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934", "length": 88, "numbers_raw": ["13", "15", "193", "4"], "numbers": [13.0, 15.0, 193.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 18, "tag": "div", "text_raw": "for the transition period from to", "text": "for the transition period from to", "length": 33, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 19, "tag": "div", "text_raw": "Commission file number 1-3215", "text": "Commission file number 1-3215", "length": 29, "numbers_raw": ["1", "321", "5"], "numbers": [1.0, 321.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 21, "tag": "div", "text_raw": "(Exact name of registrant as specified in its charter)", "text": "(Exact name of registrant as specified in its charter)", "length": 54, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 22, "tag": "div", "text_raw": "New Jersey 22-1024240 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)", "text": "New Jersey 22-1024240 (State or other jurisdiction of incorporation or organization) (I.R.S.", "length": 92, "numbers_raw": ["22", "102", "424", "0"], "numbers": [22.0, 102.0, 424.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 24, "tag": "div", "text_raw": "(State or other jurisdiction of", "text": "(State or other jurisdiction of", "length": 31, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 25, "tag": "div", "text_raw": "incorporation or organization)", "text": "incorporation or organization)", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 30, "tag": "div", "text_raw": "New Brunswick , New Jersey 08933", "text": "New Brunswick , New Jersey 08933", "length": 32, "numbers_raw": ["089", "33"], "numbers": [89.0, 33.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 31, "tag": "div", "text_raw": "(Address of principal executive offices)", "text": "(Address of principal executive offices)", "length": 40, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 32, "tag": "div", "text_raw": "Registrants telephone number, including area code ( 732 ) 524-0400", "text": "Registrants telephone number, including area code ( 732 ) 524-0400", "length": 67, "numbers_raw": ["732", "524", "040", "0"], "numbers": [732.0, 524.0, 40.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 33, "tag": "div", "text_raw": "Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No", "text": "Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.", "length": 344, "numbers_raw": ["1", "13", "15", "193", "4", "12 m", "2", "90"], "numbers": [1.0, 13.0, 15.0, 193.0, 4.0, 12000000.0, 2.0, 90.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 34, "tag": "div", "text_raw": "Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  No", "text": "Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "length": 281, "numbers_raw": ["405", "12 m"], "numbers": [405.0, 12000000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 35, "tag": "div", "text_raw": "Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.", "text": "Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.", "length": 182, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 35, "tag": "div", "text_raw": "Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.", "text": "See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.", "length": 164, "numbers_raw": ["12", "2"], "numbers": [12.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 36, "tag": "div", "text_raw": "Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company  Emerging growth company ", "text": "Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company  Emerging growth company ", "length": 123, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 38, "tag": "div", "text_raw": "If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ", "text": "If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.", "length": 251, "numbers_raw": ["13"], "numbers": [13.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 39, "tag": "div", "text_raw": "Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  No", "text": "Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).", "length": 112, "numbers_raw": ["12", "2"], "numbers": [12.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 43, "tag": "div", "text_raw": "SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT", "text": "SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT", "length": 58, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 44, "tag": "div", "text_raw": "Title of each class Trading Symbol Name of each exchange on which registered Common Stock, Par Value $1.00 JNJ New York Stock Exchange 1.150% Notes Due November 2028 JNJ28 New York Stock Exchange 2.700% Notes Due February 2029 JNJ29B New York Stock Exchange 3.200% Notes Due June 2032 JNJ32 New York Stock Exchange 3.050% Notes Due February 2033 JNJ33B New York Stock Exchange 1.650% Notes Due May 2035 JNJ35 New York Stock Exchange 3.350% Notes Due June 2036 JNJ36A New York Stock Exchange 3.350% Notes Due February 2037 JNJ37B New York Stock Exchange 3.550% Notes Due June 2044 JNJ44 New York Stock Exchange 3.600% Notes Due February 2045 JNJ45 New York Stock Exchange 3.700% Notes Due February 2055 JNJ55 New York Stock Exchange", "text": "Title of each class Trading Symbol Name of each exchange on which registered Common Stock, Par Value $1.00 JNJ New York Stock Exchange 1.150% Notes Due November 2028 JNJ28 New York Stock Exchange 2.700% Notes Due February 2029 JNJ29B New York Stock Exchange 3.200% Notes Due June 2032 JNJ32 New York Stock Exchange 3.050% Notes Due February 2033 JNJ33B New York Stock Exchange 1.650% Notes Due May 2035 JNJ35 New York Stock Exchange 3.350% Notes Due June 2036 JNJ36A New York Stock Exchange 3.350% Notes Due February 2037 JNJ37B New York Stock Exchange 3.550% Notes Due June 2044 JNJ44 New York Stock Exchange 3.600% Notes Due February 2045 JNJ45 New York Stock Exchange 3.700% Notes Due February 2055 JNJ55 New York Stock Exchange", "length": 731, "numbers_raw": ["$1.00", "1.150", "202", "8", "28", "2.700", "202", "9", "29", "3.200", "203", "2", "32", "3.050", "203", "3", "33", "1.650", "203", "5", "35", "3.350", "203", "6", "36", "3.350", "203", "7", "37", "3.550", "204", "4", "44", "3.600", "204", "5", "45", "3.700", "205", "5", "55"], "numbers": [1.0, 1.15, 202.0, 8.0, 28.0, 2.7, 202.0, 9.0, 29.0, 3.2, 203.0, 2.0, 32.0, 3.05, 203.0, 3.0, 33.0, 1.65, 203.0, 5.0, 35.0, 3.35, 203.0, 6.0, 36.0, 3.35, 203.0, 7.0, 37.0, 3.55, 204.0, 4.0, 44.0, 3.6, 204.0, 5.0, 45.0, 3.7, 205.0, 5.0, 55.0], "percents_raw": ["1.150%", "2.700%", "3.200%", "3.050%", "1.650%", "3.350%", "3.350%", "3.550%", "3.600%", "3.700%"], "percents": [0.0115, 0.027000000000000003, 0.032, 0.0305, 0.0165, 0.0335, 0.0335, 0.0355, 0.036000000000000004, 0.037000000000000005], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 45, "tag": "div", "text_raw": "Indicate the number of shares outstanding of each of the issuers classes of common stock, as of the latest practicable date.", "text": "Indicate the number of shares outstanding of each of the issuers classes of common stock, as of the latest practicable date.", "length": 125, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 46, "tag": "div", "text_raw": "On April 18, 2025, 2,406,073,279 shares of Common Stock, $1.00 par value, were outstanding.", "text": "On April 18, 2025, 2,406,073,279 shares of Common Stock, $1.00 par value, were outstanding.", "length": 91, "numbers_raw": ["18", "202", "5", "2,406,073,279", "$1.00"], "numbers": [18.0, 202.0, 5.0, 2406073279.0, 1.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 53, "tag": "div", "text_raw": "JOHNSON & JOHNSON AND SUBSIDIARIES", "text": "JOHNSON & JOHNSON AND SUBSIDIARIES", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 55, "tag": "div", "text_raw": "Item Page Part I Financial information 1 Item 1 Financial statements (unaudited) 1 Consolidated balance sheets  March 30 , 202 5 and December 29 , 202 4 1 Consolidated statements of earnings for the fiscal first quarters ended March 30 , 202 5 and March 3 1, 202 4 2 Consolidated statements of comprehensive income for the fiscal first quarters ended March 30 , 202 5 and March 3 1, 202 4 3 Consolidated statements of equity for the fiscal first quarters ended March 30 , 202 5 and March 3 1, 202 4 4 Consolidated statements of cash flows for the fiscal three mo nths ended March 30 , 202 5 and March 3 1, 202 4 5 Notes to consolidated financial statements 7 Item 2 Managements discussion and analysis of financial condition and results of operations 38 Item 3 Quantitative and qualitative disclosures about market risk 48 Item 4 Controls and procedures 48 Part II Other information 49 Item 1 Legal proceedings 49 Item 2 Unregistered sales of equity securities and use of proceeds 49 Item 5 Other information 50 Item 6 Exhibits 50 Signatures 51", "text": "Item Page Part I Financial information 1 Item 1 Financial statements (unaudited) 1 Consolidated balance sheets  March 30 , 202 5 and December 29 , 202 4 1 Consolidated statements of earnings for the fiscal first quarters ended March 30 , 202 5 and March 3 1, 202 4 2 Consolidated statements of comprehensive income for the fiscal first quarters ended March 30 , 202 5 and March 3 1, 202 4 3 Consolidated statements of equity for the fiscal first quarters ended March 30 , 202 5 and March 3 1, 202 4 4 Consolidated statements of cash flows for the fiscal three mo nths ended March 30 , 202 5 and March 3 1, 202 4 5 Notes to consolidated financial statements 7 Item 2 Managements discussion and analysis of financial condition and results of operations 38 Item 3 Quantitative and qualitative disclosures about market risk 48 Item 4 Controls and procedures 48 Part II Other information 49 Item 1 Legal proceedings 49 Item 2 Unregistered sales of equity securities and use of proceeds 49 Item 5 Other information 50 Item 6 Exhibits 50 Signatures 51", "length": 1046, "numbers_raw": ["1", "1", "1", "30", "202", "5", "29", "202", "4", "1", "30", "202", "5", "3", "1", "202", "4", "2", "30", "202", "5", "3", "1", "202", "4", "3", "30", "202", "5", "3", "1", "202", "4", "4", "30", "202", "5", "3", "1", "202", "4", "5", "7", "2 M", "38", "3", "48", "4", "48", "49", "1", "49", "2", "49", "5", "50", "6", "50", "51"], "numbers": [1.0, 1.0, 1.0, 30.0, 202.0, 5.0, 29.0, 202.0, 4.0, 1.0, 30.0, 202.0, 5.0, 3.0, 1.0, 202.0, 4.0, 2.0, 30.0, 202.0, 5.0, 3.0, 1.0, 202.0, 4.0, 3.0, 30.0, 202.0, 5.0, 3.0, 1.0, 202.0, 4.0, 4.0, 30.0, 202.0, 5.0, 3.0, 1.0, 202.0, 4.0, 5.0, 7.0, 2000000.0, 38.0, 3.0, 48.0, 4.0, 48.0, 49.0, 1.0, 49.0, 2.0, 49.0, 5.0, 50.0, 6.0, 50.0, 51.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 58, "tag": "div", "text_raw": "1", "text": "1", "length": 1, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 59, "tag": "div", "text_raw": "Item 1", "text": "Item 1", "length": 6, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 60, "tag": "div", "text_raw": "Financial statements (unaudited)", "text": "Financial statements (unaudited)", "length": 32, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 61, "tag": "div", "text_raw": "1", "text": "1", "length": 1, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 62, "tag": "div", "text_raw": "Consolidated balance sheets  March 30 , 202 5 and December 29 , 202 4", "text": "Consolidated balance sheets  March 30 , 202 5 and December 29 , 202 4", "length": 70, "numbers_raw": ["30", "202", "5", "29", "202", "4"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 63, "tag": "div", "text_raw": "1", "text": "1", "length": 1, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 64, "tag": "div", "text_raw": "Consolidated statements of earnings for the fiscal first quarters ended March 30 , 202 5 and March 3 1, 202 4", "text": "Consolidated statements of earnings for the fiscal first quarters ended March 30 , 202 5 and March 3 1, 202 4", "length": 109, "numbers_raw": ["30", "202", "5", "3", "1", "202", "4"], "numbers": [30.0, 202.0, 5.0, 3.0, 1.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 65, "tag": "div", "text_raw": "2", "text": "2", "length": 1, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 66, "tag": "div", "text_raw": "Consolidated statements of comprehensive income for the fiscal first quarters ended March 30 , 202 5 and March 3 1, 202 4", "text": "Consolidated statements of comprehensive income for the fiscal first quarters ended March 30 , 202 5 and March 3 1, 202 4", "length": 121, "numbers_raw": ["30", "202", "5", "3", "1", "202", "4"], "numbers": [30.0, 202.0, 5.0, 3.0, 1.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 67, "tag": "div", "text_raw": "3", "text": "3", "length": 1, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 68, "tag": "div", "text_raw": "Consolidated statements of equity for the fiscal first quarters ended March 30 , 202 5 and March 3 1, 202 4", "text": "Consolidated statements of equity for the fiscal first quarters ended March 30 , 202 5 and March 3 1, 202 4", "length": 107, "numbers_raw": ["30", "202", "5", "3", "1", "202", "4"], "numbers": [30.0, 202.0, 5.0, 3.0, 1.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 69, "tag": "div", "text_raw": "4", "text": "4", "length": 1, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 70, "tag": "div", "text_raw": "Consolidated statements of cash flows for the fiscal three mo nths ended March 30 , 202 5 and March 3 1, 202 4", "text": "Consolidated statements of cash flows for the fiscal three mo nths ended March 30 , 202 5 and March 3 1, 202 4", "length": 110, "numbers_raw": ["30", "202", "5", "3", "1", "202", "4"], "numbers": [30.0, 202.0, 5.0, 3.0, 1.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 71, "tag": "div", "text_raw": "5", "text": "5", "length": 1, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 72, "tag": "div", "text_raw": "Notes to consolidated financial statements", "text": "Notes to consolidated financial statements", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 73, "tag": "div", "text_raw": "7", "text": "7", "length": 1, "numbers_raw": ["7"], "numbers": [7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 74, "tag": "div", "text_raw": "Item 2", "text": "Item 2", "length": 6, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 75, "tag": "div", "text_raw": "Managements discussion and analysis of financial condition and results of operations", "text": "Managements discussion and analysis of financial condition and results of operations", "length": 85, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 76, "tag": "div", "text_raw": "38", "text": "38", "length": 2, "numbers_raw": ["38"], "numbers": [38.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 77, "tag": "div", "text_raw": "Item 3", "text": "Item 3", "length": 6, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 78, "tag": "div", "text_raw": "Quantitative and qualitative disclosures about market risk", "text": "Quantitative and qualitative disclosures about market risk", "length": 58, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 79, "tag": "div", "text_raw": "48", "text": "48", "length": 2, "numbers_raw": ["48"], "numbers": [48.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 80, "tag": "div", "text_raw": "Item 4", "text": "Item 4", "length": 6, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 82, "tag": "div", "text_raw": "48", "text": "48", "length": 2, "numbers_raw": ["48"], "numbers": [48.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 85, "tag": "div", "text_raw": "49", "text": "49", "length": 2, "numbers_raw": ["49"], "numbers": [49.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 86, "tag": "div", "text_raw": "Item 1", "text": "Item 1", "length": 6, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 88, "tag": "div", "text_raw": "49", "text": "49", "length": 2, "numbers_raw": ["49"], "numbers": [49.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 89, "tag": "div", "text_raw": "Item 2", "text": "Item 2", "length": 6, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 90, "tag": "div", "text_raw": "Unregistered sales of equity securities and use of proceeds", "text": "Unregistered sales of equity securities and use of proceeds", "length": 59, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 91, "tag": "div", "text_raw": "49", "text": "49", "length": 2, "numbers_raw": ["49"], "numbers": [49.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 92, "tag": "div", "text_raw": "Item 5", "text": "Item 5", "length": 6, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 94, "tag": "div", "text_raw": "50", "text": "50", "length": 2, "numbers_raw": ["50"], "numbers": [50.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 95, "tag": "div", "text_raw": "Item 6", "text": "Item 6", "length": 6, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 97, "tag": "div", "text_raw": "50", "text": "50", "length": 2, "numbers_raw": ["50"], "numbers": [50.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 99, "tag": "div", "text_raw": "51", "text": "51", "length": 2, "numbers_raw": ["51"], "numbers": [51.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 106, "tag": "div", "text_raw": "Cautionary note regarding forward-looking statements", "text": "Cautionary note regarding forward-looking statements", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 107, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnsons other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "This Quarterly Report on Form 10-Q and Johnson & Johnsons other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.", "length": 250, "numbers_raw": ["10", "199", "5"], "numbers": [10.0, 199.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 107, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnsons other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements.", "length": 146, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 107, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnsons other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future.", "length": 177, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 107, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnsons other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things:", "length": 204, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 107, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnsons other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "discussions of future operations, expected operating results, financial performance;", "length": 84, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 107, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnsons other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "impact of planned acquisitions and dispositions;", "length": 48, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 107, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnsons other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "impact and timing of restructuring initiatives including associated cost savings and other benefits;", "length": 100, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 107, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnsons other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "the Companys strategy for growth;", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 107, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnsons other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "product development activities;", "length": 31, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 107, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnsons other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "market position and expenditures.", "length": 33, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 108, "tag": "div", "text_raw": "Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Companys control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Companys actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:", "text": "Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Companys control.", "length": 257, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 108, "tag": "div", "text_raw": "Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Companys control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Companys actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:", "text": "Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Companys actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements.", "length": 294, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 108, "tag": "div", "text_raw": "Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Companys control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Companys actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:", "text": "Investors are therefore cautioned not to rely on these forward-looking statements.", "length": 82, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 108, "tag": "div", "text_raw": "Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Companys control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Companys actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:", "text": "Risks and uncertainties include, but are not limited to:", "length": 56, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 109, "tag": "div", "text_raw": "Risks related to product development, market success and competition", "text": "Risks related to product development, market success and competition", "length": 68, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 110, "tag": "div", "text_raw": " Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Companys continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;", "text": " Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Companys continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;", "length": 386, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 111, "tag": "div", "text_raw": " Challenges to the Companys ability to secure and maintain adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;", "text": " Challenges to the Companys ability to secure and maintain adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;", "length": 212, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 112, "tag": "div", "text_raw": " The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;", "text": " The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;", "length": 172, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 113, "tag": "div", "text_raw": " Increasingly aggressive and frequent challenges to the Companys patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;", "text": " Increasingly aggressive and frequent challenges to the Companys patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;", "length": 421, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 114, "tag": "div", "text_raw": " Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;", "text": " Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;", "length": 153, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 115, "tag": "div", "text_raw": " Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;", "text": " Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;", "length": 149, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 116, "tag": "div", "text_raw": " Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and", "text": " Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors;", "length": 123, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 117, "tag": "div", "text_raw": " Allegations that the Companys products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Companys ability to sell the products in question and require the payment of money damages and future royalties.", "text": " Allegations that the Companys products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Companys ability to sell the products in question and require the payment of money damages and future royalties.", "length": 266, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 118, "tag": "div", "text_raw": "Risks related to product liability, litigation and regulatory activity", "text": "Risks related to product liability, litigation and regulatory activity", "length": 70, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 119, "tag": "div", "text_raw": " Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (U.S. FDA) (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;", "text": " Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (U.S.", "length": 224, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 119, "tag": "div", "text_raw": " Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (U.S. FDA) (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;", "text": "FDA) (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;", "length": 128, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 120, "tag": "div", "text_raw": " The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;", "text": " The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;", "length": 260, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 121, "tag": "div", "text_raw": " The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;", "text": " The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;", "length": 273, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 127, "tag": "div", "text_raw": " Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business;", "text": " Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business;", "length": 277, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 128, "tag": "div", "text_raw": " Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;", "text": " Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;", "length": 151, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 129, "tag": "div", "text_raw": " Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;", "text": " Potential changes to applicable laws and regulations affecting United States and international operations, including relating to:", "length": 131, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 129, "tag": "div", "text_raw": " Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;", "text": "sales and promotion of healthcare products;", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 129, "tag": "div", "text_raw": " Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;", "text": "access to, and reimbursement and pricing for, healthcare products and services;", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 129, "tag": "div", "text_raw": " Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;", "text": "and sourcing of raw materials;", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 130, "tag": "div", "text_raw": " Compliance with local regulations and laws that may restrict the Companys ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Unions Medical Devices Regulation;", "text": " Compliance with local regulations and laws that may restrict the Companys ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Unions Medical Devices Regulation;", "length": 296, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": false, "has_percents": false}
{"idx_source": 131, "tag": "div", "text_raw": " Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world may cause exposures to additional tax liabilities potentially in excess of existing reserves; and", "text": " Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world may cause exposures to additional tax liabilities potentially in excess of existing reserves;", "length": 221, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 132, "tag": "div", "text_raw": " The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.", "text": " The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.", "length": 156, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 133, "tag": "div", "text_raw": "Risks related to the Companys strategic initiatives and healthcare market trends", "text": "Risks related to the Companys strategic initiatives and healthcare market trends", "length": 81, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 134, "tag": "div", "text_raw": " Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;", "text": " Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;", "length": 456, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 135, "tag": "div", "text_raw": " Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints;", "text": " Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints;", "length": 175, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 136, "tag": "div", "text_raw": " Challenges to the Companys ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;", "text": " Challenges to the Companys ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;", "length": 317, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 137, "tag": "div", "text_raw": " The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; and", "text": " The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected;", "length": 207, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 138, "tag": "div", "text_raw": " The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.", "text": " The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.", "length": 175, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 139, "tag": "div", "text_raw": "Risks related to economic conditions, financial markets and operating internationally", "text": "Risks related to economic conditions, financial markets and operating internationally", "length": 85, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 140, "tag": "div", "text_raw": " The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;", "text": " The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;", "length": 167, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 141, "tag": "div", "text_raw": " The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;", "text": " The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;", "length": 179, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 142, "tag": "div", "text_raw": " Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation, and the impact of such changes on raw material prices, supply chains market volatility and the pace of product development;", "text": " Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation, and the impact of such changes on raw material prices, supply chains market volatility and the pace of product development;", "length": 343, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 143, "tag": "div", "text_raw": " The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems;", "text": " The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems;", "length": 249, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 144, "tag": "div", "text_raw": " The impact of global public health crises and pandemics;", "text": " The impact of global public health crises and pandemics;", "length": 58, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 145, "tag": "div", "text_raw": " Changes to global climate, extreme weather and natural disasters that could affect demand for the Companys products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Companys products and operations;", "text": " Changes to global climate, extreme weather and natural disasters that could affect demand for the Companys products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Companys products and operations;", "length": 350, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 146, "tag": "div", "text_raw": " The impact of global or economic changes or events, including global tensions and war; and", "text": " The impact of global or economic changes or events, including global tensions and war;", "length": 88, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 147, "tag": "div", "text_raw": " The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.", "text": " The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.", "length": 194, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 155, "tag": "div", "text_raw": "Risks related to supply chain and operations", "text": "Risks related to supply chain and operations", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 156, "tag": "div", "text_raw": " Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;", "text": " Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;", "length": 310, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 157, "tag": "div", "text_raw": " Interruptions and breaches of the Companys information technology systems or those of the Companys vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action;", "text": " Interruptions and breaches of the Companys information technology systems or those of the Companys vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action;", "length": 245, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 158, "tag": "div", "text_raw": " Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Companys products; and", "text": " Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Companys products;", "length": 243, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 159, "tag": "div", "text_raw": " The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities.", "text": " The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities.", "length": 238, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 160, "tag": "div", "text_raw": "Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2024, for a description of certain risks that could, among other things, cause the Companys actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.", "text": "Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2024, for a description of certain risks that could, among other things, cause the Companys actual results to differ materially from those expressed in its forward-looking statements.", "length": 342, "numbers_raw": ["1", "10", "29", "202", "4"], "numbers": [1.0, 10.0, 29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 160, "tag": "div", "text_raw": "Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2024, for a description of certain risks that could, among other things, cause the Companys actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.", "text": "Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties.", "length": 210, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 160, "tag": "div", "text_raw": "Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2024, for a description of certain risks that could, among other things, cause the Companys actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.", "text": "The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.", "length": 188, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 167, "tag": "div", "text_raw": "Part I  Financial information", "text": "Part I  Financial information", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 169, "tag": "div", "text_raw": "Item 1  Financial statements", "text": "Item 1  Financial statements", "length": 29, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 171, "tag": "div", "text_raw": "Johnson & Johnson and subsidiaries consolidated balance sheets", "text": "Johnson & Johnson and subsidiaries consolidated balance sheets", "length": 62, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 172, "tag": "div", "text_raw": "(Unaudited; Dollars in Millions Except Share and Per Share Data)", "text": "Dollars in Millions Except Share and Per Share Data)", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 173, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 Assets Current assets: Cash and cash equivalents (Note 4) $ 38,474 24,105 Marketable securities 307 417 Accounts receivable, trade, less allowances $ 170 (2024, $ 167 ) 16,020 14,842 Inventories (Note 2) 12,659 12,444 Prepaid expenses and other 4,091 4,085 Total current assets 71,551 55,893 Property, plant and equipment at cost 49,884 48,768 Less: accumulated depreciation ( 29,013 ) ( 28,250 ) Property, plant and equipment, net 20,871 20,518 Intangible assets, net (Note 3) 36,755 37,618 Goodwill (Note 3) 44,468 44,200 Deferred taxes on income (Note 5) 8,492 10,461 Other assets 11,534 11,414 Total assets $ 193,671 180,104 Liabilities and shareholders equity Current liabilities: Loans and notes payable $ 13,897 5,983 Accounts payable 9,545 10,311 Accrued liabilities 7,913 8,549 Accrued rebates, returns and promotions 18,780 17,580 Accrued compensation and employee related obligations 2,551 4,126 Accrued taxes on income (Note 5) 4,217 3,772 Total current liabilities 56,903 50,321 Long-term debt (Note 4) 38,355 30,651 Deferred taxes on income (Note 5) 2,428 2,448 Employee related obligations (Note 6) 7,046 7,255 Long-term taxes payable (Note 5) 395 390 Other liabilities 10,435 17,549 Total liabilities $ 115,562 108,614 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 11,740 ) ( 11,741 ) Retained earnings and Additional paid-in capital 162,635 155,791 Less: common stock held in treasury, at cost ( 714,218,000 and 712,921,000 shares) 75,906 75,680 Total shareholders equity $ 78,109 71,490 Total liabilities and shareholders equity $ 193,671 180,104", "text": "March 30, 2025 December 29, 2024 Assets Current assets:", "length": 55, "numbers_raw": ["30", "202", "5", "29", "202", "4"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 173, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 Assets Current assets: Cash and cash equivalents (Note 4) $ 38,474 24,105 Marketable securities 307 417 Accounts receivable, trade, less allowances $ 170 (2024, $ 167 ) 16,020 14,842 Inventories (Note 2) 12,659 12,444 Prepaid expenses and other 4,091 4,085 Total current assets 71,551 55,893 Property, plant and equipment at cost 49,884 48,768 Less: accumulated depreciation ( 29,013 ) ( 28,250 ) Property, plant and equipment, net 20,871 20,518 Intangible assets, net (Note 3) 36,755 37,618 Goodwill (Note 3) 44,468 44,200 Deferred taxes on income (Note 5) 8,492 10,461 Other assets 11,534 11,414 Total assets $ 193,671 180,104 Liabilities and shareholders equity Current liabilities: Loans and notes payable $ 13,897 5,983 Accounts payable 9,545 10,311 Accrued liabilities 7,913 8,549 Accrued rebates, returns and promotions 18,780 17,580 Accrued compensation and employee related obligations 2,551 4,126 Accrued taxes on income (Note 5) 4,217 3,772 Total current liabilities 56,903 50,321 Long-term debt (Note 4) 38,355 30,651 Deferred taxes on income (Note 5) 2,428 2,448 Employee related obligations (Note 6) 7,046 7,255 Long-term taxes payable (Note 5) 395 390 Other liabilities 10,435 17,549 Total liabilities $ 115,562 108,614 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 11,740 ) ( 11,741 ) Retained earnings and Additional paid-in capital 162,635 155,791 Less: common stock held in treasury, at cost ( 714,218,000 and 712,921,000 shares) 75,906 75,680 Total shareholders equity $ 78,109 71,490 Total liabilities and shareholders equity $ 193,671 180,104", "text": "Cash and cash equivalents (Note 4) $ 38,474 24,105 Marketable securities 307 417 Accounts receivable, trade, less allowances $ 170 (2024, $ 167 ) 16,020 14,842 Inventories (Note 2) 12,659 12,444 Prepaid expenses and other 4,091 4,085 Total current assets 71,551 55,893 Property, plant and equipment at cost 49,884 48,768 Less:", "length": 326, "numbers_raw": ["4", "38,474", "24,105 M", "307", "417", "170", "202", "4", "167", "16,020", "14,842", "2", "12,659", "12,444", "4,091", "4,085", "71,551", "55,893", "49,884", "48,768"], "numbers": [4.0, 38474.0, 24105000000.0, 307.0, 417.0, 170.0, 202.0, 4.0, 167.0, 16020.0, 14842.0, 2.0, 12659.0, 12444.0, 4091.0, 4085.0, 71551.0, 55893.0, 49884.0, 48768.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 173, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 Assets Current assets: Cash and cash equivalents (Note 4) $ 38,474 24,105 Marketable securities 307 417 Accounts receivable, trade, less allowances $ 170 (2024, $ 167 ) 16,020 14,842 Inventories (Note 2) 12,659 12,444 Prepaid expenses and other 4,091 4,085 Total current assets 71,551 55,893 Property, plant and equipment at cost 49,884 48,768 Less: accumulated depreciation ( 29,013 ) ( 28,250 ) Property, plant and equipment, net 20,871 20,518 Intangible assets, net (Note 3) 36,755 37,618 Goodwill (Note 3) 44,468 44,200 Deferred taxes on income (Note 5) 8,492 10,461 Other assets 11,534 11,414 Total assets $ 193,671 180,104 Liabilities and shareholders equity Current liabilities: Loans and notes payable $ 13,897 5,983 Accounts payable 9,545 10,311 Accrued liabilities 7,913 8,549 Accrued rebates, returns and promotions 18,780 17,580 Accrued compensation and employee related obligations 2,551 4,126 Accrued taxes on income (Note 5) 4,217 3,772 Total current liabilities 56,903 50,321 Long-term debt (Note 4) 38,355 30,651 Deferred taxes on income (Note 5) 2,428 2,448 Employee related obligations (Note 6) 7,046 7,255 Long-term taxes payable (Note 5) 395 390 Other liabilities 10,435 17,549 Total liabilities $ 115,562 108,614 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 11,740 ) ( 11,741 ) Retained earnings and Additional paid-in capital 162,635 155,791 Less: common stock held in treasury, at cost ( 714,218,000 and 712,921,000 shares) 75,906 75,680 Total shareholders equity $ 78,109 71,490 Total liabilities and shareholders equity $ 193,671 180,104", "text": "accumulated depreciation ( 29,013 ) ( 28,250 ) Property, plant and equipment, net 20,871 20,518 Intangible assets, net (Note 3) 36,755 37,618 Goodwill (Note 3) 44,468 44,200 Deferred taxes on income (Note 5) 8,492 10,461 Other assets 11,534 11,414 Total assets $ 193,671 180,104 Liabilities and shareholders equity Current liabilities:", "length": 336, "numbers_raw": ["29,013", "28,250", "20,871", "20,518", "3", "36,755", "37,618", "3", "44,468", "44,200", "5", "8,492", "10,461", "11,534", "11,414", "193,671", "180,104"], "numbers": [29013.0, 28250.0, 20871.0, 20518.0, 3.0, 36755.0, 37618.0, 3.0, 44468.0, 44200.0, 5.0, 8492.0, 10461.0, 11534.0, 11414.0, 193671.0, 180104.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 173, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 Assets Current assets: Cash and cash equivalents (Note 4) $ 38,474 24,105 Marketable securities 307 417 Accounts receivable, trade, less allowances $ 170 (2024, $ 167 ) 16,020 14,842 Inventories (Note 2) 12,659 12,444 Prepaid expenses and other 4,091 4,085 Total current assets 71,551 55,893 Property, plant and equipment at cost 49,884 48,768 Less: accumulated depreciation ( 29,013 ) ( 28,250 ) Property, plant and equipment, net 20,871 20,518 Intangible assets, net (Note 3) 36,755 37,618 Goodwill (Note 3) 44,468 44,200 Deferred taxes on income (Note 5) 8,492 10,461 Other assets 11,534 11,414 Total assets $ 193,671 180,104 Liabilities and shareholders equity Current liabilities: Loans and notes payable $ 13,897 5,983 Accounts payable 9,545 10,311 Accrued liabilities 7,913 8,549 Accrued rebates, returns and promotions 18,780 17,580 Accrued compensation and employee related obligations 2,551 4,126 Accrued taxes on income (Note 5) 4,217 3,772 Total current liabilities 56,903 50,321 Long-term debt (Note 4) 38,355 30,651 Deferred taxes on income (Note 5) 2,428 2,448 Employee related obligations (Note 6) 7,046 7,255 Long-term taxes payable (Note 5) 395 390 Other liabilities 10,435 17,549 Total liabilities $ 115,562 108,614 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 11,740 ) ( 11,741 ) Retained earnings and Additional paid-in capital 162,635 155,791 Less: common stock held in treasury, at cost ( 714,218,000 and 712,921,000 shares) 75,906 75,680 Total shareholders equity $ 78,109 71,490 Total liabilities and shareholders equity $ 193,671 180,104", "text": "Loans and notes payable $ 13,897 5,983 Accounts payable 9,545 10,311 Accrued liabilities 7,913 8,549 Accrued rebates, returns and promotions 18,780 17,580 Accrued compensation and employee related obligations 2,551 4,126 Accrued taxes on income (Note 5) 4,217 3,772 Total current liabilities 56,903 50,321 Long-term debt (Note 4) 38,355 30,651 Deferred taxes on income (Note 5) 2,428 2,448 Employee related obligations (Note 6) 7,046 7,255 Long-term taxes payable (Note 5) 395 390 Other liabilities 10,435 17,549 Total liabilities $ 115,562 108,614 Commitments and Contingencies (Note 11) Shareholders equity:", "length": 610, "numbers_raw": ["13,897", "5,983", "9,545", "10,311", "7,913", "8,549", "18,780", "17,580", "2,551", "4,126", "5", "4,217", "3,772", "56,903", "50,321", "4", "38,355", "30,651", "5", "2,428", "2,448", "6", "7,046", "7,255", "5", "395", "390", "10,435", "17,549", "115,562", "108,614", "11"], "numbers": [13897.0, 5983.0, 9545.0, 10311.0, 7913.0, 8549.0, 18780.0, 17580.0, 2551.0, 4126.0, 5.0, 4217.0, 3772.0, 56903.0, 50321.0, 4.0, 38355.0, 30651.0, 5.0, 2428.0, 2448.0, 6.0, 7046.0, 7255.0, 5.0, 395.0, 390.0, 10435.0, 17549.0, 115562.0, 108614.0, 11.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 173, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 Assets Current assets: Cash and cash equivalents (Note 4) $ 38,474 24,105 Marketable securities 307 417 Accounts receivable, trade, less allowances $ 170 (2024, $ 167 ) 16,020 14,842 Inventories (Note 2) 12,659 12,444 Prepaid expenses and other 4,091 4,085 Total current assets 71,551 55,893 Property, plant and equipment at cost 49,884 48,768 Less: accumulated depreciation ( 29,013 ) ( 28,250 ) Property, plant and equipment, net 20,871 20,518 Intangible assets, net (Note 3) 36,755 37,618 Goodwill (Note 3) 44,468 44,200 Deferred taxes on income (Note 5) 8,492 10,461 Other assets 11,534 11,414 Total assets $ 193,671 180,104 Liabilities and shareholders equity Current liabilities: Loans and notes payable $ 13,897 5,983 Accounts payable 9,545 10,311 Accrued liabilities 7,913 8,549 Accrued rebates, returns and promotions 18,780 17,580 Accrued compensation and employee related obligations 2,551 4,126 Accrued taxes on income (Note 5) 4,217 3,772 Total current liabilities 56,903 50,321 Long-term debt (Note 4) 38,355 30,651 Deferred taxes on income (Note 5) 2,428 2,448 Employee related obligations (Note 6) 7,046 7,255 Long-term taxes payable (Note 5) 395 390 Other liabilities 10,435 17,549 Total liabilities $ 115,562 108,614 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 11,740 ) ( 11,741 ) Retained earnings and Additional paid-in capital 162,635 155,791 Less: common stock held in treasury, at cost ( 714,218,000 and 712,921,000 shares) 75,906 75,680 Total shareholders equity $ 78,109 71,490 Total liabilities and shareholders equity $ 193,671 180,104", "text": "Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares;", "length": 75, "numbers_raw": ["1.00", "4,320,000,000"], "numbers": [1.0, 4320000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 173, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 Assets Current assets: Cash and cash equivalents (Note 4) $ 38,474 24,105 Marketable securities 307 417 Accounts receivable, trade, less allowances $ 170 (2024, $ 167 ) 16,020 14,842 Inventories (Note 2) 12,659 12,444 Prepaid expenses and other 4,091 4,085 Total current assets 71,551 55,893 Property, plant and equipment at cost 49,884 48,768 Less: accumulated depreciation ( 29,013 ) ( 28,250 ) Property, plant and equipment, net 20,871 20,518 Intangible assets, net (Note 3) 36,755 37,618 Goodwill (Note 3) 44,468 44,200 Deferred taxes on income (Note 5) 8,492 10,461 Other assets 11,534 11,414 Total assets $ 193,671 180,104 Liabilities and shareholders equity Current liabilities: Loans and notes payable $ 13,897 5,983 Accounts payable 9,545 10,311 Accrued liabilities 7,913 8,549 Accrued rebates, returns and promotions 18,780 17,580 Accrued compensation and employee related obligations 2,551 4,126 Accrued taxes on income (Note 5) 4,217 3,772 Total current liabilities 56,903 50,321 Long-term debt (Note 4) 38,355 30,651 Deferred taxes on income (Note 5) 2,428 2,448 Employee related obligations (Note 6) 7,046 7,255 Long-term taxes payable (Note 5) 395 390 Other liabilities 10,435 17,549 Total liabilities $ 115,562 108,614 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 11,740 ) ( 11,741 ) Retained earnings and Additional paid-in capital 162,635 155,791 Less: common stock held in treasury, at cost ( 714,218,000 and 712,921,000 shares) 75,906 75,680 Total shareholders equity $ 78,109 71,490 Total liabilities and shareholders equity $ 193,671 180,104", "text": "issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 11,740 ) ( 11,741 ) Retained earnings and Additional paid-in capital 162,635 155,791 Less:", "length": 190, "numbers_raw": ["3,119,843,000", "3,120", "3,120", "7", "11,740", "11,741", "162,635", "155,791"], "numbers": [3119843000.0, 3120.0, 3120.0, 7.0, 11740.0, 11741.0, 162635.0, 155791.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 173, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 Assets Current assets: Cash and cash equivalents (Note 4) $ 38,474 24,105 Marketable securities 307 417 Accounts receivable, trade, less allowances $ 170 (2024, $ 167 ) 16,020 14,842 Inventories (Note 2) 12,659 12,444 Prepaid expenses and other 4,091 4,085 Total current assets 71,551 55,893 Property, plant and equipment at cost 49,884 48,768 Less: accumulated depreciation ( 29,013 ) ( 28,250 ) Property, plant and equipment, net 20,871 20,518 Intangible assets, net (Note 3) 36,755 37,618 Goodwill (Note 3) 44,468 44,200 Deferred taxes on income (Note 5) 8,492 10,461 Other assets 11,534 11,414 Total assets $ 193,671 180,104 Liabilities and shareholders equity Current liabilities: Loans and notes payable $ 13,897 5,983 Accounts payable 9,545 10,311 Accrued liabilities 7,913 8,549 Accrued rebates, returns and promotions 18,780 17,580 Accrued compensation and employee related obligations 2,551 4,126 Accrued taxes on income (Note 5) 4,217 3,772 Total current liabilities 56,903 50,321 Long-term debt (Note 4) 38,355 30,651 Deferred taxes on income (Note 5) 2,428 2,448 Employee related obligations (Note 6) 7,046 7,255 Long-term taxes payable (Note 5) 395 390 Other liabilities 10,435 17,549 Total liabilities $ 115,562 108,614 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 11,740 ) ( 11,741 ) Retained earnings and Additional paid-in capital 162,635 155,791 Less: common stock held in treasury, at cost ( 714,218,000 and 712,921,000 shares) 75,906 75,680 Total shareholders equity $ 78,109 71,490 Total liabilities and shareholders equity $ 193,671 180,104", "text": "common stock held in treasury, at cost ( 714,218,000 and 712,921,000 shares) 75,906 75,680 Total shareholders equity $ 78,109 71,490 Total liabilities and shareholders equity $ 193,671 180,104", "length": 194, "numbers_raw": ["714,218,000", "712,921,000", "75,906", "75,680", "78,109", "71,490", "193,671", "180,104"], "numbers": [714218000.0, 712921000.0, 75906.0, 75680.0, 78109.0, 71490.0, 193671.0, 180104.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 175, "tag": "div", "text_raw": "Accounts receivable, trade, less allowances $ 170 (2024, $ 167 )", "text": "Accounts receivable, trade, less allowances $ 170 (2024, $ 167 )", "length": 64, "numbers_raw": ["170", "202", "4", "167"], "numbers": [170.0, 202.0, 4.0, 167.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 176, "tag": "div", "text_raw": "Liabilities and shareholders equity", "text": "Liabilities and shareholders equity", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 177, "tag": "div", "text_raw": "Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)", "text": "Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares;", "length": 75, "numbers_raw": ["1.00", "4,320,000,000"], "numbers": [1.0, 4320000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 177, "tag": "div", "text_raw": "Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)", "text": "issued 3,119,843,000 shares)", "length": 28, "numbers_raw": ["3,119,843,000"], "numbers": [3119843000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 178, "tag": "div", "text_raw": "Less: common stock held in treasury, at cost ( 714,218,000 and 712,921,000 shares)", "text": "common stock held in treasury, at cost ( 714,218,000 and 712,921,000 shares)", "length": 76, "numbers_raw": ["714,218,000", "712,921,000"], "numbers": [714218000.0, 712921000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 179, "tag": "div", "text_raw": "See Notes to Consolidated Financial Statements", "text": "See Notes to Consolidated Financial Statements", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 180, "tag": "div", "text_raw": "Form 10-Q 1", "text": "Form 10-Q 1", "length": 11, "numbers_raw": ["10", "1"], "numbers": [10.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 181, "tag": "div", "text_raw": "Form 10-Q 1", "text": "Form 10-Q 1", "length": 11, "numbers_raw": ["10", "1"], "numbers": [10.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 182, "tag": "div", "text_raw": "Form 10-Q 1", "text": "Form 10-Q 1", "length": 11, "numbers_raw": ["10", "1"], "numbers": [10.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 183, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 184, "tag": "div", "text_raw": "1", "text": "1", "length": 1, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 188, "tag": "div", "text_raw": "Johnson & Johnson and subsidiaries consolidated statements of earnings", "text": "Johnson & Johnson and subsidiaries consolidated statements of earnings", "length": 70, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 189, "tag": "div", "text_raw": "(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)", "text": "Dollars & Shares in Millions Except Per Share Amounts)", "length": 54, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 190, "tag": "div", "text_raw": "Fiscal First Quarter Ended March 30, 2025 Percent to Sales March 31, 2024 Percent to Sales Sales to customers (Note 9) $ 21,893 100.0 % $ 21,383 100.0 % Cost of products sold 7,357 33.6 6,511 30.4 Gross profit 14,536 66.4 14,872 69.6 Selling, marketing and administrative expenses 5,112 23.3 5,257 24.6 Research and development expense 3,225 14.7 3,542 16.6 Interest income ( 332 ) ( 1.5 ) ( 364 ) ( 1.7 ) Interest expense, net of portion capitalized 204 0.9 155 0.7 Other (income) expense, net ( 7,321 ) ( 33.4 ) 2,404 11.2 Restructuring (Note 12) 17 0.1 164 0.8 Earnings before provision for taxes on income 13,631 62.3 3,714 17.4 Provision for taxes on income (Note 5) 2,632 12.1 459 2.2 Net earnings $ 10,999 50.2 % $ 3,255 15.2 % Net earnings per share (Note 8) Basic $ 4.57 $ 1.35 Diluted $ 4.54 $ 1.34 Avg. shares outstanding Basic 2,407.2 2,408.2 Diluted 2,423.8 2,430.1", "text": "Fiscal First Quarter Ended March 30, 2025 Percent to Sales March 31, 2024 Percent to Sales Sales to customers (Note 9) $ 21,893 100.0 % $ 21,383 100.0 % Cost of products sold 7,357 33.6 6,511 30.4 Gross profit 14,536 66.4 14,872 69.6 Selling, marketing and administrative expenses 5,112 23.3 5,257 24.6 Research and development expense 3,225 14.7 3,542 16.6 Interest income ( 332 ) ( 1.5 ) ( 364 ) ( 1.7 ) Interest expense, net of portion capitalized 204 0.9 155 0.7 Other (income) expense, net ( 7,321 ) ( 33.4 ) 2,404 11.2 Restructuring (Note 12) 17 0.1 164 0.8 Earnings before provision for taxes on income 13,631 62.3 3,714 17.4 Provision for taxes on income (Note 5) 2,632 12.1 459 2.2 Net earnings $ 10,999 50.2 % $ 3,255 15.2 % Net earnings per share (Note 8) Basic $ 4.57 $ 1.35 Diluted $ 4.54 $ 1.34 Avg.", "length": 813, "numbers_raw": ["30", "202", "5", "31", "202", "4", "9", "21,893", "100.0", "21,383", "100.0", "7,357", "33.6", "6,511", "30.4", "14,536", "66.4", "14,872", "69.6", "5,112", "23.3", "5,257", "24.6", "3,225", "14.7", "3,542", "16.6", "332", "1.5", "364", "1.7", "204", "0.9", "155", "0.7", "7,321", "33.4", "2,404", "11.2", "12", "17", "0.1", "164", "0.8", "13,631", "62.3", "3,714", "17.4", "5", "2,632", "12.1", "459", "2.2", "10,999", "50.2", "3,255", "15.2", "8", "4.57", "1.35", "4.54", "1.34"], "numbers": [30.0, 202.0, 5.0, 31.0, 202.0, 4.0, 9.0, 21893.0, 100.0, 21383.0, 100.0, 7357.0, 33.6, 6511.0, 30.4, 14536.0, 66.4, 14872.0, 69.6, 5112.0, 23.3, 5257.0, 24.6, 3225.0, 14.7, 3542.0, 16.6, 332.0, 1.5, 364.0, 1.7, 204.0, 0.9, 155.0, 0.7, 7321.0, 33.4, 2404.0, 11.2, 12.0, 17.0, 0.1, 164.0, 0.8, 13631.0, 62.3, 3714.0, 17.4, 5.0, 2632.0, 12.1, 459.0, 2.2, 10999.0, 50.2, 3255.0, 15.2, 8.0, 4.57, 1.35, 4.54, 1.34], "percents_raw": ["100.0 %", "100.0 %", "50.2 %", "15.2 %"], "percents": [1.0, 1.0, 0.502, 0.152], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 190, "tag": "div", "text_raw": "Fiscal First Quarter Ended March 30, 2025 Percent to Sales March 31, 2024 Percent to Sales Sales to customers (Note 9) $ 21,893 100.0 % $ 21,383 100.0 % Cost of products sold 7,357 33.6 6,511 30.4 Gross profit 14,536 66.4 14,872 69.6 Selling, marketing and administrative expenses 5,112 23.3 5,257 24.6 Research and development expense 3,225 14.7 3,542 16.6 Interest income ( 332 ) ( 1.5 ) ( 364 ) ( 1.7 ) Interest expense, net of portion capitalized 204 0.9 155 0.7 Other (income) expense, net ( 7,321 ) ( 33.4 ) 2,404 11.2 Restructuring (Note 12) 17 0.1 164 0.8 Earnings before provision for taxes on income 13,631 62.3 3,714 17.4 Provision for taxes on income (Note 5) 2,632 12.1 459 2.2 Net earnings $ 10,999 50.2 % $ 3,255 15.2 % Net earnings per share (Note 8) Basic $ 4.57 $ 1.35 Diluted $ 4.54 $ 1.34 Avg. shares outstanding Basic 2,407.2 2,408.2 Diluted 2,423.8 2,430.1", "text": "shares outstanding Basic 2,407.2 2,408.2 Diluted 2,423.8 2,430.1", "length": 64, "numbers_raw": ["2,407.2", "2,408.2", "2,423.8", "2,430.1"], "numbers": [2407.2, 2408.2, 2423.8, 2430.1], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 192, "tag": "div", "text_raw": "See Notes to Consolidated Financial Statements", "text": "See Notes to Consolidated Financial Statements", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 194, "tag": "div", "text_raw": "2", "text": "2", "length": 1, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 195, "tag": "div", "text_raw": "2", "text": "2", "length": 1, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 196, "tag": "div", "text_raw": "2", "text": "2", "length": 1, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 197, "tag": "div", "text_raw": "2", "text": "2", "length": 1, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 202, "tag": "div", "text_raw": "Johnson & Johnson and subsidiaries consolidated statements of comprehensive income", "text": "Johnson & Johnson and subsidiaries consolidated statements of comprehensive income", "length": 82, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 204, "tag": "div", "text_raw": "Fiscal First Quarter Ended March 30, 2025 March 31, 2024 Net earnings $ 10,999 3,255 Other comprehensive income (loss), net of tax Foreign currency translation ( 575 ) 2,123 Securities: Unrealized holding gain (loss) arising during period  2 Net change  2 Employee benefit plans: Prior service cost amortization during period ( 35 ) ( 16 ) Gain (loss) amortization during period 77 68 Net change 42 52 Derivatives & hedges: Unrealized gain (loss) arising during period ( 142 ) ( 167 ) Reclassifications to earnings 676 ( 251 ) Net change 534 ( 418 ) Other comprehensive income (loss) 1 1,759 Comprehensive income $ 11,000 5,014", "text": "Fiscal First Quarter Ended March 30, 2025 March 31, 2024 Net earnings $ 10,999 3,255 Other comprehensive income (loss), net of tax Foreign currency translation ( 575 ) 2,123 Securities:", "length": 185, "numbers_raw": ["30", "202", "5 M", "31", "202", "4", "10,999", "3,255", "575", "2,123"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 10999.0, 3255.0, 575.0, 2123.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 204, "tag": "div", "text_raw": "Fiscal First Quarter Ended March 30, 2025 March 31, 2024 Net earnings $ 10,999 3,255 Other comprehensive income (loss), net of tax Foreign currency translation ( 575 ) 2,123 Securities: Unrealized holding gain (loss) arising during period  2 Net change  2 Employee benefit plans: Prior service cost amortization during period ( 35 ) ( 16 ) Gain (loss) amortization during period 77 68 Net change 42 52 Derivatives & hedges: Unrealized gain (loss) arising during period ( 142 ) ( 167 ) Reclassifications to earnings 676 ( 251 ) Net change 534 ( 418 ) Other comprehensive income (loss) 1 1,759 Comprehensive income $ 11,000 5,014", "text": "Unrealized holding gain (loss) arising during period  2 Net change  2 Employee benefit plans:", "length": 95, "numbers_raw": ["2", "2"], "numbers": [2.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 204, "tag": "div", "text_raw": "Fiscal First Quarter Ended March 30, 2025 March 31, 2024 Net earnings $ 10,999 3,255 Other comprehensive income (loss), net of tax Foreign currency translation ( 575 ) 2,123 Securities: Unrealized holding gain (loss) arising during period  2 Net change  2 Employee benefit plans: Prior service cost amortization during period ( 35 ) ( 16 ) Gain (loss) amortization during period 77 68 Net change 42 52 Derivatives & hedges: Unrealized gain (loss) arising during period ( 142 ) ( 167 ) Reclassifications to earnings 676 ( 251 ) Net change 534 ( 418 ) Other comprehensive income (loss) 1 1,759 Comprehensive income $ 11,000 5,014", "text": "Prior service cost amortization during period ( 35 ) ( 16 ) Gain (loss) amortization during period 77 68 Net change 42 52 Derivatives & hedges:", "length": 143, "numbers_raw": ["35", "16", "77", "68", "42", "52"], "numbers": [35.0, 16.0, 77.0, 68.0, 42.0, 52.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 204, "tag": "div", "text_raw": "Fiscal First Quarter Ended March 30, 2025 March 31, 2024 Net earnings $ 10,999 3,255 Other comprehensive income (loss), net of tax Foreign currency translation ( 575 ) 2,123 Securities: Unrealized holding gain (loss) arising during period  2 Net change  2 Employee benefit plans: Prior service cost amortization during period ( 35 ) ( 16 ) Gain (loss) amortization during period 77 68 Net change 42 52 Derivatives & hedges: Unrealized gain (loss) arising during period ( 142 ) ( 167 ) Reclassifications to earnings 676 ( 251 ) Net change 534 ( 418 ) Other comprehensive income (loss) 1 1,759 Comprehensive income $ 11,000 5,014", "text": "Unrealized gain (loss) arising during period ( 142 ) ( 167 ) Reclassifications to earnings 676 ( 251 ) Net change 534 ( 418 ) Other comprehensive income (loss) 1 1,759 Comprehensive income $ 11,000 5,014", "length": 203, "numbers_raw": ["142", "167", "676", "251", "534", "418", "1", "1,759", "11,000", "5,014"], "numbers": [142.0, 167.0, 676.0, 251.0, 534.0, 418.0, 1.0, 1759.0, 11000.0, 5014.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 205, "tag": "div", "text_raw": "See Notes to Consolidated Financial Statements", "text": "See Notes to Consolidated Financial Statements", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 206, "tag": "div", "text_raw": "The tax cost/(benefit) effects in other comprehensive income for the fiscal first quarter were as follows for 2025 and 2024, respectively: Foreign Currency Translation: $ 400 million and $( 619 ) million; Employee Benefit Plans: $ 11 million and $( 42 ) million; Derivatives & Hedges: $ 142 million and $( 111 ) million.", "text": "The tax cost/(benefit) effects in other comprehensive income for the fiscal first quarter were as follows for 2025 and 2024, respectively:", "length": 138, "numbers_raw": ["202", "5", "202", "4"], "numbers": [202.0, 5.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 206, "tag": "div", "text_raw": "The tax cost/(benefit) effects in other comprehensive income for the fiscal first quarter were as follows for 2025 and 2024, respectively: Foreign Currency Translation: $ 400 million and $( 619 ) million; Employee Benefit Plans: $ 11 million and $( 42 ) million; Derivatives & Hedges: $ 142 million and $( 111 ) million.", "text": "$ 400 million and $( 619 ) million;", "length": 35, "numbers_raw": ["400 million", "619"], "numbers": [400000000.0, 619.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 206, "tag": "div", "text_raw": "The tax cost/(benefit) effects in other comprehensive income for the fiscal first quarter were as follows for 2025 and 2024, respectively: Foreign Currency Translation: $ 400 million and $( 619 ) million; Employee Benefit Plans: $ 11 million and $( 42 ) million; Derivatives & Hedges: $ 142 million and $( 111 ) million.", "text": "$ 11 million and $( 42 ) million;", "length": 33, "numbers_raw": ["11 million", "42"], "numbers": [11000000.0, 42.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 206, "tag": "div", "text_raw": "The tax cost/(benefit) effects in other comprehensive income for the fiscal first quarter were as follows for 2025 and 2024, respectively: Foreign Currency Translation: $ 400 million and $( 619 ) million; Employee Benefit Plans: $ 11 million and $( 42 ) million; Derivatives & Hedges: $ 142 million and $( 111 ) million.", "text": "$ 142 million and $( 111 ) million.", "length": 35, "numbers_raw": ["142 million", "111"], "numbers": [142000000.0, 111.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 207, "tag": "div", "text_raw": "The tax cost/(benefit) effects in other comprehensive income for the fiscal first quarter were as follows for 2025 and 2024, respectively: Foreign Currency Translation: $ 400 million and $( 619 ) million; Employee Benefit Plans: $ 11 million and $( 42 ) million; Derivatives & Hedges: $ 142 million and $( 111 ) million.", "text": "The tax cost/(benefit) effects in other comprehensive income for the fiscal first quarter were as follows for 2025 and 2024, respectively:", "length": 138, "numbers_raw": ["202", "5", "202", "4"], "numbers": [202.0, 5.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 207, "tag": "div", "text_raw": "The tax cost/(benefit) effects in other comprehensive income for the fiscal first quarter were as follows for 2025 and 2024, respectively: Foreign Currency Translation: $ 400 million and $( 619 ) million; Employee Benefit Plans: $ 11 million and $( 42 ) million; Derivatives & Hedges: $ 142 million and $( 111 ) million.", "text": "$ 400 million and $( 619 ) million;", "length": 35, "numbers_raw": ["400 million", "619"], "numbers": [400000000.0, 619.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 207, "tag": "div", "text_raw": "The tax cost/(benefit) effects in other comprehensive income for the fiscal first quarter were as follows for 2025 and 2024, respectively: Foreign Currency Translation: $ 400 million and $( 619 ) million; Employee Benefit Plans: $ 11 million and $( 42 ) million; Derivatives & Hedges: $ 142 million and $( 111 ) million.", "text": "$ 11 million and $( 42 ) million;", "length": 33, "numbers_raw": ["11 million", "42"], "numbers": [11000000.0, 42.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 207, "tag": "div", "text_raw": "The tax cost/(benefit) effects in other comprehensive income for the fiscal first quarter were as follows for 2025 and 2024, respectively: Foreign Currency Translation: $ 400 million and $( 619 ) million; Employee Benefit Plans: $ 11 million and $( 42 ) million; Derivatives & Hedges: $ 142 million and $( 111 ) million.", "text": "$ 142 million and $( 111 ) million.", "length": 35, "numbers_raw": ["142 million", "111"], "numbers": [142000000.0, 111.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 208, "tag": "div", "text_raw": "Form 10-Q 3", "text": "Form 10-Q 3", "length": 11, "numbers_raw": ["10", "3"], "numbers": [10.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 209, "tag": "div", "text_raw": "Form 10-Q 3", "text": "Form 10-Q 3", "length": 11, "numbers_raw": ["10", "3"], "numbers": [10.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 210, "tag": "div", "text_raw": "Form 10-Q 3", "text": "Form 10-Q 3", "length": 11, "numbers_raw": ["10", "3"], "numbers": [10.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 211, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 212, "tag": "div", "text_raw": "3", "text": "3", "length": 1, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 216, "tag": "div", "text_raw": "Johnson & Johnson and subsidiaries consolidated statements of equity", "text": "Johnson & Johnson and subsidiaries consolidated statements of equity", "length": 68, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 218, "tag": "div", "text_raw": "Fiscal First Quarter Ended March 30, 2025", "text": "Fiscal First Quarter Ended March 30, 2025", "length": 41, "numbers_raw": ["30", "202", "5"], "numbers": [30.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 221, "tag": "div", "text_raw": "Total Retained Earnings and Additional Paid-in Capital Accumulated Other Comprehensive Income (AOCI) Common Stock Issued Amount Treasury Stock Amount Balance, December 29, 2024 $ 71,490 155,791 ( 11,741 ) 3,120 ( 75,680 ) Net earnings 10,999 10,999    Cash dividends paid ($ 1.24 per share) ( 2,989 ) ( 2,989 )    Employee compensation and stock option plans 737 ( 1,166 )   1,903 Repurchase of common stock ( 2,129 )   ( 2,129 ) Other comprehensive income (loss), net of tax 1  1   Balance, March 30, 2025 $ 78,109 162,635 ( 11,740 ) 3,120 ( 75,906 )", "text": "Total Retained Earnings and Additional Paid-in Capital Accumulated Other Comprehensive Income (AOCI) Common Stock Issued Amount Treasury Stock Amount Balance, December 29, 2024 $ 71,490 155,791 ( 11,741 ) 3,120 ( 75,680 ) Net earnings 10,999 10,999    Cash dividends paid ($ 1.24 per share) ( 2,989 ) ( 2,989 )    Employee compensation and stock option plans 737 ( 1,166 )   1,903 Repurchase of common stock ( 2,129 )   ( 2,129 ) Other comprehensive income (loss), net of tax 1  1   Balance, March 30, 2025 $ 78,109 162,635 ( 11,740 ) 3,120 ( 75,906 )", "length": 564, "numbers_raw": ["29", "202", "4", "71,490", "155,791", "11,741", "3,120", "75,680", "10,999", "10,999", "1.24", "2,989", "2,989", "737", "1,166", "1,903", "2,129", "2,129", "1", "1", "30", "202", "5", "78,109", "162,635", "11,740", "3,120", "75,906"], "numbers": [29.0, 202.0, 4.0, 71490.0, 155791.0, 11741.0, 3120.0, 75680.0, 10999.0, 10999.0, 1.24, 2989.0, 2989.0, 737.0, 1166.0, 1903.0, 2129.0, 2129.0, 1.0, 1.0, 30.0, 202.0, 5.0, 78109.0, 162635.0, 11740.0, 3120.0, 75906.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 223, "tag": "div", "text_raw": "Earnings and Additional Paid-in Capital", "text": "Earnings and Additional Paid-in Capital", "length": 39, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 224, "tag": "div", "text_raw": "Cash dividends paid ($ 1.24 per share)", "text": "Cash dividends paid ($ 1.24 per share)", "length": 38, "numbers_raw": ["1.24"], "numbers": [1.24], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 231, "tag": "div", "text_raw": "Fiscal First Quarter Ended March 31, 2024 Total Retained Earnings and Additional Paid-in Capital Accumulated Other Comprehensive Income Common Stock Issued Amount Treasury Stock Amount Balance, December 31, 2023 $ 68,774 153,843 ( 12,527 ) 3,120 ( 75,662 ) Net earnings 3,255 3,255    Cash dividends paid ($ 1.19 per share) ( 2,869 ) ( 2,869 )    Employee compensation and stock option plans 577 ( 851 )   1,428 Repurchase of common stock ( 1,475 )    ( 1,475 ) Other ( 1 )    ( 1 ) Other comprehensive income (loss), net of tax 1,759  1,759   Balance, March 31, 2024 $ 70,020 153,378 ( 10,768 ) 3,120 ( 75,710 )", "text": "Fiscal First Quarter Ended March 31, 2024 Total Retained Earnings and Additional Paid-in Capital Accumulated Other Comprehensive Income Common Stock Issued Amount Treasury Stock Amount Balance, December 31, 2023 $ 68,774 153,843 ( 12,527 ) 3,120 ( 75,662 ) Net earnings 3,255 3,255    Cash dividends paid ($ 1.19 per share) ( 2,869 ) ( 2,869 )    Employee compensation and stock option plans 577 ( 851 )   1,428 Repurchase of common stock ( 1,475 )    ( 1,475 ) Other ( 1 )    ( 1 ) Other comprehensive income (loss), net of tax 1,759  1,759   Balance, March 31, 2024 $ 70,020 153,378 ( 10,768 ) 3,120 ( 75,710 )", "length": 629, "numbers_raw": ["31", "202", "4", "31", "202", "3", "68,774", "153,843", "12,527", "3,120", "75,662", "3,255", "3,255", "1.19", "2,869", "2,869", "577", "851", "1,428", "1,475", "1,475", "1", "1", "1,759", "1,759", "31", "202", "4", "70,020", "153,378", "10,768", "3,120", "75,710"], "numbers": [31.0, 202.0, 4.0, 31.0, 202.0, 3.0, 68774.0, 153843.0, 12527.0, 3120.0, 75662.0, 3255.0, 3255.0, 1.19, 2869.0, 2869.0, 577.0, 851.0, 1428.0, 1475.0, 1475.0, 1.0, 1.0, 1759.0, 1759.0, 31.0, 202.0, 4.0, 70020.0, 153378.0, 10768.0, 3120.0, 75710.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 233, "tag": "div", "text_raw": "Earnings and Additional Paid-in Capital", "text": "Earnings and Additional Paid-in Capital", "length": 39, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 234, "tag": "div", "text_raw": "Cash dividends paid ($ 1.19 per share)", "text": "Cash dividends paid ($ 1.19 per share)", "length": 38, "numbers_raw": ["1.19"], "numbers": [1.19], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 235, "tag": "div", "text_raw": "See Notes to Consolidated Financial Statements", "text": "See Notes to Consolidated Financial Statements", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 236, "tag": "div", "text_raw": "4", "text": "4", "length": 1, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 237, "tag": "div", "text_raw": "4", "text": "4", "length": 1, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 238, "tag": "div", "text_raw": "4", "text": "4", "length": 1, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 239, "tag": "div", "text_raw": "4", "text": "4", "length": 1, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 244, "tag": "div", "text_raw": "Johnson & Johnson and subsidiaries consolidated statements of cash flows", "text": "Johnson & Johnson and subsidiaries consolidated statements of cash flows", "length": 72, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 246, "tag": "div", "text_raw": "Fiscal Three Months Ended March 30, 2025 March 31, 2024 Cash flows from operating activities Net earnings $ 10,999 3,255 Adjustments to reconcile net earnings to cash flows from operating activities: Depreciation and amortization of property and intangibles 1,772 1,815 Stock based compensation 288 302 Asset write-downs 30 185 Charges for purchase of in-process research and development assets 16  Net gain on sale of assets/businesses ( 75 )  Deferred tax provision 2,172 ( 1,562 ) Credit losses and accounts receivable allowances ( 4 )  Changes in assets and liabilities, net of effects from acquisitions and divestitures: Increase in accounts receivable ( 926 ) ( 279 ) Increase in inventories ( 146 ) ( 348 ) Decrease in accounts payable and accrued liabilities ( 2,126 ) ( 2,483 ) (Increase)/Decrease in other current and non-current assets ( 1,317 ) 3,199 Decrease in other current and non-current liabilities ( 6,509 ) ( 427 ) Net cash flows from operating activities 4,174 3,657 Cash flows from investing activities Additions to property, plant and equipment ( 795 ) ( 807 ) Proceeds from the disposal of assets/businesses, net (Note 10) 279 210 Acquisitions, net of cash acquired (Note 10)  ( 1,811 ) Acquired in-process research and development assets (Note 10) ( 14 )  Purchases of investments ( 251 ) ( 630 ) Sales of investments 218 979 Credit support agreements activity, net 296 1,600 Other (including capitalized licenses and milestones) ( 30 ) ( 5 ) Net cash used by investing activities ( 297 ) ( 464 ) Cash flows from financing activities Dividends to shareholders ( 2,989 ) ( 2,869 ) Repurchase of common stock ( 2,127 ) ( 1,475 ) Proceeds from short-term debt, net 8,784 5,263 Repayment of short-term debt, net ( 2,120 ) ( 890 ) Proceeds from long-term debt, net of issuance costs 9,138 2 Repayment of long-term debt ( 751 ) ( 1 ) Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 450 195 Credit support agreements activity, net ( 3 ) 228 Other 40 93 Net cash from financing activities 10,422 546", "text": "Fiscal Three Months Ended March 30, 2025 March 31, 2024 Cash flows from operating activities Net earnings $ 10,999 3,255 Adjustments to reconcile net earnings to cash flows from operating activities:", "length": 199, "numbers_raw": ["30", "202", "5 M", "31", "202", "4", "10,999", "3,255"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 10999.0, 3255.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 246, "tag": "div", "text_raw": "Fiscal Three Months Ended March 30, 2025 March 31, 2024 Cash flows from operating activities Net earnings $ 10,999 3,255 Adjustments to reconcile net earnings to cash flows from operating activities: Depreciation and amortization of property and intangibles 1,772 1,815 Stock based compensation 288 302 Asset write-downs 30 185 Charges for purchase of in-process research and development assets 16  Net gain on sale of assets/businesses ( 75 )  Deferred tax provision 2,172 ( 1,562 ) Credit losses and accounts receivable allowances ( 4 )  Changes in assets and liabilities, net of effects from acquisitions and divestitures: Increase in accounts receivable ( 926 ) ( 279 ) Increase in inventories ( 146 ) ( 348 ) Decrease in accounts payable and accrued liabilities ( 2,126 ) ( 2,483 ) (Increase)/Decrease in other current and non-current assets ( 1,317 ) 3,199 Decrease in other current and non-current liabilities ( 6,509 ) ( 427 ) Net cash flows from operating activities 4,174 3,657 Cash flows from investing activities Additions to property, plant and equipment ( 795 ) ( 807 ) Proceeds from the disposal of assets/businesses, net (Note 10) 279 210 Acquisitions, net of cash acquired (Note 10)  ( 1,811 ) Acquired in-process research and development assets (Note 10) ( 14 )  Purchases of investments ( 251 ) ( 630 ) Sales of investments 218 979 Credit support agreements activity, net 296 1,600 Other (including capitalized licenses and milestones) ( 30 ) ( 5 ) Net cash used by investing activities ( 297 ) ( 464 ) Cash flows from financing activities Dividends to shareholders ( 2,989 ) ( 2,869 ) Repurchase of common stock ( 2,127 ) ( 1,475 ) Proceeds from short-term debt, net 8,784 5,263 Repayment of short-term debt, net ( 2,120 ) ( 890 ) Proceeds from long-term debt, net of issuance costs 9,138 2 Repayment of long-term debt ( 751 ) ( 1 ) Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 450 195 Credit support agreements activity, net ( 3 ) 228 Other 40 93 Net cash from financing activities 10,422 546", "text": "Depreciation and amortization of property and intangibles 1,772 1,815 Stock based compensation 288 302 Asset write-downs 30 185 Charges for purchase of in-process research and development assets 16  Net gain on sale of assets/businesses ( 75 )  Deferred tax provision 2,172 ( 1,562 ) Credit losses and accounts receivable allowances ( 4 )  Changes in assets and liabilities, net of effects from acquisitions and divestitures:", "length": 428, "numbers_raw": ["1,772", "1,815", "288", "302", "30", "185", "16", "75", "2,172", "1,562", "4"], "numbers": [1772.0, 1815.0, 288.0, 302.0, 30.0, 185.0, 16.0, 75.0, 2172.0, 1562.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 246, "tag": "div", "text_raw": "Fiscal Three Months Ended March 30, 2025 March 31, 2024 Cash flows from operating activities Net earnings $ 10,999 3,255 Adjustments to reconcile net earnings to cash flows from operating activities: Depreciation and amortization of property and intangibles 1,772 1,815 Stock based compensation 288 302 Asset write-downs 30 185 Charges for purchase of in-process research and development assets 16  Net gain on sale of assets/businesses ( 75 )  Deferred tax provision 2,172 ( 1,562 ) Credit losses and accounts receivable allowances ( 4 )  Changes in assets and liabilities, net of effects from acquisitions and divestitures: Increase in accounts receivable ( 926 ) ( 279 ) Increase in inventories ( 146 ) ( 348 ) Decrease in accounts payable and accrued liabilities ( 2,126 ) ( 2,483 ) (Increase)/Decrease in other current and non-current assets ( 1,317 ) 3,199 Decrease in other current and non-current liabilities ( 6,509 ) ( 427 ) Net cash flows from operating activities 4,174 3,657 Cash flows from investing activities Additions to property, plant and equipment ( 795 ) ( 807 ) Proceeds from the disposal of assets/businesses, net (Note 10) 279 210 Acquisitions, net of cash acquired (Note 10)  ( 1,811 ) Acquired in-process research and development assets (Note 10) ( 14 )  Purchases of investments ( 251 ) ( 630 ) Sales of investments 218 979 Credit support agreements activity, net 296 1,600 Other (including capitalized licenses and milestones) ( 30 ) ( 5 ) Net cash used by investing activities ( 297 ) ( 464 ) Cash flows from financing activities Dividends to shareholders ( 2,989 ) ( 2,869 ) Repurchase of common stock ( 2,127 ) ( 1,475 ) Proceeds from short-term debt, net 8,784 5,263 Repayment of short-term debt, net ( 2,120 ) ( 890 ) Proceeds from long-term debt, net of issuance costs 9,138 2 Repayment of long-term debt ( 751 ) ( 1 ) Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 450 195 Credit support agreements activity, net ( 3 ) 228 Other 40 93 Net cash from financing activities 10,422 546", "text": "Increase in accounts receivable ( 926 ) ( 279 ) Increase in inventories ( 146 ) ( 348 ) Decrease in accounts payable and accrued liabilities ( 2,126 ) ( 2,483 ) (Increase)/Decrease in other current and non-current assets ( 1,317 ) 3,199 Decrease in other current and non-current liabilities ( 6,509 ) ( 427 ) Net cash flows from operating activities 4,174 3,657 Cash flows from investing activities Additions to property, plant and equipment ( 795 ) ( 807 ) Proceeds from the disposal of assets/businesses, net (Note 10) 279 210 Acquisitions, net of cash acquired (Note 10)  ( 1,811 ) Acquired in-process research and development assets (Note 10) ( 14 )  Purchases of investments ( 251 ) ( 630 ) Sales of investments 218 979 Credit support agreements activity, net 296 1,600 Other (including capitalized licenses and milestones) ( 30 ) ( 5 ) Net cash used by investing activities ( 297 ) ( 464 ) Cash flows from financing activities Dividends to shareholders ( 2,989 ) ( 2,869 ) Repurchase of common stock ( 2,127 ) ( 1,475 ) Proceeds from short-term debt, net 8,784 5,263 Repayment of short-term debt, net ( 2,120 ) ( 890 ) Proceeds from long-term debt, net of issuance costs 9,138 2 Repayment of long-term debt ( 751 ) ( 1 ) Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 450 195 Credit support agreements activity, net ( 3 ) 228 Other 40 93 Net cash from financing activities 10,422 546", "length": 1434, "numbers_raw": ["926", "279", "146", "348", "2,126", "2,483", "1,317", "3,199", "6,509", "427", "4,174", "3,657", "795", "807", "10", "279", "210", "10", "1,811", "10", "14", "251", "630", "218", "979", "296", "1,600", "30", "5", "297", "464", "2,989", "2,869", "2,127", "1,475", "8,784", "5,263", "2,120", "890", "9,138", "2", "751", "1", "450", "195", "3", "228", "40", "93", "10,422", "546"], "numbers": [926.0, 279.0, 146.0, 348.0, 2126.0, 2483.0, 1317.0, 3199.0, 6509.0, 427.0, 4174.0, 3657.0, 795.0, 807.0, 10.0, 279.0, 210.0, 10.0, 1811.0, 10.0, 14.0, 251.0, 630.0, 218.0, 979.0, 296.0, 1600.0, 30.0, 5.0, 297.0, 464.0, 2989.0, 2869.0, 2127.0, 1475.0, 8784.0, 5263.0, 2120.0, 890.0, 9138.0, 2.0, 751.0, 1.0, 450.0, 195.0, 3.0, 228.0, 40.0, 93.0, 10422.0, 546.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 247, "tag": "div", "text_raw": "Cash flows from operating activities", "text": "Cash flows from operating activities", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 248, "tag": "div", "text_raw": "Net cash flows from operating activities", "text": "Net cash flows from operating activities", "length": 40, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 249, "tag": "div", "text_raw": "Cash flows from investing activities", "text": "Cash flows from investing activities", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 250, "tag": "div", "text_raw": "Cash flows from financing activities", "text": "Cash flows from financing activities", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 251, "tag": "div", "text_raw": "Form 10-Q 5", "text": "Form 10-Q 5", "length": 11, "numbers_raw": ["10", "5"], "numbers": [10.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 252, "tag": "div", "text_raw": "Form 10-Q 5", "text": "Form 10-Q 5", "length": 11, "numbers_raw": ["10", "5"], "numbers": [10.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 253, "tag": "div", "text_raw": "Form 10-Q 5", "text": "Form 10-Q 5", "length": 11, "numbers_raw": ["10", "5"], "numbers": [10.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 254, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 255, "tag": "div", "text_raw": "5", "text": "5", "length": 1, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 258, "tag": "div", "text_raw": "Fiscal Three Months Ended March 30, 2025 March 31, 2024 Effect of exchange rate changes on cash and cash equivalents 70 ( 125 ) Increase in cash and cash equivalents 14,369 3,614 Cash and Cash equivalents beginning of period 24,105 21,859 Cash and cash equivalents, end of period 38,474 25,473 Acquisitions (Note 10) Fair value of assets acquired $  1,899 Fair value of liabilities assumed  ( 88 ) Net cash paid for acquisitions $  1,811", "text": "Fiscal Three Months Ended March 30, 2025 March 31, 2024 Effect of exchange rate changes on cash and cash equivalents 70 ( 125 ) Increase in cash and cash equivalents 14,369 3,614 Cash and Cash equivalents beginning of period 24,105 21,859 Cash and cash equivalents, end of period 38,474 25,473 Acquisitions (Note 10) Fair value of assets acquired $  1,899 Fair value of liabilities assumed  ( 88 ) Net cash paid for acquisitions $  1,811", "length": 440, "numbers_raw": ["30", "202", "5 M", "31", "202", "4", "70", "125", "14,369", "3,614", "24,105", "21,859", "38,474", "25,473", "10", "1,899", "88", "1,811"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 70.0, 125.0, 14369.0, 3614.0, 24105.0, 21859.0, 38474.0, 25473.0, 10.0, 1899.0, 88.0, 1811.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 259, "tag": "div", "text_raw": "See Notes to Consolidated Financial Statements", "text": "See Notes to Consolidated Financial Statements", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 261, "tag": "div", "text_raw": "6", "text": "6", "length": 1, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 262, "tag": "div", "text_raw": "6", "text": "6", "length": 1, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 263, "tag": "div", "text_raw": "6", "text": "6", "length": 1, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 264, "tag": "div", "text_raw": "6", "text": "6", "length": 1, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 269, "tag": "div", "text_raw": "Notes to consolidated financial statements", "text": "Notes to consolidated financial statements", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 271, "tag": "div", "text_raw": "Note 1  The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Companys Annual Report on Form 10-K for the fiscal year ended December 29, 2024. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.", "text": "Note 1  The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Companys Annual Report on Form 10-K for the fiscal year ended December 29, 2024.", "length": 352, "numbers_raw": ["1", "10", "29", "202", "4"], "numbers": [1.0, 10.0, 29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 271, "tag": "div", "text_raw": "Note 1  The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Companys Annual Report on Form 10-K for the fiscal year ended December 29, 2024. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.", "text": "The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.", "length": 232, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 272, "tag": "div", "text_raw": "Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.", "text": "Columns and rows within tables may not add due to rounding.", "length": 59, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 272, "tag": "div", "text_raw": "Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.", "text": "Percentages have been calculated using actual, non-rounded figures.", "length": 67, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 274, "tag": "div", "text_raw": "The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Companys Annual Report on Form 10-K for the fiscal year ended December 29, 2024.", "text": "The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Companys Annual Report on Form 10-K for the fiscal year ended December 29, 2024.", "length": 315, "numbers_raw": ["10", "29", "202", "4"], "numbers": [10.0, 29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 275, "tag": "div", "text_raw": "Recently adopted accounting standards", "text": "Recently adopted accounting standards", "length": 37, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 276, "tag": "div", "text_raw": "There were no new material accounting standards adopted in the fiscal first quarter of 2025.", "text": "There were no new material accounting standards adopted in the fiscal first quarter of 2025.", "length": 92, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 277, "tag": "div", "text_raw": "Recently issued accounting standards", "text": "Recently issued accounting standards", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 278, "tag": "div", "text_raw": "There were no new material accounting standards issued in the fiscal first quarter of 2025.", "text": "There were no new material accounting standards issued in the fiscal first quarter of 2025.", "length": 91, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 279, "tag": "div", "text_raw": "Supplier finance program obligations", "text": "Supplier finance program obligations", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 280, "tag": "div", "text_raw": "The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Companys obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating suppliers decision to participate in the program.", "text": "The Company has agreements for supplier finance programs with third-party financial institutions.", "length": 97, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 280, "tag": "div", "text_raw": "The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Companys obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating suppliers decision to participate in the program.", "text": "These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions.", "length": 151, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 280, "tag": "div", "text_raw": "The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Companys obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating suppliers decision to participate in the program.", "text": "The Company is not a party to the arrangements between the suppliers and the third-party financial institutions.", "length": 112, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 280, "tag": "div", "text_raw": "The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Companys obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating suppliers decision to participate in the program.", "text": "The Companys obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating suppliers decision to participate in the program.", "length": 228, "numbers_raw": ["90"], "numbers": [90.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 281, "tag": "div", "text_raw": "Confirmed obligations under the program as of March 30, 2025, and December 29, 2024, were $ 0.6 billion and $ 0.8 billion, respectively. The obligations are presented as Accounts payable on the Consolidated Balance Sheets.", "text": "Confirmed obligations under the program as of March 30, 2025, and December 29, 2024, were $ 0.6 billion and $ 0.8 billion, respectively.", "length": 136, "numbers_raw": ["30", "202", "5", "29", "202", "4", "0.6 billion", "0.8 billion"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4.0, 600000000.0, 800000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 281, "tag": "div", "text_raw": "Confirmed obligations under the program as of March 30, 2025, and December 29, 2024, were $ 0.6 billion and $ 0.8 billion, respectively. The obligations are presented as Accounts payable on the Consolidated Balance Sheets.", "text": "The obligations are presented as Accounts payable on the Consolidated Balance Sheets.", "length": 85, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 284, "tag": "div", "text_raw": "Note 2  Inventories", "text": "Note 2  Inventories", "length": 20, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 285, "tag": "div", "text_raw": "(Dollars in Millions) March 30, 2025 December 29, 2024 Raw materials and supplies $ 2,371 2,337 Goods in process 3,203 2,815 Finished goods 7,085 7,292 Total inventories $ 12,659 12,444", "text": "(Dollars in Millions) March 30, 2025 December 29, 2024 Raw materials and supplies $ 2,371 2,337 Goods in process 3,203 2,815 Finished goods 7,085 7,292 Total inventories $ 12,659 12,444", "length": 185, "numbers_raw": ["30", "202", "5", "29", "202", "4", "2,371", "2,337", "3,203", "2,815", "7,085", "7,292", "12,659", "12,444"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4.0, 2371.0, 2337.0, 3203.0, 2815.0, 7085.0, 7292.0, 12659.0, 12444.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 286, "tag": "div", "text_raw": "Form 10-Q 7", "text": "Form 10-Q 7", "length": 11, "numbers_raw": ["10", "7"], "numbers": [10.0, 7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 287, "tag": "div", "text_raw": "Form 10-Q 7", "text": "Form 10-Q 7", "length": 11, "numbers_raw": ["10", "7"], "numbers": [10.0, 7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 288, "tag": "div", "text_raw": "Form 10-Q 7", "text": "Form 10-Q 7", "length": 11, "numbers_raw": ["10", "7"], "numbers": [10.0, 7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 289, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 290, "tag": "div", "text_raw": "7", "text": "7", "length": 1, "numbers_raw": ["7"], "numbers": [7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 295, "tag": "div", "text_raw": "Note 3  Intangible assets and goodwill", "text": "Note 3  Intangible assets and goodwill", "length": 39, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 296, "tag": "div", "text_raw": "Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2024. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.", "text": "Intangible assets that have finite useful lives are amortized over their estimated useful lives.", "length": 96, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 296, "tag": "div", "text_raw": "Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2024. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.", "text": "The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2024.", "length": 142, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 296, "tag": "div", "text_raw": "Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2024. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.", "text": "Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.", "length": 157, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 297, "tag": "div", "text_raw": "(Dollars in Millions) March 30, 2025 December 29, 2024 Intangible assets with definite lives: Patents and trademarks  gross $ 45,591 44,695 Less accumulated amortization ( 27,748 ) ( 26,124 ) Patents and trademarks  net $ 17,843 18,571 Customer relationships and other intangibles  gross 20,493 20,310 Less accumulated amortization ( 13,882 ) ( 13,544 ) Customer relationships and other intangibles  net (1) $ 6,611 6,766 Intangible assets with indefinite lives: Purchased in-process research and development 12,301 12,281 Total intangible assets  net $ 36,755 37,618", "text": "(Dollars in Millions) March 30, 2025 December 29, 2024 Intangible assets with definite lives:", "length": 93, "numbers_raw": ["30", "202", "5", "29", "202", "4"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 297, "tag": "div", "text_raw": "(Dollars in Millions) March 30, 2025 December 29, 2024 Intangible assets with definite lives: Patents and trademarks  gross $ 45,591 44,695 Less accumulated amortization ( 27,748 ) ( 26,124 ) Patents and trademarks  net $ 17,843 18,571 Customer relationships and other intangibles  gross 20,493 20,310 Less accumulated amortization ( 13,882 ) ( 13,544 ) Customer relationships and other intangibles  net (1) $ 6,611 6,766 Intangible assets with indefinite lives: Purchased in-process research and development 12,301 12,281 Total intangible assets  net $ 36,755 37,618", "text": "Patents and trademarks  gross $ 45,591 44,695 Less accumulated amortization ( 27,748 ) ( 26,124 ) Patents and trademarks  net $ 17,843 18,571 Customer relationships and other intangibles  gross 20,493 20,310 Less accumulated amortization ( 13,882 ) ( 13,544 ) Customer relationships and other intangibles  net (1) $ 6,611 6,766 Intangible assets with indefinite lives:", "length": 372, "numbers_raw": ["45,591", "44,695", "27,748", "26,124", "17,843", "18,571", "20,493", "20,310", "13,882", "13,544", "1", "6,611", "6,766"], "numbers": [45591.0, 44695.0, 27748.0, 26124.0, 17843.0, 18571.0, 20493.0, 20310.0, 13882.0, 13544.0, 1.0, 6611.0, 6766.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 297, "tag": "div", "text_raw": "(Dollars in Millions) March 30, 2025 December 29, 2024 Intangible assets with definite lives: Patents and trademarks  gross $ 45,591 44,695 Less accumulated amortization ( 27,748 ) ( 26,124 ) Patents and trademarks  net $ 17,843 18,571 Customer relationships and other intangibles  gross 20,493 20,310 Less accumulated amortization ( 13,882 ) ( 13,544 ) Customer relationships and other intangibles  net (1) $ 6,611 6,766 Intangible assets with indefinite lives: Purchased in-process research and development 12,301 12,281 Total intangible assets  net $ 36,755 37,618", "text": "Purchased in-process research and development 12,301 12,281 Total intangible assets  net $ 36,755 37,618", "length": 105, "numbers_raw": ["12,301", "12,281", "36,755", "37,618"], "numbers": [12301.0, 12281.0, 36755.0, 37618.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 298, "tag": "div", "text_raw": "Customer relationships and other intangibles  net (1)", "text": "Customer relationships and other intangibles  net (1)", "length": 54, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 299, "tag": "div", "text_raw": "(1) The majority is comprised of customer relationships", "text": "(1) The majority is comprised of customer relationships", "length": 55, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 300, "tag": "div", "text_raw": "Goodwill as of March 30, 2025 was allocated by segment of business as follows:", "text": "Goodwill as of March 30, 2025 was allocated by segment of business as follows:", "length": 78, "numbers_raw": ["30", "202", "5"], "numbers": [30.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 301, "tag": "div", "text_raw": "(Dollars in Millions) Innovative Medicine MedTech Total Goodwill at December 29, 2024 $ 10,692 33,508 44,200 Goodwill, related to acquisitions    Goodwill, related to divestitures  ( 29 ) ( 29 ) Currency translation/Other 215 82 297 Goodwill at March 30, 2025 $ 10,907 33,561 44,468", "text": "(Dollars in Millions) Innovative Medicine MedTech Total Goodwill at December 29, 2024 $ 10,692 33,508 44,200 Goodwill, related to acquisitions    Goodwill, related to divestitures  ( 29 ) ( 29 ) Currency translation/Other 215 82 297 Goodwill at March 30, 2025 $ 10,907 33,561 44,468", "length": 286, "numbers_raw": ["29", "202", "4", "10,692", "33,508", "44,200", "29", "29", "215", "82", "297", "30", "202", "5", "10,907", "33,561", "44,468"], "numbers": [29.0, 202.0, 4.0, 10692.0, 33508.0, 44200.0, 29.0, 29.0, 215.0, 82.0, 297.0, 30.0, 202.0, 5.0, 10907.0, 33561.0, 44468.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 304, "tag": "div", "text_raw": "Goodwill at December 29, 2024", "text": "Goodwill at December 29, 2024", "length": 29, "numbers_raw": ["29", "202", "4"], "numbers": [29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 305, "tag": "div", "text_raw": "Goodwill at March 30, 2025", "text": "Goodwill at March 30, 2025", "length": 26, "numbers_raw": ["30", "202", "5"], "numbers": [30.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 307, "tag": "div", "text_raw": "The weighted average amortization period for patents and trademarks is approximately 12 years. The weighted average amortization period for customer relationships and other intangible assets is approximately 19 years. The amortization expense of amortizable intangible assets included in the cost of products sold was $ 1.1 billion for both of the fiscal first quarters ended March 30, 2025 and March 31, 2024.", "text": "The weighted average amortization period for patents and trademarks is approximately 12 years.", "length": 94, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 307, "tag": "div", "text_raw": "The weighted average amortization period for patents and trademarks is approximately 12 years. The weighted average amortization period for customer relationships and other intangible assets is approximately 19 years. The amortization expense of amortizable intangible assets included in the cost of products sold was $ 1.1 billion for both of the fiscal first quarters ended March 30, 2025 and March 31, 2024.", "text": "The weighted average amortization period for customer relationships and other intangible assets is approximately 19 years.", "length": 122, "numbers_raw": ["19"], "numbers": [19.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 307, "tag": "div", "text_raw": "The weighted average amortization period for patents and trademarks is approximately 12 years. The weighted average amortization period for customer relationships and other intangible assets is approximately 19 years. The amortization expense of amortizable intangible assets included in the cost of products sold was $ 1.1 billion for both of the fiscal first quarters ended March 30, 2025 and March 31, 2024.", "text": "The amortization expense of amortizable intangible assets included in the cost of products sold was $ 1.1 billion for both of the fiscal first quarters ended March 30, 2025 and March 31, 2024.", "length": 192, "numbers_raw": ["1.1 billion", "30", "202", "5", "31", "202", "4"], "numbers": [1100000000.0, 30.0, 202.0, 5.0, 31.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 308, "tag": "div", "text_raw": "The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:", "text": "The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:", "length": 117, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 309, "tag": "div", "text_raw": "(Dollars in Millions) 2025 2026 2027 2028 2029 $ 4,000 3,400 2,800 2,200 2,200", "text": "(Dollars in Millions) 2025 2026 2027 2028 2029 $ 4,000 3,400 2,800 2,200 2,200", "length": 78, "numbers_raw": ["202", "5", "202", "6", "202", "7", "202", "8", "202", "9", "4,000", "3,400", "2,800", "2,200", "2,200"], "numbers": [202.0, 5.0, 202.0, 6.0, 202.0, 7.0, 202.0, 8.0, 202.0, 9.0, 4000.0, 3400.0, 2800.0, 2200.0, 2200.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 310, "tag": "div", "text_raw": "See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.", "text": "See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.", "length": 117, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 311, "tag": "div", "text_raw": "8", "text": "8", "length": 1, "numbers_raw": ["8"], "numbers": [8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 312, "tag": "div", "text_raw": "8", "text": "8", "length": 1, "numbers_raw": ["8"], "numbers": [8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 313, "tag": "div", "text_raw": "8", "text": "8", "length": 1, "numbers_raw": ["8"], "numbers": [8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 314, "tag": "div", "text_raw": "8", "text": "8", "length": 1, "numbers_raw": ["8"], "numbers": [8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 321, "tag": "div", "text_raw": "Note 4  Fair value measurements", "text": "Note 4  Fair value measurements", "length": 32, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 322, "tag": "div", "text_raw": "The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.", "text": "The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency.", "length": 268, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 322, "tag": "div", "text_raw": "The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.", "text": "The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings.", "length": 108, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 322, "tag": "div", "text_raw": "The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.", "text": "Both types of derivatives are designated as cash flow hedges.", "length": 61, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 323, "tag": "div", "text_raw": "Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.", "text": "Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.", "length": 130, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 323, "tag": "div", "text_raw": "Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.", "text": "These derivatives are designated as fair value hedges.", "length": 54, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 323, "tag": "div", "text_raw": "Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.", "text": "The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges.", "length": 127, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 323, "tag": "div", "text_raw": "Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.", "text": "Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities.", "length": 140, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 323, "tag": "div", "text_raw": "Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.", "text": "These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.", "length": 264, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 324, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of March 30, 2025, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.9 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of March 30, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.2 billion, $ 40.0 billion and $ 9.0 billion, respectively. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.1 billion, $ 40.5 billion and $ 9.0 billion, respectively.", "text": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features.", "length": 158, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 324, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of March 30, 2025, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.9 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of March 30, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.2 billion, $ 40.0 billion and $ 9.0 billion, respectively. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.1 billion, $ 40.5 billion and $ 9.0 billion, respectively.", "text": "The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements.", "length": 186, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 324, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of March 30, 2025, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.9 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of March 30, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.2 billion, $ 40.0 billion and $ 9.0 billion, respectively. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.1 billion, $ 40.5 billion and $ 9.0 billion, respectively.", "text": "As of March 30, 2025, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.9 billion net, related to net investment and cash flow hedges.", "length": 175, "numbers_raw": ["30", "202", "5", "1.9 billion"], "numbers": [30.0, 202.0, 5.0, 1900000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 324, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of March 30, 2025, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.9 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of March 30, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.2 billion, $ 40.0 billion and $ 9.0 billion, respectively. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.1 billion, $ 40.5 billion and $ 9.0 billion, respectively.", "text": "On an ongoing basis, the Company monitors counter-party credit ratings.", "length": 71, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 324, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of March 30, 2025, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.9 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of March 30, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.2 billion, $ 40.0 billion and $ 9.0 billion, respectively. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.1 billion, $ 40.5 billion and $ 9.0 billion, respectively.", "text": "The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.", "length": 195, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 324, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of March 30, 2025, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.9 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of March 30, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.2 billion, $ 40.0 billion and $ 9.0 billion, respectively. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.1 billion, $ 40.5 billion and $ 9.0 billion, respectively.", "text": "Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions.", "length": 181, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 324, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of March 30, 2025, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.9 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of March 30, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.2 billion, $ 40.0 billion and $ 9.0 billion, respectively. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.1 billion, $ 40.5 billion and $ 9.0 billion, respectively.", "text": "As of March 30, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.2 billion, $ 40.0 billion and $ 9.0 billion, respectively.", "length": 232, "numbers_raw": ["30", "202", "5", "45.2 billion", "40.0 billion", "9.0 billion"], "numbers": [30.0, 202.0, 5.0, 45200000000.0, 40000000000.0, 9000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 324, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of March 30, 2025, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.9 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of March 30, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.2 billion, $ 40.0 billion and $ 9.0 billion, respectively. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.1 billion, $ 40.5 billion and $ 9.0 billion, respectively.", "text": "As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 45.1 billion, $ 40.5 billion and $ 9.0 billion, respectively.", "length": 235, "numbers_raw": ["29", "202", "4", "45.1 billion", "40.5 billion", "9.0 billion"], "numbers": [29.0, 202.0, 4.0, 45100000000.0, 40500000000.0, 9000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 325, "tag": "div", "text_raw": "All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.", "text": "All derivative instruments are recorded on the balance sheet at fair value.", "length": 75, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 325, "tag": "div", "text_raw": "All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.", "text": "Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.", "length": 240, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 326, "tag": "div", "text_raw": "The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.", "text": "The designation as a cash flow hedge is made at the entrance date of the derivative contract.", "length": 93, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 326, "tag": "div", "text_raw": "The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.", "text": "At inception, all derivatives are expected to be highly effective.", "length": 66, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 326, "tag": "div", "text_raw": "The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.", "text": "Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.", "length": 235, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 326, "tag": "div", "text_raw": "The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.", "text": "Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.", "length": 236, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 327, "tag": "div", "text_raw": "Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.", "text": "Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.", "length": 203, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 327, "tag": "div", "text_raw": "Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.", "text": "Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income.", "length": 147, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 327, "tag": "div", "text_raw": "Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.", "text": "The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method.", "length": 116, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 327, "tag": "div", "text_raw": "Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.", "text": "On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items.", "length": 137, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 327, "tag": "div", "text_raw": "Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.", "text": "If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.", "length": 104, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 328, "tag": "div", "text_raw": "The Company designated its Euro denominated notes with due dates ranging from 2028 to 2055 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates.", "text": "The Company designated its Euro denominated notes with due dates ranging from 2028 to 2055 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates.", "length": 308, "numbers_raw": ["202", "8", "205", "5"], "numbers": [202.0, 8.0, 205.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": true, "has_percents": false}
{"idx_source": 329, "tag": "div", "text_raw": "As of March 30, 2025, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 1.2 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "text": "As of March 30, 2025, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 1.2 billion after-tax.", "length": 149, "numbers_raw": ["30", "202", "5", "1.2 billion"], "numbers": [30.0, 202.0, 5.0, 1200000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 329, "tag": "div", "text_raw": "As of March 30, 2025, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 1.2 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "text": "For additional information, see the Consolidated Statements of Comprehensive Income and Note 7.", "length": 95, "numbers_raw": ["7"], "numbers": [7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 329, "tag": "div", "text_raw": "As of March 30, 2025, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 1.2 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "text": "The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period.", "length": 235, "numbers_raw": ["12 m"], "numbers": [12000000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 329, "tag": "div", "text_raw": "As of March 30, 2025, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 1.2 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "text": "The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts.", "length": 165, "numbers_raw": ["18 m"], "numbers": [18000000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 329, "tag": "div", "text_raw": "As of March 30, 2025, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 1.2 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "text": "The amount ultimately realized in earnings may differ as foreign exchange rates change.", "length": 87, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 329, "tag": "div", "text_raw": "As of March 30, 2025, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 1.2 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "text": "Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "length": 107, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 330, "tag": "div", "text_raw": "Form 10-Q 9", "text": "Form 10-Q 9", "length": 11, "numbers_raw": ["10", "9"], "numbers": [10.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 331, "tag": "div", "text_raw": "Form 10-Q 9", "text": "Form 10-Q 9", "length": 11, "numbers_raw": ["10", "9"], "numbers": [10.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 332, "tag": "div", "text_raw": "Form 10-Q 9", "text": "Form 10-Q 9", "length": 11, "numbers_raw": ["10", "9"], "numbers": [10.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 333, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 334, "tag": "div", "text_raw": "9", "text": "9", "length": 1, "numbers_raw": ["9"], "numbers": [9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 337, "tag": "div", "text_raw": "The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended March 30, 2025 and March 31, 2024, net of tax:", "text": "The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended March 30, 2025 and March 31, 2024, net of tax:", "length": 165, "numbers_raw": ["30", "202", "5", "31", "202", "4"], "numbers": [30.0, 202.0, 5.0, 31.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 338, "tag": "div", "text_raw": "March 30, 2025 March 31, 2024 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    188     8  Derivatives designated as hedging instruments    ( 188 )     ( 8 )  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    49     34  Amount of gain or (loss) recognized in AOCI    49     34  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income ( 1 ) 10 1   1 165 4  ( 2 ) Amount of gain or (loss) recognized in AOCI 3 105 ( 36 )  ( 11 ) ( 3 ) ( 19 ) 22  4 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    83     49  Amount of gain or (loss) recognized in AOCI $    566     ( 205 ) ", "text": "March 30, 2025 March 31, 2024 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging:", "length": 294, "numbers_raw": ["30", "202", "5 M", "31", "202", "4"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 338, "tag": "div", "text_raw": "March 30, 2025 March 31, 2024 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    188     8  Derivatives designated as hedging instruments    ( 188 )     ( 8 )  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    49     34  Amount of gain or (loss) recognized in AOCI    49     34  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income ( 1 ) 10 1   1 165 4  ( 2 ) Amount of gain or (loss) recognized in AOCI 3 105 ( 36 )  ( 11 ) ( 3 ) ( 19 ) 22  4 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    83     49  Amount of gain or (loss) recognized in AOCI $    566     ( 205 ) ", "text": "Gain (Loss) on fair value hedging relationship:", "length": 47, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 338, "tag": "div", "text_raw": "March 30, 2025 March 31, 2024 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    188     8  Derivatives designated as hedging instruments    ( 188 )     ( 8 )  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    49     34  Amount of gain or (loss) recognized in AOCI    49     34  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income ( 1 ) 10 1   1 165 4  ( 2 ) Amount of gain or (loss) recognized in AOCI 3 105 ( 36 )  ( 11 ) ( 3 ) ( 19 ) 22  4 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    83     49  Amount of gain or (loss) recognized in AOCI $    566     ( 205 ) ", "text": "Interest rate swaps contracts:", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 338, "tag": "div", "text_raw": "March 30, 2025 March 31, 2024 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    188     8  Derivatives designated as hedging instruments    ( 188 )     ( 8 )  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    49     34  Amount of gain or (loss) recognized in AOCI    49     34  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income ( 1 ) 10 1   1 165 4  ( 2 ) Amount of gain or (loss) recognized in AOCI 3 105 ( 36 )  ( 11 ) ( 3 ) ( 19 ) 22  4 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    83     49  Amount of gain or (loss) recognized in AOCI $    566     ( 205 ) ", "text": "Hedged items $    188     8  Derivatives designated as hedging instruments    ( 188 )     ( 8 )  Gain (Loss) on net investment hedging relationship:", "length": 164, "numbers_raw": ["188", "8", "188", "8"], "numbers": [188.0, 8.0, 188.0, 8.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 338, "tag": "div", "text_raw": "March 30, 2025 March 31, 2024 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    188     8  Derivatives designated as hedging instruments    ( 188 )     ( 8 )  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    49     34  Amount of gain or (loss) recognized in AOCI    49     34  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income ( 1 ) 10 1   1 165 4  ( 2 ) Amount of gain or (loss) recognized in AOCI 3 105 ( 36 )  ( 11 ) ( 3 ) ( 19 ) 22  4 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    83     49  Amount of gain or (loss) recognized in AOCI $    566     ( 205 ) ", "text": "Cross currency interest rate swaps contracts:", "length": 45, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 338, "tag": "div", "text_raw": "March 30, 2025 March 31, 2024 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    188     8  Derivatives designated as hedging instruments    ( 188 )     ( 8 )  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    49     34  Amount of gain or (loss) recognized in AOCI    49     34  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income ( 1 ) 10 1   1 165 4  ( 2 ) Amount of gain or (loss) recognized in AOCI 3 105 ( 36 )  ( 11 ) ( 3 ) ( 19 ) 22  4 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    83     49  Amount of gain or (loss) recognized in AOCI $    566     ( 205 ) ", "text": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    49     34  Amount of gain or (loss) recognized in AOCI    49     34  Gain (Loss) on cash flow hedging relationship:", "length": 237, "numbers_raw": ["49", "34", "49", "34"], "numbers": [49.0, 34.0, 49.0, 34.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 338, "tag": "div", "text_raw": "March 30, 2025 March 31, 2024 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    188     8  Derivatives designated as hedging instruments    ( 188 )     ( 8 )  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    49     34  Amount of gain or (loss) recognized in AOCI    49     34  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income ( 1 ) 10 1   1 165 4  ( 2 ) Amount of gain or (loss) recognized in AOCI 3 105 ( 36 )  ( 11 ) ( 3 ) ( 19 ) 22  4 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    83     49  Amount of gain or (loss) recognized in AOCI $    566     ( 205 ) ", "text": "Forward foreign exchange contracts:", "length": 35, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 338, "tag": "div", "text_raw": "March 30, 2025 March 31, 2024 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    188     8  Derivatives designated as hedging instruments    ( 188 )     ( 8 )  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    49     34  Amount of gain or (loss) recognized in AOCI    49     34  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income ( 1 ) 10 1   1 165 4  ( 2 ) Amount of gain or (loss) recognized in AOCI 3 105 ( 36 )  ( 11 ) ( 3 ) ( 19 ) 22  4 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    83     49  Amount of gain or (loss) recognized in AOCI $    566     ( 205 ) ", "text": "Amount of gain or (loss) reclassified from AOCI into income ( 1 ) 10 1   1 165 4  ( 2 ) Amount of gain or (loss) recognized in AOCI 3 105 ( 36 )  ( 11 ) ( 3 ) ( 19 ) 22  4 Cross currency interest rate swaps contracts:", "length": 222, "numbers_raw": ["1", "10", "1", "1", "165", "4", "2", "3", "105", "36", "11", "3", "19", "22", "4"], "numbers": [1.0, 10.0, 1.0, 1.0, 165.0, 4.0, 2.0, 3.0, 105.0, 36.0, 11.0, 3.0, 19.0, 22.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 338, "tag": "div", "text_raw": "March 30, 2025 March 31, 2024 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    188     8  Derivatives designated as hedging instruments    ( 188 )     ( 8 )  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    49     34  Amount of gain or (loss) recognized in AOCI    49     34  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income ( 1 ) 10 1   1 165 4  ( 2 ) Amount of gain or (loss) recognized in AOCI 3 105 ( 36 )  ( 11 ) ( 3 ) ( 19 ) 22  4 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    83     49  Amount of gain or (loss) recognized in AOCI $    566     ( 205 ) ", "text": "Amount of gain or (loss) reclassified from AOCI into income    83     49  Amount of gain or (loss) recognized in AOCI $    566     ( 205 ) ", "length": 155, "numbers_raw": ["83", "49", "566", "205"], "numbers": [83.0, 49.0, 566.0, 205.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 366, "tag": "div", "text_raw": "10", "text": "10", "length": 2, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 367, "tag": "div", "text_raw": "10", "text": "10", "length": 2, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 368, "tag": "div", "text_raw": "10", "text": "10", "length": 2, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 369, "tag": "div", "text_raw": "10", "text": "10", "length": 2, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 375, "tag": "div", "text_raw": "As of March 30, 2025, and December 29, 2024, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:", "text": "As of March 30, 2025, and December 29, 2024, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:", "length": 176, "numbers_raw": ["30", "202", "5", "29", "202", "4"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 376, "tag": "div", "text_raw": "Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) March 30, 2025 December 29, 2024 March 30, 2025 December 29, 2024 Long-term Debt $ 8,147 7,935 ( 889 ) ( 1,132 )", "text": "Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) March 30, 2025 December 29, 2024 March 30, 2025 December 29, 2024 Long-term Debt $ 8,147 7,935 ( 889 ) ( 1,132 )", "length": 364, "numbers_raw": ["30", "202", "5", "29", "202", "4 M", "30", "202", "5", "29", "202", "4", "8,147", "7,935", "889", "1,132"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4000000.0, 30.0, 202.0, 5.0, 29.0, 202.0, 4.0, 8147.0, 7935.0, 889.0, 1132.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 377, "tag": "div", "text_raw": "Cumulative Amount of Fair Value", "text": "Cumulative Amount of Fair Value", "length": 31, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 378, "tag": "div", "text_raw": "Hedging Gain/ (Loss) Included in the", "text": "Hedging Gain/ (Loss) Included in the", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 379, "tag": "div", "text_raw": "Carrying Amount of the Hedged Liability", "text": "Carrying Amount of the Hedged Liability", "length": 39, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 381, "tag": "div", "text_raw": "The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2025 and 2024:", "text": "The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2025 and 2024:", "length": 137, "numbers_raw": ["202", "5", "202", "4"], "numbers": [202.0, 5.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 382, "tag": "div", "text_raw": "Gain/(Loss) Recognized In Income on Derivative (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal First Quarter Ended Derivatives Not Designated as Hedging Instruments March 30, 2025 March 31, 2024 Foreign Exchange Contracts Other (income) expense $ 62 25", "text": "Gain/(Loss) Recognized In Income on Derivative (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal First Quarter Ended Derivatives Not Designated as Hedging Instruments March 30, 2025 March 31, 2024 Foreign Exchange Contracts Other (income) expense $ 62 25", "length": 293, "numbers_raw": ["30", "202", "5 M", "31", "202", "4", "62", "25"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 62.0, 25.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 384, "tag": "div", "text_raw": "The following table is the effect of net investment hedges for the fiscal first quarters ended in 2025 and 2024:", "text": "The following table is the effect of net investment hedges for the fiscal first quarters ended in 2025 and 2024:", "length": 112, "numbers_raw": ["202", "5", "202", "4"], "numbers": [202.0, 5.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 385, "tag": "div", "text_raw": "Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated OCI Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) March 30, 2025 March 31, 2024 March 30, 2025 March 31, 2024 Debt $( 316 ) 84 Interest (income) expense   Cross Currency interest rate swaps $ 840 728 Interest (income) expense  ", "text": "Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated OCI Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) March 30, 2025 March 31, 2024 March 30, 2025 March 31, 2024 Debt $( 316 ) 84 Interest (income) expense   Cross Currency interest rate swaps $ 840 728 Interest (income) expense  ", "length": 376, "numbers_raw": ["30", "202", "5 M", "31", "202", "4 M", "30", "202", "5 M", "31", "202", "4", "316", "84", "840", "728"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4000000.0, 30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 316.0, 84.0, 840.0, 728.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 393, "tag": "div", "text_raw": "Form 10-Q 11", "text": "Form 10-Q 11", "length": 12, "numbers_raw": ["10", "11"], "numbers": [10.0, 11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 394, "tag": "div", "text_raw": "Form 10-Q 11", "text": "Form 10-Q 11", "length": 12, "numbers_raw": ["10", "11"], "numbers": [10.0, 11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 395, "tag": "div", "text_raw": "Form 10-Q 11", "text": "Form 10-Q 11", "length": 12, "numbers_raw": ["10", "11"], "numbers": [10.0, 11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 396, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 397, "tag": "div", "text_raw": "11", "text": "11", "length": 2, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 400, "tag": "div", "text_raw": "The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.", "text": "The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.", "length": 139, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 400, "tag": "div", "text_raw": "The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.", "text": "The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.", "length": 285, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 401, "tag": "div", "text_raw": "The following table is a summary of the activity related to equity investments:", "text": "The following table is a summary of the activity related to equity investments:", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 402, "tag": "div", "text_raw": "December 29, 2024 March 30, 2025 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) (Sales)/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 451 ( 36 ) 56 471 471 Equity Investments without readily determinable value $ 773 ( 27 ) 41 787 787", "text": "December 29, 2024 March 30, 2025 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) (Sales)/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 451 ( 36 ) 56 471 471 Equity Investments without readily determinable value $ 773 ( 27 ) 41 787 787", "length": 341, "numbers_raw": ["29", "202", "4 M", "30", "202", "5", "1", "2", "451", "36", "56", "471", "471", "773", "27", "41", "787", "787"], "numbers": [29.0, 202.0, 4000000.0, 30.0, 202.0, 5.0, 1.0, 2.0, 451.0, 36.0, 56.0, 471.0, 471.0, 773.0, 27.0, 41.0, 787.0, 787.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 403, "tag": "div", "text_raw": "Changes in Fair Value Reflected in Net Income (1)", "text": "Changes in Fair Value Reflected in Net Income (1)", "length": 49, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 404, "tag": "div", "text_raw": "(Sales)/ Purchases/Other (2)", "text": "(Sales)/ Purchases/Other (2)", "length": 28, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 405, "tag": "div", "text_raw": "(1) Recorded in Other (income)/expense, net", "text": "(1) Recorded in Other (income)/expense, net", "length": 43, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 406, "tag": "div", "text_raw": "(2) Other includes impact of currency", "text": "(2) Other includes impact of currency", "length": 37, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 408, "tag": "div", "text_raw": "Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.", "text": "Fair value is the exit price that would be received to sell an asset or paid to transfer a liability.", "length": 101, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 408, "tag": "div", "text_raw": "Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.", "text": "Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability.", "length": 138, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 408, "tag": "div", "text_raw": "Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.", "text": "In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value.", "length": 122, "numbers_raw": ["820"], "numbers": [820.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 408, "tag": "div", "text_raw": "Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.", "text": "The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.", "length": 137, "numbers_raw": ["1", "3"], "numbers": [1.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Companys results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.", "text": "The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.", "length": 286, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Companys results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.", "text": "Dollar at the current spot foreign exchange rate.", "length": 49, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Companys results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.", "text": "The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Companys results of operations, cash flows or financial position.", "length": 300, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Companys results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.", "text": "The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2.", "length": 126, "numbers_raw": ["1", "2"], "numbers": [1.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Companys results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.", "text": "The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.", "length": 325, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 410, "tag": "div", "text_raw": "The following three levels of inputs are used to measure fair value:", "text": "The following three levels of inputs are used to measure fair value:", "length": 68, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 411, "tag": "div", "text_raw": "Level 1  Quoted prices in active markets for identical assets and liabilities.", "text": "Level 1  Quoted prices in active markets for identical assets and liabilities.", "length": 79, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 412, "tag": "div", "text_raw": "Level 2  Significant other observable inputs.", "text": "Level 2  Significant other observable inputs.", "length": 46, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 413, "tag": "div", "text_raw": "Level 3  Significant unobservable inputs.", "text": "Level 3  Significant unobservable inputs.", "length": 42, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 414, "tag": "div", "text_raw": "12", "text": "12", "length": 2, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 415, "tag": "div", "text_raw": "12", "text": "12", "length": 2, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 416, "tag": "div", "text_raw": "12", "text": "12", "length": 2, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 417, "tag": "div", "text_raw": "12", "text": "12", "length": 2, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 421, "tag": "div", "text_raw": "The Companys significant financial assets and liabilities measured at fair value as of March 30, 2025 and December 29, 2024 were as follows:", "text": "The Companys significant financial assets and liabilities measured at fair value as of March 30, 2025 and December 29, 2024 were as follows:", "length": 141, "numbers_raw": ["30", "202", "5", "29", "202", "4"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 422, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $  389  389 660 Interest rate contracts (2)  1,285  1,285 1,484 Total  1,674  1,674 2,144 Liabilities: Forward foreign exchange contracts  345  345 794 Interest rate contracts (2)  3,415  3,415 3,753 Total  3,760  3,760 4,547 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts  37  37 50 Liabilities: Forward foreign exchange contracts  25  25 17 Other Investments: Equity investments (3) 471   471 451 Debt securities (4)  8,448  8,448 7,216 Other Liabilities: Contingent consideration (5) $   1,231 1,231 1,217", "text": "March 30, 2025 December 29, 2024 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments:", "length": 141, "numbers_raw": ["30", "202", "5", "29", "202", "4", "1", "2", "3", "1"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4.0, 1.0, 2.0, 3.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 422, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $  389  389 660 Interest rate contracts (2)  1,285  1,285 1,484 Total  1,674  1,674 2,144 Liabilities: Forward foreign exchange contracts  345  345 794 Interest rate contracts (2)  3,415  3,415 3,753 Total  3,760  3,760 4,547 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts  37  37 50 Liabilities: Forward foreign exchange contracts  25  25 17 Other Investments: Equity investments (3) 471   471 451 Debt securities (4)  8,448  8,448 7,216 Other Liabilities: Contingent consideration (5) $   1,231 1,231 1,217", "text": "Forward foreign exchange contracts $  389  389 660 Interest rate contracts (2)  1,285  1,285 1,484 Total  1,674  1,674 2,144 Liabilities:", "length": 143, "numbers_raw": ["389", "389", "660", "2", "1,285", "1,285", "1,484", "1,674", "1,674", "2,144"], "numbers": [389.0, 389.0, 660.0, 2.0, 1285.0, 1285.0, 1484.0, 1674.0, 1674.0, 2144.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 422, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $  389  389 660 Interest rate contracts (2)  1,285  1,285 1,484 Total  1,674  1,674 2,144 Liabilities: Forward foreign exchange contracts  345  345 794 Interest rate contracts (2)  3,415  3,415 3,753 Total  3,760  3,760 4,547 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts  37  37 50 Liabilities: Forward foreign exchange contracts  25  25 17 Other Investments: Equity investments (3) 471   471 451 Debt securities (4)  8,448  8,448 7,216 Other Liabilities: Contingent consideration (5) $   1,231 1,231 1,217", "text": "Forward foreign exchange contracts  345  345 794 Interest rate contracts (2)  3,415  3,415 3,753 Total  3,760  3,760 4,547 Derivatives not designated as hedging instruments:", "length": 179, "numbers_raw": ["345", "345", "794", "2", "3,415", "3,415", "3,753", "3,760", "3,760", "4,547"], "numbers": [345.0, 345.0, 794.0, 2.0, 3415.0, 3415.0, 3753.0, 3760.0, 3760.0, 4547.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 422, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $  389  389 660 Interest rate contracts (2)  1,285  1,285 1,484 Total  1,674  1,674 2,144 Liabilities: Forward foreign exchange contracts  345  345 794 Interest rate contracts (2)  3,415  3,415 3,753 Total  3,760  3,760 4,547 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts  37  37 50 Liabilities: Forward foreign exchange contracts  25  25 17 Other Investments: Equity investments (3) 471   471 451 Debt securities (4)  8,448  8,448 7,216 Other Liabilities: Contingent consideration (5) $   1,231 1,231 1,217", "text": "Forward foreign exchange contracts  37  37 50 Liabilities:", "length": 60, "numbers_raw": ["37", "37", "50"], "numbers": [37.0, 37.0, 50.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 422, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $  389  389 660 Interest rate contracts (2)  1,285  1,285 1,484 Total  1,674  1,674 2,144 Liabilities: Forward foreign exchange contracts  345  345 794 Interest rate contracts (2)  3,415  3,415 3,753 Total  3,760  3,760 4,547 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts  37  37 50 Liabilities: Forward foreign exchange contracts  25  25 17 Other Investments: Equity investments (3) 471   471 451 Debt securities (4)  8,448  8,448 7,216 Other Liabilities: Contingent consideration (5) $   1,231 1,231 1,217", "text": "Forward foreign exchange contracts  25  25 17 Other Investments:", "length": 66, "numbers_raw": ["25", "25", "17"], "numbers": [25.0, 25.0, 17.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 422, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $  389  389 660 Interest rate contracts (2)  1,285  1,285 1,484 Total  1,674  1,674 2,144 Liabilities: Forward foreign exchange contracts  345  345 794 Interest rate contracts (2)  3,415  3,415 3,753 Total  3,760  3,760 4,547 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts  37  37 50 Liabilities: Forward foreign exchange contracts  25  25 17 Other Investments: Equity investments (3) 471   471 451 Debt securities (4)  8,448  8,448 7,216 Other Liabilities: Contingent consideration (5) $   1,231 1,231 1,217", "text": "Equity investments (3) 471   471 451 Debt securities (4)  8,448  8,448 7,216 Other Liabilities:", "length": 99, "numbers_raw": ["3", "471", "471", "451", "4", "8,448", "8,448", "7,216"], "numbers": [3.0, 471.0, 471.0, 451.0, 4.0, 8448.0, 8448.0, 7216.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 422, "tag": "div", "text_raw": "March 30, 2025 December 29, 2024 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $  389  389 660 Interest rate contracts (2)  1,285  1,285 1,484 Total  1,674  1,674 2,144 Liabilities: Forward foreign exchange contracts  345  345 794 Interest rate contracts (2)  3,415  3,415 3,753 Total  3,760  3,760 4,547 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts  37  37 50 Liabilities: Forward foreign exchange contracts  25  25 17 Other Investments: Equity investments (3) 471   471 451 Debt securities (4)  8,448  8,448 7,216 Other Liabilities: Contingent consideration (5) $   1,231 1,231 1,217", "text": "Contingent consideration (5) $   1,231 1,231 1,217", "length": 52, "numbers_raw": ["5", "1,231", "1,231", "1,217"], "numbers": [5.0, 1231.0, 1231.0, 1217.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 423, "tag": "div", "text_raw": "Total (1)", "text": "Total (1)", "length": 9, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 424, "tag": "div", "text_raw": "Interest rate contracts (2)", "text": "Interest rate contracts (2)", "length": 27, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 425, "tag": "div", "text_raw": "Interest rate contracts (2)", "text": "Interest rate contracts (2)", "length": 27, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 426, "tag": "div", "text_raw": "Equity investments (3)", "text": "Equity investments (3)", "length": 22, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 427, "tag": "div", "text_raw": "Debt securities (4)", "text": "Debt securities (4)", "length": 19, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 428, "tag": "div", "text_raw": "Contingent consideration (5)", "text": "Contingent consideration (5)", "length": 28, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 429, "tag": "div", "text_raw": "Gross to Net Derivative Reconciliation March 30, 2025 December 29, 2024 (Dollars in Millions) Total Gross Assets $ 1,711 2,194 Credit Support Agreement (CSA) ( 1,700 ) ( 2,172 ) Total Net Asset 11 22 Total Gross Liabilities 3,785 4,564 Credit Support Agreement (CSA) ( 3,648 ) ( 4,412 ) Total Net Liabilities $ 137 152", "text": "Gross to Net Derivative Reconciliation March 30, 2025 December 29, 2024 (Dollars in Millions) Total Gross Assets $ 1,711 2,194 Credit Support Agreement (CSA) ( 1,700 ) ( 2,172 ) Total Net Asset 11 22 Total Gross Liabilities 3,785 4,564 Credit Support Agreement (CSA) ( 3,648 ) ( 4,412 ) Total Net Liabilities $ 137 152", "length": 318, "numbers_raw": ["30", "202", "5", "29", "202", "4", "1,711", "2,194", "1,700", "2,172", "11", "22", "3,785", "4,564", "3,648", "4,412", "137", "152"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4.0, 1711.0, 2194.0, 1700.0, 2172.0, 11.0, 22.0, 3785.0, 4564.0, 3648.0, 4412.0, 137.0, 152.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 430, "tag": "div", "text_raw": "Summarized information about changes in liabilities for contingent consideration for the fiscal first quarters ended March 30, 2025 and March 31, 2024 is as follows:", "text": "Summarized information about changes in liabilities for contingent consideration for the fiscal first quarters ended March 30, 2025 and March 31, 2024 is as follows:", "length": 165, "numbers_raw": ["30", "202", "5", "31", "202", "4"], "numbers": [30.0, 202.0, 5.0, 31.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 431, "tag": "div", "text_raw": "March 30, 2025 March 31, 2024 (Dollars in Millions) Beginning Balance $ 1,217 1,092 Changes in estimated fair value (6) 14 22 Additions   Payments   Ending Balance $ 1,231 1,114", "text": "March 30, 2025 March 31, 2024 (Dollars in Millions) Beginning Balance $ 1,217 1,092 Changes in estimated fair value (6) 14 22 Additions   Payments   Ending Balance $ 1,231 1,114", "length": 181, "numbers_raw": ["30", "202", "5 M", "31", "202", "4", "1,217", "1,092", "6", "14", "22", "1,231", "1,114"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 1217.0, 1092.0, 6.0, 14.0, 22.0, 1231.0, 1114.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 432, "tag": "div", "text_raw": "Changes in estimated fair value (6)", "text": "Changes in estimated fair value (6)", "length": 35, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 433, "tag": "div", "text_raw": "(1) 2024 assets and liabilities are all classified as Level 2 with the exception of equity investments of $ 451 million, which are classified as Level 1 and contingent consideration of $ 1,217 million, classified as Level 3.", "text": "(1) 2024 assets and liabilities are all classified as Level 2 with the exception of equity investments of $ 451 million, which are classified as Level 1 and contingent consideration of $ 1,217 million, classified as Level 3.", "length": 224, "numbers_raw": ["1", "202", "4", "2", "451 million", "1", "1,217 million", "3"], "numbers": [1.0, 202.0, 4.0, 2.0, 451000000.0, 1.0, 1217000000.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 434, "tag": "div", "text_raw": "(2) Includes cross currency interest rate swaps and interest rate swaps.", "text": "(2) Includes cross currency interest rate swaps and interest rate swaps.", "length": 72, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 435, "tag": "div", "text_raw": "Form 10-Q 13", "text": "Form 10-Q 13", "length": 12, "numbers_raw": ["10", "13"], "numbers": [10.0, 13.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 436, "tag": "div", "text_raw": "Form 10-Q 13", "text": "Form 10-Q 13", "length": 12, "numbers_raw": ["10", "13"], "numbers": [10.0, 13.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 437, "tag": "div", "text_raw": "Form 10-Q 13", "text": "Form 10-Q 13", "length": 12, "numbers_raw": ["10", "13"], "numbers": [10.0, 13.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 438, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 439, "tag": "div", "text_raw": "13", "text": "13", "length": 2, "numbers_raw": ["13"], "numbers": [13.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 442, "tag": "div", "text_raw": "(3) Classified as non-current other assets.", "text": "(3) Classified as non-current other assets.", "length": 43, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 443, "tag": "div", "text_raw": "(4) Classified within cash equivalents and current marketable securities.", "text": "(4) Classified within cash equivalents and current marketable securities.", "length": 73, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 444, "tag": "div", "text_raw": "(5) Includes $ 1,181 million and $ 1,217 million classified as non-current other liabilities as of March 30, 2025 and December 29, 2024, respectively. Includes $ 50 million classified as current liabilities as of March 30, 2025.", "text": "(5) Includes $ 1,181 million and $ 1,217 million classified as non-current other liabilities as of March 30, 2025 and December 29, 2024, respectively.", "length": 150, "numbers_raw": ["5", "1,181 million", "1,217 million", "30", "202", "5", "29", "202", "4"], "numbers": [5.0, 1181000000.0, 1217000000.0, 30.0, 202.0, 5.0, 29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 444, "tag": "div", "text_raw": "(5) Includes $ 1,181 million and $ 1,217 million classified as non-current other liabilities as of March 30, 2025 and December 29, 2024, respectively. Includes $ 50 million classified as current liabilities as of March 30, 2025.", "text": "Includes $ 50 million classified as current liabilities as of March 30, 2025.", "length": 77, "numbers_raw": ["50 million", "30", "202", "5"], "numbers": [50000000.0, 30.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 445, "tag": "div", "text_raw": "(6) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.", "text": "(6) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.", "length": 101, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 446, "tag": "div", "text_raw": "The Company's cash, cash equivalents and current marketable securities as of March 30, 2025 comprised:", "text": "The Company's cash, cash equivalents and current marketable securities as of March 30, 2025 comprised:", "length": 102, "numbers_raw": ["30", "202", "5"], "numbers": [30.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 447, "tag": "div", "text_raw": "(Dollars in Millions) Carrying Amount Unrealized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,059  3,059 3,059  U.S. Gov't securities      Non-U.S. sovereign securities      U.S. reverse repurchase agreements 6,938  6,938 6,938  Corporate debt securities (1)      Money market funds 19,690  19,690 19,690  Time deposits (1) 646  646 646  Subtotal 30,333  30,333 30,333  U.S. Govt securities 8,032 1 8,033 8,020 13 U.S. Govt Agencies      Other sovereign securities 180  180 64 116 Corporate debt securities 235  235 57 178 Subtotal available for sale debt (2) $ 8,447 1 8,448 8,141 307 Total cash, cash equivalents and current marketable securities $ 38,780 1 38,781 38,474 307", "text": "(Dollars in Millions) Carrying Amount Unrealized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,059  3,059 3,059  U.S.", "length": 162, "numbers_raw": ["3,059", "3,059", "3,059"], "numbers": [3059.0, 3059.0, 3059.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 447, "tag": "div", "text_raw": "(Dollars in Millions) Carrying Amount Unrealized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,059  3,059 3,059  U.S. Gov't securities      Non-U.S. sovereign securities      U.S. reverse repurchase agreements 6,938  6,938 6,938  Corporate debt securities (1)      Money market funds 19,690  19,690 19,690  Time deposits (1) 646  646 646  Subtotal 30,333  30,333 30,333  U.S. Govt securities 8,032 1 8,033 8,020 13 U.S. Govt Agencies      Other sovereign securities 180  180 64 116 Corporate debt securities 235  235 57 178 Subtotal available for sale debt (2) $ 8,447 1 8,448 8,141 307 Total cash, cash equivalents and current marketable securities $ 38,780 1 38,781 38,474 307", "text": "Gov't securities      Non-U.S.", "length": 35, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 447, "tag": "div", "text_raw": "(Dollars in Millions) Carrying Amount Unrealized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,059  3,059 3,059  U.S. Gov't securities      Non-U.S. sovereign securities      U.S. reverse repurchase agreements 6,938  6,938 6,938  Corporate debt securities (1)      Money market funds 19,690  19,690 19,690  Time deposits (1) 646  646 646  Subtotal 30,333  30,333 30,333  U.S. Govt securities 8,032 1 8,033 8,020 13 U.S. Govt Agencies      Other sovereign securities 180  180 64 116 Corporate debt securities 235  235 57 178 Subtotal available for sale debt (2) $ 8,447 1 8,448 8,141 307 Total cash, cash equivalents and current marketable securities $ 38,780 1 38,781 38,474 307", "text": "sovereign securities      U.S.", "length": 35, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 447, "tag": "div", "text_raw": "(Dollars in Millions) Carrying Amount Unrealized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,059  3,059 3,059  U.S. Gov't securities      Non-U.S. sovereign securities      U.S. reverse repurchase agreements 6,938  6,938 6,938  Corporate debt securities (1)      Money market funds 19,690  19,690 19,690  Time deposits (1) 646  646 646  Subtotal 30,333  30,333 30,333  U.S. Govt securities 8,032 1 8,033 8,020 13 U.S. Govt Agencies      Other sovereign securities 180  180 64 116 Corporate debt securities 235  235 57 178 Subtotal available for sale debt (2) $ 8,447 1 8,448 8,141 307 Total cash, cash equivalents and current marketable securities $ 38,780 1 38,781 38,474 307", "text": "reverse repurchase agreements 6,938  6,938 6,938  Corporate debt securities (1)      Money market funds 19,690  19,690 19,690  Time deposits (1) 646  646 646  Subtotal 30,333  30,333 30,333  U.S.", "length": 208, "numbers_raw": ["6,938", "6,938", "6,938", "1", "19,690", "19,690", "19,690", "1", "646", "646", "646", "30,333", "30,333", "30,333"], "numbers": [6938.0, 6938.0, 6938.0, 1.0, 19690.0, 19690.0, 19690.0, 1.0, 646.0, 646.0, 646.0, 30333.0, 30333.0, 30333.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 447, "tag": "div", "text_raw": "(Dollars in Millions) Carrying Amount Unrealized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,059  3,059 3,059  U.S. Gov't securities      Non-U.S. sovereign securities      U.S. reverse repurchase agreements 6,938  6,938 6,938  Corporate debt securities (1)      Money market funds 19,690  19,690 19,690  Time deposits (1) 646  646 646  Subtotal 30,333  30,333 30,333  U.S. Govt securities 8,032 1 8,033 8,020 13 U.S. Govt Agencies      Other sovereign securities 180  180 64 116 Corporate debt securities 235  235 57 178 Subtotal available for sale debt (2) $ 8,447 1 8,448 8,141 307 Total cash, cash equivalents and current marketable securities $ 38,780 1 38,781 38,474 307", "text": "Govt securities 8,032 1 8,033 8,020 13 U.S.", "length": 44, "numbers_raw": ["8,032", "1", "8,033", "8,020", "13"], "numbers": [8032.0, 1.0, 8033.0, 8020.0, 13.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 447, "tag": "div", "text_raw": "(Dollars in Millions) Carrying Amount Unrealized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,059  3,059 3,059  U.S. Gov't securities      Non-U.S. sovereign securities      U.S. reverse repurchase agreements 6,938  6,938 6,938  Corporate debt securities (1)      Money market funds 19,690  19,690 19,690  Time deposits (1) 646  646 646  Subtotal 30,333  30,333 30,333  U.S. Govt securities 8,032 1 8,033 8,020 13 U.S. Govt Agencies      Other sovereign securities 180  180 64 116 Corporate debt securities 235  235 57 178 Subtotal available for sale debt (2) $ 8,447 1 8,448 8,141 307 Total cash, cash equivalents and current marketable securities $ 38,780 1 38,781 38,474 307", "text": "Govt Agencies      Other sovereign securities 180  180 64 116 Corporate debt securities 235  235 57 178 Subtotal available for sale debt (2) $ 8,447 1 8,448 8,141 307 Total cash, cash equivalents and current marketable securities $ 38,780 1 38,781 38,474 307", "length": 266, "numbers_raw": ["180", "180", "64", "116", "235", "235", "57", "178", "2", "8,447", "1", "8,448", "8,141", "307", "38,780", "1", "38,781", "38,474", "307"], "numbers": [180.0, 180.0, 64.0, 116.0, 235.0, 235.0, 57.0, 178.0, 2.0, 8447.0, 1.0, 8448.0, 8141.0, 307.0, 38780.0, 1.0, 38781.0, 38474.0, 307.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 457, "tag": "div", "text_raw": "Corporate debt securities (1)", "text": "Corporate debt securities (1)", "length": 29, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 458, "tag": "div", "text_raw": "Time deposits (1)", "text": "Time deposits (1)", "length": 17, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 459, "tag": "div", "text_raw": "Subtotal available for sale debt (2)", "text": "Subtotal available for sale debt (2)", "length": 36, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 460, "tag": "div", "text_raw": "(1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.", "text": "(1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.", "length": 109, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 461, "tag": "div", "text_raw": "(2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.", "text": "(2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.", "length": 151, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 462, "tag": "div", "text_raw": "As of the fiscal year ended December 29, 2024, the carrying amount of cash, cash equivalents and current marketable securities was approximately the same as the estimated fair value.", "text": "As of the fiscal year ended December 29, 2024, the carrying amount of cash, cash equivalents and current marketable securities was approximately the same as the estimated fair value.", "length": 182, "numbers_raw": ["29", "202", "4"], "numbers": [29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 463, "tag": "div", "text_raw": "Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.", "text": "Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.", "length": 163, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 464, "tag": "div", "text_raw": "The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as current marketable securities.", "text": "The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities.", "length": 287, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 464, "tag": "div", "text_raw": "The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as current marketable securities.", "text": "Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as current marketable securities.", "length": 197, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 465, "tag": "div", "text_raw": "The contractual maturities of the available for sale securities as of March 30, 2025 are as follows:", "text": "The contractual maturities of the available for sale securities as of March 30, 2025 are as follows:", "length": 100, "numbers_raw": ["30", "202", "5"], "numbers": [30.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 466, "tag": "div", "text_raw": "(Dollars in Millions) Cost Basis Fair Value Due within one year $ 8,428 8,429 Due after one year through five years 19 19 Due after five years through ten years   Total debt securities $ 8,447 8,448", "text": "(Dollars in Millions) Cost Basis Fair Value Due within one year $ 8,428 8,429 Due after one year through five years 19 19 Due after five years through ten years   Total debt securities $ 8,447 8,448", "length": 200, "numbers_raw": ["8,428", "8,429", "19", "19", "8,447", "8,448"], "numbers": [8428.0, 8429.0, 19.0, 19.0, 8447.0, 8448.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 467, "tag": "div", "text_raw": "14", "text": "14", "length": 2, "numbers_raw": ["14"], "numbers": [14.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 468, "tag": "div", "text_raw": "14", "text": "14", "length": 2, "numbers_raw": ["14"], "numbers": [14.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 469, "tag": "div", "text_raw": "14", "text": "14", "length": 2, "numbers_raw": ["14"], "numbers": [14.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 470, "tag": "div", "text_raw": "14", "text": "14", "length": 2, "numbers_raw": ["14"], "numbers": [14.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 474, "tag": "div", "text_raw": "Financial instruments not measured at fair value", "text": "Financial instruments not measured at fair value", "length": 48, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 475, "tag": "div", "text_raw": "The following financial liabilities are held at carrying amount on the consolidated balance sheet as of March 30, 2025: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 13,897 13,855 Non-Current Debt 2.95 % Notes due 2027 950 980 0.95 % Notes due 2027 1,479 1,395 4.50 % Notes due 2027 (1) 749 757 2.90 % Notes due 2028 1,498 1,452 1.150 % Notes due 2028 ( 750 MM Euro 1.0784 ) 806 772 4.55 % Notes due 2028 (1) 748 758 4.80 % Notes due 2029 1,146 1,175 6.95 % Notes due 2029 299 334 2.70 % Notes due 2029 ( 600 MM Euro 1.0784 ) (1) 646 648 1.30 % Notes due 2030 1,672 1,499 4.70 % Notes due 2030 (1) 995 1,017 4.90 % Notes due 2031 1,146 1,178 3.20 % Notes due 2032 ( 700 MM Euro 1.0784 ) 752 762 4.85 % Notes due 2032 (1) 1,242 1,268 4.95 % Notes due 2033 499 514 4.375 % Notes due 2033 854 838 3.050 % Notes due 2033 ( 700 MM Euro 1.0784 ) (1) 752 749 4.95 % Notes due 2034 846 870 1.650 % Notes due 2035 ( 1.5 B Euro 1.0784 ) 1,607 1,393 5.00 % Notes due 2035 (1) 1,243 1,270 3.35 % Notes due 2036 ( 800 MM Euro 1.0784 ) 858 849 3.587 % Notes due 2036 897 894 5.95 % Notes due 2037 994 1,094 3.625 % Notes due 2037 1,387 1,333 3.350 % Notes due 2037 ( 1.0 B Euro 1.0784 ) (1) 1,075 1,058 3.40 % Notes due 2038 993 855 5.85 % Notes due 2038 697 760 4.50 % Notes due 2040 542 524 2.10 % Notes due 2040 874 689 4.85 % Notes due 2041 298 293 4.50 % Notes due 2043 496 464 3.55 % Notes due 2044 ( 1.0 B Euro 1.0784 ) 1,068 1,037 3.60 % Notes due 2045 ( 700 MM Euro 1.0784 ) (1) 749 723 3.73 % Notes due 2046 1,979 1,604 3.75 % Notes due 2047 852 802 3.50 % Notes due 2048 744 569 2.25 % Notes due 2050 837 582 5.25 % Notes due 2054 843 850", "text": "The following financial liabilities are held at carrying amount on the consolidated balance sheet as of March 30, 2025:", "length": 119, "numbers_raw": ["30", "202", "5"], "numbers": [30.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 475, "tag": "div", "text_raw": "The following financial liabilities are held at carrying amount on the consolidated balance sheet as of March 30, 2025: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 13,897 13,855 Non-Current Debt 2.95 % Notes due 2027 950 980 0.95 % Notes due 2027 1,479 1,395 4.50 % Notes due 2027 (1) 749 757 2.90 % Notes due 2028 1,498 1,452 1.150 % Notes due 2028 ( 750 MM Euro 1.0784 ) 806 772 4.55 % Notes due 2028 (1) 748 758 4.80 % Notes due 2029 1,146 1,175 6.95 % Notes due 2029 299 334 2.70 % Notes due 2029 ( 600 MM Euro 1.0784 ) (1) 646 648 1.30 % Notes due 2030 1,672 1,499 4.70 % Notes due 2030 (1) 995 1,017 4.90 % Notes due 2031 1,146 1,178 3.20 % Notes due 2032 ( 700 MM Euro 1.0784 ) 752 762 4.85 % Notes due 2032 (1) 1,242 1,268 4.95 % Notes due 2033 499 514 4.375 % Notes due 2033 854 838 3.050 % Notes due 2033 ( 700 MM Euro 1.0784 ) (1) 752 749 4.95 % Notes due 2034 846 870 1.650 % Notes due 2035 ( 1.5 B Euro 1.0784 ) 1,607 1,393 5.00 % Notes due 2035 (1) 1,243 1,270 3.35 % Notes due 2036 ( 800 MM Euro 1.0784 ) 858 849 3.587 % Notes due 2036 897 894 5.95 % Notes due 2037 994 1,094 3.625 % Notes due 2037 1,387 1,333 3.350 % Notes due 2037 ( 1.0 B Euro 1.0784 ) (1) 1,075 1,058 3.40 % Notes due 2038 993 855 5.85 % Notes due 2038 697 760 4.50 % Notes due 2040 542 524 2.10 % Notes due 2040 874 689 4.85 % Notes due 2041 298 293 4.50 % Notes due 2043 496 464 3.55 % Notes due 2044 ( 1.0 B Euro 1.0784 ) 1,068 1,037 3.60 % Notes due 2045 ( 700 MM Euro 1.0784 ) (1) 749 723 3.73 % Notes due 2046 1,979 1,604 3.75 % Notes due 2047 852 802 3.50 % Notes due 2048 744 569 2.25 % Notes due 2050 837 582 5.25 % Notes due 2054 843 850", "text": "(Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 13,897 13,855 Non-Current Debt 2.95 % Notes due 2027 950 980 0.95 % Notes due 2027 1,479 1,395 4.50 % Notes due 2027 (1) 749 757 2.90 % Notes due 2028 1,498 1,452 1.150 % Notes due 2028 ( 750 MM Euro 1.0784 ) 806 772 4.55 % Notes due 2028 (1) 748 758 4.80 % Notes due 2029 1,146 1,175 6.95 % Notes due 2029 299 334 2.70 % Notes due 2029 ( 600 MM Euro 1.0784 ) (1) 646 648 1.30 % Notes due 2030 1,672 1,499 4.70 % Notes due 2030 (1) 995 1,017 4.90 % Notes due 2031 1,146 1,178 3.20 % Notes due 2032 ( 700 MM Euro 1.0784 ) 752 762 4.85 % Notes due 2032 (1) 1,242 1,268 4.95 % Notes due 2033 499 514 4.375 % Notes due 2033 854 838 3.050 % Notes due 2033 ( 700 MM Euro 1.0784 ) (1) 752 749 4.95 % Notes due 2034 846 870 1.650 % Notes due 2035 ( 1.5 B Euro 1.0784 ) 1,607 1,393 5.00 % Notes due 2035 (1) 1,243 1,270 3.35 % Notes due 2036 ( 800 MM Euro 1.0784 ) 858 849 3.587 % Notes due 2036 897 894 5.95 % Notes due 2037 994 1,094 3.625 % Notes due 2037 1,387 1,333 3.350 % Notes due 2037 ( 1.0 B Euro 1.0784 ) (1) 1,075 1,058 3.40 % Notes due 2038 993 855 5.85 % Notes due 2038 697 760 4.50 % Notes due 2040 542 524 2.10 % Notes due 2040 874 689 4.85 % Notes due 2041 298 293 4.50 % Notes due 2043 496 464 3.55 % Notes due 2044 ( 1.0 B Euro 1.0784 ) 1,068 1,037 3.60 % Notes due 2045 ( 700 MM Euro 1.0784 ) (1) 749 723 3.73 % Notes due 2046 1,979 1,604 3.75 % Notes due 2047 852 802 3.50 % Notes due 2048 744 569 2.25 % Notes due 2050 837 582 5.25 % Notes due 2054 843 850", "length": 1565, "numbers_raw": ["13,897", "13,855", "2.95", "202", "7", "950", "980", "0.95", "202", "7", "1,479", "1,395", "4.50", "202", "7", "1", "749", "757", "2.90", "202", "8", "1,498", "1,452", "1.150", "202", "8", "750 M", "1.0784", "806", "772", "4.55", "202", "8", "1", "748", "758", "4.80", "202", "9", "1,146", "1,175", "6.95", "202", "9", "299", "334", "2.70", "202", "9", "600 M", "1.0784", "1", "646", "648", "1.30", "203", "0", "1,672", "1,499", "4.70", "203", "0", "1", "995", "1,017", "4.90", "203", "1", "1,146", "1,178", "3.20", "203", "2", "700 M", "1.0784", "752", "762", "4.85", "203", "2", "1", "1,242", "1,268", "4.95", "203", "3", "499", "514", "4.375", "203", "3", "854", "838", "3.050", "203", "3", "700 M", "1.0784", "1", "752", "749", "4.95", "203", "4", "846", "870", "1.650", "203", "5", "1.5", "1.0784", "1,607", "1,393", "5.00", "203", "5", "1", "1,243", "1,270", "3.35", "203", "6", "800 M", "1.0784", "858", "849", "3.587", "203", "6", "897", "894", "5.95", "203", "7", "994", "1,094", "3.625", "203", "7", "1,387", "1,333", "3.350", "203", "7", "1.0", "1.0784", "1", "1,075", "1,058", "3.40", "203", "8", "993", "855", "5.85", "203", "8", "697", "760", "4.50", "204", "0", "542", "524", "2.10", "204", "0", "874", "689", "4.85", "204", "1", "298", "293", "4.50", "204", "3", "496", "464", "3.55", "204", "4", "1.0", "1.0784", "1,068", "1,037", "3.60", "204", "5", "700 M", "1.0784", "1", "749", "723", "3.73", "204", "6", "1,979", "1,604", "3.75", "204", "7", "852", "802", "3.50", "204", "8", "744", "569", "2.25", "205", "0", "837", "582", "5.25", "205", "4", "843", "850"], "numbers": [13897.0, 13855.0, 2.95, 202.0, 7.0, 950.0, 980.0, 0.95, 202.0, 7.0, 1479.0, 1395.0, 4.5, 202.0, 7.0, 1.0, 749.0, 757.0, 2.9, 202.0, 8.0, 1498.0, 1452.0, 1.15, 202.0, 8.0, 750000000.0, 1.0784, 806.0, 772.0, 4.55, 202.0, 8.0, 1.0, 748.0, 758.0, 4.8, 202.0, 9.0, 1146.0, 1175.0, 6.95, 202.0, 9.0, 299.0, 334.0, 2.7, 202.0, 9.0, 600000000.0, 1.0784, 1.0, 646.0, 648.0, 1.3, 203.0, 0.0, 1672.0, 1499.0, 4.7, 203.0, 0.0, 1.0, 995.0, 1017.0, 4.9, 203.0, 1.0, 1146.0, 1178.0, 3.2, 203.0, 2.0, 700000000.0, 1.0784, 752.0, 762.0, 4.85, 203.0, 2.0, 1.0, 1242.0, 1268.0, 4.95, 203.0, 3.0, 499.0, 514.0, 4.375, 203.0, 3.0, 854.0, 838.0, 3.05, 203.0, 3.0, 700000000.0, 1.0784, 1.0, 752.0, 749.0, 4.95, 203.0, 4.0, 846.0, 870.0, 1.65, 203.0, 5.0, 1.5, 1.0784, 1607.0, 1393.0, 5.0, 203.0, 5.0, 1.0, 1243.0, 1270.0, 3.35, 203.0, 6.0, 800000000.0, 1.0784, 858.0, 849.0, 3.587, 203.0, 6.0, 897.0, 894.0, 5.95, 203.0, 7.0, 994.0, 1094.0, 3.625, 203.0, 7.0, 1387.0, 1333.0, 3.35, 203.0, 7.0, 1.0, 1.0784, 1.0, 1075.0, 1058.0, 3.4, 203.0, 8.0, 993.0, 855.0, 5.85, 203.0, 8.0, 697.0, 760.0, 4.5, 204.0, 0.0, 542.0, 524.0, 2.1, 204.0, 0.0, 874.0, 689.0, 4.85, 204.0, 1.0, 298.0, 293.0, 4.5, 204.0, 3.0, 496.0, 464.0, 3.55, 204.0, 4.0, 1.0, 1.0784, 1068.0, 1037.0, 3.6, 204.0, 5.0, 700000000.0, 1.0784, 1.0, 749.0, 723.0, 3.73, 204.0, 6.0, 1979.0, 1604.0, 3.75, 204.0, 7.0, 852.0, 802.0, 3.5, 204.0, 8.0, 744.0, 569.0, 2.25, 205.0, 0.0, 837.0, 582.0, 5.25, 205.0, 4.0, 843.0, 850.0], "percents_raw": ["2.95 %", "0.95 %", "4.50 %", "2.90 %", "1.150 %", "4.55 %", "4.80 %", "6.95 %", "2.70 %", "1.30 %", "4.70 %", "4.90 %", "3.20 %", "4.85 %", "4.95 %", "4.375 %", "3.050 %", "4.95 %", "1.650 %", "5.00 %", "3.35 %", "3.587 %", "5.95 %", "3.625 %", "3.350 %", "3.40 %", "5.85 %", "4.50 %", "2.10 %", "4.85 %", "4.50 %", "3.55 %", "3.60 %", "3.73 %", "3.75 %", "3.50 %", "2.25 %", "5.25 %"], "percents": [0.029500000000000002, 0.0095, 0.045, 0.028999999999999998, 0.0115, 0.0455, 0.048, 0.0695, 0.027000000000000003, 0.013000000000000001, 0.047, 0.049, 0.032, 0.048499999999999995, 0.0495, 0.04375, 0.0305, 0.0495, 0.0165, 0.05, 0.0335, 0.03587, 0.059500000000000004, 0.03625, 0.0335, 0.034, 0.058499999999999996, 0.045, 0.021, 0.048499999999999995, 0.045, 0.0355, 0.036000000000000004, 0.0373, 0.0375, 0.035, 0.0225, 0.0525], "currencies": ["EUR", "USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 480, "tag": "div", "text_raw": "2.95 % Notes due 2027", "text": "2.95 % Notes due 2027", "length": 21, "numbers_raw": ["2.95", "202", "7"], "numbers": [2.95, 202.0, 7.0], "percents_raw": ["2.95 %"], "percents": [0.029500000000000002], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 481, "tag": "div", "text_raw": "0.95 % Notes due 2027", "text": "0.95 % Notes due 2027", "length": 21, "numbers_raw": ["0.95", "202", "7"], "numbers": [0.95, 202.0, 7.0], "percents_raw": ["0.95 %"], "percents": [0.0095], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 482, "tag": "div", "text_raw": "4.50 % Notes due 2027 (1)", "text": "4.50 % Notes due 2027 (1)", "length": 25, "numbers_raw": ["4.50", "202", "7", "1"], "numbers": [4.5, 202.0, 7.0, 1.0], "percents_raw": ["4.50 %"], "percents": [0.045], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 483, "tag": "div", "text_raw": "2.90 % Notes due 2028", "text": "2.90 % Notes due 2028", "length": 21, "numbers_raw": ["2.90", "202", "8"], "numbers": [2.9, 202.0, 8.0], "percents_raw": ["2.90 %"], "percents": [0.028999999999999998], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 484, "tag": "div", "text_raw": "1.150 % Notes due 2028 ( 750 MM Euro 1.0784 )", "text": "1.150 % Notes due 2028 ( 750 MM Euro 1.0784 )", "length": 45, "numbers_raw": ["1.150", "202", "8", "750 M", "1.0784"], "numbers": [1.15, 202.0, 8.0, 750000000.0, 1.0784], "percents_raw": ["1.150 %"], "percents": [0.0115], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 485, "tag": "div", "text_raw": "4.55 % Notes due 2028 (1)", "text": "4.55 % Notes due 2028 (1)", "length": 25, "numbers_raw": ["4.55", "202", "8", "1"], "numbers": [4.55, 202.0, 8.0, 1.0], "percents_raw": ["4.55 %"], "percents": [0.0455], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 486, "tag": "div", "text_raw": "4.80 % Notes due 2029", "text": "4.80 % Notes due 2029", "length": 21, "numbers_raw": ["4.80", "202", "9"], "numbers": [4.8, 202.0, 9.0], "percents_raw": ["4.80 %"], "percents": [0.048], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 487, "tag": "div", "text_raw": "6.95 % Notes due 2029", "text": "6.95 % Notes due 2029", "length": 21, "numbers_raw": ["6.95", "202", "9"], "numbers": [6.95, 202.0, 9.0], "percents_raw": ["6.95 %"], "percents": [0.0695], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 488, "tag": "div", "text_raw": "2.70 % Notes due 2029 ( 600 MM Euro 1.0784 ) (1)", "text": "2.70 % Notes due 2029 ( 600 MM Euro 1.0784 ) (1)", "length": 48, "numbers_raw": ["2.70", "202", "9", "600 M", "1.0784", "1"], "numbers": [2.7, 202.0, 9.0, 600000000.0, 1.0784, 1.0], "percents_raw": ["2.70 %"], "percents": [0.027000000000000003], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 489, "tag": "div", "text_raw": "1.30 % Notes due 2030", "text": "1.30 % Notes due 2030", "length": 21, "numbers_raw": ["1.30", "203", "0"], "numbers": [1.3, 203.0, 0.0], "percents_raw": ["1.30 %"], "percents": [0.013000000000000001], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 490, "tag": "div", "text_raw": "4.70 % Notes due 2030 (1)", "text": "4.70 % Notes due 2030 (1)", "length": 25, "numbers_raw": ["4.70", "203", "0", "1"], "numbers": [4.7, 203.0, 0.0, 1.0], "percents_raw": ["4.70 %"], "percents": [0.047], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 491, "tag": "div", "text_raw": "4.90 % Notes due 2031", "text": "4.90 % Notes due 2031", "length": 21, "numbers_raw": ["4.90", "203", "1"], "numbers": [4.9, 203.0, 1.0], "percents_raw": ["4.90 %"], "percents": [0.049], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 492, "tag": "div", "text_raw": "3.20 % Notes due 2032 ( 700 MM Euro 1.0784 )", "text": "3.20 % Notes due 2032 ( 700 MM Euro 1.0784 )", "length": 44, "numbers_raw": ["3.20", "203", "2", "700 M", "1.0784"], "numbers": [3.2, 203.0, 2.0, 700000000.0, 1.0784], "percents_raw": ["3.20 %"], "percents": [0.032], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 493, "tag": "div", "text_raw": "4.85 % Notes due 2032 (1)", "text": "4.85 % Notes due 2032 (1)", "length": 25, "numbers_raw": ["4.85", "203", "2", "1"], "numbers": [4.85, 203.0, 2.0, 1.0], "percents_raw": ["4.85 %"], "percents": [0.048499999999999995], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 494, "tag": "div", "text_raw": "4.95 % Notes due 2033", "text": "4.95 % Notes due 2033", "length": 21, "numbers_raw": ["4.95", "203", "3"], "numbers": [4.95, 203.0, 3.0], "percents_raw": ["4.95 %"], "percents": [0.0495], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 495, "tag": "div", "text_raw": "4.375 % Notes due 2033", "text": "4.375 % Notes due 2033", "length": 22, "numbers_raw": ["4.375", "203", "3"], "numbers": [4.375, 203.0, 3.0], "percents_raw": ["4.375 %"], "percents": [0.04375], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 496, "tag": "div", "text_raw": "3.050 % Notes due 2033 ( 700 MM Euro 1.0784 ) (1)", "text": "3.050 % Notes due 2033 ( 700 MM Euro 1.0784 ) (1)", "length": 49, "numbers_raw": ["3.050", "203", "3", "700 M", "1.0784", "1"], "numbers": [3.05, 203.0, 3.0, 700000000.0, 1.0784, 1.0], "percents_raw": ["3.050 %"], "percents": [0.0305], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 497, "tag": "div", "text_raw": "4.95 % Notes due 2034", "text": "4.95 % Notes due 2034", "length": 21, "numbers_raw": ["4.95", "203", "4"], "numbers": [4.95, 203.0, 4.0], "percents_raw": ["4.95 %"], "percents": [0.0495], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 499, "tag": "div", "text_raw": "1.650 % Notes due 2035 ( 1.5 B Euro 1.0784 )", "text": "1.650 % Notes due 2035 ( 1.5 B Euro 1.0784 )", "length": 44, "numbers_raw": ["1.650", "203", "5", "1.5", "1.0784"], "numbers": [1.65, 203.0, 5.0, 1.5, 1.0784], "percents_raw": ["1.650 %"], "percents": [0.0165], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 500, "tag": "div", "text_raw": "5.00 % Notes due 2035 (1)", "text": "5.00 % Notes due 2035 (1)", "length": 25, "numbers_raw": ["5.00", "203", "5", "1"], "numbers": [5.0, 203.0, 5.0, 1.0], "percents_raw": ["5.00 %"], "percents": [0.05], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 501, "tag": "div", "text_raw": "3.35 % Notes due 2036 ( 800 MM Euro 1.0784 )", "text": "3.35 % Notes due 2036 ( 800 MM Euro 1.0784 )", "length": 44, "numbers_raw": ["3.35", "203", "6", "800 M", "1.0784"], "numbers": [3.35, 203.0, 6.0, 800000000.0, 1.0784], "percents_raw": ["3.35 %"], "percents": [0.0335], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 503, "tag": "div", "text_raw": "3.587 % Notes due 2036", "text": "3.587 % Notes due 2036", "length": 22, "numbers_raw": ["3.587", "203", "6"], "numbers": [3.587, 203.0, 6.0], "percents_raw": ["3.587 %"], "percents": [0.03587], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 504, "tag": "div", "text_raw": "5.95 % Notes due 2037", "text": "5.95 % Notes due 2037", "length": 21, "numbers_raw": ["5.95", "203", "7"], "numbers": [5.95, 203.0, 7.0], "percents_raw": ["5.95 %"], "percents": [0.059500000000000004], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 505, "tag": "div", "text_raw": "3.625 % Notes due 2037", "text": "3.625 % Notes due 2037", "length": 22, "numbers_raw": ["3.625", "203", "7"], "numbers": [3.625, 203.0, 7.0], "percents_raw": ["3.625 %"], "percents": [0.03625], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 506, "tag": "div", "text_raw": "3.350 % Notes due 2037 ( 1.0 B Euro 1.0784 ) (1)", "text": "3.350 % Notes due 2037 ( 1.0 B Euro 1.0784 ) (1)", "length": 48, "numbers_raw": ["3.350", "203", "7", "1.0", "1.0784", "1"], "numbers": [3.35, 203.0, 7.0, 1.0, 1.0784, 1.0], "percents_raw": ["3.350 %"], "percents": [0.0335], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 507, "tag": "div", "text_raw": "3.40 % Notes due 2038", "text": "3.40 % Notes due 2038", "length": 21, "numbers_raw": ["3.40", "203", "8"], "numbers": [3.4, 203.0, 8.0], "percents_raw": ["3.40 %"], "percents": [0.034], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 508, "tag": "div", "text_raw": "5.85 % Notes due 2038", "text": "5.85 % Notes due 2038", "length": 21, "numbers_raw": ["5.85", "203", "8"], "numbers": [5.85, 203.0, 8.0], "percents_raw": ["5.85 %"], "percents": [0.058499999999999996], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 509, "tag": "div", "text_raw": "4.50 % Notes due 2040", "text": "4.50 % Notes due 2040", "length": 21, "numbers_raw": ["4.50", "204", "0"], "numbers": [4.5, 204.0, 0.0], "percents_raw": ["4.50 %"], "percents": [0.045], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 510, "tag": "div", "text_raw": "2.10 % Notes due 2040", "text": "2.10 % Notes due 2040", "length": 21, "numbers_raw": ["2.10", "204", "0"], "numbers": [2.1, 204.0, 0.0], "percents_raw": ["2.10 %"], "percents": [0.021], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 511, "tag": "div", "text_raw": "4.85 % Notes due 2041", "text": "4.85 % Notes due 2041", "length": 21, "numbers_raw": ["4.85", "204", "1"], "numbers": [4.85, 204.0, 1.0], "percents_raw": ["4.85 %"], "percents": [0.048499999999999995], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 512, "tag": "div", "text_raw": "4.50 % Notes due 2043", "text": "4.50 % Notes due 2043", "length": 21, "numbers_raw": ["4.50", "204", "3"], "numbers": [4.5, 204.0, 3.0], "percents_raw": ["4.50 %"], "percents": [0.045], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 513, "tag": "div", "text_raw": "3.55 % Notes due 2044 ( 1.0 B Euro 1.0784 )", "text": "3.55 % Notes due 2044 ( 1.0 B Euro 1.0784 )", "length": 43, "numbers_raw": ["3.55", "204", "4", "1.0", "1.0784"], "numbers": [3.55, 204.0, 4.0, 1.0, 1.0784], "percents_raw": ["3.55 %"], "percents": [0.0355], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 514, "tag": "div", "text_raw": "3.60 % Notes due 2045 ( 700 MM Euro 1.0784 ) (1)", "text": "3.60 % Notes due 2045 ( 700 MM Euro 1.0784 ) (1)", "length": 48, "numbers_raw": ["3.60", "204", "5", "700 M", "1.0784", "1"], "numbers": [3.6, 204.0, 5.0, 700000000.0, 1.0784, 1.0], "percents_raw": ["3.60 %"], "percents": [0.036000000000000004], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 515, "tag": "div", "text_raw": "3.73 % Notes due 2046", "text": "3.73 % Notes due 2046", "length": 21, "numbers_raw": ["3.73", "204", "6"], "numbers": [3.73, 204.0, 6.0], "percents_raw": ["3.73 %"], "percents": [0.0373], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 516, "tag": "div", "text_raw": "3.75 % Notes due 2047", "text": "3.75 % Notes due 2047", "length": 21, "numbers_raw": ["3.75", "204", "7"], "numbers": [3.75, 204.0, 7.0], "percents_raw": ["3.75 %"], "percents": [0.0375], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 517, "tag": "div", "text_raw": "3.50 % Notes due 2048", "text": "3.50 % Notes due 2048", "length": 21, "numbers_raw": ["3.50", "204", "8"], "numbers": [3.5, 204.0, 8.0], "percents_raw": ["3.50 %"], "percents": [0.035], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 518, "tag": "div", "text_raw": "2.25 % Notes due 2050", "text": "2.25 % Notes due 2050", "length": 21, "numbers_raw": ["2.25", "205", "0"], "numbers": [2.25, 205.0, 0.0], "percents_raw": ["2.25 %"], "percents": [0.0225], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 519, "tag": "div", "text_raw": "5.25 % Notes due 2054", "text": "5.25 % Notes due 2054", "length": 21, "numbers_raw": ["5.25", "205", "4"], "numbers": [5.25, 205.0, 4.0], "percents_raw": ["5.25 %"], "percents": [0.0525], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 521, "tag": "div", "text_raw": "Form 10-Q 15", "text": "Form 10-Q 15", "length": 12, "numbers_raw": ["10", "15"], "numbers": [10.0, 15.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 522, "tag": "div", "text_raw": "Form 10-Q 15", "text": "Form 10-Q 15", "length": 12, "numbers_raw": ["10", "15"], "numbers": [10.0, 15.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 523, "tag": "div", "text_raw": "Form 10-Q 15", "text": "Form 10-Q 15", "length": 12, "numbers_raw": ["10", "15"], "numbers": [10.0, 15.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 524, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 525, "tag": "div", "text_raw": "15", "text": "15", "length": 2, "numbers_raw": ["15"], "numbers": [15.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 528, "tag": "div", "text_raw": "3.70 % Notes due 2055 ( 1.0 B Euro 1.0784 ) (1) 1,072 1,020 2.45 % Notes due 2060 1,088 694 Other 83 83 Total Non-Current Debt $ 38,355 36,406", "text": "3.70 % Notes due 2055 ( 1.0 B Euro 1.0784 ) (1) 1,072 1,020 2.45 % Notes due 2060 1,088 694 Other 83 83 Total Non-Current Debt $ 38,355 36,406", "length": 142, "numbers_raw": ["3.70", "205", "5", "1.0", "1.0784", "1", "1,072", "1,020", "2.45", "206", "0", "1,088", "694", "83", "83", "38,355", "36,406"], "numbers": [3.7, 205.0, 5.0, 1.0, 1.0784, 1.0, 1072.0, 1020.0, 2.45, 206.0, 0.0, 1088.0, 694.0, 83.0, 83.0, 38355.0, 36406.0], "percents_raw": ["3.70 %", "2.45 %"], "percents": [0.037000000000000005, 0.0245], "currencies": ["EUR", "USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 529, "tag": "div", "text_raw": "3.70 % Notes due 2055 ( 1.0 B Euro 1.0784 ) (1)", "text": "3.70 % Notes due 2055 ( 1.0 B Euro 1.0784 ) (1)", "length": 47, "numbers_raw": ["3.70", "205", "5", "1.0", "1.0784", "1"], "numbers": [3.7, 205.0, 5.0, 1.0, 1.0784, 1.0], "percents_raw": ["3.70 %"], "percents": [0.037000000000000005], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 530, "tag": "div", "text_raw": "2.45 % Notes due 2060", "text": "2.45 % Notes due 2060", "length": 21, "numbers_raw": ["2.45", "206", "0"], "numbers": [2.45, 206.0, 0.0], "percents_raw": ["2.45 %"], "percents": [0.0245], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 531, "tag": "div", "text_raw": "(1) In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $ 9.2 billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition which closed on April 2, 2025, and for general corporate purposes.", "text": "(1) In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $ 9.2 billion.", "length": 115, "numbers_raw": ["1", "202", "5", "9.2 billion"], "numbers": [1.0, 202.0, 5.0, 9200000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 531, "tag": "div", "text_raw": "(1) In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $ 9.2 billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition which closed on April 2, 2025, and for general corporate purposes.", "text": "The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc.", "length": 88, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 531, "tag": "div", "text_raw": "(1) In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $ 9.2 billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition which closed on April 2, 2025, and for general corporate purposes.", "text": "acquisition which closed on April 2, 2025, and for general corporate purposes.", "length": 78, "numbers_raw": ["2", "202", "5"], "numbers": [2.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 532, "tag": "div", "text_raw": "The weighted average effective interest rate on non-current debt is 3.58 %.", "text": "The weighted average effective interest rate on non-current debt is 3.58 %.", "length": 75, "numbers_raw": ["3.58"], "numbers": [3.58], "percents_raw": ["3.58 %"], "percents": [0.0358], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 533, "tag": "div", "text_raw": "The excess of the carrying value over the estimated fair value of debt was $ 2.0 billion at December 29, 2024.", "text": "The excess of the carrying value over the estimated fair value of debt was $ 2.0 billion at December 29, 2024.", "length": 110, "numbers_raw": ["2.0 billion", "29", "202", "4"], "numbers": [2000000000.0, 29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 534, "tag": "div", "text_raw": "Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.", "text": "Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.", "length": 158, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 535, "tag": "div", "text_raw": "The current debt balance as of March 30, 2025, includes $ 10.9 billion of commercial paper which has a weighted average interest rate of 4.28 % and a weighted average maturity of approximately two months .", "text": "The current debt balance as of March 30, 2025, includes $ 10.9 billion of commercial paper which has a weighted average interest rate of 4.28 % and a weighted average maturity of approximately two months .", "length": 205, "numbers_raw": ["30", "202", "5", "10.9 billion", "4.28"], "numbers": [30.0, 202.0, 5.0, 10900000000.0, 4.28], "percents_raw": ["4.28 %"], "percents": [0.042800000000000005], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 538, "tag": "div", "text_raw": "Note 5  Income taxes", "text": "Note 5  Income taxes", "length": 21, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 539, "tag": "div", "text_raw": "The worldwide effective income tax rates for the fiscal first quarter of 2025 and 2024 were 19.3 % and 12.4 %, respectively. The increase in the consolidated tax rate is primarily due to more income in higher tax jurisdictions, specifically in the U.S. In the fiscal first quarter of 2025 the Company reversed approximately $ 7.0 billion, a significant portion of the previously accrued talc reserve versus a charge of $ 2.7 billion recorded in the fiscal first quarter of 2024 for the talc settlement proposal. Both charges were recorded at an effective U.S. federal and state tax rate of approximately 22 % (for further information see Note 11 to the Consolidated Financial Statements).", "text": "The worldwide effective income tax rates for the fiscal first quarter of 2025 and 2024 were 19.3 % and 12.4 %, respectively.", "length": 124, "numbers_raw": ["202", "5", "202", "4", "19.3", "12.4"], "numbers": [202.0, 5.0, 202.0, 4.0, 19.3, 12.4], "percents_raw": ["19.3 %", "12.4 %"], "percents": [0.193, 0.124], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 539, "tag": "div", "text_raw": "The worldwide effective income tax rates for the fiscal first quarter of 2025 and 2024 were 19.3 % and 12.4 %, respectively. The increase in the consolidated tax rate is primarily due to more income in higher tax jurisdictions, specifically in the U.S. In the fiscal first quarter of 2025 the Company reversed approximately $ 7.0 billion, a significant portion of the previously accrued talc reserve versus a charge of $ 2.7 billion recorded in the fiscal first quarter of 2024 for the talc settlement proposal. Both charges were recorded at an effective U.S. federal and state tax rate of approximately 22 % (for further information see Note 11 to the Consolidated Financial Statements).", "text": "The increase in the consolidated tax rate is primarily due to more income in higher tax jurisdictions, specifically in the U.S.", "length": 127, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 539, "tag": "div", "text_raw": "The worldwide effective income tax rates for the fiscal first quarter of 2025 and 2024 were 19.3 % and 12.4 %, respectively. The increase in the consolidated tax rate is primarily due to more income in higher tax jurisdictions, specifically in the U.S. In the fiscal first quarter of 2025 the Company reversed approximately $ 7.0 billion, a significant portion of the previously accrued talc reserve versus a charge of $ 2.7 billion recorded in the fiscal first quarter of 2024 for the talc settlement proposal. Both charges were recorded at an effective U.S. federal and state tax rate of approximately 22 % (for further information see Note 11 to the Consolidated Financial Statements).", "text": "In the fiscal first quarter of 2025 the Company reversed approximately $ 7.0 billion, a significant portion of the previously accrued talc reserve versus a charge of $ 2.7 billion recorded in the fiscal first quarter of 2024 for the talc settlement proposal.", "length": 258, "numbers_raw": ["202", "5", "7.0 billion", "2.7 billion", "202", "4"], "numbers": [202.0, 5.0, 7000000000.0, 2700000000.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 539, "tag": "div", "text_raw": "The worldwide effective income tax rates for the fiscal first quarter of 2025 and 2024 were 19.3 % and 12.4 %, respectively. The increase in the consolidated tax rate is primarily due to more income in higher tax jurisdictions, specifically in the U.S. In the fiscal first quarter of 2025 the Company reversed approximately $ 7.0 billion, a significant portion of the previously accrued talc reserve versus a charge of $ 2.7 billion recorded in the fiscal first quarter of 2024 for the talc settlement proposal. Both charges were recorded at an effective U.S. federal and state tax rate of approximately 22 % (for further information see Note 11 to the Consolidated Financial Statements).", "text": "Both charges were recorded at an effective U.S.", "length": 47, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 539, "tag": "div", "text_raw": "The worldwide effective income tax rates for the fiscal first quarter of 2025 and 2024 were 19.3 % and 12.4 %, respectively. The increase in the consolidated tax rate is primarily due to more income in higher tax jurisdictions, specifically in the U.S. In the fiscal first quarter of 2025 the Company reversed approximately $ 7.0 billion, a significant portion of the previously accrued talc reserve versus a charge of $ 2.7 billion recorded in the fiscal first quarter of 2024 for the talc settlement proposal. Both charges were recorded at an effective U.S. federal and state tax rate of approximately 22 % (for further information see Note 11 to the Consolidated Financial Statements).", "text": "federal and state tax rate of approximately 22 % (for further information see Note 11 to the Consolidated Financial Statements).", "length": 128, "numbers_raw": ["22", "11"], "numbers": [22.0, 11.0], "percents_raw": ["22 %"], "percents": [0.22], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 540, "tag": "div", "text_raw": "As of March 30, 2025, the Company had approximately $ 2.1 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the Internal Revenue Service has completed its audit for the tax years through 2016 and has commenced the audit for tax years 2017 through 2020.", "text": "As of March 30, 2025, the Company had approximately $ 2.1 billion of liabilities from unrecognized tax benefits.", "length": 112, "numbers_raw": ["30", "202", "5", "2.1 billion"], "numbers": [30.0, 202.0, 5.0, 2100000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 540, "tag": "div", "text_raw": "As of March 30, 2025, the Company had approximately $ 2.1 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the Internal Revenue Service has completed its audit for the tax years through 2016 and has commenced the audit for tax years 2017 through 2020.", "text": "The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions.", "length": 144, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 540, "tag": "div", "text_raw": "As of March 30, 2025, the Company had approximately $ 2.1 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the Internal Revenue Service has completed its audit for the tax years through 2016 and has commenced the audit for tax years 2017 through 2020.", "text": "With respect to the United States, the Internal Revenue Service has completed its audit for the tax years through 2016 and has commenced the audit for tax years 2017 through 2020.", "length": 179, "numbers_raw": ["201", "6", "201", "7", "202", "0"], "numbers": [201.0, 6.0, 201.0, 7.0, 202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 541, "tag": "div", "text_raw": "In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2013. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States.", "text": "In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2013.", "length": 131, "numbers_raw": ["201", "3"], "numbers": [201.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 541, "tag": "div", "text_raw": "In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2013. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States.", "text": "The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States.", "length": 170, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 542, "tag": "div", "text_raw": "16", "text": "16", "length": 2, "numbers_raw": ["16"], "numbers": [16.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 543, "tag": "div", "text_raw": "16", "text": "16", "length": 2, "numbers_raw": ["16"], "numbers": [16.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 544, "tag": "div", "text_raw": "16", "text": "16", "length": 2, "numbers_raw": ["16"], "numbers": [16.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 545, "tag": "div", "text_raw": "16", "text": "16", "length": 2, "numbers_raw": ["16"], "numbers": [16.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 551, "tag": "div", "text_raw": "Note 6  Pensions and other benefit plans", "text": "Note 6  Pensions and other benefit plans", "length": 41, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 552, "tag": "div", "text_raw": "Components of net periodic benefit cost", "text": "Components of net periodic benefit cost", "length": 39, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 553, "tag": "div", "text_raw": "Net periodic benefit costs for the Companys defined benefit retirement plans and other benefit plans include the following components:", "text": "Net periodic benefit costs for the Companys defined benefit retirement plans and other benefit plans include the following components:", "length": 135, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 554, "tag": "div", "text_raw": "Fiscal First Quarter Ended Retirement Plans Other Benefit Plans (Dollars in Millions) March 30, 2025 March 31, 2024 March 30, 2025 March 31, 2024 Service cost $ 214 224 72 69 Interest cost 351 352 54 52 Expected return on plan assets ( 587 ) ( 642 ) ( 2 ) ( 2 ) Amortization of prior service cost/(credit) ( 46 ) ( 46 )   Recognized actuarial (gains)/losses 83 43 16 13 Net periodic benefit cost/(credit) $ 15 ( 69 ) 140 132", "text": "Fiscal First Quarter Ended Retirement Plans Other Benefit Plans (Dollars in Millions) March 30, 2025 March 31, 2024 March 30, 2025 March 31, 2024 Service cost $ 214 224 72 69 Interest cost 351 352 54 52 Expected return on plan assets ( 587 ) ( 642 ) ( 2 ) ( 2 ) Amortization of prior service cost/(credit) ( 46 ) ( 46 )   Recognized actuarial (gains)/losses 83 43 16 13 Net periodic benefit cost/(credit) $ 15 ( 69 ) 140 132", "length": 426, "numbers_raw": ["30", "202", "5 M", "31", "202", "4 M", "30", "202", "5 M", "31", "202", "4", "214", "224", "72", "69", "351", "352", "54", "52", "587", "642", "2", "2", "46", "46", "83", "43", "16", "13", "15", "69", "140", "132"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4000000.0, 30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 214.0, 224.0, 72.0, 69.0, 351.0, 352.0, 54.0, 52.0, 587.0, 642.0, 2.0, 2.0, 46.0, 46.0, 83.0, 43.0, 16.0, 13.0, 15.0, 69.0, 140.0, 132.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 555, "tag": "div", "text_raw": "Amortization of prior service cost/(credit)", "text": "Amortization of prior service cost/(credit)", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 556, "tag": "div", "text_raw": "The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.", "text": "The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses.", "length": 306, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 556, "tag": "div", "text_raw": "The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.", "text": "All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.", "length": 145, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 558, "tag": "div", "text_raw": "For the fiscal three months ended March 30, 2025, the Company contributed $ 34 million and $ 4 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.", "text": "For the fiscal three months ended March 30, 2025, the Company contributed $ 34 million and $ 4 million to its U.S.", "length": 114, "numbers_raw": ["30", "202", "5", "34 million", "4 million"], "numbers": [30.0, 202.0, 5.0, 34000000.0, 4000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 558, "tag": "div", "text_raw": "For the fiscal three months ended March 30, 2025, the Company contributed $ 34 million and $ 4 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.", "text": "and international retirement plans, respectively.", "length": 49, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 558, "tag": "div", "text_raw": "For the fiscal three months ended March 30, 2025, the Company contributed $ 34 million and $ 4 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.", "text": "The Company plans to continue to fund its U.S.", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 558, "tag": "div", "text_raw": "For the fiscal three months ended March 30, 2025, the Company contributed $ 34 million and $ 4 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.", "text": "defined benefit plans to comply with the Pension Protection Act of 2006.", "length": 72, "numbers_raw": ["200", "6"], "numbers": [200.0, 6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 558, "tag": "div", "text_raw": "For the fiscal three months ended March 30, 2025, the Company contributed $ 34 million and $ 4 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.", "text": "International plans are funded in accordance with local regulations.", "length": 68, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 561, "tag": "div", "text_raw": "Note 7  Accumulated other comprehensive income", "text": "Note 7  Accumulated other comprehensive income", "length": 47, "numbers_raw": ["7"], "numbers": [7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 562, "tag": "div", "text_raw": "Components of other comprehensive income/(loss) consist of the following:", "text": "Components of other comprehensive income/(loss) consist of the following:", "length": 73, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 563, "tag": "div", "text_raw": "(Dollars in Millions) Foreign Currency Translation Gain/ (Loss) On Securities Employee Benefit Plans Gain/ (Loss) On Derivatives & Hedges Total Accumulated Other Comprehensive Income/(Loss) December 29, 2024 $( 8,441 ) 1 ( 1,551 ) ( 1,750 ) ( 11,741 ) Net change ( 575 ) 0 42 534 1 March 30, 2025 ( 9,016 ) 1 ( 1,509 ) ( 1,216 ) ( 11,740 )", "text": "(Dollars in Millions) Foreign Currency Translation Gain/ (Loss) On Securities Employee Benefit Plans Gain/ (Loss) On Derivatives & Hedges Total Accumulated Other Comprehensive Income/(Loss) December 29, 2024 $( 8,441 ) 1 ( 1,551 ) ( 1,750 ) ( 11,741 ) Net change ( 575 ) 0 42 534 1 March 30, 2025 ( 9,016 ) 1 ( 1,509 ) ( 1,216 ) ( 11,740 )", "length": 339, "numbers_raw": ["29", "202", "4", "8,441", "1", "1,551", "1,750", "11,741", "575", "0", "42", "534", "1 M", "30", "202", "5", "9,016", "1", "1,509", "1,216", "11,740"], "numbers": [29.0, 202.0, 4.0, 8441.0, 1.0, 1551.0, 1750.0, 11741.0, 575.0, 0.0, 42.0, 534.0, 1000000.0, 30.0, 202.0, 5.0, 9016.0, 1.0, 1509.0, 1216.0, 11740.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 582, "tag": "div", "text_raw": "Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.", "text": "Amounts in accumulated other comprehensive income are presented net of the related tax impact.", "length": 94, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 582, "tag": "div", "text_raw": "Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.", "text": "Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.", "length": 134, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 582, "tag": "div", "text_raw": "Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.", "text": "For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.", "length": 103, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 583, "tag": "div", "text_raw": "Details on reclassifications out of Accumulated Other Comprehensive Income:", "text": "Details on reclassifications out of Accumulated Other Comprehensive Income:", "length": 75, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 584, "tag": "div", "text_raw": "Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.", "text": "Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.", "length": 86, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 585, "tag": "div", "text_raw": "Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.", "text": "Employee Benefit Plans - reclassifications are included in net periodic benefit cost.", "length": 85, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 585, "tag": "div", "text_raw": "Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.", "text": "See Note 6 for additional details.", "length": 34, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 586, "tag": "div", "text_raw": "Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.", "text": "Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction.", "length": 131, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 586, "tag": "div", "text_raw": "Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.", "text": "See Note 4 for additional details.", "length": 34, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 588, "tag": "div", "text_raw": "Form 10-Q 17", "text": "Form 10-Q 17", "length": 12, "numbers_raw": ["10", "17"], "numbers": [10.0, 17.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 589, "tag": "div", "text_raw": "Form 10-Q 17", "text": "Form 10-Q 17", "length": 12, "numbers_raw": ["10", "17"], "numbers": [10.0, 17.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 590, "tag": "div", "text_raw": "Form 10-Q 17", "text": "Form 10-Q 17", "length": 12, "numbers_raw": ["10", "17"], "numbers": [10.0, 17.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 591, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 592, "tag": "div", "text_raw": "17", "text": "17", "length": 2, "numbers_raw": ["17"], "numbers": [17.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 596, "tag": "div", "text_raw": "Note 8  Earnings per share", "text": "Note 8  Earnings per share", "length": 27, "numbers_raw": ["8"], "numbers": [8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 597, "tag": "div", "text_raw": "The following is a reconciliation of basic net earnings per share to diluted net earnings per share:", "text": "The following is a reconciliation of basic net earnings per share to diluted net earnings per share:", "length": 100, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 598, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Shares in Millions) March 30, 2025 March 31, 2024 Basic net earnings per share $ 4.57 1.35 Average shares outstanding  basic 2,407.2 2,408.2 Potential shares exercisable under stock option plans 69.0 87.6 Less: shares which could be repurchased under treasury stock method ( 52.4 ) ( 65.7 ) Average shares outstanding  diluted 2,423.8 2,430.1 Diluted net earnings per share $ 4.54 1.34 (Shares in Millions) The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Companys stock. 60.9 44.2", "text": "Fiscal First Quarter Ended (Shares in Millions) March 30, 2025 March 31, 2024 Basic net earnings per share $ 4.57 1.35 Average shares outstanding  basic 2,407.2 2,408.2 Potential shares exercisable under stock option plans 69.0 87.6 Less:", "length": 239, "numbers_raw": ["30", "202", "5 M", "31", "202", "4", "4.57", "1.35", "2,407.2", "2,408.2", "69.0", "87.6"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 4.57, 1.35, 2407.2, 2408.2, 69.0, 87.6], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 598, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Shares in Millions) March 30, 2025 March 31, 2024 Basic net earnings per share $ 4.57 1.35 Average shares outstanding  basic 2,407.2 2,408.2 Potential shares exercisable under stock option plans 69.0 87.6 Less: shares which could be repurchased under treasury stock method ( 52.4 ) ( 65.7 ) Average shares outstanding  diluted 2,423.8 2,430.1 Diluted net earnings per share $ 4.54 1.34 (Shares in Millions) The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Companys stock. 60.9 44.2", "text": "shares which could be repurchased under treasury stock method ( 52.4 ) ( 65.7 ) Average shares outstanding  diluted 2,423.8 2,430.1 Diluted net earnings per share $ 4.54 1.34 (Shares in Millions) The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Companys stock.", "length": 414, "numbers_raw": ["52.4", "65.7", "2,423.8", "2,430.1", "4.54", "1.34"], "numbers": [52.4, 65.7, 2423.8, 2430.1, 4.54, 1.34], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 598, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Shares in Millions) March 30, 2025 March 31, 2024 Basic net earnings per share $ 4.57 1.35 Average shares outstanding  basic 2,407.2 2,408.2 Potential shares exercisable under stock option plans 69.0 87.6 Less: shares which could be repurchased under treasury stock method ( 52.4 ) ( 65.7 ) Average shares outstanding  diluted 2,423.8 2,430.1 Diluted net earnings per share $ 4.54 1.34 (Shares in Millions) The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Companys stock. 60.9 44.2", "text": "60.9 44.2", "length": 9, "numbers_raw": ["60.9", "44.2"], "numbers": [60.9, 44.2], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 602, "tag": "div", "text_raw": "18", "text": "18", "length": 2, "numbers_raw": ["18"], "numbers": [18.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 603, "tag": "div", "text_raw": "18", "text": "18", "length": 2, "numbers_raw": ["18"], "numbers": [18.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 604, "tag": "div", "text_raw": "18", "text": "18", "length": 2, "numbers_raw": ["18"], "numbers": [18.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 605, "tag": "div", "text_raw": "18", "text": "18", "length": 2, "numbers_raw": ["18"], "numbers": [18.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 611, "tag": "div", "text_raw": "Note 9  Segments of business and geographic areas", "text": "Note 9  Segments of business and geographic areas", "length": 50, "numbers_raw": ["9"], "numbers": [9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 612, "tag": "div", "text_raw": "The Company is organized into two business segments: Innovative Medicine and MedTech.", "text": "The Company is organized into two business segments:", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 612, "tag": "div", "text_raw": "The Company is organized into two business segments: Innovative Medicine and MedTech.", "text": "Innovative Medicine and MedTech.", "length": 32, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 613, "tag": "div", "text_raw": "The Companys chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.", "text": "The Companys chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer).", "length": 113, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 613, "tag": "div", "text_raw": "The Companys chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.", "text": "For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process.", "length": 233, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 613, "tag": "div", "text_raw": "The Companys chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.", "text": "The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.", "length": 153, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 615, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change INNOVATIVE MEDICINE Oncology U.S. $ 3,013 2,383 26.4 % International 2,664 2,430 9.6 Worldwide 5,678 4,814 17.9 CARVYKTI U.S. 318 140 * International 51 16 * Worldwide 369 157 * DARZALEX U.S. 1,829 1,464 24.9 International 1,409 1,228 14.7 Worldwide 3,237 2,692 20.3 ERLEADA U.S. 292 285 2.5 International 479 404 18.5 Worldwide 771 689 11.9 IMBRUVICA U.S. 235 265 ( 11.5 ) International 474 518 ( 8.5 ) Worldwide 709 784 ( 9.5 ) RYBREVANT/ LAZCLUZE (1) U.S. 113 36 * International 28 11 * Worldwide 141 47 * TALVEY (1) U.S. 68 50 35.2 International 18 8 * Worldwide 86 58 48.4 TECVAYLI U.S. 105 101 4.9 International 46 33 38.8 Worldwide 151 133 13.3", "text": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change INNOVATIVE MEDICINE Oncology U.S.", "length": 127, "numbers_raw": ["30", "202", "5 M", "31", "202", "4"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 615, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change INNOVATIVE MEDICINE Oncology U.S. $ 3,013 2,383 26.4 % International 2,664 2,430 9.6 Worldwide 5,678 4,814 17.9 CARVYKTI U.S. 318 140 * International 51 16 * Worldwide 369 157 * DARZALEX U.S. 1,829 1,464 24.9 International 1,409 1,228 14.7 Worldwide 3,237 2,692 20.3 ERLEADA U.S. 292 285 2.5 International 479 404 18.5 Worldwide 771 689 11.9 IMBRUVICA U.S. 235 265 ( 11.5 ) International 474 518 ( 8.5 ) Worldwide 709 784 ( 9.5 ) RYBREVANT/ LAZCLUZE (1) U.S. 113 36 * International 28 11 * Worldwide 141 47 * TALVEY (1) U.S. 68 50 35.2 International 18 8 * Worldwide 86 58 48.4 TECVAYLI U.S. 105 101 4.9 International 46 33 38.8 Worldwide 151 133 13.3", "text": "$ 3,013 2,383 26.4 % International 2,664 2,430 9.6 Worldwide 5,678 4,814 17.9 CARVYKTI U.S.", "length": 91, "numbers_raw": ["3,013", "2,383", "26.4", "2,664", "2,430", "9.6", "5,678", "4,814", "17.9"], "numbers": [3013.0, 2383.0, 26.4, 2664.0, 2430.0, 9.6, 5678.0, 4814.0, 17.9], "percents_raw": ["26.4 %"], "percents": [0.264], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 615, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change INNOVATIVE MEDICINE Oncology U.S. $ 3,013 2,383 26.4 % International 2,664 2,430 9.6 Worldwide 5,678 4,814 17.9 CARVYKTI U.S. 318 140 * International 51 16 * Worldwide 369 157 * DARZALEX U.S. 1,829 1,464 24.9 International 1,409 1,228 14.7 Worldwide 3,237 2,692 20.3 ERLEADA U.S. 292 285 2.5 International 479 404 18.5 Worldwide 771 689 11.9 IMBRUVICA U.S. 235 265 ( 11.5 ) International 474 518 ( 8.5 ) Worldwide 709 784 ( 9.5 ) RYBREVANT/ LAZCLUZE (1) U.S. 113 36 * International 28 11 * Worldwide 141 47 * TALVEY (1) U.S. 68 50 35.2 International 18 8 * Worldwide 86 58 48.4 TECVAYLI U.S. 105 101 4.9 International 46 33 38.8 Worldwide 151 133 13.3", "text": "318 140 * International 51 16 * Worldwide 369 157 * DARZALEX U.S.", "length": 65, "numbers_raw": ["318", "140", "51", "16", "369", "157"], "numbers": [318.0, 140.0, 51.0, 16.0, 369.0, 157.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 615, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change INNOVATIVE MEDICINE Oncology U.S. $ 3,013 2,383 26.4 % International 2,664 2,430 9.6 Worldwide 5,678 4,814 17.9 CARVYKTI U.S. 318 140 * International 51 16 * Worldwide 369 157 * DARZALEX U.S. 1,829 1,464 24.9 International 1,409 1,228 14.7 Worldwide 3,237 2,692 20.3 ERLEADA U.S. 292 285 2.5 International 479 404 18.5 Worldwide 771 689 11.9 IMBRUVICA U.S. 235 265 ( 11.5 ) International 474 518 ( 8.5 ) Worldwide 709 784 ( 9.5 ) RYBREVANT/ LAZCLUZE (1) U.S. 113 36 * International 28 11 * Worldwide 141 47 * TALVEY (1) U.S. 68 50 35.2 International 18 8 * Worldwide 86 58 48.4 TECVAYLI U.S. 105 101 4.9 International 46 33 38.8 Worldwide 151 133 13.3", "text": "1,829 1,464 24.9 International 1,409 1,228 14.7 Worldwide 3,237 2,692 20.3 ERLEADA U.S.", "length": 87, "numbers_raw": ["1,829", "1,464", "24.9", "1,409", "1,228", "14.7", "3,237", "2,692", "20.3"], "numbers": [1829.0, 1464.0, 24.9, 1409.0, 1228.0, 14.7, 3237.0, 2692.0, 20.3], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 615, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change INNOVATIVE MEDICINE Oncology U.S. $ 3,013 2,383 26.4 % International 2,664 2,430 9.6 Worldwide 5,678 4,814 17.9 CARVYKTI U.S. 318 140 * International 51 16 * Worldwide 369 157 * DARZALEX U.S. 1,829 1,464 24.9 International 1,409 1,228 14.7 Worldwide 3,237 2,692 20.3 ERLEADA U.S. 292 285 2.5 International 479 404 18.5 Worldwide 771 689 11.9 IMBRUVICA U.S. 235 265 ( 11.5 ) International 474 518 ( 8.5 ) Worldwide 709 784 ( 9.5 ) RYBREVANT/ LAZCLUZE (1) U.S. 113 36 * International 28 11 * Worldwide 141 47 * TALVEY (1) U.S. 68 50 35.2 International 18 8 * Worldwide 86 58 48.4 TECVAYLI U.S. 105 101 4.9 International 46 33 38.8 Worldwide 151 133 13.3", "text": "292 285 2.5 International 479 404 18.5 Worldwide 771 689 11.9 IMBRUVICA U.S.", "length": 76, "numbers_raw": ["292", "285", "2.5", "479", "404", "18.5", "771", "689", "11.9"], "numbers": [292.0, 285.0, 2.5, 479.0, 404.0, 18.5, 771.0, 689.0, 11.9], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 615, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change INNOVATIVE MEDICINE Oncology U.S. $ 3,013 2,383 26.4 % International 2,664 2,430 9.6 Worldwide 5,678 4,814 17.9 CARVYKTI U.S. 318 140 * International 51 16 * Worldwide 369 157 * DARZALEX U.S. 1,829 1,464 24.9 International 1,409 1,228 14.7 Worldwide 3,237 2,692 20.3 ERLEADA U.S. 292 285 2.5 International 479 404 18.5 Worldwide 771 689 11.9 IMBRUVICA U.S. 235 265 ( 11.5 ) International 474 518 ( 8.5 ) Worldwide 709 784 ( 9.5 ) RYBREVANT/ LAZCLUZE (1) U.S. 113 36 * International 28 11 * Worldwide 141 47 * TALVEY (1) U.S. 68 50 35.2 International 18 8 * Worldwide 86 58 48.4 TECVAYLI U.S. 105 101 4.9 International 46 33 38.8 Worldwide 151 133 13.3", "text": "235 265 ( 11.5 ) International 474 518 ( 8.5 ) Worldwide 709 784 ( 9.5 ) RYBREVANT/ LAZCLUZE (1) U.S.", "length": 101, "numbers_raw": ["235", "265", "11.5", "474", "518", "8.5", "709", "784", "9.5", "1"], "numbers": [235.0, 265.0, 11.5, 474.0, 518.0, 8.5, 709.0, 784.0, 9.5, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 615, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change INNOVATIVE MEDICINE Oncology U.S. $ 3,013 2,383 26.4 % International 2,664 2,430 9.6 Worldwide 5,678 4,814 17.9 CARVYKTI U.S. 318 140 * International 51 16 * Worldwide 369 157 * DARZALEX U.S. 1,829 1,464 24.9 International 1,409 1,228 14.7 Worldwide 3,237 2,692 20.3 ERLEADA U.S. 292 285 2.5 International 479 404 18.5 Worldwide 771 689 11.9 IMBRUVICA U.S. 235 265 ( 11.5 ) International 474 518 ( 8.5 ) Worldwide 709 784 ( 9.5 ) RYBREVANT/ LAZCLUZE (1) U.S. 113 36 * International 28 11 * Worldwide 141 47 * TALVEY (1) U.S. 68 50 35.2 International 18 8 * Worldwide 86 58 48.4 TECVAYLI U.S. 105 101 4.9 International 46 33 38.8 Worldwide 151 133 13.3", "text": "113 36 * International 28 11 * Worldwide 141 47 * TALVEY (1) U.S.", "length": 65, "numbers_raw": ["113", "36", "28", "11", "141", "47", "1"], "numbers": [113.0, 36.0, 28.0, 11.0, 141.0, 47.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 615, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change INNOVATIVE MEDICINE Oncology U.S. $ 3,013 2,383 26.4 % International 2,664 2,430 9.6 Worldwide 5,678 4,814 17.9 CARVYKTI U.S. 318 140 * International 51 16 * Worldwide 369 157 * DARZALEX U.S. 1,829 1,464 24.9 International 1,409 1,228 14.7 Worldwide 3,237 2,692 20.3 ERLEADA U.S. 292 285 2.5 International 479 404 18.5 Worldwide 771 689 11.9 IMBRUVICA U.S. 235 265 ( 11.5 ) International 474 518 ( 8.5 ) Worldwide 709 784 ( 9.5 ) RYBREVANT/ LAZCLUZE (1) U.S. 113 36 * International 28 11 * Worldwide 141 47 * TALVEY (1) U.S. 68 50 35.2 International 18 8 * Worldwide 86 58 48.4 TECVAYLI U.S. 105 101 4.9 International 46 33 38.8 Worldwide 151 133 13.3", "text": "68 50 35.2 International 18 8 * Worldwide 86 58 48.4 TECVAYLI U.S.", "length": 66, "numbers_raw": ["68", "50", "35.2", "18", "8", "86", "58", "48.4"], "numbers": [68.0, 50.0, 35.2, 18.0, 8.0, 86.0, 58.0, 48.4], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 615, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change INNOVATIVE MEDICINE Oncology U.S. $ 3,013 2,383 26.4 % International 2,664 2,430 9.6 Worldwide 5,678 4,814 17.9 CARVYKTI U.S. 318 140 * International 51 16 * Worldwide 369 157 * DARZALEX U.S. 1,829 1,464 24.9 International 1,409 1,228 14.7 Worldwide 3,237 2,692 20.3 ERLEADA U.S. 292 285 2.5 International 479 404 18.5 Worldwide 771 689 11.9 IMBRUVICA U.S. 235 265 ( 11.5 ) International 474 518 ( 8.5 ) Worldwide 709 784 ( 9.5 ) RYBREVANT/ LAZCLUZE (1) U.S. 113 36 * International 28 11 * Worldwide 141 47 * TALVEY (1) U.S. 68 50 35.2 International 18 8 * Worldwide 86 58 48.4 TECVAYLI U.S. 105 101 4.9 International 46 33 38.8 Worldwide 151 133 13.3", "text": "105 101 4.9 International 46 33 38.8 Worldwide 151 133 13.3", "length": 59, "numbers_raw": ["105", "101", "4.9", "46", "33", "38.8", "151", "133", "13.3"], "numbers": [105.0, 101.0, 4.9, 46.0, 33.0, 38.8, 151.0, 133.0, 13.3], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 635, "tag": "div", "text_raw": "RYBREVANT/ LAZCLUZE (1)", "text": "RYBREVANT/ LAZCLUZE (1)", "length": 23, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 639, "tag": "div", "text_raw": "TALVEY (1)", "text": "TALVEY (1)", "length": 10, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 646, "tag": "div", "text_raw": "Form 10-Q 19", "text": "Form 10-Q 19", "length": 12, "numbers_raw": ["10", "19"], "numbers": [10.0, 19.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 647, "tag": "div", "text_raw": "Form 10-Q 19", "text": "Form 10-Q 19", "length": 12, "numbers_raw": ["10", "19"], "numbers": [10.0, 19.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 648, "tag": "div", "text_raw": "Form 10-Q 19", "text": "Form 10-Q 19", "length": 12, "numbers_raw": ["10", "19"], "numbers": [10.0, 19.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 649, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 650, "tag": "div", "text_raw": "19", "text": "19", "length": 2, "numbers_raw": ["19"], "numbers": [19.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 653, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change ZYTIGA / abiraterone acetate U.S. 7 9 ( 24.3 ) International 118 172 ( 31.3 ) Worldwide 125 181 ( 30.9 ) OTHER ONCOLOGY U.S. 47 33 42.9 International 42 41 4.6 Worldwide 89 73 21.7 Immunology U.S. 2,196 2,453 ( 10.5 ) International 1,510 1,794 ( 15.8 ) Worldwide 3,707 4,247 ( 12.7 ) REMICADE U.S. 314 266 18.1 U.S. Exports 10 27 ( 64.2 ) International 143 141 1.3 Worldwide 467 434 7.5 SIMPONI / SIMPONI ARIA U.S. 292 254 14.8 International 366 299 22.4 Worldwide 659 554 18.9 STELARA U.S. 981 1,396 ( 29.8 ) International 644 1,055 ( 38.9 ) Worldwide 1,625 2,451 ( 33.7 ) TREMFYA U.S. 599 509 17.6 International 356 299 19.2 Worldwide 956 808 18.2 OTHER IMMUNOLOGY U.S. 1 0 * International 0 0  Worldwide 1 0 *", "text": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change ZYTIGA / abiraterone acetate U.S.", "length": 127, "numbers_raw": ["30", "202", "5 M", "31", "202", "4"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 653, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change ZYTIGA / abiraterone acetate U.S. 7 9 ( 24.3 ) International 118 172 ( 31.3 ) Worldwide 125 181 ( 30.9 ) OTHER ONCOLOGY U.S. 47 33 42.9 International 42 41 4.6 Worldwide 89 73 21.7 Immunology U.S. 2,196 2,453 ( 10.5 ) International 1,510 1,794 ( 15.8 ) Worldwide 3,707 4,247 ( 12.7 ) REMICADE U.S. 314 266 18.1 U.S. Exports 10 27 ( 64.2 ) International 143 141 1.3 Worldwide 467 434 7.5 SIMPONI / SIMPONI ARIA U.S. 292 254 14.8 International 366 299 22.4 Worldwide 659 554 18.9 STELARA U.S. 981 1,396 ( 29.8 ) International 644 1,055 ( 38.9 ) Worldwide 1,625 2,451 ( 33.7 ) TREMFYA U.S. 599 509 17.6 International 356 299 19.2 Worldwide 956 808 18.2 OTHER IMMUNOLOGY U.S. 1 0 * International 0 0  Worldwide 1 0 *", "text": "7 9 ( 24.3 ) International 118 172 ( 31.3 ) Worldwide 125 181 ( 30.9 ) OTHER ONCOLOGY U.S.", "length": 90, "numbers_raw": ["7", "9", "24.3", "118", "172", "31.3", "125", "181", "30.9"], "numbers": [7.0, 9.0, 24.3, 118.0, 172.0, 31.3, 125.0, 181.0, 30.9], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 653, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change ZYTIGA / abiraterone acetate U.S. 7 9 ( 24.3 ) International 118 172 ( 31.3 ) Worldwide 125 181 ( 30.9 ) OTHER ONCOLOGY U.S. 47 33 42.9 International 42 41 4.6 Worldwide 89 73 21.7 Immunology U.S. 2,196 2,453 ( 10.5 ) International 1,510 1,794 ( 15.8 ) Worldwide 3,707 4,247 ( 12.7 ) REMICADE U.S. 314 266 18.1 U.S. Exports 10 27 ( 64.2 ) International 143 141 1.3 Worldwide 467 434 7.5 SIMPONI / SIMPONI ARIA U.S. 292 254 14.8 International 366 299 22.4 Worldwide 659 554 18.9 STELARA U.S. 981 1,396 ( 29.8 ) International 644 1,055 ( 38.9 ) Worldwide 1,625 2,451 ( 33.7 ) TREMFYA U.S. 599 509 17.6 International 356 299 19.2 Worldwide 956 808 18.2 OTHER IMMUNOLOGY U.S. 1 0 * International 0 0  Worldwide 1 0 *", "text": "47 33 42.9 International 42 41 4.6 Worldwide 89 73 21.7 Immunology U.S.", "length": 71, "numbers_raw": ["47", "33", "42.9", "42", "41", "4.6", "89", "73", "21.7"], "numbers": [47.0, 33.0, 42.9, 42.0, 41.0, 4.6, 89.0, 73.0, 21.7], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 653, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change ZYTIGA / abiraterone acetate U.S. 7 9 ( 24.3 ) International 118 172 ( 31.3 ) Worldwide 125 181 ( 30.9 ) OTHER ONCOLOGY U.S. 47 33 42.9 International 42 41 4.6 Worldwide 89 73 21.7 Immunology U.S. 2,196 2,453 ( 10.5 ) International 1,510 1,794 ( 15.8 ) Worldwide 3,707 4,247 ( 12.7 ) REMICADE U.S. 314 266 18.1 U.S. Exports 10 27 ( 64.2 ) International 143 141 1.3 Worldwide 467 434 7.5 SIMPONI / SIMPONI ARIA U.S. 292 254 14.8 International 366 299 22.4 Worldwide 659 554 18.9 STELARA U.S. 981 1,396 ( 29.8 ) International 644 1,055 ( 38.9 ) Worldwide 1,625 2,451 ( 33.7 ) TREMFYA U.S. 599 509 17.6 International 356 299 19.2 Worldwide 956 808 18.2 OTHER IMMUNOLOGY U.S. 1 0 * International 0 0  Worldwide 1 0 *", "text": "2,196 2,453 ( 10.5 ) International 1,510 1,794 ( 15.8 ) Worldwide 3,707 4,247 ( 12.7 ) REMICADE U.S.", "length": 100, "numbers_raw": ["2,196", "2,453", "10.5", "1,510", "1,794", "15.8", "3,707", "4,247", "12.7"], "numbers": [2196.0, 2453.0, 10.5, 1510.0, 1794.0, 15.8, 3707.0, 4247.0, 12.7], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 653, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change ZYTIGA / abiraterone acetate U.S. 7 9 ( 24.3 ) International 118 172 ( 31.3 ) Worldwide 125 181 ( 30.9 ) OTHER ONCOLOGY U.S. 47 33 42.9 International 42 41 4.6 Worldwide 89 73 21.7 Immunology U.S. 2,196 2,453 ( 10.5 ) International 1,510 1,794 ( 15.8 ) Worldwide 3,707 4,247 ( 12.7 ) REMICADE U.S. 314 266 18.1 U.S. Exports 10 27 ( 64.2 ) International 143 141 1.3 Worldwide 467 434 7.5 SIMPONI / SIMPONI ARIA U.S. 292 254 14.8 International 366 299 22.4 Worldwide 659 554 18.9 STELARA U.S. 981 1,396 ( 29.8 ) International 644 1,055 ( 38.9 ) Worldwide 1,625 2,451 ( 33.7 ) TREMFYA U.S. 599 509 17.6 International 356 299 19.2 Worldwide 956 808 18.2 OTHER IMMUNOLOGY U.S. 1 0 * International 0 0  Worldwide 1 0 *", "text": "314 266 18.1 U.S.", "length": 17, "numbers_raw": ["314", "266", "18.1"], "numbers": [314.0, 266.0, 18.1], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 653, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change ZYTIGA / abiraterone acetate U.S. 7 9 ( 24.3 ) International 118 172 ( 31.3 ) Worldwide 125 181 ( 30.9 ) OTHER ONCOLOGY U.S. 47 33 42.9 International 42 41 4.6 Worldwide 89 73 21.7 Immunology U.S. 2,196 2,453 ( 10.5 ) International 1,510 1,794 ( 15.8 ) Worldwide 3,707 4,247 ( 12.7 ) REMICADE U.S. 314 266 18.1 U.S. Exports 10 27 ( 64.2 ) International 143 141 1.3 Worldwide 467 434 7.5 SIMPONI / SIMPONI ARIA U.S. 292 254 14.8 International 366 299 22.4 Worldwide 659 554 18.9 STELARA U.S. 981 1,396 ( 29.8 ) International 644 1,055 ( 38.9 ) Worldwide 1,625 2,451 ( 33.7 ) TREMFYA U.S. 599 509 17.6 International 356 299 19.2 Worldwide 956 808 18.2 OTHER IMMUNOLOGY U.S. 1 0 * International 0 0  Worldwide 1 0 *", "text": "Exports 10 27 ( 64.2 ) International 143 141 1.3 Worldwide 467 434 7.5 SIMPONI / SIMPONI ARIA U.S.", "length": 98, "numbers_raw": ["10", "27", "64.2", "143", "141", "1.3", "467", "434", "7.5"], "numbers": [10.0, 27.0, 64.2, 143.0, 141.0, 1.3, 467.0, 434.0, 7.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 653, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change ZYTIGA / abiraterone acetate U.S. 7 9 ( 24.3 ) International 118 172 ( 31.3 ) Worldwide 125 181 ( 30.9 ) OTHER ONCOLOGY U.S. 47 33 42.9 International 42 41 4.6 Worldwide 89 73 21.7 Immunology U.S. 2,196 2,453 ( 10.5 ) International 1,510 1,794 ( 15.8 ) Worldwide 3,707 4,247 ( 12.7 ) REMICADE U.S. 314 266 18.1 U.S. Exports 10 27 ( 64.2 ) International 143 141 1.3 Worldwide 467 434 7.5 SIMPONI / SIMPONI ARIA U.S. 292 254 14.8 International 366 299 22.4 Worldwide 659 554 18.9 STELARA U.S. 981 1,396 ( 29.8 ) International 644 1,055 ( 38.9 ) Worldwide 1,625 2,451 ( 33.7 ) TREMFYA U.S. 599 509 17.6 International 356 299 19.2 Worldwide 956 808 18.2 OTHER IMMUNOLOGY U.S. 1 0 * International 0 0  Worldwide 1 0 *", "text": "292 254 14.8 International 366 299 22.4 Worldwide 659 554 18.9 STELARA U.S.", "length": 75, "numbers_raw": ["292", "254", "14.8", "366", "299", "22.4", "659", "554", "18.9"], "numbers": [292.0, 254.0, 14.8, 366.0, 299.0, 22.4, 659.0, 554.0, 18.9], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 653, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change ZYTIGA / abiraterone acetate U.S. 7 9 ( 24.3 ) International 118 172 ( 31.3 ) Worldwide 125 181 ( 30.9 ) OTHER ONCOLOGY U.S. 47 33 42.9 International 42 41 4.6 Worldwide 89 73 21.7 Immunology U.S. 2,196 2,453 ( 10.5 ) International 1,510 1,794 ( 15.8 ) Worldwide 3,707 4,247 ( 12.7 ) REMICADE U.S. 314 266 18.1 U.S. Exports 10 27 ( 64.2 ) International 143 141 1.3 Worldwide 467 434 7.5 SIMPONI / SIMPONI ARIA U.S. 292 254 14.8 International 366 299 22.4 Worldwide 659 554 18.9 STELARA U.S. 981 1,396 ( 29.8 ) International 644 1,055 ( 38.9 ) Worldwide 1,625 2,451 ( 33.7 ) TREMFYA U.S. 599 509 17.6 International 356 299 19.2 Worldwide 956 808 18.2 OTHER IMMUNOLOGY U.S. 1 0 * International 0 0  Worldwide 1 0 *", "text": "981 1,396 ( 29.8 ) International 644 1,055 ( 38.9 ) Worldwide 1,625 2,451 ( 33.7 ) TREMFYA U.S.", "length": 95, "numbers_raw": ["981", "1,396", "29.8", "644", "1,055", "38.9", "1,625", "2,451", "33.7"], "numbers": [981.0, 1396.0, 29.8, 644.0, 1055.0, 38.9, 1625.0, 2451.0, 33.7], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 653, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change ZYTIGA / abiraterone acetate U.S. 7 9 ( 24.3 ) International 118 172 ( 31.3 ) Worldwide 125 181 ( 30.9 ) OTHER ONCOLOGY U.S. 47 33 42.9 International 42 41 4.6 Worldwide 89 73 21.7 Immunology U.S. 2,196 2,453 ( 10.5 ) International 1,510 1,794 ( 15.8 ) Worldwide 3,707 4,247 ( 12.7 ) REMICADE U.S. 314 266 18.1 U.S. Exports 10 27 ( 64.2 ) International 143 141 1.3 Worldwide 467 434 7.5 SIMPONI / SIMPONI ARIA U.S. 292 254 14.8 International 366 299 22.4 Worldwide 659 554 18.9 STELARA U.S. 981 1,396 ( 29.8 ) International 644 1,055 ( 38.9 ) Worldwide 1,625 2,451 ( 33.7 ) TREMFYA U.S. 599 509 17.6 International 356 299 19.2 Worldwide 956 808 18.2 OTHER IMMUNOLOGY U.S. 1 0 * International 0 0  Worldwide 1 0 *", "text": "599 509 17.6 International 356 299 19.2 Worldwide 956 808 18.2 OTHER IMMUNOLOGY U.S.", "length": 84, "numbers_raw": ["599", "509", "17.6", "356", "299", "19.2", "956", "808", "18.2"], "numbers": [599.0, 509.0, 17.6, 356.0, 299.0, 19.2, 956.0, 808.0, 18.2], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 653, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change ZYTIGA / abiraterone acetate U.S. 7 9 ( 24.3 ) International 118 172 ( 31.3 ) Worldwide 125 181 ( 30.9 ) OTHER ONCOLOGY U.S. 47 33 42.9 International 42 41 4.6 Worldwide 89 73 21.7 Immunology U.S. 2,196 2,453 ( 10.5 ) International 1,510 1,794 ( 15.8 ) Worldwide 3,707 4,247 ( 12.7 ) REMICADE U.S. 314 266 18.1 U.S. Exports 10 27 ( 64.2 ) International 143 141 1.3 Worldwide 467 434 7.5 SIMPONI / SIMPONI ARIA U.S. 292 254 14.8 International 366 299 22.4 Worldwide 659 554 18.9 STELARA U.S. 981 1,396 ( 29.8 ) International 644 1,055 ( 38.9 ) Worldwide 1,625 2,451 ( 33.7 ) TREMFYA U.S. 599 509 17.6 International 356 299 19.2 Worldwide 956 808 18.2 OTHER IMMUNOLOGY U.S. 1 0 * International 0 0  Worldwide 1 0 *", "text": "1 0 * International 0 0  Worldwide 1 0 *", "length": 41, "numbers_raw": ["1", "0", "0", "0", "1", "0"], "numbers": [1.0, 0.0, 0.0, 0.0, 1.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 685, "tag": "div", "text_raw": "20", "text": "20", "length": 2, "numbers_raw": ["20"], "numbers": [20.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 686, "tag": "div", "text_raw": "20", "text": "20", "length": 2, "numbers_raw": ["20"], "numbers": [20.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 687, "tag": "div", "text_raw": "20", "text": "20", "length": 2, "numbers_raw": ["20"], "numbers": [20.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 688, "tag": "div", "text_raw": "20", "text": "20", "length": 2, "numbers_raw": ["20"], "numbers": [20.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 692, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Neuroscience U.S. 968 1,054 ( 8.1 ) International 679 749 ( 9.3 ) Worldwide 1,647 1,803 ( 8.6 ) CONCERTA / methylphenidate U.S. 38 41 ( 7.4 ) International 110 136 ( 18.9 ) Worldwide 148 177 ( 16.3 ) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 625 765 ( 18.2 ) International 277 292 ( 4.9 ) Worldwide 903 1,056 ( 14.5 ) SPRAVATO U.S. 276 191 45.0 International 43 34 25.0 Worldwide 320 225 41.9 OTHER NEUROSCIENCE U.S. 28 58 ( 50.6 ) International 248 287 ( 13.4 ) Worldwide 277 345 ( 19.6 ) Pulmonary Hypertension U.S. 744 766 ( 2.9 ) International 281 283 ( 0.6 ) Worldwide 1,025 1,049 ( 2.3 ) OPSUMIT/OPSYNVI (2) U.S. 363 356 2.1 International 159 169 ( 6.0 ) Worldwide 522 524 ( 0.5 ) UPTRAVI U.S. 365 392 ( 6.9 ) International 86 76 13.4 Worldwide 451 468 ( 3.6 ) OTHER PULMONARY HYPERTENSION (2) U.S. 15 18 ( 12.7 ) International 37 39 ( 4.6 ) Worldwide 52 56 ( 7.2 ) Infectious Diseases U.S. 315 324 ( 2.8 ) International 487 497 ( 1.9 ) Worldwide 802 821 ( 2.2 )", "text": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Neuroscience U.S.", "length": 111, "numbers_raw": ["30", "202", "5 M", "31", "202", "4"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": true, "has_percents": false}
{"idx_source": 692, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Neuroscience U.S. 968 1,054 ( 8.1 ) International 679 749 ( 9.3 ) Worldwide 1,647 1,803 ( 8.6 ) CONCERTA / methylphenidate U.S. 38 41 ( 7.4 ) International 110 136 ( 18.9 ) Worldwide 148 177 ( 16.3 ) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 625 765 ( 18.2 ) International 277 292 ( 4.9 ) Worldwide 903 1,056 ( 14.5 ) SPRAVATO U.S. 276 191 45.0 International 43 34 25.0 Worldwide 320 225 41.9 OTHER NEUROSCIENCE U.S. 28 58 ( 50.6 ) International 248 287 ( 13.4 ) Worldwide 277 345 ( 19.6 ) Pulmonary Hypertension U.S. 744 766 ( 2.9 ) International 281 283 ( 0.6 ) Worldwide 1,025 1,049 ( 2.3 ) OPSUMIT/OPSYNVI (2) U.S. 363 356 2.1 International 159 169 ( 6.0 ) Worldwide 522 524 ( 0.5 ) UPTRAVI U.S. 365 392 ( 6.9 ) International 86 76 13.4 Worldwide 451 468 ( 3.6 ) OTHER PULMONARY HYPERTENSION (2) U.S. 15 18 ( 12.7 ) International 37 39 ( 4.6 ) Worldwide 52 56 ( 7.2 ) Infectious Diseases U.S. 315 324 ( 2.8 ) International 487 497 ( 1.9 ) Worldwide 802 821 ( 2.2 )", "text": "968 1,054 ( 8.1 ) International 679 749 ( 9.3 ) Worldwide 1,647 1,803 ( 8.6 ) CONCERTA / methylphenidate U.S.", "length": 109, "numbers_raw": ["968", "1,054", "8.1", "679", "749", "9.3", "1,647", "1,803", "8.6"], "numbers": [968.0, 1054.0, 8.1, 679.0, 749.0, 9.3, 1647.0, 1803.0, 8.6], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 692, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Neuroscience U.S. 968 1,054 ( 8.1 ) International 679 749 ( 9.3 ) Worldwide 1,647 1,803 ( 8.6 ) CONCERTA / methylphenidate U.S. 38 41 ( 7.4 ) International 110 136 ( 18.9 ) Worldwide 148 177 ( 16.3 ) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 625 765 ( 18.2 ) International 277 292 ( 4.9 ) Worldwide 903 1,056 ( 14.5 ) SPRAVATO U.S. 276 191 45.0 International 43 34 25.0 Worldwide 320 225 41.9 OTHER NEUROSCIENCE U.S. 28 58 ( 50.6 ) International 248 287 ( 13.4 ) Worldwide 277 345 ( 19.6 ) Pulmonary Hypertension U.S. 744 766 ( 2.9 ) International 281 283 ( 0.6 ) Worldwide 1,025 1,049 ( 2.3 ) OPSUMIT/OPSYNVI (2) U.S. 363 356 2.1 International 159 169 ( 6.0 ) Worldwide 522 524 ( 0.5 ) UPTRAVI U.S. 365 392 ( 6.9 ) International 86 76 13.4 Worldwide 451 468 ( 3.6 ) OTHER PULMONARY HYPERTENSION (2) U.S. 15 18 ( 12.7 ) International 37 39 ( 4.6 ) Worldwide 52 56 ( 7.2 ) Infectious Diseases U.S. 315 324 ( 2.8 ) International 487 497 ( 1.9 ) Worldwide 802 821 ( 2.2 )", "text": "38 41 ( 7.4 ) International 110 136 ( 18.9 ) Worldwide 148 177 ( 16.3 ) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S.", "length": 129, "numbers_raw": ["38", "41", "7.4", "110", "136", "18.9", "148", "177", "16.3"], "numbers": [38.0, 41.0, 7.4, 110.0, 136.0, 18.9, 148.0, 177.0, 16.3], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 692, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Neuroscience U.S. 968 1,054 ( 8.1 ) International 679 749 ( 9.3 ) Worldwide 1,647 1,803 ( 8.6 ) CONCERTA / methylphenidate U.S. 38 41 ( 7.4 ) International 110 136 ( 18.9 ) Worldwide 148 177 ( 16.3 ) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 625 765 ( 18.2 ) International 277 292 ( 4.9 ) Worldwide 903 1,056 ( 14.5 ) SPRAVATO U.S. 276 191 45.0 International 43 34 25.0 Worldwide 320 225 41.9 OTHER NEUROSCIENCE U.S. 28 58 ( 50.6 ) International 248 287 ( 13.4 ) Worldwide 277 345 ( 19.6 ) Pulmonary Hypertension U.S. 744 766 ( 2.9 ) International 281 283 ( 0.6 ) Worldwide 1,025 1,049 ( 2.3 ) OPSUMIT/OPSYNVI (2) U.S. 363 356 2.1 International 159 169 ( 6.0 ) Worldwide 522 524 ( 0.5 ) UPTRAVI U.S. 365 392 ( 6.9 ) International 86 76 13.4 Worldwide 451 468 ( 3.6 ) OTHER PULMONARY HYPERTENSION (2) U.S. 15 18 ( 12.7 ) International 37 39 ( 4.6 ) Worldwide 52 56 ( 7.2 ) Infectious Diseases U.S. 315 324 ( 2.8 ) International 487 497 ( 1.9 ) Worldwide 802 821 ( 2.2 )", "text": "625 765 ( 18.2 ) International 277 292 ( 4.9 ) Worldwide 903 1,056 ( 14.5 ) SPRAVATO U.S.", "length": 89, "numbers_raw": ["625", "765", "18.2", "277", "292", "4.9", "903", "1,056", "14.5"], "numbers": [625.0, 765.0, 18.2, 277.0, 292.0, 4.9, 903.0, 1056.0, 14.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 692, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Neuroscience U.S. 968 1,054 ( 8.1 ) International 679 749 ( 9.3 ) Worldwide 1,647 1,803 ( 8.6 ) CONCERTA / methylphenidate U.S. 38 41 ( 7.4 ) International 110 136 ( 18.9 ) Worldwide 148 177 ( 16.3 ) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 625 765 ( 18.2 ) International 277 292 ( 4.9 ) Worldwide 903 1,056 ( 14.5 ) SPRAVATO U.S. 276 191 45.0 International 43 34 25.0 Worldwide 320 225 41.9 OTHER NEUROSCIENCE U.S. 28 58 ( 50.6 ) International 248 287 ( 13.4 ) Worldwide 277 345 ( 19.6 ) Pulmonary Hypertension U.S. 744 766 ( 2.9 ) International 281 283 ( 0.6 ) Worldwide 1,025 1,049 ( 2.3 ) OPSUMIT/OPSYNVI (2) U.S. 363 356 2.1 International 159 169 ( 6.0 ) Worldwide 522 524 ( 0.5 ) UPTRAVI U.S. 365 392 ( 6.9 ) International 86 76 13.4 Worldwide 451 468 ( 3.6 ) OTHER PULMONARY HYPERTENSION (2) U.S. 15 18 ( 12.7 ) International 37 39 ( 4.6 ) Worldwide 52 56 ( 7.2 ) Infectious Diseases U.S. 315 324 ( 2.8 ) International 487 497 ( 1.9 ) Worldwide 802 821 ( 2.2 )", "text": "276 191 45.0 International 43 34 25.0 Worldwide 320 225 41.9 OTHER NEUROSCIENCE U.S.", "length": 84, "numbers_raw": ["276", "191", "45.0", "43", "34", "25.0", "320", "225", "41.9"], "numbers": [276.0, 191.0, 45.0, 43.0, 34.0, 25.0, 320.0, 225.0, 41.9], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": true, "has_percents": false}
{"idx_source": 692, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Neuroscience U.S. 968 1,054 ( 8.1 ) International 679 749 ( 9.3 ) Worldwide 1,647 1,803 ( 8.6 ) CONCERTA / methylphenidate U.S. 38 41 ( 7.4 ) International 110 136 ( 18.9 ) Worldwide 148 177 ( 16.3 ) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 625 765 ( 18.2 ) International 277 292 ( 4.9 ) Worldwide 903 1,056 ( 14.5 ) SPRAVATO U.S. 276 191 45.0 International 43 34 25.0 Worldwide 320 225 41.9 OTHER NEUROSCIENCE U.S. 28 58 ( 50.6 ) International 248 287 ( 13.4 ) Worldwide 277 345 ( 19.6 ) Pulmonary Hypertension U.S. 744 766 ( 2.9 ) International 281 283 ( 0.6 ) Worldwide 1,025 1,049 ( 2.3 ) OPSUMIT/OPSYNVI (2) U.S. 363 356 2.1 International 159 169 ( 6.0 ) Worldwide 522 524 ( 0.5 ) UPTRAVI U.S. 365 392 ( 6.9 ) International 86 76 13.4 Worldwide 451 468 ( 3.6 ) OTHER PULMONARY HYPERTENSION (2) U.S. 15 18 ( 12.7 ) International 37 39 ( 4.6 ) Worldwide 52 56 ( 7.2 ) Infectious Diseases U.S. 315 324 ( 2.8 ) International 487 497 ( 1.9 ) Worldwide 802 821 ( 2.2 )", "text": "28 58 ( 50.6 ) International 248 287 ( 13.4 ) Worldwide 277 345 ( 19.6 ) Pulmonary Hypertension U.S.", "length": 100, "numbers_raw": ["28", "58", "50.6", "248", "287", "13.4", "277", "345", "19.6"], "numbers": [28.0, 58.0, 50.6, 248.0, 287.0, 13.4, 277.0, 345.0, 19.6], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 692, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Neuroscience U.S. 968 1,054 ( 8.1 ) International 679 749 ( 9.3 ) Worldwide 1,647 1,803 ( 8.6 ) CONCERTA / methylphenidate U.S. 38 41 ( 7.4 ) International 110 136 ( 18.9 ) Worldwide 148 177 ( 16.3 ) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 625 765 ( 18.2 ) International 277 292 ( 4.9 ) Worldwide 903 1,056 ( 14.5 ) SPRAVATO U.S. 276 191 45.0 International 43 34 25.0 Worldwide 320 225 41.9 OTHER NEUROSCIENCE U.S. 28 58 ( 50.6 ) International 248 287 ( 13.4 ) Worldwide 277 345 ( 19.6 ) Pulmonary Hypertension U.S. 744 766 ( 2.9 ) International 281 283 ( 0.6 ) Worldwide 1,025 1,049 ( 2.3 ) OPSUMIT/OPSYNVI (2) U.S. 363 356 2.1 International 159 169 ( 6.0 ) Worldwide 522 524 ( 0.5 ) UPTRAVI U.S. 365 392 ( 6.9 ) International 86 76 13.4 Worldwide 451 468 ( 3.6 ) OTHER PULMONARY HYPERTENSION (2) U.S. 15 18 ( 12.7 ) International 37 39 ( 4.6 ) Worldwide 52 56 ( 7.2 ) Infectious Diseases U.S. 315 324 ( 2.8 ) International 487 497 ( 1.9 ) Worldwide 802 821 ( 2.2 )", "text": "744 766 ( 2.9 ) International 281 283 ( 0.6 ) Worldwide 1,025 1,049 ( 2.3 ) OPSUMIT/OPSYNVI (2) U.S.", "length": 100, "numbers_raw": ["744", "766", "2.9", "281", "283", "0.6", "1,025", "1,049", "2.3", "2"], "numbers": [744.0, 766.0, 2.9, 281.0, 283.0, 0.6, 1025.0, 1049.0, 2.3, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 692, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Neuroscience U.S. 968 1,054 ( 8.1 ) International 679 749 ( 9.3 ) Worldwide 1,647 1,803 ( 8.6 ) CONCERTA / methylphenidate U.S. 38 41 ( 7.4 ) International 110 136 ( 18.9 ) Worldwide 148 177 ( 16.3 ) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 625 765 ( 18.2 ) International 277 292 ( 4.9 ) Worldwide 903 1,056 ( 14.5 ) SPRAVATO U.S. 276 191 45.0 International 43 34 25.0 Worldwide 320 225 41.9 OTHER NEUROSCIENCE U.S. 28 58 ( 50.6 ) International 248 287 ( 13.4 ) Worldwide 277 345 ( 19.6 ) Pulmonary Hypertension U.S. 744 766 ( 2.9 ) International 281 283 ( 0.6 ) Worldwide 1,025 1,049 ( 2.3 ) OPSUMIT/OPSYNVI (2) U.S. 363 356 2.1 International 159 169 ( 6.0 ) Worldwide 522 524 ( 0.5 ) UPTRAVI U.S. 365 392 ( 6.9 ) International 86 76 13.4 Worldwide 451 468 ( 3.6 ) OTHER PULMONARY HYPERTENSION (2) U.S. 15 18 ( 12.7 ) International 37 39 ( 4.6 ) Worldwide 52 56 ( 7.2 ) Infectious Diseases U.S. 315 324 ( 2.8 ) International 487 497 ( 1.9 ) Worldwide 802 821 ( 2.2 )", "text": "363 356 2.1 International 159 169 ( 6.0 ) Worldwide 522 524 ( 0.5 ) UPTRAVI U.S.", "length": 80, "numbers_raw": ["363", "356", "2.1", "159", "169", "6.0", "522", "524", "0.5"], "numbers": [363.0, 356.0, 2.1, 159.0, 169.0, 6.0, 522.0, 524.0, 0.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 692, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Neuroscience U.S. 968 1,054 ( 8.1 ) International 679 749 ( 9.3 ) Worldwide 1,647 1,803 ( 8.6 ) CONCERTA / methylphenidate U.S. 38 41 ( 7.4 ) International 110 136 ( 18.9 ) Worldwide 148 177 ( 16.3 ) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 625 765 ( 18.2 ) International 277 292 ( 4.9 ) Worldwide 903 1,056 ( 14.5 ) SPRAVATO U.S. 276 191 45.0 International 43 34 25.0 Worldwide 320 225 41.9 OTHER NEUROSCIENCE U.S. 28 58 ( 50.6 ) International 248 287 ( 13.4 ) Worldwide 277 345 ( 19.6 ) Pulmonary Hypertension U.S. 744 766 ( 2.9 ) International 281 283 ( 0.6 ) Worldwide 1,025 1,049 ( 2.3 ) OPSUMIT/OPSYNVI (2) U.S. 363 356 2.1 International 159 169 ( 6.0 ) Worldwide 522 524 ( 0.5 ) UPTRAVI U.S. 365 392 ( 6.9 ) International 86 76 13.4 Worldwide 451 468 ( 3.6 ) OTHER PULMONARY HYPERTENSION (2) U.S. 15 18 ( 12.7 ) International 37 39 ( 4.6 ) Worldwide 52 56 ( 7.2 ) Infectious Diseases U.S. 315 324 ( 2.8 ) International 487 497 ( 1.9 ) Worldwide 802 821 ( 2.2 )", "text": "365 392 ( 6.9 ) International 86 76 13.4 Worldwide 451 468 ( 3.6 ) OTHER PULMONARY HYPERTENSION (2) U.S.", "length": 104, "numbers_raw": ["365", "392", "6.9", "86", "76", "13.4", "451", "468", "3.6", "2"], "numbers": [365.0, 392.0, 6.9, 86.0, 76.0, 13.4, 451.0, 468.0, 3.6, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 692, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Neuroscience U.S. 968 1,054 ( 8.1 ) International 679 749 ( 9.3 ) Worldwide 1,647 1,803 ( 8.6 ) CONCERTA / methylphenidate U.S. 38 41 ( 7.4 ) International 110 136 ( 18.9 ) Worldwide 148 177 ( 16.3 ) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 625 765 ( 18.2 ) International 277 292 ( 4.9 ) Worldwide 903 1,056 ( 14.5 ) SPRAVATO U.S. 276 191 45.0 International 43 34 25.0 Worldwide 320 225 41.9 OTHER NEUROSCIENCE U.S. 28 58 ( 50.6 ) International 248 287 ( 13.4 ) Worldwide 277 345 ( 19.6 ) Pulmonary Hypertension U.S. 744 766 ( 2.9 ) International 281 283 ( 0.6 ) Worldwide 1,025 1,049 ( 2.3 ) OPSUMIT/OPSYNVI (2) U.S. 363 356 2.1 International 159 169 ( 6.0 ) Worldwide 522 524 ( 0.5 ) UPTRAVI U.S. 365 392 ( 6.9 ) International 86 76 13.4 Worldwide 451 468 ( 3.6 ) OTHER PULMONARY HYPERTENSION (2) U.S. 15 18 ( 12.7 ) International 37 39 ( 4.6 ) Worldwide 52 56 ( 7.2 ) Infectious Diseases U.S. 315 324 ( 2.8 ) International 487 497 ( 1.9 ) Worldwide 802 821 ( 2.2 )", "text": "15 18 ( 12.7 ) International 37 39 ( 4.6 ) Worldwide 52 56 ( 7.2 ) Infectious Diseases U.S.", "length": 91, "numbers_raw": ["15", "18", "12.7", "37", "39", "4.6", "52", "56", "7.2"], "numbers": [15.0, 18.0, 12.7, 37.0, 39.0, 4.6, 52.0, 56.0, 7.2], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 692, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Neuroscience U.S. 968 1,054 ( 8.1 ) International 679 749 ( 9.3 ) Worldwide 1,647 1,803 ( 8.6 ) CONCERTA / methylphenidate U.S. 38 41 ( 7.4 ) International 110 136 ( 18.9 ) Worldwide 148 177 ( 16.3 ) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 625 765 ( 18.2 ) International 277 292 ( 4.9 ) Worldwide 903 1,056 ( 14.5 ) SPRAVATO U.S. 276 191 45.0 International 43 34 25.0 Worldwide 320 225 41.9 OTHER NEUROSCIENCE U.S. 28 58 ( 50.6 ) International 248 287 ( 13.4 ) Worldwide 277 345 ( 19.6 ) Pulmonary Hypertension U.S. 744 766 ( 2.9 ) International 281 283 ( 0.6 ) Worldwide 1,025 1,049 ( 2.3 ) OPSUMIT/OPSYNVI (2) U.S. 363 356 2.1 International 159 169 ( 6.0 ) Worldwide 522 524 ( 0.5 ) UPTRAVI U.S. 365 392 ( 6.9 ) International 86 76 13.4 Worldwide 451 468 ( 3.6 ) OTHER PULMONARY HYPERTENSION (2) U.S. 15 18 ( 12.7 ) International 37 39 ( 4.6 ) Worldwide 52 56 ( 7.2 ) Infectious Diseases U.S. 315 324 ( 2.8 ) International 487 497 ( 1.9 ) Worldwide 802 821 ( 2.2 )", "text": "315 324 ( 2.8 ) International 487 497 ( 1.9 ) Worldwide 802 821 ( 2.2 )", "length": 71, "numbers_raw": ["315", "324", "2.8", "487", "497", "1.9", "802", "821", "2.2"], "numbers": [315.0, 324.0, 2.8, 487.0, 497.0, 1.9, 802.0, 821.0, 2.2], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 700, "tag": "div", "text_raw": "INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA", "text": "INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 714, "tag": "div", "text_raw": "OPSUMIT/OPSYNVI (2)", "text": "OPSUMIT/OPSYNVI (2)", "length": 19, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 716, "tag": "div", "text_raw": "OTHER PULMONARY HYPERTENSION (2)", "text": "OTHER PULMONARY HYPERTENSION (2)", "length": 32, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 721, "tag": "div", "text_raw": "Form 10-Q 21", "text": "Form 10-Q 21", "length": 12, "numbers_raw": ["10", "21"], "numbers": [10.0, 21.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 722, "tag": "div", "text_raw": "Form 10-Q 21", "text": "Form 10-Q 21", "length": 12, "numbers_raw": ["10", "21"], "numbers": [10.0, 21.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 723, "tag": "div", "text_raw": "Form 10-Q 21", "text": "Form 10-Q 21", "length": 12, "numbers_raw": ["10", "21"], "numbers": [10.0, 21.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 724, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 725, "tag": "div", "text_raw": "21", "text": "21", "length": 2, "numbers_raw": ["21"], "numbers": [21.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 728, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change EDURANT / rilpivirine U.S. 8 8 ( 1.3 ) International 350 315 11.0 Worldwide 358 323 10.7 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 305 314 ( 2.9 ) International 98 104 ( 6.2 ) Worldwide 403 418 ( 3.7 ) OTHER INFECTIOUS DISEASES (3) U.S. 2 2 7.7 International 39 77 ( 48.8 ) Worldwide 41 78 ( 47.6 ) Cardiovascular / Metabolism / Other U.S. 855 631 35.4 International 158 197 ( 19.7 ) Worldwide 1,013 829 22.3 XARELTO U.S. 690 518 33.3 International    Worldwide 690 518 33.3 OTHER U.S. 165 114 45.0 International 158 197 ( 19.7 ) Worldwide 323 311 3.9 TOTAL INNOVATIVE MEDICINE U.S. 8,092 7,612 6.3 International 5,781 5,950 ( 2.9 ) Worldwide 13,873 13,562 2.3 MEDTECH Cardiovascular U.S. 1,261 1,025 23.0 International 842 781 7.8 Worldwide 2,103 1,806 16.4 ELECTROPHYSIOLOGY U.S. 684 692 ( 1.1 ) International 638 652 ( 2.0 ) Worldwide 1,323 1,344 ( 1.6 ) ABIOMED U.S. 339 303 11.9 International 81 67 19.7 Worldwide 420 371 13.3", "text": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change EDURANT / rilpivirine U.S.", "length": 120, "numbers_raw": ["30", "202", "5 M", "31", "202", "4"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 728, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change EDURANT / rilpivirine U.S. 8 8 ( 1.3 ) International 350 315 11.0 Worldwide 358 323 10.7 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 305 314 ( 2.9 ) International 98 104 ( 6.2 ) Worldwide 403 418 ( 3.7 ) OTHER INFECTIOUS DISEASES (3) U.S. 2 2 7.7 International 39 77 ( 48.8 ) Worldwide 41 78 ( 47.6 ) Cardiovascular / Metabolism / Other U.S. 855 631 35.4 International 158 197 ( 19.7 ) Worldwide 1,013 829 22.3 XARELTO U.S. 690 518 33.3 International    Worldwide 690 518 33.3 OTHER U.S. 165 114 45.0 International 158 197 ( 19.7 ) Worldwide 323 311 3.9 TOTAL INNOVATIVE MEDICINE U.S. 8,092 7,612 6.3 International 5,781 5,950 ( 2.9 ) Worldwide 13,873 13,562 2.3 MEDTECH Cardiovascular U.S. 1,261 1,025 23.0 International 842 781 7.8 Worldwide 2,103 1,806 16.4 ELECTROPHYSIOLOGY U.S. 684 692 ( 1.1 ) International 638 652 ( 2.0 ) Worldwide 1,323 1,344 ( 1.6 ) ABIOMED U.S. 339 303 11.9 International 81 67 19.7 Worldwide 420 371 13.3", "text": "8 8 ( 1.3 ) International 350 315 11.0 Worldwide 358 323 10.7 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S.", "length": 108, "numbers_raw": ["8", "8", "1.3", "350", "315", "11.0", "358", "323", "10.7"], "numbers": [8.0, 8.0, 1.3, 350.0, 315.0, 11.0, 358.0, 323.0, 10.7], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 728, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change EDURANT / rilpivirine U.S. 8 8 ( 1.3 ) International 350 315 11.0 Worldwide 358 323 10.7 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 305 314 ( 2.9 ) International 98 104 ( 6.2 ) Worldwide 403 418 ( 3.7 ) OTHER INFECTIOUS DISEASES (3) U.S. 2 2 7.7 International 39 77 ( 48.8 ) Worldwide 41 78 ( 47.6 ) Cardiovascular / Metabolism / Other U.S. 855 631 35.4 International 158 197 ( 19.7 ) Worldwide 1,013 829 22.3 XARELTO U.S. 690 518 33.3 International    Worldwide 690 518 33.3 OTHER U.S. 165 114 45.0 International 158 197 ( 19.7 ) Worldwide 323 311 3.9 TOTAL INNOVATIVE MEDICINE U.S. 8,092 7,612 6.3 International 5,781 5,950 ( 2.9 ) Worldwide 13,873 13,562 2.3 MEDTECH Cardiovascular U.S. 1,261 1,025 23.0 International 842 781 7.8 Worldwide 2,103 1,806 16.4 ELECTROPHYSIOLOGY U.S. 684 692 ( 1.1 ) International 638 652 ( 2.0 ) Worldwide 1,323 1,344 ( 1.6 ) ABIOMED U.S. 339 303 11.9 International 81 67 19.7 Worldwide 420 371 13.3", "text": "305 314 ( 2.9 ) International 98 104 ( 6.2 ) Worldwide 403 418 ( 3.7 ) OTHER INFECTIOUS DISEASES (3) U.S.", "length": 105, "numbers_raw": ["305", "314", "2.9", "98", "104", "6.2", "403", "418", "3.7", "3"], "numbers": [305.0, 314.0, 2.9, 98.0, 104.0, 6.2, 403.0, 418.0, 3.7, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 728, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change EDURANT / rilpivirine U.S. 8 8 ( 1.3 ) International 350 315 11.0 Worldwide 358 323 10.7 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 305 314 ( 2.9 ) International 98 104 ( 6.2 ) Worldwide 403 418 ( 3.7 ) OTHER INFECTIOUS DISEASES (3) U.S. 2 2 7.7 International 39 77 ( 48.8 ) Worldwide 41 78 ( 47.6 ) Cardiovascular / Metabolism / Other U.S. 855 631 35.4 International 158 197 ( 19.7 ) Worldwide 1,013 829 22.3 XARELTO U.S. 690 518 33.3 International    Worldwide 690 518 33.3 OTHER U.S. 165 114 45.0 International 158 197 ( 19.7 ) Worldwide 323 311 3.9 TOTAL INNOVATIVE MEDICINE U.S. 8,092 7,612 6.3 International 5,781 5,950 ( 2.9 ) Worldwide 13,873 13,562 2.3 MEDTECH Cardiovascular U.S. 1,261 1,025 23.0 International 842 781 7.8 Worldwide 2,103 1,806 16.4 ELECTROPHYSIOLOGY U.S. 684 692 ( 1.1 ) International 638 652 ( 2.0 ) Worldwide 1,323 1,344 ( 1.6 ) ABIOMED U.S. 339 303 11.9 International 81 67 19.7 Worldwide 420 371 13.3", "text": "2 2 7.7 International 39 77 ( 48.8 ) Worldwide 41 78 ( 47.6 ) Cardiovascular / Metabolism / Other U.S.", "length": 102, "numbers_raw": ["2", "2", "7.7", "39", "77", "48.8", "41", "78", "47.6"], "numbers": [2.0, 2.0, 7.7, 39.0, 77.0, 48.8, 41.0, 78.0, 47.6], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 728, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change EDURANT / rilpivirine U.S. 8 8 ( 1.3 ) International 350 315 11.0 Worldwide 358 323 10.7 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 305 314 ( 2.9 ) International 98 104 ( 6.2 ) Worldwide 403 418 ( 3.7 ) OTHER INFECTIOUS DISEASES (3) U.S. 2 2 7.7 International 39 77 ( 48.8 ) Worldwide 41 78 ( 47.6 ) Cardiovascular / Metabolism / Other U.S. 855 631 35.4 International 158 197 ( 19.7 ) Worldwide 1,013 829 22.3 XARELTO U.S. 690 518 33.3 International    Worldwide 690 518 33.3 OTHER U.S. 165 114 45.0 International 158 197 ( 19.7 ) Worldwide 323 311 3.9 TOTAL INNOVATIVE MEDICINE U.S. 8,092 7,612 6.3 International 5,781 5,950 ( 2.9 ) Worldwide 13,873 13,562 2.3 MEDTECH Cardiovascular U.S. 1,261 1,025 23.0 International 842 781 7.8 Worldwide 2,103 1,806 16.4 ELECTROPHYSIOLOGY U.S. 684 692 ( 1.1 ) International 638 652 ( 2.0 ) Worldwide 1,323 1,344 ( 1.6 ) ABIOMED U.S. 339 303 11.9 International 81 67 19.7 Worldwide 420 371 13.3", "text": "855 631 35.4 International 158 197 ( 19.7 ) Worldwide 1,013 829 22.3 XARELTO U.S.", "length": 81, "numbers_raw": ["855", "631", "35.4", "158", "197", "19.7", "1,013", "829", "22.3"], "numbers": [855.0, 631.0, 35.4, 158.0, 197.0, 19.7, 1013.0, 829.0, 22.3], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 728, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change EDURANT / rilpivirine U.S. 8 8 ( 1.3 ) International 350 315 11.0 Worldwide 358 323 10.7 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 305 314 ( 2.9 ) International 98 104 ( 6.2 ) Worldwide 403 418 ( 3.7 ) OTHER INFECTIOUS DISEASES (3) U.S. 2 2 7.7 International 39 77 ( 48.8 ) Worldwide 41 78 ( 47.6 ) Cardiovascular / Metabolism / Other U.S. 855 631 35.4 International 158 197 ( 19.7 ) Worldwide 1,013 829 22.3 XARELTO U.S. 690 518 33.3 International    Worldwide 690 518 33.3 OTHER U.S. 165 114 45.0 International 158 197 ( 19.7 ) Worldwide 323 311 3.9 TOTAL INNOVATIVE MEDICINE U.S. 8,092 7,612 6.3 International 5,781 5,950 ( 2.9 ) Worldwide 13,873 13,562 2.3 MEDTECH Cardiovascular U.S. 1,261 1,025 23.0 International 842 781 7.8 Worldwide 2,103 1,806 16.4 ELECTROPHYSIOLOGY U.S. 684 692 ( 1.1 ) International 638 652 ( 2.0 ) Worldwide 1,323 1,344 ( 1.6 ) ABIOMED U.S. 339 303 11.9 International 81 67 19.7 Worldwide 420 371 13.3", "text": "690 518 33.3 International    Worldwide 690 518 33.3 OTHER U.S.", "length": 66, "numbers_raw": ["690", "518", "33.3", "690", "518", "33.3"], "numbers": [690.0, 518.0, 33.3, 690.0, 518.0, 33.3], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 728, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change EDURANT / rilpivirine U.S. 8 8 ( 1.3 ) International 350 315 11.0 Worldwide 358 323 10.7 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 305 314 ( 2.9 ) International 98 104 ( 6.2 ) Worldwide 403 418 ( 3.7 ) OTHER INFECTIOUS DISEASES (3) U.S. 2 2 7.7 International 39 77 ( 48.8 ) Worldwide 41 78 ( 47.6 ) Cardiovascular / Metabolism / Other U.S. 855 631 35.4 International 158 197 ( 19.7 ) Worldwide 1,013 829 22.3 XARELTO U.S. 690 518 33.3 International    Worldwide 690 518 33.3 OTHER U.S. 165 114 45.0 International 158 197 ( 19.7 ) Worldwide 323 311 3.9 TOTAL INNOVATIVE MEDICINE U.S. 8,092 7,612 6.3 International 5,781 5,950 ( 2.9 ) Worldwide 13,873 13,562 2.3 MEDTECH Cardiovascular U.S. 1,261 1,025 23.0 International 842 781 7.8 Worldwide 2,103 1,806 16.4 ELECTROPHYSIOLOGY U.S. 684 692 ( 1.1 ) International 638 652 ( 2.0 ) Worldwide 1,323 1,344 ( 1.6 ) ABIOMED U.S. 339 303 11.9 International 81 67 19.7 Worldwide 420 371 13.3", "text": "165 114 45.0 International 158 197 ( 19.7 ) Worldwide 323 311 3.9 TOTAL INNOVATIVE MEDICINE U.S.", "length": 96, "numbers_raw": ["165", "114", "45.0", "158", "197", "19.7", "323", "311", "3.9"], "numbers": [165.0, 114.0, 45.0, 158.0, 197.0, 19.7, 323.0, 311.0, 3.9], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 728, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change EDURANT / rilpivirine U.S. 8 8 ( 1.3 ) International 350 315 11.0 Worldwide 358 323 10.7 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 305 314 ( 2.9 ) International 98 104 ( 6.2 ) Worldwide 403 418 ( 3.7 ) OTHER INFECTIOUS DISEASES (3) U.S. 2 2 7.7 International 39 77 ( 48.8 ) Worldwide 41 78 ( 47.6 ) Cardiovascular / Metabolism / Other U.S. 855 631 35.4 International 158 197 ( 19.7 ) Worldwide 1,013 829 22.3 XARELTO U.S. 690 518 33.3 International    Worldwide 690 518 33.3 OTHER U.S. 165 114 45.0 International 158 197 ( 19.7 ) Worldwide 323 311 3.9 TOTAL INNOVATIVE MEDICINE U.S. 8,092 7,612 6.3 International 5,781 5,950 ( 2.9 ) Worldwide 13,873 13,562 2.3 MEDTECH Cardiovascular U.S. 1,261 1,025 23.0 International 842 781 7.8 Worldwide 2,103 1,806 16.4 ELECTROPHYSIOLOGY U.S. 684 692 ( 1.1 ) International 638 652 ( 2.0 ) Worldwide 1,323 1,344 ( 1.6 ) ABIOMED U.S. 339 303 11.9 International 81 67 19.7 Worldwide 420 371 13.3", "text": "8,092 7,612 6.3 International 5,781 5,950 ( 2.9 ) Worldwide 13,873 13,562 2.3 MEDTECH Cardiovascular U.S.", "length": 105, "numbers_raw": ["8,092", "7,612", "6.3", "5,781", "5,950", "2.9", "13,873", "13,562", "2.3 M"], "numbers": [8092.0, 7612.0, 6.3, 5781.0, 5950.0, 2.9, 13873.0, 13562.0, 2300000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 728, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change EDURANT / rilpivirine U.S. 8 8 ( 1.3 ) International 350 315 11.0 Worldwide 358 323 10.7 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 305 314 ( 2.9 ) International 98 104 ( 6.2 ) Worldwide 403 418 ( 3.7 ) OTHER INFECTIOUS DISEASES (3) U.S. 2 2 7.7 International 39 77 ( 48.8 ) Worldwide 41 78 ( 47.6 ) Cardiovascular / Metabolism / Other U.S. 855 631 35.4 International 158 197 ( 19.7 ) Worldwide 1,013 829 22.3 XARELTO U.S. 690 518 33.3 International    Worldwide 690 518 33.3 OTHER U.S. 165 114 45.0 International 158 197 ( 19.7 ) Worldwide 323 311 3.9 TOTAL INNOVATIVE MEDICINE U.S. 8,092 7,612 6.3 International 5,781 5,950 ( 2.9 ) Worldwide 13,873 13,562 2.3 MEDTECH Cardiovascular U.S. 1,261 1,025 23.0 International 842 781 7.8 Worldwide 2,103 1,806 16.4 ELECTROPHYSIOLOGY U.S. 684 692 ( 1.1 ) International 638 652 ( 2.0 ) Worldwide 1,323 1,344 ( 1.6 ) ABIOMED U.S. 339 303 11.9 International 81 67 19.7 Worldwide 420 371 13.3", "text": "1,261 1,025 23.0 International 842 781 7.8 Worldwide 2,103 1,806 16.4 ELECTROPHYSIOLOGY U.S.", "length": 92, "numbers_raw": ["1,261", "1,025", "23.0", "842", "781", "7.8", "2,103", "1,806", "16.4"], "numbers": [1261.0, 1025.0, 23.0, 842.0, 781.0, 7.8, 2103.0, 1806.0, 16.4], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 728, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change EDURANT / rilpivirine U.S. 8 8 ( 1.3 ) International 350 315 11.0 Worldwide 358 323 10.7 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 305 314 ( 2.9 ) International 98 104 ( 6.2 ) Worldwide 403 418 ( 3.7 ) OTHER INFECTIOUS DISEASES (3) U.S. 2 2 7.7 International 39 77 ( 48.8 ) Worldwide 41 78 ( 47.6 ) Cardiovascular / Metabolism / Other U.S. 855 631 35.4 International 158 197 ( 19.7 ) Worldwide 1,013 829 22.3 XARELTO U.S. 690 518 33.3 International    Worldwide 690 518 33.3 OTHER U.S. 165 114 45.0 International 158 197 ( 19.7 ) Worldwide 323 311 3.9 TOTAL INNOVATIVE MEDICINE U.S. 8,092 7,612 6.3 International 5,781 5,950 ( 2.9 ) Worldwide 13,873 13,562 2.3 MEDTECH Cardiovascular U.S. 1,261 1,025 23.0 International 842 781 7.8 Worldwide 2,103 1,806 16.4 ELECTROPHYSIOLOGY U.S. 684 692 ( 1.1 ) International 638 652 ( 2.0 ) Worldwide 1,323 1,344 ( 1.6 ) ABIOMED U.S. 339 303 11.9 International 81 67 19.7 Worldwide 420 371 13.3", "text": "684 692 ( 1.1 ) International 638 652 ( 2.0 ) Worldwide 1,323 1,344 ( 1.6 ) ABIOMED U.S.", "length": 88, "numbers_raw": ["684", "692", "1.1", "638", "652", "2.0", "1,323", "1,344", "1.6"], "numbers": [684.0, 692.0, 1.1, 638.0, 652.0, 2.0, 1323.0, 1344.0, 1.6], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 728, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change EDURANT / rilpivirine U.S. 8 8 ( 1.3 ) International 350 315 11.0 Worldwide 358 323 10.7 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 305 314 ( 2.9 ) International 98 104 ( 6.2 ) Worldwide 403 418 ( 3.7 ) OTHER INFECTIOUS DISEASES (3) U.S. 2 2 7.7 International 39 77 ( 48.8 ) Worldwide 41 78 ( 47.6 ) Cardiovascular / Metabolism / Other U.S. 855 631 35.4 International 158 197 ( 19.7 ) Worldwide 1,013 829 22.3 XARELTO U.S. 690 518 33.3 International    Worldwide 690 518 33.3 OTHER U.S. 165 114 45.0 International 158 197 ( 19.7 ) Worldwide 323 311 3.9 TOTAL INNOVATIVE MEDICINE U.S. 8,092 7,612 6.3 International 5,781 5,950 ( 2.9 ) Worldwide 13,873 13,562 2.3 MEDTECH Cardiovascular U.S. 1,261 1,025 23.0 International 842 781 7.8 Worldwide 2,103 1,806 16.4 ELECTROPHYSIOLOGY U.S. 684 692 ( 1.1 ) International 638 652 ( 2.0 ) Worldwide 1,323 1,344 ( 1.6 ) ABIOMED U.S. 339 303 11.9 International 81 67 19.7 Worldwide 420 371 13.3", "text": "339 303 11.9 International 81 67 19.7 Worldwide 420 371 13.3", "length": 60, "numbers_raw": ["339", "303", "11.9", "81", "67", "19.7", "420", "371", "13.3"], "numbers": [339.0, 303.0, 11.9, 81.0, 67.0, 19.7, 420.0, 371.0, 13.3], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 733, "tag": "div", "text_raw": "PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA", "text": "PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA", "length": 41, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 737, "tag": "div", "text_raw": "OTHER INFECTIOUS DISEASES (3)", "text": "OTHER INFECTIOUS DISEASES (3)", "length": 29, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 745, "tag": "div", "text_raw": "22", "text": "22", "length": 2, "numbers_raw": ["22"], "numbers": [22.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 746, "tag": "div", "text_raw": "22", "text": "22", "length": 2, "numbers_raw": ["22"], "numbers": [22.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 747, "tag": "div", "text_raw": "22", "text": "22", "length": 2, "numbers_raw": ["22"], "numbers": [22.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 748, "tag": "div", "text_raw": "22", "text": "22", "length": 2, "numbers_raw": ["22"], "numbers": [22.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 752, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change SHOCKWAVE U.S. 206  * International 52  * Worldwide 258  * OTHER CARDIOVASCULAR U.S. 32 30 7.1 International 72 62 15.1 Worldwide 103 92 12.5 Orthopaedics U.S. 1,384 1,448 ( 4.4 ) International 857 892 ( 3.9 ) Worldwide 2,241 2,340 ( 4.2 ) HIPS U.S. 263 270 ( 2.5 ) International 146 152 ( 4.0 ) Worldwide 409 422 ( 3.1 ) KNEES U.S. 231 242 ( 4.3 ) International 158 160 ( 1.0 ) Worldwide 389 401 ( 3.0 ) TRAUMA U.S. 502 504 ( 0.5 ) International 270 261 3.7 Worldwide 772 765 0.9 SPINE, SPORTS & OTHER U.S. 388 432 ( 10.2 ) International 283 320 ( 11.6 ) Worldwide 671 752 ( 10.8 ) Surgery U.S. 1,002 987 1.5 International 1,394 1,429 ( 2.5 ) Worldwide 2,396 2,416 ( 0.8 ) ADVANCED U.S. 457 446 2.7 International 616 641 ( 4.0 ) Worldwide 1,073 1,087 ( 1.2 ) GENERAL U.S. 544 542 0.5 International 778 788 ( 1.2 ) Worldwide 1,323 1,330 ( 0.5 )", "text": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change SHOCKWAVE U.S.", "length": 108, "numbers_raw": ["30", "202", "5 M", "31", "202", "4"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 752, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change SHOCKWAVE U.S. 206  * International 52  * Worldwide 258  * OTHER CARDIOVASCULAR U.S. 32 30 7.1 International 72 62 15.1 Worldwide 103 92 12.5 Orthopaedics U.S. 1,384 1,448 ( 4.4 ) International 857 892 ( 3.9 ) Worldwide 2,241 2,340 ( 4.2 ) HIPS U.S. 263 270 ( 2.5 ) International 146 152 ( 4.0 ) Worldwide 409 422 ( 3.1 ) KNEES U.S. 231 242 ( 4.3 ) International 158 160 ( 1.0 ) Worldwide 389 401 ( 3.0 ) TRAUMA U.S. 502 504 ( 0.5 ) International 270 261 3.7 Worldwide 772 765 0.9 SPINE, SPORTS & OTHER U.S. 388 432 ( 10.2 ) International 283 320 ( 11.6 ) Worldwide 671 752 ( 10.8 ) Surgery U.S. 1,002 987 1.5 International 1,394 1,429 ( 2.5 ) Worldwide 2,396 2,416 ( 0.8 ) ADVANCED U.S. 457 446 2.7 International 616 641 ( 4.0 ) Worldwide 1,073 1,087 ( 1.2 ) GENERAL U.S. 544 542 0.5 International 778 788 ( 1.2 ) Worldwide 1,323 1,330 ( 0.5 )", "text": "206  * International 52  * Worldwide 258  * OTHER CARDIOVASCULAR U.S.", "length": 72, "numbers_raw": ["206", "52", "258"], "numbers": [206.0, 52.0, 258.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 752, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change SHOCKWAVE U.S. 206  * International 52  * Worldwide 258  * OTHER CARDIOVASCULAR U.S. 32 30 7.1 International 72 62 15.1 Worldwide 103 92 12.5 Orthopaedics U.S. 1,384 1,448 ( 4.4 ) International 857 892 ( 3.9 ) Worldwide 2,241 2,340 ( 4.2 ) HIPS U.S. 263 270 ( 2.5 ) International 146 152 ( 4.0 ) Worldwide 409 422 ( 3.1 ) KNEES U.S. 231 242 ( 4.3 ) International 158 160 ( 1.0 ) Worldwide 389 401 ( 3.0 ) TRAUMA U.S. 502 504 ( 0.5 ) International 270 261 3.7 Worldwide 772 765 0.9 SPINE, SPORTS & OTHER U.S. 388 432 ( 10.2 ) International 283 320 ( 11.6 ) Worldwide 671 752 ( 10.8 ) Surgery U.S. 1,002 987 1.5 International 1,394 1,429 ( 2.5 ) Worldwide 2,396 2,416 ( 0.8 ) ADVANCED U.S. 457 446 2.7 International 616 641 ( 4.0 ) Worldwide 1,073 1,087 ( 1.2 ) GENERAL U.S. 544 542 0.5 International 778 788 ( 1.2 ) Worldwide 1,323 1,330 ( 0.5 )", "text": "32 30 7.1 International 72 62 15.1 Worldwide 103 92 12.5 Orthopaedics U.S.", "length": 74, "numbers_raw": ["32", "30", "7.1", "72", "62", "15.1", "103", "92", "12.5"], "numbers": [32.0, 30.0, 7.1, 72.0, 62.0, 15.1, 103.0, 92.0, 12.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 752, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change SHOCKWAVE U.S. 206  * International 52  * Worldwide 258  * OTHER CARDIOVASCULAR U.S. 32 30 7.1 International 72 62 15.1 Worldwide 103 92 12.5 Orthopaedics U.S. 1,384 1,448 ( 4.4 ) International 857 892 ( 3.9 ) Worldwide 2,241 2,340 ( 4.2 ) HIPS U.S. 263 270 ( 2.5 ) International 146 152 ( 4.0 ) Worldwide 409 422 ( 3.1 ) KNEES U.S. 231 242 ( 4.3 ) International 158 160 ( 1.0 ) Worldwide 389 401 ( 3.0 ) TRAUMA U.S. 502 504 ( 0.5 ) International 270 261 3.7 Worldwide 772 765 0.9 SPINE, SPORTS & OTHER U.S. 388 432 ( 10.2 ) International 283 320 ( 11.6 ) Worldwide 671 752 ( 10.8 ) Surgery U.S. 1,002 987 1.5 International 1,394 1,429 ( 2.5 ) Worldwide 2,396 2,416 ( 0.8 ) ADVANCED U.S. 457 446 2.7 International 616 641 ( 4.0 ) Worldwide 1,073 1,087 ( 1.2 ) GENERAL U.S. 544 542 0.5 International 778 788 ( 1.2 ) Worldwide 1,323 1,330 ( 0.5 )", "text": "1,384 1,448 ( 4.4 ) International 857 892 ( 3.9 ) Worldwide 2,241 2,340 ( 4.2 ) HIPS U.S.", "length": 89, "numbers_raw": ["1,384", "1,448", "4.4", "857", "892", "3.9", "2,241", "2,340", "4.2"], "numbers": [1384.0, 1448.0, 4.4, 857.0, 892.0, 3.9, 2241.0, 2340.0, 4.2], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 752, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change SHOCKWAVE U.S. 206  * International 52  * Worldwide 258  * OTHER CARDIOVASCULAR U.S. 32 30 7.1 International 72 62 15.1 Worldwide 103 92 12.5 Orthopaedics U.S. 1,384 1,448 ( 4.4 ) International 857 892 ( 3.9 ) Worldwide 2,241 2,340 ( 4.2 ) HIPS U.S. 263 270 ( 2.5 ) International 146 152 ( 4.0 ) Worldwide 409 422 ( 3.1 ) KNEES U.S. 231 242 ( 4.3 ) International 158 160 ( 1.0 ) Worldwide 389 401 ( 3.0 ) TRAUMA U.S. 502 504 ( 0.5 ) International 270 261 3.7 Worldwide 772 765 0.9 SPINE, SPORTS & OTHER U.S. 388 432 ( 10.2 ) International 283 320 ( 11.6 ) Worldwide 671 752 ( 10.8 ) Surgery U.S. 1,002 987 1.5 International 1,394 1,429 ( 2.5 ) Worldwide 2,396 2,416 ( 0.8 ) ADVANCED U.S. 457 446 2.7 International 616 641 ( 4.0 ) Worldwide 1,073 1,087 ( 1.2 ) GENERAL U.S. 544 542 0.5 International 778 788 ( 1.2 ) Worldwide 1,323 1,330 ( 0.5 )", "text": "263 270 ( 2.5 ) International 146 152 ( 4.0 ) Worldwide 409 422 ( 3.1 ) KNEES U.S.", "length": 82, "numbers_raw": ["263", "270", "2.5", "146", "152", "4.0", "409", "422", "3.1"], "numbers": [263.0, 270.0, 2.5, 146.0, 152.0, 4.0, 409.0, 422.0, 3.1], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 752, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change SHOCKWAVE U.S. 206  * International 52  * Worldwide 258  * OTHER CARDIOVASCULAR U.S. 32 30 7.1 International 72 62 15.1 Worldwide 103 92 12.5 Orthopaedics U.S. 1,384 1,448 ( 4.4 ) International 857 892 ( 3.9 ) Worldwide 2,241 2,340 ( 4.2 ) HIPS U.S. 263 270 ( 2.5 ) International 146 152 ( 4.0 ) Worldwide 409 422 ( 3.1 ) KNEES U.S. 231 242 ( 4.3 ) International 158 160 ( 1.0 ) Worldwide 389 401 ( 3.0 ) TRAUMA U.S. 502 504 ( 0.5 ) International 270 261 3.7 Worldwide 772 765 0.9 SPINE, SPORTS & OTHER U.S. 388 432 ( 10.2 ) International 283 320 ( 11.6 ) Worldwide 671 752 ( 10.8 ) Surgery U.S. 1,002 987 1.5 International 1,394 1,429 ( 2.5 ) Worldwide 2,396 2,416 ( 0.8 ) ADVANCED U.S. 457 446 2.7 International 616 641 ( 4.0 ) Worldwide 1,073 1,087 ( 1.2 ) GENERAL U.S. 544 542 0.5 International 778 788 ( 1.2 ) Worldwide 1,323 1,330 ( 0.5 )", "text": "231 242 ( 4.3 ) International 158 160 ( 1.0 ) Worldwide 389 401 ( 3.0 ) TRAUMA U.S.", "length": 83, "numbers_raw": ["231", "242", "4.3", "158", "160", "1.0", "389", "401", "3.0"], "numbers": [231.0, 242.0, 4.3, 158.0, 160.0, 1.0, 389.0, 401.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 752, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change SHOCKWAVE U.S. 206  * International 52  * Worldwide 258  * OTHER CARDIOVASCULAR U.S. 32 30 7.1 International 72 62 15.1 Worldwide 103 92 12.5 Orthopaedics U.S. 1,384 1,448 ( 4.4 ) International 857 892 ( 3.9 ) Worldwide 2,241 2,340 ( 4.2 ) HIPS U.S. 263 270 ( 2.5 ) International 146 152 ( 4.0 ) Worldwide 409 422 ( 3.1 ) KNEES U.S. 231 242 ( 4.3 ) International 158 160 ( 1.0 ) Worldwide 389 401 ( 3.0 ) TRAUMA U.S. 502 504 ( 0.5 ) International 270 261 3.7 Worldwide 772 765 0.9 SPINE, SPORTS & OTHER U.S. 388 432 ( 10.2 ) International 283 320 ( 11.6 ) Worldwide 671 752 ( 10.8 ) Surgery U.S. 1,002 987 1.5 International 1,394 1,429 ( 2.5 ) Worldwide 2,396 2,416 ( 0.8 ) ADVANCED U.S. 457 446 2.7 International 616 641 ( 4.0 ) Worldwide 1,073 1,087 ( 1.2 ) GENERAL U.S. 544 542 0.5 International 778 788 ( 1.2 ) Worldwide 1,323 1,330 ( 0.5 )", "text": "502 504 ( 0.5 ) International 270 261 3.7 Worldwide 772 765 0.9 SPINE, SPORTS & OTHER U.S.", "length": 90, "numbers_raw": ["502", "504", "0.5", "270", "261", "3.7", "772", "765", "0.9"], "numbers": [502.0, 504.0, 0.5, 270.0, 261.0, 3.7, 772.0, 765.0, 0.9], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 752, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change SHOCKWAVE U.S. 206  * International 52  * Worldwide 258  * OTHER CARDIOVASCULAR U.S. 32 30 7.1 International 72 62 15.1 Worldwide 103 92 12.5 Orthopaedics U.S. 1,384 1,448 ( 4.4 ) International 857 892 ( 3.9 ) Worldwide 2,241 2,340 ( 4.2 ) HIPS U.S. 263 270 ( 2.5 ) International 146 152 ( 4.0 ) Worldwide 409 422 ( 3.1 ) KNEES U.S. 231 242 ( 4.3 ) International 158 160 ( 1.0 ) Worldwide 389 401 ( 3.0 ) TRAUMA U.S. 502 504 ( 0.5 ) International 270 261 3.7 Worldwide 772 765 0.9 SPINE, SPORTS & OTHER U.S. 388 432 ( 10.2 ) International 283 320 ( 11.6 ) Worldwide 671 752 ( 10.8 ) Surgery U.S. 1,002 987 1.5 International 1,394 1,429 ( 2.5 ) Worldwide 2,396 2,416 ( 0.8 ) ADVANCED U.S. 457 446 2.7 International 616 641 ( 4.0 ) Worldwide 1,073 1,087 ( 1.2 ) GENERAL U.S. 544 542 0.5 International 778 788 ( 1.2 ) Worldwide 1,323 1,330 ( 0.5 )", "text": "388 432 ( 10.2 ) International 283 320 ( 11.6 ) Worldwide 671 752 ( 10.8 ) Surgery U.S.", "length": 87, "numbers_raw": ["388", "432", "10.2", "283", "320", "11.6", "671", "752", "10.8"], "numbers": [388.0, 432.0, 10.2, 283.0, 320.0, 11.6, 671.0, 752.0, 10.8], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 752, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change SHOCKWAVE U.S. 206  * International 52  * Worldwide 258  * OTHER CARDIOVASCULAR U.S. 32 30 7.1 International 72 62 15.1 Worldwide 103 92 12.5 Orthopaedics U.S. 1,384 1,448 ( 4.4 ) International 857 892 ( 3.9 ) Worldwide 2,241 2,340 ( 4.2 ) HIPS U.S. 263 270 ( 2.5 ) International 146 152 ( 4.0 ) Worldwide 409 422 ( 3.1 ) KNEES U.S. 231 242 ( 4.3 ) International 158 160 ( 1.0 ) Worldwide 389 401 ( 3.0 ) TRAUMA U.S. 502 504 ( 0.5 ) International 270 261 3.7 Worldwide 772 765 0.9 SPINE, SPORTS & OTHER U.S. 388 432 ( 10.2 ) International 283 320 ( 11.6 ) Worldwide 671 752 ( 10.8 ) Surgery U.S. 1,002 987 1.5 International 1,394 1,429 ( 2.5 ) Worldwide 2,396 2,416 ( 0.8 ) ADVANCED U.S. 457 446 2.7 International 616 641 ( 4.0 ) Worldwide 1,073 1,087 ( 1.2 ) GENERAL U.S. 544 542 0.5 International 778 788 ( 1.2 ) Worldwide 1,323 1,330 ( 0.5 )", "text": "1,002 987 1.5 International 1,394 1,429 ( 2.5 ) Worldwide 2,396 2,416 ( 0.8 ) ADVANCED U.S.", "length": 91, "numbers_raw": ["1,002", "987", "1.5", "1,394", "1,429", "2.5", "2,396", "2,416", "0.8"], "numbers": [1002.0, 987.0, 1.5, 1394.0, 1429.0, 2.5, 2396.0, 2416.0, 0.8], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 752, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change SHOCKWAVE U.S. 206  * International 52  * Worldwide 258  * OTHER CARDIOVASCULAR U.S. 32 30 7.1 International 72 62 15.1 Worldwide 103 92 12.5 Orthopaedics U.S. 1,384 1,448 ( 4.4 ) International 857 892 ( 3.9 ) Worldwide 2,241 2,340 ( 4.2 ) HIPS U.S. 263 270 ( 2.5 ) International 146 152 ( 4.0 ) Worldwide 409 422 ( 3.1 ) KNEES U.S. 231 242 ( 4.3 ) International 158 160 ( 1.0 ) Worldwide 389 401 ( 3.0 ) TRAUMA U.S. 502 504 ( 0.5 ) International 270 261 3.7 Worldwide 772 765 0.9 SPINE, SPORTS & OTHER U.S. 388 432 ( 10.2 ) International 283 320 ( 11.6 ) Worldwide 671 752 ( 10.8 ) Surgery U.S. 1,002 987 1.5 International 1,394 1,429 ( 2.5 ) Worldwide 2,396 2,416 ( 0.8 ) ADVANCED U.S. 457 446 2.7 International 616 641 ( 4.0 ) Worldwide 1,073 1,087 ( 1.2 ) GENERAL U.S. 544 542 0.5 International 778 788 ( 1.2 ) Worldwide 1,323 1,330 ( 0.5 )", "text": "457 446 2.7 International 616 641 ( 4.0 ) Worldwide 1,073 1,087 ( 1.2 ) GENERAL U.S.", "length": 84, "numbers_raw": ["457", "446", "2.7", "616", "641", "4.0", "1,073", "1,087", "1.2"], "numbers": [457.0, 446.0, 2.7, 616.0, 641.0, 4.0, 1073.0, 1087.0, 1.2], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 752, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change SHOCKWAVE U.S. 206  * International 52  * Worldwide 258  * OTHER CARDIOVASCULAR U.S. 32 30 7.1 International 72 62 15.1 Worldwide 103 92 12.5 Orthopaedics U.S. 1,384 1,448 ( 4.4 ) International 857 892 ( 3.9 ) Worldwide 2,241 2,340 ( 4.2 ) HIPS U.S. 263 270 ( 2.5 ) International 146 152 ( 4.0 ) Worldwide 409 422 ( 3.1 ) KNEES U.S. 231 242 ( 4.3 ) International 158 160 ( 1.0 ) Worldwide 389 401 ( 3.0 ) TRAUMA U.S. 502 504 ( 0.5 ) International 270 261 3.7 Worldwide 772 765 0.9 SPINE, SPORTS & OTHER U.S. 388 432 ( 10.2 ) International 283 320 ( 11.6 ) Worldwide 671 752 ( 10.8 ) Surgery U.S. 1,002 987 1.5 International 1,394 1,429 ( 2.5 ) Worldwide 2,396 2,416 ( 0.8 ) ADVANCED U.S. 457 446 2.7 International 616 641 ( 4.0 ) Worldwide 1,073 1,087 ( 1.2 ) GENERAL U.S. 544 542 0.5 International 778 788 ( 1.2 ) Worldwide 1,323 1,330 ( 0.5 )", "text": "544 542 0.5 International 778 788 ( 1.2 ) Worldwide 1,323 1,330 ( 0.5 )", "length": 71, "numbers_raw": ["544", "542", "0.5", "778", "788", "1.2", "1,323", "1,330", "0.5"], "numbers": [544.0, 542.0, 0.5, 778.0, 788.0, 1.2, 1323.0, 1330.0, 0.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 759, "tag": "div", "text_raw": "Form 10-Q 23", "text": "Form 10-Q 23", "length": 12, "numbers_raw": ["10", "23"], "numbers": [10.0, 23.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 760, "tag": "div", "text_raw": "Form 10-Q 23", "text": "Form 10-Q 23", "length": 12, "numbers_raw": ["10", "23"], "numbers": [10.0, 23.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 761, "tag": "div", "text_raw": "Form 10-Q 23", "text": "Form 10-Q 23", "length": 12, "numbers_raw": ["10", "23"], "numbers": [10.0, 23.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 762, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 763, "tag": "div", "text_raw": "23", "text": "23", "length": 2, "numbers_raw": ["23"], "numbers": [23.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 766, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Vision U.S. 566 547 3.4 International 713 710 0.4 Worldwide 1,279 1,258 1.7 CONTACT LENSES / OTHER U.S. 452 438 3.1 International 467 472 ( 1.1 ) Worldwide 919 910 1.0 SURGICAL U.S. 114 110 4.3 International 246 238 3.4 Worldwide 361 348 3.7 TOTAL MEDTECH U.S. 4,213 4,008 5.1 International 3,807 3,813 ( 0.2 ) Worldwide 8,020 7,821 2.5 WORLDWIDE U.S. 12,305 11,620 5.9 International 9,588 9,763 ( 1.8 ) Worldwide $ 21,893 21,383 2.4 %", "text": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Vision U.S.", "length": 105, "numbers_raw": ["30", "202", "5 M", "31", "202", "4"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 766, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Vision U.S. 566 547 3.4 International 713 710 0.4 Worldwide 1,279 1,258 1.7 CONTACT LENSES / OTHER U.S. 452 438 3.1 International 467 472 ( 1.1 ) Worldwide 919 910 1.0 SURGICAL U.S. 114 110 4.3 International 246 238 3.4 Worldwide 361 348 3.7 TOTAL MEDTECH U.S. 4,213 4,008 5.1 International 3,807 3,813 ( 0.2 ) Worldwide 8,020 7,821 2.5 WORLDWIDE U.S. 12,305 11,620 5.9 International 9,588 9,763 ( 1.8 ) Worldwide $ 21,893 21,383 2.4 %", "text": "566 547 3.4 International 713 710 0.4 Worldwide 1,279 1,258 1.7 CONTACT LENSES / OTHER U.S.", "length": 91, "numbers_raw": ["566", "547", "3.4", "713", "710", "0.4", "1,279", "1,258", "1.7"], "numbers": [566.0, 547.0, 3.4, 713.0, 710.0, 0.4, 1279.0, 1258.0, 1.7], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 766, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Vision U.S. 566 547 3.4 International 713 710 0.4 Worldwide 1,279 1,258 1.7 CONTACT LENSES / OTHER U.S. 452 438 3.1 International 467 472 ( 1.1 ) Worldwide 919 910 1.0 SURGICAL U.S. 114 110 4.3 International 246 238 3.4 Worldwide 361 348 3.7 TOTAL MEDTECH U.S. 4,213 4,008 5.1 International 3,807 3,813 ( 0.2 ) Worldwide 8,020 7,821 2.5 WORLDWIDE U.S. 12,305 11,620 5.9 International 9,588 9,763 ( 1.8 ) Worldwide $ 21,893 21,383 2.4 %", "text": "452 438 3.1 International 467 472 ( 1.1 ) Worldwide 919 910 1.0 SURGICAL U.S.", "length": 77, "numbers_raw": ["452", "438", "3.1", "467", "472", "1.1", "919", "910", "1.0"], "numbers": [452.0, 438.0, 3.1, 467.0, 472.0, 1.1, 919.0, 910.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 766, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Vision U.S. 566 547 3.4 International 713 710 0.4 Worldwide 1,279 1,258 1.7 CONTACT LENSES / OTHER U.S. 452 438 3.1 International 467 472 ( 1.1 ) Worldwide 919 910 1.0 SURGICAL U.S. 114 110 4.3 International 246 238 3.4 Worldwide 361 348 3.7 TOTAL MEDTECH U.S. 4,213 4,008 5.1 International 3,807 3,813 ( 0.2 ) Worldwide 8,020 7,821 2.5 WORLDWIDE U.S. 12,305 11,620 5.9 International 9,588 9,763 ( 1.8 ) Worldwide $ 21,893 21,383 2.4 %", "text": "114 110 4.3 International 246 238 3.4 Worldwide 361 348 3.7 TOTAL MEDTECH U.S.", "length": 78, "numbers_raw": ["114", "110", "4.3", "246", "238", "3.4", "361", "348", "3.7"], "numbers": [114.0, 110.0, 4.3, 246.0, 238.0, 3.4, 361.0, 348.0, 3.7], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 766, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Vision U.S. 566 547 3.4 International 713 710 0.4 Worldwide 1,279 1,258 1.7 CONTACT LENSES / OTHER U.S. 452 438 3.1 International 467 472 ( 1.1 ) Worldwide 919 910 1.0 SURGICAL U.S. 114 110 4.3 International 246 238 3.4 Worldwide 361 348 3.7 TOTAL MEDTECH U.S. 4,213 4,008 5.1 International 3,807 3,813 ( 0.2 ) Worldwide 8,020 7,821 2.5 WORLDWIDE U.S. 12,305 11,620 5.9 International 9,588 9,763 ( 1.8 ) Worldwide $ 21,893 21,383 2.4 %", "text": "4,213 4,008 5.1 International 3,807 3,813 ( 0.2 ) Worldwide 8,020 7,821 2.5 WORLDWIDE U.S.", "length": 90, "numbers_raw": ["4,213", "4,008", "5.1", "3,807", "3,813", "0.2", "8,020", "7,821", "2.5"], "numbers": [4213.0, 4008.0, 5.1, 3807.0, 3813.0, 0.2, 8020.0, 7821.0, 2.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 766, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change Vision U.S. 566 547 3.4 International 713 710 0.4 Worldwide 1,279 1,258 1.7 CONTACT LENSES / OTHER U.S. 452 438 3.1 International 467 472 ( 1.1 ) Worldwide 919 910 1.0 SURGICAL U.S. 114 110 4.3 International 246 238 3.4 Worldwide 361 348 3.7 TOTAL MEDTECH U.S. 4,213 4,008 5.1 International 3,807 3,813 ( 0.2 ) Worldwide 8,020 7,821 2.5 WORLDWIDE U.S. 12,305 11,620 5.9 International 9,588 9,763 ( 1.8 ) Worldwide $ 21,893 21,383 2.4 %", "text": "12,305 11,620 5.9 International 9,588 9,763 ( 1.8 ) Worldwide $ 21,893 21,383 2.4 %", "length": 83, "numbers_raw": ["12,305", "11,620", "5.9", "9,588", "9,763", "1.8", "21,893", "21,383", "2.4"], "numbers": [12305.0, 11620.0, 5.9, 9588.0, 9763.0, 1.8, 21893.0, 21383.0, 2.4], "percents_raw": ["2.4 %"], "percents": [0.024], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 769, "tag": "div", "text_raw": "* Percentage greater than 100% or not meaningful", "text": "* Percentage greater than 100% or not meaningful", "length": 48, "numbers_raw": ["100"], "numbers": [100.0], "percents_raw": ["100%"], "percents": [1.0], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 770, "tag": "div", "text_raw": "(1) Previously in Other Oncology", "text": "(1) Previously in Other Oncology", "length": 32, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 771, "tag": "div", "text_raw": "(2) Opsynvi was previously in Other Pulmonary Hypertension", "text": "(2) Opsynvi was previously in Other Pulmonary Hypertension", "length": 58, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 772, "tag": "div", "text_raw": "(3) Includes the Covid-19 Vaccine in 2024", "text": "(3) Includes the Covid-19 Vaccine in 2024", "length": 41, "numbers_raw": ["3", "19", "202", "4"], "numbers": [3.0, 19.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 774, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Innovative Medicine (1) MedTech (2) Total Innovative Medicine (1) MedTech (2) Total Sales to customers $ 13,873 8,020 13,562 7,821 Cost of products sold 4,020 3,326 3,370 3,120 Selling, marketing and administrative 2,261 2,656 2,438 2,582 Research and development expense 2,548 677 2,896 646 Other segment items (3) ( 166 ) ( 60 ) ( 111 ) ( 47 ) Segment income before tax $ 5,210 1,421 6,631 4,969 1,520 6,489 (Income) Expense not allocated to segments (4) ( 7,000 ) 2,775 Earnings before provision for taxes on income $ 13,631 $ 3,714", "text": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Innovative Medicine (1) MedTech (2) Total Innovative Medicine (1) MedTech (2) Total Sales to customers $ 13,873 8,020 13,562 7,821 Cost of products sold 4,020 3,326 3,370 3,120 Selling, marketing and administrative 2,261 2,656 2,438 2,582 Research and development expense 2,548 677 2,896 646 Other segment items (3) ( 166 ) ( 60 ) ( 111 ) ( 47 ) Segment income before tax $ 5,210 1,421 6,631 4,969 1,520 6,489 (Income) Expense not allocated to segments (4) ( 7,000 ) 2,775 Earnings before provision for taxes on income $ 13,631 $ 3,714", "length": 614, "numbers_raw": ["30", "202", "5 M", "31", "202", "4", "1", "2", "1", "2", "13,873", "8,020", "13,562", "7,821", "4,020", "3,326", "3,370", "3,120", "2,261", "2,656", "2,438", "2,582", "2,548", "677", "2,896", "646", "3", "166", "60", "111", "47", "5,210", "1,421", "6,631", "4,969", "1,520", "6,489", "4", "7,000", "2,775", "13,631", "3,714"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 1.0, 2.0, 1.0, 2.0, 13873.0, 8020.0, 13562.0, 7821.0, 4020.0, 3326.0, 3370.0, 3120.0, 2261.0, 2656.0, 2438.0, 2582.0, 2548.0, 677.0, 2896.0, 646.0, 3.0, 166.0, 60.0, 111.0, 47.0, 5210.0, 1421.0, 6631.0, 4969.0, 1520.0, 6489.0, 4.0, 7000.0, 2775.0, 13631.0, 3714.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 775, "tag": "div", "text_raw": "Innovative Medicine (1)", "text": "Innovative Medicine (1)", "length": 23, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 776, "tag": "div", "text_raw": "MedTech (2)", "text": "MedTech (2)", "length": 11, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 777, "tag": "div", "text_raw": "Innovative Medicine (1)", "text": "Innovative Medicine (1)", "length": 23, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 778, "tag": "div", "text_raw": "MedTech (2)", "text": "MedTech (2)", "length": 11, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 779, "tag": "div", "text_raw": "Other segment items (3)", "text": "Other segment items (3)", "length": 23, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 780, "tag": "div", "text_raw": "(Income) Expense not allocated to segments (4)", "text": "(Income) Expense not allocated to segments (4)", "length": 46, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 783, "tag": "div", "text_raw": "24", "text": "24", "length": 2, "numbers_raw": ["24"], "numbers": [24.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 784, "tag": "div", "text_raw": "24", "text": "24", "length": 2, "numbers_raw": ["24"], "numbers": [24.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 785, "tag": "div", "text_raw": "24", "text": "24", "length": 2, "numbers_raw": ["24"], "numbers": [24.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 786, "tag": "div", "text_raw": "24", "text": "24", "length": 2, "numbers_raw": ["24"], "numbers": [24.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 790, "tag": "div", "text_raw": "(1) Innovative Medicine includes:", "text": "(1) Innovative Medicine includes:", "length": 33, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 791, "tag": "div", "text_raw": " Intangible amortization expense of $ 0.6 billion and $ 0.7 billion in the fiscal first quarter of 2025 and 2024, respectively.", "text": " Intangible amortization expense of $ 0.6 billion and $ 0.7 billion in the fiscal first quarter of 2025 and 2024, respectively.", "length": 128, "numbers_raw": ["0.6 billion", "0.7 billion", "202", "5", "202", "4"], "numbers": [600000000.0, 700000000.0, 202.0, 5.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 792, "tag": "div", "text_raw": " A restructuring related charge of $ 0.1 billion in the fiscal first quarter of 2024. Refer to Note 12 for additional details.", "text": " A restructuring related charge of $ 0.1 billion in the fiscal first quarter of 2024.", "length": 86, "numbers_raw": ["0.1 billion", "202", "4"], "numbers": [100000000.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 792, "tag": "div", "text_raw": " A restructuring related charge of $ 0.1 billion in the fiscal first quarter of 2024. Refer to Note 12 for additional details.", "text": "Refer to Note 12 for additional details.", "length": 40, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 793, "tag": "div", "text_raw": "(2) MedTech includes:", "text": "(2) MedTech includes:", "length": 21, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 794, "tag": "div", "text_raw": " Intangible amortization expense of $ 0.5 billion and $ 0.4 billion in the fiscal first quarter of 2025 and 2024, respectively.", "text": " Intangible amortization expense of $ 0.5 billion and $ 0.4 billion in the fiscal first quarter of 2025 and 2024, respectively.", "length": 128, "numbers_raw": ["0.5 billion", "0.4 billion", "202", "5", "202", "4"], "numbers": [500000000.0, 400000000.0, 202.0, 5.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 795, "tag": "div", "text_raw": " Acquisition and integration related expense of $ 0.1 billion in both the fiscal first quarters of 2025 and 2024 primarily driven by the Shockwave acquisition in fiscal 2025 and Abiomed in fiscal 2024.", "text": " Acquisition and integration related expense of $ 0.1 billion in both the fiscal first quarters of 2025 and 2024 primarily driven by the Shockwave acquisition in fiscal 2025 and Abiomed in fiscal 2024.", "length": 202, "numbers_raw": ["0.1 billion", "202", "5", "202", "4", "202", "5", "202", "4"], "numbers": [100000000.0, 202.0, 5.0, 202.0, 4.0, 202.0, 5.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 796, "tag": "div", "text_raw": " A restructuring related charge of $ 0.1 billion in the fiscal first quarter of 2025.", "text": " A restructuring related charge of $ 0.1 billion in the fiscal first quarter of 2025.", "length": 86, "numbers_raw": ["0.1 billion", "202", "5"], "numbers": [100000000.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 797, "tag": "div", "text_raw": "(3) Other segment expenses for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.", "text": "(3) Other segment expenses for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.", "length": 204, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 798, "tag": "div", "text_raw": "(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarter of 2025 includes the reversal of approximately $ 7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of $ 2.7 billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "text": "(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense.", "length": 111, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 798, "tag": "div", "text_raw": "(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarter of 2025 includes the reversal of approximately $ 7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of $ 2.7 billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "text": "The fiscal first quarter of 2025 includes the reversal of approximately $ 7.0 billion, a significant portion of the previously accrued talc reserve.", "length": 148, "numbers_raw": ["202", "5", "7.0 billion"], "numbers": [202.0, 5.0, 7000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 798, "tag": "div", "text_raw": "(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarter of 2025 includes the reversal of approximately $ 7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of $ 2.7 billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "text": "The fiscal first quarter of 2024 includes charges for talc matters of $ 2.7 billion.", "length": 84, "numbers_raw": ["202", "4", "2.7 billion"], "numbers": [202.0, 4.0, 2700000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 798, "tag": "div", "text_raw": "(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarter of 2025 includes the reversal of approximately $ 7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of $ 2.7 billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "text": "For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "length": 97, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 801, "tag": "div", "text_raw": "Identifiable Assets (Dollars in Millions) March 30, 2025 December 29, 2024 Innovative Medicine $ 58,727 57,070 MedTech 85,111 84,322 Total 143,838 141,392 General corporate (1) 49,833 38,712 Worldwide total $ 193,671 180,104 (1) General corporate includes cash, cash equivalents, marketable securities and other corporate assets.", "text": "Identifiable Assets (Dollars in Millions) March 30, 2025 December 29, 2024 Innovative Medicine $ 58,727 57,070 MedTech 85,111 84,322 Total 143,838 141,392 General corporate (1) 49,833 38,712 Worldwide total $ 193,671 180,104 (1) General corporate includes cash, cash equivalents, marketable securities and other corporate assets.", "length": 329, "numbers_raw": ["30", "202", "5", "29", "202", "4", "58,727", "57,070 M", "85,111", "84,322", "143,838", "141,392", "1", "49,833", "38,712", "193,671", "180,104", "1"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4.0, 58727.0, 57070000000.0, 85111.0, 84322.0, 143838.0, 141392.0, 1.0, 49833.0, 38712.0, 193671.0, 180104.0, 1.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 802, "tag": "div", "text_raw": "General corporate (1)", "text": "General corporate (1)", "length": 21, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 803, "tag": "div", "text_raw": "Additions to Property, Plant & Equipment Depreciation and Amortization (Dollars in Millions) March 30, 2025 March 31, 2024 March 30, 2025 March 31, 2024 Innovative Medicine $ 276 232 $ 884 1,011 MedTech 480 493 836 746 Segments total 756 725 1,720 1,757 General corporate 39 82 52 58 Worldwide total $ 795 807 $ 1,772 1,815", "text": "Additions to Property, Plant & Equipment Depreciation and Amortization (Dollars in Millions) March 30, 2025 March 31, 2024 March 30, 2025 March 31, 2024 Innovative Medicine $ 276 232 $ 884 1,011 MedTech 480 493 836 746 Segments total 756 725 1,720 1,757 General corporate 39 82 52 58 Worldwide total $ 795 807 $ 1,772 1,815", "length": 323, "numbers_raw": ["30", "202", "5 M", "31", "202", "4 M", "30", "202", "5 M", "31", "202", "4", "276", "232", "884", "1,011 M", "480", "493", "836", "746", "756", "725", "1,720", "1,757", "39", "82", "52", "58", "795", "807", "1,772", "1,815"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4000000.0, 30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 276.0, 232.0, 884.0, 1011000000.0, 480.0, 493.0, 836.0, 746.0, 756.0, 725.0, 1720.0, 1757.0, 39.0, 82.0, 52.0, 58.0, 795.0, 807.0, 1772.0, 1815.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 806, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change United States $ 12,305 11,620 5.9 % Europe 5,110 5,163 ( 1.0 ) Western Hemisphere, excluding U.S. 1,167 1,194 ( 2.3 ) Asia-Pacific, Africa 3,311 3,406 ( 2.8 ) Total $ 21,893 21,383 2.4 %", "text": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change United States $ 12,305 11,620 5.9 % Europe 5,110 5,163 ( 1.0 ) Western Hemisphere, excluding U.S.", "length": 191, "numbers_raw": ["30", "202", "5 M", "31", "202", "4", "12,305", "11,620", "5.9", "5,110", "5,163", "1.0"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 12305.0, 11620.0, 5.9, 5110.0, 5163.0, 1.0], "percents_raw": ["5.9 %"], "percents": [0.059000000000000004], "currencies": ["EUR", "USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 806, "tag": "div", "text_raw": "Fiscal First Quarter Ended (Dollars in Millions) March 30, 2025 March 31, 2024 Percent Change United States $ 12,305 11,620 5.9 % Europe 5,110 5,163 ( 1.0 ) Western Hemisphere, excluding U.S. 1,167 1,194 ( 2.3 ) Asia-Pacific, Africa 3,311 3,406 ( 2.8 ) Total $ 21,893 21,383 2.4 %", "text": "1,167 1,194 ( 2.3 ) Asia-Pacific, Africa 3,311 3,406 ( 2.8 ) Total $ 21,893 21,383 2.4 %", "length": 88, "numbers_raw": ["1,167", "1,194", "2.3", "3,311", "3,406", "2.8", "21,893", "21,383", "2.4"], "numbers": [1167.0, 1194.0, 2.3, 3311.0, 3406.0, 2.8, 21893.0, 21383.0, 2.4], "percents_raw": ["2.4 %"], "percents": [0.024], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 807, "tag": "div", "text_raw": "Form 10-Q 25", "text": "Form 10-Q 25", "length": 12, "numbers_raw": ["10", "25"], "numbers": [10.0, 25.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 808, "tag": "div", "text_raw": "Form 10-Q 25", "text": "Form 10-Q 25", "length": 12, "numbers_raw": ["10", "25"], "numbers": [10.0, 25.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 809, "tag": "div", "text_raw": "Form 10-Q 25", "text": "Form 10-Q 25", "length": 12, "numbers_raw": ["10", "25"], "numbers": [10.0, 25.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 810, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 811, "tag": "div", "text_raw": "25", "text": "25", "length": 2, "numbers_raw": ["25"], "numbers": [25.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 816, "tag": "div", "text_raw": "Note 10  Acquisitions and divestitures", "text": "Note 10  Acquisitions and divestitures", "length": 39, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 818, "tag": "div", "text_raw": "Subsequent to the fiscal first quarter of 2025, on April 2, 2025, the Company completed the acquisition of Intra-Cellular Therapies, Inc. (Intra-Cellular), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders. The Company acquired all the outstanding shares of Intra-Cellulars common stock for $ 132.00 per share in cash for a total equity value of approximately $ 14.6 billion. The Company funded the transaction through a combination of cash on hand and proceeds from the issuance of debt in the fiscal first quarter of 2025. See Note 4 to the Consolidated Financial Statements for additional details.", "text": "Subsequent to the fiscal first quarter of 2025, on April 2, 2025, the Company completed the acquisition of Intra-Cellular Therapies, Inc.", "length": 137, "numbers_raw": ["202", "5", "2", "202", "5"], "numbers": [202.0, 5.0, 2.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 818, "tag": "div", "text_raw": "Subsequent to the fiscal first quarter of 2025, on April 2, 2025, the Company completed the acquisition of Intra-Cellular Therapies, Inc. (Intra-Cellular), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders. The Company acquired all the outstanding shares of Intra-Cellulars common stock for $ 132.00 per share in cash for a total equity value of approximately $ 14.6 billion. The Company funded the transaction through a combination of cash on hand and proceeds from the issuance of debt in the fiscal first quarter of 2025. See Note 4 to the Consolidated Financial Statements for additional details.", "text": "(Intra-Cellular), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders.", "length": 148, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 818, "tag": "div", "text_raw": "Subsequent to the fiscal first quarter of 2025, on April 2, 2025, the Company completed the acquisition of Intra-Cellular Therapies, Inc. (Intra-Cellular), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders. The Company acquired all the outstanding shares of Intra-Cellulars common stock for $ 132.00 per share in cash for a total equity value of approximately $ 14.6 billion. The Company funded the transaction through a combination of cash on hand and proceeds from the issuance of debt in the fiscal first quarter of 2025. See Note 4 to the Consolidated Financial Statements for additional details.", "text": "The Company acquired all the outstanding shares of Intra-Cellulars common stock for $ 132.00 per share in cash for a total equity value of approximately $ 14.6 billion.", "length": 169, "numbers_raw": ["132.00", "14.6 billion"], "numbers": [132.0, 14600000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 818, "tag": "div", "text_raw": "Subsequent to the fiscal first quarter of 2025, on April 2, 2025, the Company completed the acquisition of Intra-Cellular Therapies, Inc. (Intra-Cellular), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders. The Company acquired all the outstanding shares of Intra-Cellulars common stock for $ 132.00 per share in cash for a total equity value of approximately $ 14.6 billion. The Company funded the transaction through a combination of cash on hand and proceeds from the issuance of debt in the fiscal first quarter of 2025. See Note 4 to the Consolidated Financial Statements for additional details.", "text": "The Company funded the transaction through a combination of cash on hand and proceeds from the issuance of debt in the fiscal first quarter of 2025.", "length": 148, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 818, "tag": "div", "text_raw": "Subsequent to the fiscal first quarter of 2025, on April 2, 2025, the Company completed the acquisition of Intra-Cellular Therapies, Inc. (Intra-Cellular), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders. The Company acquired all the outstanding shares of Intra-Cellulars common stock for $ 132.00 per share in cash for a total equity value of approximately $ 14.6 billion. The Company funded the transaction through a combination of cash on hand and proceeds from the issuance of debt in the fiscal first quarter of 2025. See Note 4 to the Consolidated Financial Statements for additional details.", "text": "See Note 4 to the Consolidated Financial Statements for additional details.", "length": 75, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 820, "tag": "div", "text_raw": "The Company is in the process of determining the preliminary fair value of assets acquired which will primarily be comprised of amortizable intangible assets and in-process research and development assets associated with CAPLYTA, liabilities assumed and total consideration transferred. This transaction will be accounted for as a business combination and the results of operations will be included in the Innovative Medicine segment beginning on the acquisition date.", "text": "The Company is in the process of determining the preliminary fair value of assets acquired which will primarily be comprised of amortizable intangible assets and in-process research and development assets associated with CAPLYTA, liabilities assumed and total consideration transferred.", "length": 286, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 820, "tag": "div", "text_raw": "The Company is in the process of determining the preliminary fair value of assets acquired which will primarily be comprised of amortizable intangible assets and in-process research and development assets associated with CAPLYTA, liabilities assumed and total consideration transferred. This transaction will be accounted for as a business combination and the results of operations will be included in the Innovative Medicine segment beginning on the acquisition date.", "text": "This transaction will be accounted for as a business combination and the results of operations will be included in the Innovative Medicine segment beginning on the acquisition date.", "length": 181, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 824, "tag": "div", "text_raw": "In the fiscal first quarter of 2025, there were no material business combinations.", "text": "In the fiscal first quarter of 2025, there were no material business combinations.", "length": 82, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 826, "tag": "div", "text_raw": "On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, in an all-cash merger transaction for total consideration of $ 0.8 billion net of cash acquired, with potential for an additional milestone payment. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 1.2 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $ 0.9 billion, goodwill for $ 0.3 billion, and liabilities assumed of $ 0.3 billion, including $ 0.1 billion of contingent consideration. The goodwill is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal first quarter of 2025 were not material. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period.", "text": "On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, in an all-cash merger transaction for total consideration of $ 0.8 billion net of cash acquired, with potential for an additional milestone payment.", "length": 328, "numbers_raw": ["20", "202", "4", "0.8 billion"], "numbers": [20.0, 202.0, 4.0, 800000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 826, "tag": "div", "text_raw": "On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, in an all-cash merger transaction for total consideration of $ 0.8 billion net of cash acquired, with potential for an additional milestone payment. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 1.2 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $ 0.9 billion, goodwill for $ 0.3 billion, and liabilities assumed of $ 0.3 billion, including $ 0.1 billion of contingent consideration. The goodwill is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal first quarter of 2025 were not material. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period.", "text": "The results of operations were included in the Innovative Medicine segment as of the acquisition date.", "length": 102, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 826, "tag": "div", "text_raw": "On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, in an all-cash merger transaction for total consideration of $ 0.8 billion net of cash acquired, with potential for an additional milestone payment. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 1.2 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $ 0.9 billion, goodwill for $ 0.3 billion, and liabilities assumed of $ 0.3 billion, including $ 0.1 billion of contingent consideration. The goodwill is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal first quarter of 2025 were not material. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period.", "text": "The fair value of the acquisition was allocated to assets acquired of $ 1.2 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $ 0.9 billion, goodwill for $ 0.3 billion, and liabilities assumed of $ 0.3 billion, including $ 0.1 billion of contingent consideration.", "length": 301, "numbers_raw": ["1.2 billion", "0.9 billion", "0.3 billion", "0.3 billion", "0.1 billion"], "numbers": [1200000000.0, 900000000.0, 300000000.0, 300000000.0, 100000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 826, "tag": "div", "text_raw": "On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, in an all-cash merger transaction for total consideration of $ 0.8 billion net of cash acquired, with potential for an additional milestone payment. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 1.2 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $ 0.9 billion, goodwill for $ 0.3 billion, and liabilities assumed of $ 0.3 billion, including $ 0.1 billion of contingent consideration. The goodwill is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal first quarter of 2025 were not material. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period.", "text": "The goodwill is not expected to be deductible for tax purposes.", "length": 63, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 826, "tag": "div", "text_raw": "On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, in an all-cash merger transaction for total consideration of $ 0.8 billion net of cash acquired, with potential for an additional milestone payment. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 1.2 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $ 0.9 billion, goodwill for $ 0.3 billion, and liabilities assumed of $ 0.3 billion, including $ 0.1 billion of contingent consideration. The goodwill is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal first quarter of 2025 were not material. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period.", "text": "Acquisition related costs before tax for the fiscal first quarter of 2025 were not material.", "length": 92, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 826, "tag": "div", "text_raw": "On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, in an all-cash merger transaction for total consideration of $ 0.8 billion net of cash acquired, with potential for an additional milestone payment. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 1.2 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $ 0.9 billion, goodwill for $ 0.3 billion, and liabilities assumed of $ 0.3 billion, including $ 0.1 billion of contingent consideration. The goodwill is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal first quarter of 2025 were not material. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period.", "text": "The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period.", "length": 123, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "On May 31, 2024, the Company acquired all the outstanding shares of Shockwave Medical Inc. a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), in an all-cash merger transaction for total consideration of $ 11.5 billion, net of cash acquired. The results of operations were included in the MedTech segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 14.4 billion primarily amortizable intangible assets of $ 5.3 billion, purchased IPR&D of $ 0.6 billion, goodwill for $ 7.6 billion, $ 0.5 billion of inventory and $ 0.4 billion of other assets, and liabilities assumed of $ 2.9 billion. The goodwill is not expected to be deductible for tax purposes. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. Acquisition related costs before tax for the fiscal first quarter of 2025 were $ 0.1 billion, primarily related to the fair value of the inventory step-up and were recorded in Cost of products sold.", "text": "On May 31, 2024, the Company acquired all the outstanding shares of Shockwave Medical Inc.", "length": 90, "numbers_raw": ["31", "202", "4"], "numbers": [31.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "On May 31, 2024, the Company acquired all the outstanding shares of Shockwave Medical Inc. a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), in an all-cash merger transaction for total consideration of $ 11.5 billion, net of cash acquired. The results of operations were included in the MedTech segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 14.4 billion primarily amortizable intangible assets of $ 5.3 billion, purchased IPR&D of $ 0.6 billion, goodwill for $ 7.6 billion, $ 0.5 billion of inventory and $ 0.4 billion of other assets, and liabilities assumed of $ 2.9 billion. The goodwill is not expected to be deductible for tax purposes. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. Acquisition related costs before tax for the fiscal first quarter of 2025 were $ 0.1 billion, primarily related to the fair value of the inventory step-up and were recorded in Cost of products sold.", "text": "a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), in an all-cash merger transaction for total consideration of $ 11.5 billion, net of cash acquired.", "length": 289, "numbers_raw": ["11.5 billion"], "numbers": [11500000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "On May 31, 2024, the Company acquired all the outstanding shares of Shockwave Medical Inc. a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), in an all-cash merger transaction for total consideration of $ 11.5 billion, net of cash acquired. The results of operations were included in the MedTech segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 14.4 billion primarily amortizable intangible assets of $ 5.3 billion, purchased IPR&D of $ 0.6 billion, goodwill for $ 7.6 billion, $ 0.5 billion of inventory and $ 0.4 billion of other assets, and liabilities assumed of $ 2.9 billion. The goodwill is not expected to be deductible for tax purposes. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. Acquisition related costs before tax for the fiscal first quarter of 2025 were $ 0.1 billion, primarily related to the fair value of the inventory step-up and were recorded in Cost of products sold.", "text": "The results of operations were included in the MedTech segment as of the acquisition date.", "length": 90, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "On May 31, 2024, the Company acquired all the outstanding shares of Shockwave Medical Inc. a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), in an all-cash merger transaction for total consideration of $ 11.5 billion, net of cash acquired. The results of operations were included in the MedTech segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 14.4 billion primarily amortizable intangible assets of $ 5.3 billion, purchased IPR&D of $ 0.6 billion, goodwill for $ 7.6 billion, $ 0.5 billion of inventory and $ 0.4 billion of other assets, and liabilities assumed of $ 2.9 billion. The goodwill is not expected to be deductible for tax purposes. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. Acquisition related costs before tax for the fiscal first quarter of 2025 were $ 0.1 billion, primarily related to the fair value of the inventory step-up and were recorded in Cost of products sold.", "text": "The fair value of the acquisition was allocated to assets acquired of $ 14.4 billion primarily amortizable intangible assets of $ 5.3 billion, purchased IPR&D of $ 0.6 billion, goodwill for $ 7.6 billion, $ 0.5 billion of inventory and $ 0.4 billion of other assets, and liabilities assumed of $ 2.9 billion.", "length": 308, "numbers_raw": ["14.4 billion", "5.3 billion", "0.6 billion", "7.6 billion", "0.5 billion", "0.4 billion", "2.9 billion"], "numbers": [14400000000.0, 5300000000.0, 600000000.0, 7600000000.0, 500000000.0, 400000000.0, 2900000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "On May 31, 2024, the Company acquired all the outstanding shares of Shockwave Medical Inc. a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), in an all-cash merger transaction for total consideration of $ 11.5 billion, net of cash acquired. The results of operations were included in the MedTech segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 14.4 billion primarily amortizable intangible assets of $ 5.3 billion, purchased IPR&D of $ 0.6 billion, goodwill for $ 7.6 billion, $ 0.5 billion of inventory and $ 0.4 billion of other assets, and liabilities assumed of $ 2.9 billion. The goodwill is not expected to be deductible for tax purposes. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. Acquisition related costs before tax for the fiscal first quarter of 2025 were $ 0.1 billion, primarily related to the fair value of the inventory step-up and were recorded in Cost of products sold.", "text": "The goodwill is not expected to be deductible for tax purposes.", "length": 63, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "On May 31, 2024, the Company acquired all the outstanding shares of Shockwave Medical Inc. a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), in an all-cash merger transaction for total consideration of $ 11.5 billion, net of cash acquired. The results of operations were included in the MedTech segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 14.4 billion primarily amortizable intangible assets of $ 5.3 billion, purchased IPR&D of $ 0.6 billion, goodwill for $ 7.6 billion, $ 0.5 billion of inventory and $ 0.4 billion of other assets, and liabilities assumed of $ 2.9 billion. The goodwill is not expected to be deductible for tax purposes. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. Acquisition related costs before tax for the fiscal first quarter of 2025 were $ 0.1 billion, primarily related to the fair value of the inventory step-up and were recorded in Cost of products sold.", "text": "The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period.", "length": 123, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "On May 31, 2024, the Company acquired all the outstanding shares of Shockwave Medical Inc. a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), in an all-cash merger transaction for total consideration of $ 11.5 billion, net of cash acquired. The results of operations were included in the MedTech segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 14.4 billion primarily amortizable intangible assets of $ 5.3 billion, purchased IPR&D of $ 0.6 billion, goodwill for $ 7.6 billion, $ 0.5 billion of inventory and $ 0.4 billion of other assets, and liabilities assumed of $ 2.9 billion. The goodwill is not expected to be deductible for tax purposes. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. Acquisition related costs before tax for the fiscal first quarter of 2025 were $ 0.1 billion, primarily related to the fair value of the inventory step-up and were recorded in Cost of products sold.", "text": "Acquisition related costs before tax for the fiscal first quarter of 2025 were $ 0.1 billion, primarily related to the fair value of the inventory step-up and were recorded in Cost of products sold.", "length": 198, "numbers_raw": ["202", "5", "0.1 billion"], "numbers": [202.0, 5.0, 100000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total consideration of approximately $ 1.8 billion net of cash acquired. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 2.3 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $ 1.9 billion, goodwill for $ 0.3 billion and liabilities assumed of $ 0.5 billion, which includes deferred taxes of $ 0.4 billion. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal first quarter of 2025 were not material.", "text": "On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total consideration of approximately $ 1.8 billion net of cash acquired.", "length": 374, "numbers_raw": ["7", "202", "4", "1.8 billion"], "numbers": [7.0, 202.0, 4.0, 1800000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total consideration of approximately $ 1.8 billion net of cash acquired. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 2.3 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $ 1.9 billion, goodwill for $ 0.3 billion and liabilities assumed of $ 0.5 billion, which includes deferred taxes of $ 0.4 billion. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal first quarter of 2025 were not material.", "text": "The results of operations were included in the Innovative Medicine segment as of the acquisition date.", "length": 102, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total consideration of approximately $ 1.8 billion net of cash acquired. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 2.3 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $ 1.9 billion, goodwill for $ 0.3 billion and liabilities assumed of $ 0.5 billion, which includes deferred taxes of $ 0.4 billion. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal first quarter of 2025 were not material.", "text": "The fair value of the acquisition was allocated to assets acquired of $ 2.3 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $ 1.9 billion, goodwill for $ 0.3 billion and liabilities assumed of $ 0.5 billion, which includes deferred taxes of $ 0.4 billion.", "length": 295, "numbers_raw": ["2.3 billion", "1.9 billion", "0.3 billion", "0.5 billion", "0.4 billion"], "numbers": [2300000000.0, 1900000000.0, 300000000.0, 500000000.0, 400000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total consideration of approximately $ 1.8 billion net of cash acquired. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 2.3 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $ 1.9 billion, goodwill for $ 0.3 billion and liabilities assumed of $ 0.5 billion, which includes deferred taxes of $ 0.4 billion. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal first quarter of 2025 were not material.", "text": "The goodwill is not deductible for tax purposes.", "length": 48, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total consideration of approximately $ 1.8 billion net of cash acquired. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $ 2.3 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $ 1.9 billion, goodwill for $ 0.3 billion and liabilities assumed of $ 0.5 billion, which includes deferred taxes of $ 0.4 billion. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal first quarter of 2025 were not material.", "text": "Acquisition related costs before tax for the fiscal first quarter of 2025 were not material.", "length": 92, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 834, "tag": "div", "text_raw": "In the fiscal first quarters of 2025 and 2024, there were no material asset acquisitions.", "text": "In the fiscal first quarters of 2025 and 2024, there were no material asset acquisitions.", "length": 89, "numbers_raw": ["202", "5", "202", "4"], "numbers": [202.0, 5.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 836, "tag": "div", "text_raw": "In the fiscal first quarter of 2025, there were no material divestitures.", "text": "In the fiscal first quarter of 2025, there were no material divestitures.", "length": 73, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 837, "tag": "div", "text_raw": "In the fiscal first quarter of 2024, the Company completed the divestiture of Ponvory outside of the U.S. resulting in approximately $ 0.2 billion in proceeds.", "text": "In the fiscal first quarter of 2024, the Company completed the divestiture of Ponvory outside of the U.S.", "length": 105, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 837, "tag": "div", "text_raw": "In the fiscal first quarter of 2024, the Company completed the divestiture of Ponvory outside of the U.S. resulting in approximately $ 0.2 billion in proceeds.", "text": "resulting in approximately $ 0.2 billion in proceeds.", "length": 53, "numbers_raw": ["0.2 billion"], "numbers": [200000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 838, "tag": "div", "text_raw": "26", "text": "26", "length": 2, "numbers_raw": ["26"], "numbers": [26.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 839, "tag": "div", "text_raw": "26", "text": "26", "length": 2, "numbers_raw": ["26"], "numbers": [26.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 840, "tag": "div", "text_raw": "26", "text": "26", "length": 2, "numbers_raw": ["26"], "numbers": [26.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 841, "tag": "div", "text_raw": "26", "text": "26", "length": 2, "numbers_raw": ["26"], "numbers": [26.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 846, "tag": "div", "text_raw": "Note 11  Legal proceedings", "text": "Note 11  Legal proceedings", "length": 27, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 847, "tag": "div", "text_raw": "Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.", "text": "Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability;", "length": 122, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 847, "tag": "div", "text_raw": "Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.", "text": "indemnification and other matters;", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 847, "tag": "div", "text_raw": "Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.", "text": "and other legal proceedings that arise from time to time in the ordinary course of their business.", "length": 98, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated.", "length": 198, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated.", "length": 158, "numbers_raw": ["30", "202", "5"], "numbers": [30.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25.", "length": 221, "numbers_raw": ["450", "20", "25"], "numbers": [450.0, 20.0, 25.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued.", "length": 219, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments.", "length": 210, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate;", "length": 194, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "scientific and legal discovery has not commenced or is not complete;", "length": 68, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "proceedings are in early stages;", "length": 32, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "matters present legal uncertainties;", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "there are significant facts in dispute;", "length": 39, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "procedural or jurisdictional issues;", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "the uncertainty and unpredictability of the number of potential claims;", "length": 71, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "ability to achieve comprehensive multi-party settlements;", "length": 57, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "complexity of related cross-claims and counterclaims;", "length": 53, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "and/or there are numerous parties involved.", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "length": 205, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 849, "tag": "div", "text_raw": "In the Companys opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Companys balance sheet, is not expected to have a material adverse effect on the Companys financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Companys results of operations and cash flows for that period.", "text": "In the Companys opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Companys balance sheet, is not expected to have a material adverse effect on the Companys financial position.", "length": 310, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 849, "tag": "div", "text_raw": "In the Companys opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Companys balance sheet, is not expected to have a material adverse effect on the Companys financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Companys results of operations and cash flows for that period.", "text": "However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Companys results of operations and cash flows for that period.", "length": 215, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 851, "tag": "div", "text_raw": "A significant number of personal injury claims alleging that talc causes cancer have been asserted against the Company and its affiliates arising out of the use of body powders containing talc, primarily JOHNSONS Baby Powder.", "text": "A significant number of personal injury claims alleging that talc causes cancer have been asserted against the Company and its affiliates arising out of the use of body powders containing talc, primarily JOHNSONS Baby Powder.", "length": 226, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal.", "length": 192, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v.", "length": 131, "numbers_raw": ["202", "0", "201", "8", "4.7 billion"], "numbers": [202.0, 0.0, 201.0, 8.0, 4700000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "Johnson & Johnson, et al., No.", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "ED 207476 (Mo.", "length": 14, "numbers_raw": ["207", "476"], "numbers": [207.0, 476.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "App.), reducing the overall award to $ 2.1 billion.", "length": 51, "numbers_raw": ["2.1 billion"], "numbers": [2100000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied.", "length": 227, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion.", "length": 105, "numbers_raw": ["202", "1", "2.5 billion"], "numbers": [202.0, 1.0, 2500000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company.", "length": 165, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed.", "length": 122, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "length": 132, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 853, "tag": "div", "text_raw": "In June 2014, the Mississippi Attorney General filed a complaint against the Company alleging violation of the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers use of talc contained in JOHNSONS Baby Powder and JOHNSONS Shower to Shower (a product divested in 2012). The Company has reached an agreement to resolve this matter.", "text": "In June 2014, the Mississippi Attorney General filed a complaint against the Company alleging violation of the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers use of talc contained in JOHNSONS Baby Powder and JOHNSONS Shower to Shower (a product divested in 2012).", "length": 332, "numbers_raw": ["201", "4", "201", "2"], "numbers": [201.0, 4.0, 201.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 853, "tag": "div", "text_raw": "In June 2014, the Mississippi Attorney General filed a complaint against the Company alleging violation of the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers use of talc contained in JOHNSONS Baby Powder and JOHNSONS Shower to Shower (a product divested in 2012). The Company has reached an agreement to resolve this matter.", "text": "The Company has reached an agreement to resolve this matter.", "length": 60, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 854, "tag": "div", "text_raw": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The Company has reached an agreement to resolve this matter.", "text": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos.", "length": 271, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 854, "tag": "div", "text_raw": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The Company has reached an agreement to resolve this matter.", "text": "The Company has reached an agreement to resolve this matter.", "length": 60, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 855, "tag": "div", "text_raw": "Forty-two states and the District of Columbia commenced a joint investigation into the Companys marketing of its talcum powder products. In January 2024, the Company reached an agreement in principle with the multi-state group of state Attorneys General, subject to ongoing negotiation of non-monetary terms. In June 2024, the settlements were finalized.", "text": "Forty-two states and the District of Columbia commenced a joint investigation into the Companys marketing of its talcum powder products.", "length": 137, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 855, "tag": "div", "text_raw": "Forty-two states and the District of Columbia commenced a joint investigation into the Companys marketing of its talcum powder products. In January 2024, the Company reached an agreement in principle with the multi-state group of state Attorneys General, subject to ongoing negotiation of non-monetary terms. In June 2024, the settlements were finalized.", "text": "In January 2024, the Company reached an agreement in principle with the multi-state group of state Attorneys General, subject to ongoing negotiation of non-monetary terms.", "length": 171, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 855, "tag": "div", "text_raw": "Forty-two states and the District of Columbia commenced a joint investigation into the Companys marketing of its talcum powder products. In January 2024, the Company reached an agreement in principle with the multi-state group of state Attorneys General, subject to ongoing negotiation of non-monetary terms. In June 2024, the settlements were finalized.", "text": "In June 2024, the settlements were finalized.", "length": 45, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 856, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old", "text": "In October 2021, Johnson & Johnson Consumer Inc.", "length": 48, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 856, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old", "text": "(Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring).", "length": 84, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 856, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old", "text": "As a result of that restructuring, Old JJCI ceased to exist and three new entities were created:", "length": 96, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 856, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old", "text": "(a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor);", "length": 83, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 856, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old", "text": "(b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM);", "length": 101, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 856, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old", "text": "and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI).", "length": 101, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 856, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old", "text": "The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old", "length": 118, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 857, "tag": "div", "text_raw": "Form 10-Q 27", "text": "Form 10-Q 27", "length": 12, "numbers_raw": ["10", "27"], "numbers": [10.0, 27.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 858, "tag": "div", "text_raw": "Form 10-Q 27", "text": "Form 10-Q 27", "length": 12, "numbers_raw": ["10", "27"], "numbers": [10.0, 27.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 859, "tag": "div", "text_raw": "Form 10-Q 27", "text": "Form 10-Q 27", "length": 12, "numbers_raw": ["10", "27"], "numbers": [10.0, 27.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 860, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 861, "tag": "div", "text_raw": "27", "text": "27", "length": 2, "numbers_raw": ["27"], "numbers": [27.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 864, "tag": "div", "text_raw": "JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers compensation statute or act (the Talc-Related Liabilities).", "text": "JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers compensation statute or act (the Talc-Related Liabilities).", "length": 428, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 865, "tag": "div", "text_raw": "In October 2021, notwithstanding the Companys confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under Chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022.", "text": "In October 2021, notwithstanding the Companys confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under Chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case).", "length": 317, "numbers_raw": ["202", "1", "11"], "numbers": [202.0, 1.0, 11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 865, "tag": "div", "text_raw": "In October 2021, notwithstanding the Companys confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under Chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022.", "text": "All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed.", "length": 202, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 865, "tag": "div", "text_raw": "In October 2021, notwithstanding the Companys confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under Chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022.", "text": "The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey.", "length": 109, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 865, "tag": "div", "text_raw": "In October 2021, notwithstanding the Companys confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under Chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022.", "text": "Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022.", "length": 165, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 866, "tag": "div", "text_raw": "The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Courts ruling and remanded to the Bankruptcy Court to dismiss the LTL Bankruptcy Case.", "text": "The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties.", "length": 173, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 866, "tag": "div", "text_raw": "The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Courts ruling and remanded to the Bankruptcy Court to dismiss the LTL Bankruptcy Case.", "text": "On January 30, 2023, the Third Circuit reversed the Bankruptcy Courts ruling and remanded to the Bankruptcy Court to dismiss the LTL Bankruptcy Case.", "length": 150, "numbers_raw": ["30", "202", "3"], "numbers": [30.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 867, "tag": "div", "text_raw": "In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under Chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties).", "text": "In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system.", "length": 182, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 867, "tag": "div", "text_raw": "In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under Chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties).", "text": "LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under Chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case).", "length": 165, "numbers_raw": ["11", "2"], "numbers": [11.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 867, "tag": "div", "text_raw": "In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under Chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties).", "text": "As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code.", "length": 138, "numbers_raw": ["362"], "numbers": [362.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 867, "tag": "div", "text_raw": "In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under Chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties).", "text": "Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties).", "length": 226, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 868, "tag": "div", "text_raw": "Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Courts extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed.", "text": "Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction).", "length": 189, "numbers_raw": ["202", "3", "2"], "numbers": [202.0, 3.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 868, "tag": "div", "text_raw": "Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Courts extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed.", "text": "The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Courts extension of the initial LTL 2 Preliminary Injunction in June 2023.", "length": 175, "numbers_raw": ["2", "202", "3", "2", "202", "3"], "numbers": [2.0, 202.0, 3.0, 2.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 868, "tag": "div", "text_raw": "Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Courts extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed.", "text": "Under the LTL 2 Preliminary Injunction, except for those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed.", "length": 217, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 869, "tag": "div", "text_raw": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy Case followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. In July 2023, the court dismissed the LTL 2 Bankruptcy Case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. In October 2023, the Third Circuit granted LTLs petition for a direct appeal. In July 2024, the Third Circuit issued a non-precedential opinion affirming the Bankruptcy Court's decision to dismiss the LTL 2 Bankruptcy Case.", "text": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy Case followed by similar motions from other claimants.", "length": 159, "numbers_raw": ["202", "3", "2"], "numbers": [202.0, 3.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 869, "tag": "div", "text_raw": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy Case followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. In July 2023, the court dismissed the LTL 2 Bankruptcy Case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. In October 2023, the Third Circuit granted LTLs petition for a direct appeal. In July 2024, the Third Circuit issued a non-precedential opinion affirming the Bankruptcy Court's decision to dismiss the LTL 2 Bankruptcy Case.", "text": "Hearings on the motions to dismiss occurred in June 2023.", "length": 57, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 869, "tag": "div", "text_raw": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy Case followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. In July 2023, the court dismissed the LTL 2 Bankruptcy Case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. In October 2023, the Third Circuit granted LTLs petition for a direct appeal. In July 2024, the Third Circuit issued a non-precedential opinion affirming the Bankruptcy Court's decision to dismiss the LTL 2 Bankruptcy Case.", "text": "In July 2023, the court dismissed the LTL 2 Bankruptcy Case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims.", "length": 202, "numbers_raw": ["202", "3", "2"], "numbers": [202.0, 3.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 869, "tag": "div", "text_raw": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy Case followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. In July 2023, the court dismissed the LTL 2 Bankruptcy Case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. In October 2023, the Third Circuit granted LTLs petition for a direct appeal. In July 2024, the Third Circuit issued a non-precedential opinion affirming the Bankruptcy Court's decision to dismiss the LTL 2 Bankruptcy Case.", "text": "In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals.", "length": 138, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 869, "tag": "div", "text_raw": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy Case followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. In July 2023, the court dismissed the LTL 2 Bankruptcy Case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. In October 2023, the Third Circuit granted LTLs petition for a direct appeal. In July 2024, the Third Circuit issued a non-precedential opinion affirming the Bankruptcy Court's decision to dismiss the LTL 2 Bankruptcy Case.", "text": "In October 2023, the Third Circuit granted LTLs petition for a direct appeal.", "length": 78, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 869, "tag": "div", "text_raw": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy Case followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. In July 2023, the court dismissed the LTL 2 Bankruptcy Case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. In October 2023, the Third Circuit granted LTLs petition for a direct appeal. In July 2024, the Third Circuit issued a non-precedential opinion affirming the Bankruptcy Court's decision to dismiss the LTL 2 Bankruptcy Case.", "text": "In July 2024, the Third Circuit issued a non-precedential opinion affirming the Bankruptcy Court's decision to dismiss the LTL 2 Bankruptcy Case.", "length": 145, "numbers_raw": ["202", "4", "2"], "numbers": [202.0, 4.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 870, "tag": "div", "text_raw": "In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual prepackaged bankruptcy case, as strongly encouraged by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Companys talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC (LLT).", "text": "In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims:", "length": 177, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 870, "tag": "div", "text_raw": "In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual prepackaged bankruptcy case, as strongly encouraged by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Companys talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC (LLT).", "text": "(i) the appeal of the LTL 2 dismissal decision;", "length": 47, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 870, "tag": "div", "text_raw": "In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual prepackaged bankruptcy case, as strongly encouraged by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Companys talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC (LLT).", "text": "(ii) pursuing a consensual prepackaged bankruptcy case, as strongly encouraged by the Bankruptcy Court in its dismissal decision;", "length": 133, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 870, "tag": "div", "text_raw": "In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual prepackaged bankruptcy case, as strongly encouraged by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Companys talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC (LLT).", "text": "(iii) aggressively litigating the talc claims in the tort system;", "length": 65, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 870, "tag": "div", "text_raw": "In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual prepackaged bankruptcy case, as strongly encouraged by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Companys talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC (LLT).", "text": "and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Companys talc powder products.", "length": 134, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 870, "tag": "div", "text_raw": "In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual prepackaged bankruptcy case, as strongly encouraged by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Companys talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC (LLT).", "text": "In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC (LLT).", "length": 103, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 871, "tag": "div", "text_raw": "Following the dismissal of the LTL 2 Bankruptcy Case, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials commenced. The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, case-specific discovery proceeded. The MDL proceedings were stayed by order of the bankruptcy court in the Red River Bankruptcy case discussed below. In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial. The briefing on the renewed Daubert issues was completed in August 2024.", "text": "Following the dismissal of the LTL 2 Bankruptcy Case, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials commenced.", "length": 164, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 871, "tag": "div", "text_raw": "Following the dismissal of the LTL 2 Bankruptcy Case, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials commenced. The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, case-specific discovery proceeded. The MDL proceedings were stayed by order of the bankruptcy court in the Red River Bankruptcy case discussed below. In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial. The briefing on the renewed Daubert issues was completed in August 2024.", "text": "The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey.", "length": 170, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 871, "tag": "div", "text_raw": "Following the dismissal of the LTL 2 Bankruptcy Case, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials commenced. The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, case-specific discovery proceeded. The MDL proceedings were stayed by order of the bankruptcy court in the Red River Bankruptcy case discussed below. In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial. The briefing on the renewed Daubert issues was completed in August 2024.", "text": "In the MDL, case-specific discovery proceeded.", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 871, "tag": "div", "text_raw": "Following the dismissal of the LTL 2 Bankruptcy Case, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials commenced. The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, case-specific discovery proceeded. The MDL proceedings were stayed by order of the bankruptcy court in the Red River Bankruptcy case discussed below. In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial. The briefing on the renewed Daubert issues was completed in August 2024.", "text": "The MDL proceedings were stayed by order of the bankruptcy court in the Red River Bankruptcy case discussed below.", "length": 114, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 871, "tag": "div", "text_raw": "Following the dismissal of the LTL 2 Bankruptcy Case, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials commenced. The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, case-specific discovery proceeded. The MDL proceedings were stayed by order of the bankruptcy court in the Red River Bankruptcy case discussed below. In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial. The briefing on the renewed Daubert issues was completed in August 2024.", "text": "In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial.", "length": 103, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 871, "tag": "div", "text_raw": "Following the dismissal of the LTL 2 Bankruptcy Case, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials commenced. The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, case-specific discovery proceeded. The MDL proceedings were stayed by order of the bankruptcy court in the Red River Bankruptcy case discussed below. In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial. The briefing on the renewed Daubert issues was completed in August 2024.", "text": "The briefing on the renewed Daubert issues was completed in August 2024.", "length": 72, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 872, "tag": "div", "text_raw": "In May 2024, the Company commenced a three-month solicitation period of its proposed consensual prepackaged Chapter 11 bankruptcy plan (the Proposed Plan) for the comprehensive and final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $ 6.475 billion payable over 25 years (nominal value of approximately $ 8.0 billion, discounted at a rate of 4.4 %). The claims encompassed by the Proposed Plan constitute 99.75 % of pending lawsuits against the Company relating to its talc powder products.", "text": "In May 2024, the Company commenced a three-month solicitation period of its proposed consensual prepackaged Chapter 11 bankruptcy plan (the Proposed Plan) for the comprehensive and final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $ 6.475 billion payable over 25 years (nominal value of approximately $ 8.0 billion, discounted at a rate of 4.4 %).", "length": 551, "numbers_raw": ["202", "4", "11", "6.475 billion", "25", "8.0 billion", "4.4"], "numbers": [202.0, 4.0, 11.0, 6475000000.0, 25.0, 8000000000.0, 4.4], "percents_raw": ["4.4 %"], "percents": [0.044000000000000004], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 872, "tag": "div", "text_raw": "In May 2024, the Company commenced a three-month solicitation period of its proposed consensual prepackaged Chapter 11 bankruptcy plan (the Proposed Plan) for the comprehensive and final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $ 6.475 billion payable over 25 years (nominal value of approximately $ 8.0 billion, discounted at a rate of 4.4 %). The claims encompassed by the Proposed Plan constitute 99.75 % of pending lawsuits against the Company relating to its talc powder products.", "text": "The claims encompassed by the Proposed Plan constitute 99.75 % of pending lawsuits against the Company relating to its talc powder products.", "length": 140, "numbers_raw": ["99.75"], "numbers": [99.75], "percents_raw": ["99.75 %"], "percents": [0.9975], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 873, "tag": "div", "text_raw": "In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC (Red River); (b) Pecos River Talc LLC (Pecos River); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.", "text": "In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies:", "length": 124, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 873, "tag": "div", "text_raw": "In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC (Red River); (b) Pecos River Talc LLC (Pecos River); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.", "text": "(a) Red River Talc, LLC (Red River);", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 873, "tag": "div", "text_raw": "In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC (Red River); (b) Pecos River Talc LLC (Pecos River); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.", "text": "(b) Pecos River Talc LLC (Pecos River);", "length": 39, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 873, "tag": "div", "text_raw": "In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC (Red River); (b) Pecos River Talc LLC (Pecos River); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.", "text": "and (3) New Holdco (Texas) LLC.", "length": 31, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 873, "tag": "div", "text_raw": "In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC (Red River); (b) Pecos River Talc LLC (Pecos River); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.", "text": "As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.", "length": 231, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 874, "tag": "div", "text_raw": "28", "text": "28", "length": 2, "numbers_raw": ["28"], "numbers": [28.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 875, "tag": "div", "text_raw": "28", "text": "28", "length": 2, "numbers_raw": ["28"], "numbers": [28.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 876, "tag": "div", "text_raw": "28", "text": "28", "length": 2, "numbers_raw": ["28"], "numbers": [28.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 877, "tag": "div", "text_raw": "28", "text": "28", "length": 2, "numbers_raw": ["28"], "numbers": [28.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 881, "tag": "div", "text_raw": "In September 2024, while reiterating the Company's continued confidence in the safety of its talc products, Red River filed a voluntary petition with the United States Bankruptcy Court for the Southern District of Texas, seeking relief under Chapter 11 of the Bankruptcy Code (the Red River Bankruptcy Case), in furtherance of the Company's consensual \"prepackaged\" Proposed Plan. Red River also filed a motion for a temporary restraining order, seeking to extend the automatic stay to additional non-debtor entities.", "text": "In September 2024, while reiterating the Company's continued confidence in the safety of its talc products, Red River filed a voluntary petition with the United States Bankruptcy Court for the Southern District of Texas, seeking relief under Chapter 11 of the Bankruptcy Code (the Red River Bankruptcy Case), in furtherance of the Company's consensual \"prepackaged\" Proposed Plan.", "length": 380, "numbers_raw": ["202", "4", "11"], "numbers": [202.0, 4.0, 11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 881, "tag": "div", "text_raw": "In September 2024, while reiterating the Company's continued confidence in the safety of its talc products, Red River filed a voluntary petition with the United States Bankruptcy Court for the Southern District of Texas, seeking relief under Chapter 11 of the Bankruptcy Code (the Red River Bankruptcy Case), in furtherance of the Company's consensual \"prepackaged\" Proposed Plan. Red River also filed a motion for a temporary restraining order, seeking to extend the automatic stay to additional non-debtor entities.", "text": "Red River also filed a motion for a temporary restraining order, seeking to extend the automatic stay to additional non-debtor entities.", "length": 136, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 882, "tag": "div", "text_raw": "Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024 (the Stay Order). The Stay Order was extended in October 2024, December 2024, and on March 13, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation began on February 18, 2025 and concluded on February 28, 2025.", "text": "Shortly after Red River filed its Chapter 11 petition, the U.S.", "length": 63, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 882, "tag": "div", "text_raw": "Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024 (the Stay Order). The Stay Order was extended in October 2024, December 2024, and on March 13, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation began on February 18, 2025 and concluded on February 28, 2025.", "text": "Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court.", "length": 183, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 882, "tag": "div", "text_raw": "Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024 (the Stay Order). The Stay Order was extended in October 2024, December 2024, and on March 13, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation began on February 18, 2025 and concluded on February 28, 2025.", "text": "A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court.", "length": 131, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 882, "tag": "div", "text_raw": "Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024 (the Stay Order). The Stay Order was extended in October 2024, December 2024, and on March 13, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation began on February 18, 2025 and concluded on February 28, 2025.", "text": "In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024 (the Stay Order).", "length": 242, "numbers_raw": ["202", "4", "11", "202", "4"], "numbers": [202.0, 4.0, 11.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 882, "tag": "div", "text_raw": "Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024 (the Stay Order). The Stay Order was extended in October 2024, December 2024, and on March 13, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation began on February 18, 2025 and concluded on February 28, 2025.", "text": "The Stay Order was extended in October 2024, December 2024, and on March 13, 2025.", "length": 82, "numbers_raw": ["202", "4", "202", "4", "13", "202", "5"], "numbers": [202.0, 4.0, 202.0, 4.0, 13.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 882, "tag": "div", "text_raw": "Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024 (the Stay Order). The Stay Order was extended in October 2024, December 2024, and on March 13, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation began on February 18, 2025 and concluded on February 28, 2025.", "text": "Also in September 2024, the New Jersey Bankruptcy Court denied the U.S.", "length": 71, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 882, "tag": "div", "text_raw": "Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024 (the Stay Order). The Stay Order was extended in October 2024, December 2024, and on March 13, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation began on February 18, 2025 and concluded on February 28, 2025.", "text": "Trustee's motion to transfer venue without prejudice.", "length": 53, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 882, "tag": "div", "text_raw": "Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024 (the Stay Order). The Stay Order was extended in October 2024, December 2024, and on March 13, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation began on February 18, 2025 and concluded on February 28, 2025.", "text": "In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court.", "length": 122, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 882, "tag": "div", "text_raw": "Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024 (the Stay Order). The Stay Order was extended in October 2024, December 2024, and on March 13, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation began on February 18, 2025 and concluded on February 28, 2025.", "text": "A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation began on February 18, 2025 and concluded on February 28, 2025.", "length": 162, "numbers_raw": ["18", "202", "5", "28", "202", "5"], "numbers": [18.0, 202.0, 5.0, 28.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 883, "tag": "div", "text_raw": "To account for the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $ 5.0 billion during fiscal year 2024. As of the end of fiscal year 2024, the total present value of the reserve was approximately $ 11.6 billion (or nominal value of approximately $ 13.5 billion). On March 31, 2025, the Texas Bankruptcy Court issued an order dismissing the case and, as a result, the Company reversed substantially all, or approximately $ 7 billion, from amounts previously reserved for the bankruptcy resolution. Further, as a result of the dismissal, the Stay Order was dissolved. On April 1, 2025, the Company provided notice to the MDL court that the pending Daubert motion should proceed.", "text": "To account for the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $ 5.0 billion during fiscal year 2024.", "length": 192, "numbers_raw": ["5.0 billion", "202", "4"], "numbers": [5000000000.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 883, "tag": "div", "text_raw": "To account for the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $ 5.0 billion during fiscal year 2024. As of the end of fiscal year 2024, the total present value of the reserve was approximately $ 11.6 billion (or nominal value of approximately $ 13.5 billion). On March 31, 2025, the Texas Bankruptcy Court issued an order dismissing the case and, as a result, the Company reversed substantially all, or approximately $ 7 billion, from amounts previously reserved for the bankruptcy resolution. Further, as a result of the dismissal, the Stay Order was dissolved. On April 1, 2025, the Company provided notice to the MDL court that the pending Daubert motion should proceed.", "text": "As of the end of fiscal year 2024, the total present value of the reserve was approximately $ 11.6 billion (or nominal value of approximately $ 13.5 billion).", "length": 158, "numbers_raw": ["202", "4", "11.6 billion", "13.5 billion"], "numbers": [202.0, 4.0, 11600000000.0, 13500000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 883, "tag": "div", "text_raw": "To account for the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $ 5.0 billion during fiscal year 2024. As of the end of fiscal year 2024, the total present value of the reserve was approximately $ 11.6 billion (or nominal value of approximately $ 13.5 billion). On March 31, 2025, the Texas Bankruptcy Court issued an order dismissing the case and, as a result, the Company reversed substantially all, or approximately $ 7 billion, from amounts previously reserved for the bankruptcy resolution. Further, as a result of the dismissal, the Stay Order was dissolved. On April 1, 2025, the Company provided notice to the MDL court that the pending Daubert motion should proceed.", "text": "On March 31, 2025, the Texas Bankruptcy Court issued an order dismissing the case and, as a result, the Company reversed substantially all, or approximately $ 7 billion, from amounts previously reserved for the bankruptcy resolution.", "length": 233, "numbers_raw": ["31", "202", "5", "7 billion"], "numbers": [31.0, 202.0, 5.0, 7000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 883, "tag": "div", "text_raw": "To account for the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $ 5.0 billion during fiscal year 2024. As of the end of fiscal year 2024, the total present value of the reserve was approximately $ 11.6 billion (or nominal value of approximately $ 13.5 billion). On March 31, 2025, the Texas Bankruptcy Court issued an order dismissing the case and, as a result, the Company reversed substantially all, or approximately $ 7 billion, from amounts previously reserved for the bankruptcy resolution. Further, as a result of the dismissal, the Stay Order was dissolved. On April 1, 2025, the Company provided notice to the MDL court that the pending Daubert motion should proceed.", "text": "Further, as a result of the dismissal, the Stay Order was dissolved.", "length": 68, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 883, "tag": "div", "text_raw": "To account for the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $ 5.0 billion during fiscal year 2024. As of the end of fiscal year 2024, the total present value of the reserve was approximately $ 11.6 billion (or nominal value of approximately $ 13.5 billion). On March 31, 2025, the Texas Bankruptcy Court issued an order dismissing the case and, as a result, the Company reversed substantially all, or approximately $ 7 billion, from amounts previously reserved for the bankruptcy resolution. Further, as a result of the dismissal, the Stay Order was dissolved. On April 1, 2025, the Company provided notice to the MDL court that the pending Daubert motion should proceed.", "text": "On April 1, 2025, the Company provided notice to the MDL court that the pending Daubert motion should proceed.", "length": 110, "numbers_raw": ["1", "202", "5"], "numbers": [1.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 885, "tag": "div", "text_raw": "While the Company has resolved 95 % of the mesothelioma lawsuits filed to date, cases continue to be filed. Trials have commenced in various state courts. As of the first quarter 2025, the total present value of the reserve is approximately $ 4.2 billion, comprising previously executed settlement arrangements, litigation defense and other costs. Approximately one-third of the reserve is recorded as a current liability.", "text": "While the Company has resolved 95 % of the mesothelioma lawsuits filed to date, cases continue to be filed.", "length": 107, "numbers_raw": ["95"], "numbers": [95.0], "percents_raw": ["95 %"], "percents": [0.95], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 885, "tag": "div", "text_raw": "While the Company has resolved 95 % of the mesothelioma lawsuits filed to date, cases continue to be filed. Trials have commenced in various state courts. As of the first quarter 2025, the total present value of the reserve is approximately $ 4.2 billion, comprising previously executed settlement arrangements, litigation defense and other costs. Approximately one-third of the reserve is recorded as a current liability.", "text": "Trials have commenced in various state courts.", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 885, "tag": "div", "text_raw": "While the Company has resolved 95 % of the mesothelioma lawsuits filed to date, cases continue to be filed. Trials have commenced in various state courts. As of the first quarter 2025, the total present value of the reserve is approximately $ 4.2 billion, comprising previously executed settlement arrangements, litigation defense and other costs. Approximately one-third of the reserve is recorded as a current liability.", "text": "As of the first quarter 2025, the total present value of the reserve is approximately $ 4.2 billion, comprising previously executed settlement arrangements, litigation defense and other costs.", "length": 192, "numbers_raw": ["202", "5", "4.2 billion"], "numbers": [202.0, 5.0, 4200000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 885, "tag": "div", "text_raw": "While the Company has resolved 95 % of the mesothelioma lawsuits filed to date, cases continue to be filed. Trials have commenced in various state courts. As of the first quarter 2025, the total present value of the reserve is approximately $ 4.2 billion, comprising previously executed settlement arrangements, litigation defense and other costs. Approximately one-third of the reserve is recorded as a current liability.", "text": "Approximately one-third of the reserve is recorded as a current liability.", "length": 74, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 886, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.", "text": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc.", "length": 72, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 886, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.", "text": "and two of its affiliates, Imerys Talc Vermont, Inc.", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 886, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.", "text": "(collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy).", "length": 213, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 886, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.", "text": "The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys.", "length": 128, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 886, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.", "text": "In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.", "length": 127, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 886, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.", "text": "In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company.", "length": 217, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 886, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.", "text": "Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.", "length": 193, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 887, "tag": "div", "text_raw": "In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the Delaware Bankruptcy Court and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties. Cyprus also asserts it has claims for indemnity against the Company arising out of talc personal injury claims. Under the Cyprus Plan, Cyprus would also contribute its alleged indemnification rights to the trust.", "text": "In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the Delaware Bankruptcy Court and filed its Disclosure Statement and Plan (the Cyprus Plan).", "length": 269, "numbers_raw": ["202", "1", "11"], "numbers": [202.0, 1.0, 11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 887, "tag": "div", "text_raw": "In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the Delaware Bankruptcy Court and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties. Cyprus also asserts it has claims for indemnity against the Company arising out of talc personal injury claims. Under the Cyprus Plan, Cyprus would also contribute its alleged indemnification rights to the trust.", "text": "The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties.", "length": 267, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 887, "tag": "div", "text_raw": "In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the Delaware Bankruptcy Court and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties. Cyprus also asserts it has claims for indemnity against the Company arising out of talc personal injury claims. Under the Cyprus Plan, Cyprus would also contribute its alleged indemnification rights to the trust.", "text": "Cyprus also asserts it has claims for indemnity against the Company arising out of talc personal injury claims.", "length": 111, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 887, "tag": "div", "text_raw": "In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the Delaware Bankruptcy Court and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties. Cyprus also asserts it has claims for indemnity against the Company arising out of talc personal injury claims. Under the Cyprus Plan, Cyprus would also contribute its alleged indemnification rights to the trust.", "text": "Under the Cyprus Plan, Cyprus would also contribute its alleged indemnification rights to the trust.", "length": 100, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 888, "tag": "div", "text_raw": "In September 2023, Imerys and Cyprus filed amended plans of reorganization. The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imeryss and Cypruss alleged indemnification rights against the Company. The Company opposed both plans on the basis that the plans inflated Imeryss and Cypruss liability for talc claims and had the potential effect of imposing those inflated liabilities on the Company through the Companys alleged indemnification obligations.", "text": "In September 2023, Imerys and Cyprus filed amended plans of reorganization.", "length": 75, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 888, "tag": "div", "text_raw": "In September 2023, Imerys and Cyprus filed amended plans of reorganization. The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imeryss and Cypruss alleged indemnification rights against the Company. The Company opposed both plans on the basis that the plans inflated Imeryss and Cypruss liability for talc claims and had the potential effect of imposing those inflated liabilities on the Company through the Companys alleged indemnification obligations.", "text": "The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imeryss and Cypruss alleged indemnification rights against the Company.", "length": 289, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 888, "tag": "div", "text_raw": "In September 2023, Imerys and Cyprus filed amended plans of reorganization. The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imeryss and Cypruss alleged indemnification rights against the Company. The Company opposed both plans on the basis that the plans inflated Imeryss and Cypruss liability for talc claims and had the potential effect of imposing those inflated liabilities on the Company through the Companys alleged indemnification obligations.", "text": "The Company opposed both plans on the basis that the plans inflated Imeryss and Cypruss liability for talc claims and had the potential effect of imposing those inflated liabilities on the Company through the Companys alleged indemnification obligations.", "length": 257, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 889, "tag": "div", "text_raw": "In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in the Imerys debtors' and Cyprus debtors' respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve the parties ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. Under the global settlement, the Company and its affiliates, on the one hand, and Imerys and Cyprus and their respective affiliates, on the other hand, release their claims against one another arising out of talc claims, including indemnification and contribution claims. In addition, under the settlement, the Company purchased the Imerys and Cyprus debtors' indemnification rights against the Company free and clear of all claims and interest (the Indemnity Buyback). In August 2024, Imerys and Cyprus filed amended Chapter 11 plans and disclosure statements incorporating the terms of the settlement with the Company. In October 2024, the Delaware Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order). The effectiveness of certain provisions of the settlement, including the mutual", "text": "In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in the Imerys debtors' and Cyprus debtors' respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve the parties ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies.", "length": 449, "numbers_raw": ["202", "4", "11"], "numbers": [202.0, 4.0, 11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 889, "tag": "div", "text_raw": "In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in the Imerys debtors' and Cyprus debtors' respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve the parties ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. Under the global settlement, the Company and its affiliates, on the one hand, and Imerys and Cyprus and their respective affiliates, on the other hand, release their claims against one another arising out of talc claims, including indemnification and contribution claims. In addition, under the settlement, the Company purchased the Imerys and Cyprus debtors' indemnification rights against the Company free and clear of all claims and interest (the Indemnity Buyback). In August 2024, Imerys and Cyprus filed amended Chapter 11 plans and disclosure statements incorporating the terms of the settlement with the Company. In October 2024, the Delaware Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order). The effectiveness of certain provisions of the settlement, including the mutual", "text": "Under the global settlement, the Company and its affiliates, on the one hand, and Imerys and Cyprus and their respective affiliates, on the other hand, release their claims against one another arising out of talc claims, including indemnification and contribution claims.", "length": 271, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 889, "tag": "div", "text_raw": "In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in the Imerys debtors' and Cyprus debtors' respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve the parties ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. Under the global settlement, the Company and its affiliates, on the one hand, and Imerys and Cyprus and their respective affiliates, on the other hand, release their claims against one another arising out of talc claims, including indemnification and contribution claims. In addition, under the settlement, the Company purchased the Imerys and Cyprus debtors' indemnification rights against the Company free and clear of all claims and interest (the Indemnity Buyback). In August 2024, Imerys and Cyprus filed amended Chapter 11 plans and disclosure statements incorporating the terms of the settlement with the Company. In October 2024, the Delaware Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order). The effectiveness of certain provisions of the settlement, including the mutual", "text": "In addition, under the settlement, the Company purchased the Imerys and Cyprus debtors' indemnification rights against the Company free and clear of all claims and interest (the Indemnity Buyback).", "length": 197, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 889, "tag": "div", "text_raw": "In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in the Imerys debtors' and Cyprus debtors' respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve the parties ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. Under the global settlement, the Company and its affiliates, on the one hand, and Imerys and Cyprus and their respective affiliates, on the other hand, release their claims against one another arising out of talc claims, including indemnification and contribution claims. In addition, under the settlement, the Company purchased the Imerys and Cyprus debtors' indemnification rights against the Company free and clear of all claims and interest (the Indemnity Buyback). In August 2024, Imerys and Cyprus filed amended Chapter 11 plans and disclosure statements incorporating the terms of the settlement with the Company. In October 2024, the Delaware Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order). The effectiveness of certain provisions of the settlement, including the mutual", "text": "In August 2024, Imerys and Cyprus filed amended Chapter 11 plans and disclosure statements incorporating the terms of the settlement with the Company.", "length": 150, "numbers_raw": ["202", "4", "11"], "numbers": [202.0, 4.0, 11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 889, "tag": "div", "text_raw": "In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in the Imerys debtors' and Cyprus debtors' respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve the parties ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. Under the global settlement, the Company and its affiliates, on the one hand, and Imerys and Cyprus and their respective affiliates, on the other hand, release their claims against one another arising out of talc claims, including indemnification and contribution claims. In addition, under the settlement, the Company purchased the Imerys and Cyprus debtors' indemnification rights against the Company free and clear of all claims and interest (the Indemnity Buyback). In August 2024, Imerys and Cyprus filed amended Chapter 11 plans and disclosure statements incorporating the terms of the settlement with the Company. In October 2024, the Delaware Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order). The effectiveness of certain provisions of the settlement, including the mutual", "text": "In October 2024, the Delaware Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order).", "length": 129, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 889, "tag": "div", "text_raw": "In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in the Imerys debtors' and Cyprus debtors' respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve the parties ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. Under the global settlement, the Company and its affiliates, on the one hand, and Imerys and Cyprus and their respective affiliates, on the other hand, release their claims against one another arising out of talc claims, including indemnification and contribution claims. In addition, under the settlement, the Company purchased the Imerys and Cyprus debtors' indemnification rights against the Company free and clear of all claims and interest (the Indemnity Buyback). In August 2024, Imerys and Cyprus filed amended Chapter 11 plans and disclosure statements incorporating the terms of the settlement with the Company. In October 2024, the Delaware Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order). The effectiveness of certain provisions of the settlement, including the mutual", "text": "The effectiveness of certain provisions of the settlement, including the mutual", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 890, "tag": "div", "text_raw": "Form 10-Q 29", "text": "Form 10-Q 29", "length": 12, "numbers_raw": ["10", "29"], "numbers": [10.0, 29.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 891, "tag": "div", "text_raw": "Form 10-Q 29", "text": "Form 10-Q 29", "length": 12, "numbers_raw": ["10", "29"], "numbers": [10.0, 29.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 892, "tag": "div", "text_raw": "Form 10-Q 29", "text": "Form 10-Q 29", "length": 12, "numbers_raw": ["10", "29"], "numbers": [10.0, 29.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 893, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "29", "text": "29", "length": 2, "numbers_raw": ["29"], "numbers": [29.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 897, "tag": "div", "text_raw": "releases, and Indemnity Buyback, were subject to certain conditions, which have since been satisfied. Accordingly, the mutual releases and Indemnity Buyback are now in effect.", "text": "releases, and Indemnity Buyback, were subject to certain conditions, which have since been satisfied.", "length": 101, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 897, "tag": "div", "text_raw": "releases, and Indemnity Buyback, were subject to certain conditions, which have since been satisfied. Accordingly, the mutual releases and Indemnity Buyback are now in effect.", "text": "Accordingly, the mutual releases and Indemnity Buyback are now in effect.", "length": 73, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 898, "tag": "div", "text_raw": "Certain insurers have appealed the Settlement Order and sought a stay of the order pending appeal, which the Delaware Bankruptcy Court denied on January 13, 2025. The insurers then sought a stay of the order in the District Court for the District of Delaware, which also was denied. The insurers then appealed the denial of their request for a stay of the order to the Third Circuit Court of Appeals. The briefing of the Settlement Order appeal in the Delaware District Court is scheduled to be completed in April 2025.", "text": "Certain insurers have appealed the Settlement Order and sought a stay of the order pending appeal, which the Delaware Bankruptcy Court denied on January 13, 2025.", "length": 162, "numbers_raw": ["13", "202", "5"], "numbers": [13.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 898, "tag": "div", "text_raw": "Certain insurers have appealed the Settlement Order and sought a stay of the order pending appeal, which the Delaware Bankruptcy Court denied on January 13, 2025. The insurers then sought a stay of the order in the District Court for the District of Delaware, which also was denied. The insurers then appealed the denial of their request for a stay of the order to the Third Circuit Court of Appeals. The briefing of the Settlement Order appeal in the Delaware District Court is scheduled to be completed in April 2025.", "text": "The insurers then sought a stay of the order in the District Court for the District of Delaware, which also was denied.", "length": 119, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 898, "tag": "div", "text_raw": "Certain insurers have appealed the Settlement Order and sought a stay of the order pending appeal, which the Delaware Bankruptcy Court denied on January 13, 2025. The insurers then sought a stay of the order in the District Court for the District of Delaware, which also was denied. The insurers then appealed the denial of their request for a stay of the order to the Third Circuit Court of Appeals. The briefing of the Settlement Order appeal in the Delaware District Court is scheduled to be completed in April 2025.", "text": "The insurers then appealed the denial of their request for a stay of the order to the Third Circuit Court of Appeals.", "length": 117, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 898, "tag": "div", "text_raw": "Certain insurers have appealed the Settlement Order and sought a stay of the order pending appeal, which the Delaware Bankruptcy Court denied on January 13, 2025. The insurers then sought a stay of the order in the District Court for the District of Delaware, which also was denied. The insurers then appealed the denial of their request for a stay of the order to the Third Circuit Court of Appeals. The briefing of the Settlement Order appeal in the Delaware District Court is scheduled to be completed in April 2025.", "text": "The briefing of the Settlement Order appeal in the Delaware District Court is scheduled to be completed in April 2025.", "length": 118, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 899, "tag": "div", "text_raw": "On January 5, 2025, Imerys and Cyprus each filed a certification of voting results, indicating that their respective Chapter 11 plans had been accepted by each voting class of talc claimants. A joint confirmation hearing for the plans is scheduled for April 2025.", "text": "On January 5, 2025, Imerys and Cyprus each filed a certification of voting results, indicating that their respective Chapter 11 plans had been accepted by each voting class of talc claimants.", "length": 191, "numbers_raw": ["5", "202", "5", "11"], "numbers": [5.0, 202.0, 5.0, 11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 899, "tag": "div", "text_raw": "On January 5, 2025, Imerys and Cyprus each filed a certification of voting results, indicating that their respective Chapter 11 plans had been accepted by each voting class of talc claimants. A joint confirmation hearing for the plans is scheduled for April 2025.", "text": "A joint confirmation hearing for the plans is scheduled for April 2025.", "length": 71, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 900, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiffs motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Courts order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.", "text": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result.", "length": 432, "numbers_raw": ["201", "8"], "numbers": [201.0, 8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 900, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiffs motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Courts order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.", "text": "In April 2019, the Company moved to dismiss the complaint.", "length": 58, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 900, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiffs motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Courts order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.", "text": "In December 2019, the Court denied, in part, the motion to dismiss.", "length": 67, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 900, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiffs motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Courts order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.", "text": "The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023.", "length": 97, "numbers_raw": ["202", "2", "202", "3"], "numbers": [202.0, 2.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 900, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiffs motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Courts order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.", "text": "In December 2023, the Court granted Plaintiffs motion for class certification.", "length": 79, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 900, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiffs motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Courts order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.", "text": "In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Courts order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition.", "length": 254, "numbers_raw": ["202", "4", "23", "202", "4"], "numbers": [202.0, 4.0, 23.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 900, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiffs motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Courts order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.", "text": "In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation.", "length": 121, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 900, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiffs motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Courts order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.", "text": "In May 2024, the parties participated in an unsuccessful mediation.", "length": 67, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 900, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiffs motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Courts order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.", "text": "In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition.", "length": 197, "numbers_raw": ["202", "4", "23"], "numbers": [202.0, 4.0, 23.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 900, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiffs motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Courts order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.", "text": "Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.", "length": 121, "numbers_raw": ["23", "202", "4", "202", "5"], "numbers": [23.0, 202.0, 4.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 902, "tag": "div", "text_raw": "Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.", "text": "Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc.", "length": 94, "numbers_raw": ["201", "4"], "numbers": [201.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 902, "tag": "div", "text_raw": "Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.", "text": "(JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER.", "length": 174, "numbers_raw": ["3,500"], "numbers": [3500.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 902, "tag": "div", "text_raw": "Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.", "text": "Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following:", "length": 122, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 902, "tag": "div", "text_raw": "Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.", "text": "individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS);", "length": 89, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 903, "tag": "div", "text_raw": "To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal.", "text": "To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal.", "length": 130, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 904, "tag": "div", "text_raw": "In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $ 5.0 billion. Approximately 70 % of the all-in settlement was paid by the end of fiscal first quarter 2025. A few government entities opted out of the settlement. In September 2024, the Company reached an agreement to resolve the hospital cases.", "text": "In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $ 5.0 billion.", "length": 132, "numbers_raw": ["202", "1", "5.0 billion"], "numbers": [202.0, 1.0, 5000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 904, "tag": "div", "text_raw": "In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $ 5.0 billion. Approximately 70 % of the all-in settlement was paid by the end of fiscal first quarter 2025. A few government entities opted out of the settlement. In September 2024, the Company reached an agreement to resolve the hospital cases.", "text": "Approximately 70 % of the all-in settlement was paid by the end of fiscal first quarter 2025.", "length": 93, "numbers_raw": ["70", "202", "5"], "numbers": [70.0, 202.0, 5.0], "percents_raw": ["70 %"], "percents": [0.7], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 904, "tag": "div", "text_raw": "In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $ 5.0 billion. Approximately 70 % of the all-in settlement was paid by the end of fiscal first quarter 2025. A few government entities opted out of the settlement. In September 2024, the Company reached an agreement to resolve the hospital cases.", "text": "A few government entities opted out of the settlement.", "length": 54, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 904, "tag": "div", "text_raw": "In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $ 5.0 billion. Approximately 70 % of the all-in settlement was paid by the end of fiscal first quarter 2025. A few government entities opted out of the settlement. In September 2024, the Company reached an agreement to resolve the hospital cases.", "text": "In September 2024, the Company reached an agreement to resolve the hospital cases.", "length": 82, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 905, "tag": "div", "text_raw": "The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants. In total, there are under 35 remaining opioid cases against the Company and JPI in various state courts, 325 remaining cases in the Ohio multi-district litigation (MDL), and 3 additional cases in other federal courts.", "text": "The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants.", "length": 152, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 905, "tag": "div", "text_raw": "The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants. In total, there are under 35 remaining opioid cases against the Company and JPI in various state courts, 325 remaining cases in the Ohio multi-district litigation (MDL), and 3 additional cases in other federal courts.", "text": "In total, there are under 35 remaining opioid cases against the Company and JPI in various state courts, 325 remaining cases in the Ohio multi-district litigation (MDL), and 3 additional cases in other federal courts.", "length": 217, "numbers_raw": ["35", "325", "3"], "numbers": [35.0, 325.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 906, "tag": "div", "text_raw": "In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024. The defendants including the Company filed appeals from the certification order in late February 2025.", "text": "In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada.", "length": 161, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 906, "tag": "div", "text_raw": "In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024. The defendants including the Company filed appeals from the certification order in late February 2025.", "text": "That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025.", "length": 148, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 906, "tag": "div", "text_raw": "In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024. The defendants including the Company filed appeals from the certification order in late February 2025.", "text": "Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands.", "length": 239, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 906, "tag": "div", "text_raw": "In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024. The defendants including the Company filed appeals from the certification order in late February 2025.", "text": "The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc.", "length": 140, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 906, "tag": "div", "text_raw": "In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024. The defendants including the Company filed appeals from the certification order in late February 2025.", "text": "and other industry members in April 2024;", "length": 41, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 906, "tag": "div", "text_raw": "In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024. The defendants including the Company filed appeals from the certification order in late February 2025.", "text": "and leave to appeal was denied in October 2024.", "length": 47, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 906, "tag": "div", "text_raw": "In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024. The defendants including the Company filed appeals from the certification order in late February 2025.", "text": "The defendants including the Company filed appeals from the certification order in late February 2025.", "length": 102, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 907, "tag": "div", "text_raw": "Starting in November 2019, a series of shareholder derivative complaints were filed against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. As of September 2024, all the complaints had been dismissed, and all appeals exhausted.", "text": "Starting in November 2019, a series of shareholder derivative complaints were filed against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey.", "length": 233, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 907, "tag": "div", "text_raw": "Starting in November 2019, a series of shareholder derivative complaints were filed against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. As of September 2024, all the complaints had been dismissed, and all appeals exhausted.", "text": "The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches.", "length": 168, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 907, "tag": "div", "text_raw": "Starting in November 2019, a series of shareholder derivative complaints were filed against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. As of September 2024, all the complaints had been dismissed, and all appeals exhausted.", "text": "As of September 2024, all the complaints had been dismissed, and all appeals exhausted.", "length": 87, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 909, "tag": "div", "text_raw": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued", "text": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products.", "length": 135, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 909, "tag": "div", "text_raw": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued", "text": "Claimants in these cases seek substantial compensatory and, where available, punitive damages.", "length": 94, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 909, "tag": "div", "text_raw": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued", "text": "While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation.", "length": 121, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 909, "tag": "div", "text_raw": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued", "text": "From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances.", "length": 135, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 910, "tag": "div", "text_raw": "30", "text": "30", "length": 2, "numbers_raw": ["30"], "numbers": [30.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 911, "tag": "div", "text_raw": "30", "text": "30", "length": 2, "numbers_raw": ["30"], "numbers": [30.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 912, "tag": "div", "text_raw": "30", "text": "30", "length": 2, "numbers_raw": ["30"], "numbers": [30.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 913, "tag": "div", "text_raw": "30", "text": "30", "length": 2, "numbers_raw": ["30"], "numbers": [30.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 917, "tag": "div", "text_raw": "for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies.", "length": 212, "numbers_raw": ["450", "20", "25"], "numbers": [450.0, 20.0, 25.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 917, "tag": "div", "text_raw": "for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated.", "length": 150, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 917, "tag": "div", "text_raw": "for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses.", "length": 151, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 917, "tag": "div", "text_raw": "for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns.", "length": 186, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 917, "tag": "div", "text_raw": "for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "Changes to the accruals may be required in the future as additional information becomes available.", "length": 98, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 918, "tag": "div", "text_raw": "The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of March 30, 2025:", "text": "The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of March 30, 2025:", "length": 269, "numbers_raw": ["30", "202", "5"], "numbers": [30.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 919, "tag": "div", "text_raw": "Product or product category Number of plaintiffs Body powders containing talc, primarily JOHNSONS Baby Powder 62,850 DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System 50 PINNACLE Acetabular Cup System 910 Pelvic meshes 5,910 ETHICON PHYSIOMESH Flexible Composite Mesh 140 ELMIRON 1,140", "text": "Product or product category Number of plaintiffs Body powders containing talc, primarily JOHNSONS Baby Powder 62,850 DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System 50 PINNACLE Acetabular Cup System 910 Pelvic meshes 5,910 ETHICON PHYSIOMESH Flexible Composite Mesh 140 ELMIRON 1,140", "length": 304, "numbers_raw": ["62,850", "50", "910", "5,910", "140", "1,140"], "numbers": [62850.0, 50.0, 910.0, 5910.0, 140.0, 1140.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 921, "tag": "div", "text_raw": "The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed.", "text": "The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.", "length": 135, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 921, "tag": "div", "text_raw": "The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed.", "text": "There may be additional claims that have not yet been filed.", "length": 60, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 923, "tag": "div", "text_raw": "DePuy ASR XL Acetabular System and ASR Hip Resurfacing System", "text": "DePuy ASR XL Acetabular System and ASR Hip Resurfacing System", "length": 61, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "In August 2010, DePuy Orthopaedics, Inc.", "length": 40, "numbers_raw": ["201", "0"], "numbers": [201.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "(DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery.", "length": 158, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "Claims for personal injury have been made against DePuy and the Company.", "length": 72, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio.", "length": 172, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy.", "length": 132, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States.", "length": 213, "numbers_raw": ["201", "3"], "numbers": [201.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States.", "length": 154, "numbers_raw": ["10,000"], "numbers": [10000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States.", "length": 131, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis.", "length": 137, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "length": 153, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 925, "tag": "div", "text_raw": "DePuy PINNACLE Acetabular Cup System", "text": "DePuy PINNACLE Acetabular Cup System", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 926, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc.", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 926, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery.", "length": 117, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 926, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases.", "length": 166, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 926, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL).", "length": 190, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 926, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL.", "length": 194, "numbers_raw": ["1", "202", "2"], "numbers": [1.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 926, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "Litigation also has been filed in state courts and in countries outside of the United States.", "length": 93, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 926, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases.", "length": 110, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 926, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "As part of the settlement program, adverse verdicts have been settled.", "length": 70, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 926, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "length": 158, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 928, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally", "text": "Claims for personal injury have been made against Ethicon, Inc.", "length": 63, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 928, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally", "text": "(Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse.", "length": 139, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 928, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally", "text": "The Company continues to receive information with respect to potential costs and additional cases.", "length": 98, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 928, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally", "text": "Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia.", "length": 186, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 928, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally", "text": "In March 2021, the MDL Court entered an order closing the MDL.", "length": 62, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 928, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally", "text": "The MDL Court has remanded cases for trial to the jurisdictions where the case was originally", "length": 93, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 929, "tag": "div", "text_raw": "Form 10-Q 31", "text": "Form 10-Q 31", "length": 12, "numbers_raw": ["10", "31"], "numbers": [10.0, 31.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 930, "tag": "div", "text_raw": "Form 10-Q 31", "text": "Form 10-Q 31", "length": 12, "numbers_raw": ["10", "31"], "numbers": [10.0, 31.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 931, "tag": "div", "text_raw": "Form 10-Q 31", "text": "Form 10-Q 31", "length": 12, "numbers_raw": ["10", "31"], "numbers": [10.0, 31.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 932, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 933, "tag": "div", "text_raw": "31", "text": "31", "length": 2, "numbers_raw": ["31"], "numbers": [31.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 936, "tag": "div", "text_raw": "filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "text": "filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL.", "length": 90, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 936, "tag": "div", "text_raw": "filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "text": "The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals.", "length": 208, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 936, "tag": "div", "text_raw": "filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "text": "In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa.", "length": 369, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 936, "tag": "div", "text_raw": "filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "text": "The vast majority of these actions are now resolved.", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 936, "tag": "div", "text_raw": "filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "text": "The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "length": 129, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 938, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.", "text": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc.", "length": 173, "numbers_raw": ["201", "6"], "numbers": [201.0, 6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 938, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.", "text": "(Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device.", "length": 101, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 938, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.", "text": "Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia.", "length": 181, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 938, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.", "text": "A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey.", "length": 143, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 938, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.", "text": "In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R.", "length": 233, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 938, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.", "text": "Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States.", "length": 172, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 938, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.", "text": "In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time.", "length": 213, "numbers_raw": ["202", "1", "3,600", "4,300"], "numbers": [202.0, 1.0, 3600.0, 4300.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 938, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.", "text": "A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL.", "length": 115, "numbers_raw": ["202", "1", "3,729"], "numbers": [202.0, 1.0, 3729.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 938, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.", "text": "Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.", "length": 183, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States.", "text": "Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products.", "length": 164, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States.", "text": "In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court.", "length": 153, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States.", "text": "Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States.", "length": 138, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 940, "tag": "div", "text_raw": "Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States.", "text": "Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System.", "length": 132, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 940, "tag": "div", "text_raw": "Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States.", "text": "In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases.", "length": 116, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 940, "tag": "div", "text_raw": "Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States.", "text": "Cases involving this product have also been filed in other federal and state courts in the United States.", "length": 105, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 941, "tag": "div", "text_raw": "In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.", "text": "In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims.", "length": 274, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 941, "tag": "div", "text_raw": "In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.", "text": "All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement.", "length": 112, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 941, "tag": "div", "text_raw": "In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.", "text": "Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.", "length": 150, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 942, "tag": "div", "text_raw": "The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.", "text": "The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.", "length": 231, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 945, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc.", "length": 130, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 945, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.", "length": 171, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 945, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States.", "length": 192, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 945, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL).", "length": 258, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 945, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation.", "length": 265, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 945, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "In addition, three class action lawsuits have been filed in Canada.", "length": 67, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 945, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims.", "length": 133, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 945, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement.", "length": 100, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 945, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "length": 130, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 947, "tag": "div", "text_raw": "Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the scope and/", "text": "Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses.", "length": 201, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 947, "tag": "div", "text_raw": "Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the scope and/", "text": "Many of these matters involve challenges to the scope and/", "length": 58, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 948, "tag": "div", "text_raw": "32", "text": "32", "length": 2, "numbers_raw": ["32"], "numbers": [32.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 949, "tag": "div", "text_raw": "32", "text": "32", "length": 2, "numbers_raw": ["32"], "numbers": [32.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 950, "tag": "div", "text_raw": "32", "text": "32", "length": 2, "numbers_raw": ["32"], "numbers": [32.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 951, "tag": "div", "text_raw": "32", "text": "32", "length": 2, "numbers_raw": ["32"], "numbers": [32.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 955, "tag": "div", "text_raw": "or validity of patents that relate to various products and allegations that certain of the Companys products infringe the intellectual property rights of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.", "text": "or validity of patents that relate to various products and allegations that certain of the Companys products infringe the intellectual property rights of third parties.", "length": 169, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 955, "tag": "div", "text_raw": "or validity of patents that relate to various products and allegations that certain of the Companys products infringe the intellectual property rights of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.", "text": "Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters.", "length": 210, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 955, "tag": "div", "text_raw": "or validity of patents that relate to various products and allegations that certain of the Companys products infringe the intellectual property rights of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.", "text": "A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.", "length": 310, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 956, "tag": "div", "text_raw": "Innovative Medicine - litigation against filers of abbreviated new drug applications (ANDAs)", "text": "Innovative Medicine - litigation against filers of abbreviated new drug applications (ANDAs)", "length": 92, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 957, "tag": "div", "text_raw": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "text": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S.", "length": 110, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 957, "tag": "div", "text_raw": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "text": "FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products.", "length": 216, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 957, "tag": "div", "text_raw": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "text": "These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book).", "length": 224, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 957, "tag": "div", "text_raw": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "text": "In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents).", "length": 220, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 957, "tag": "div", "text_raw": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "text": "In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset.", "length": 488, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 957, "tag": "div", "text_raw": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "text": "In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "length": 250, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 958, "tag": "div", "text_raw": "The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.", "text": "The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.", "length": 266, "numbers_raw": ["201", "1"], "numbers": [201.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 960, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; and InvaGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310.", "text": "Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents.", "length": 349, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 960, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; and InvaGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 960, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; and InvaGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310.", "text": "Taro Pharmaceutical Industries Ltd.;", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 960, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; and InvaGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310.", "text": "Taro Pharmaceuticals U.S.A., Inc.;", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 960, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; and InvaGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310.", "text": "Teva Pharmaceuticals USA, Inc.;", "length": 31, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 960, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; and InvaGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310.", "text": "and InvaGen Pharmaceuticals, Inc.", "length": 33, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 960, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; and InvaGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310.", "text": "patents are included in one or more cases:", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 960, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; and InvaGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310.", "text": "9,539,218 and 10,828,310.", "length": 25, "numbers_raw": ["9,539,218", "10,828,310"], "numbers": [9539218.0, 10828310.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 961, "tag": "div", "text_raw": "U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit. Oral argument is scheduled to be heard in May 2025.", "text": "10,828,310 was also under consideration by the USPTO in an IPR proceeding.", "length": 74, "numbers_raw": ["10,828,310"], "numbers": [10828310.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 961, "tag": "div", "text_raw": "U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit. Oral argument is scheduled to be heard in May 2025.", "text": "In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid.", "length": 97, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 961, "tag": "div", "text_raw": "U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit. Oral argument is scheduled to be heard in May 2025.", "text": "In September 2023, Bayer Pharma AG filed an appeal to the U.S.", "length": 62, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 961, "tag": "div", "text_raw": "U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit. Oral argument is scheduled to be heard in May 2025.", "text": "Court of Appeals for the Federal Circuit.", "length": 41, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 961, "tag": "div", "text_raw": "U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit. Oral argument is scheduled to be heard in May 2025.", "text": "Oral argument is scheduled to be heard in May 2025.", "length": 51, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.", "length": 85, "numbers_raw": ["201", "8"], "numbers": [201.0, 8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent.", "length": 233, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "Teva Pharmaceuticals USA, Inc.;", "length": 31, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "patent is included in one or more cases:", "length": 40, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "9,439,906.", "length": 10, "numbers_raw": ["9,439,906"], "numbers": [9439906.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No.", "length": 143, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "9,439,906 is not invalid.", "length": 25, "numbers_raw": ["9,439,906"], "numbers": [9439906.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "Teva previously stipulated to infringement.", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings.", "length": 183, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "In November 2024, the district court issued its decision on remand, finding that United States Patent No.", "length": 105, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "9,439,906 is not invalid.", "length": 25, "numbers_raw": ["9,439,906"], "numbers": [9439906.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025.", "length": 109, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "In February 2024, the district court issued a decision in the case against Tolmar Inc.", "length": 86, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "finding that United States Patent No.", "length": 37, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "9,439,906 is not invalid.", "length": 25, "numbers_raw": ["9,439,906"], "numbers": [9439906.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "Tolmar previously stipulated to infringement.", "length": 45, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 963, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.", "text": "Tolmar has appealed the decision.", "length": 33, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 964, "tag": "div", "text_raw": "Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.", "text": "Beginning in February 2018, Janssen Inc.", "length": 40, "numbers_raw": ["201", "8"], "numbers": [201.0, 8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 964, "tag": "div", "text_raw": "Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.", "text": "and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent.", "length": 290, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 964, "tag": "div", "text_raw": "Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 964, "tag": "div", "text_raw": "Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.", "text": "The following Canadian patent is included in one or more cases:", "length": 63, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 964, "tag": "div", "text_raw": "Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.", "text": "2,655,335.", "length": 10, "numbers_raw": ["2,655,335"], "numbers": [2655335.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 964, "tag": "div", "text_raw": "Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.", "text": "In June 2024, the Supreme Court dismissed the Apotex case.", "length": 58, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 964, "tag": "div", "text_raw": "Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.", "text": "In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.", "length": 148, "numbers_raw": ["202", "4", "2,655,335"], "numbers": [202.0, 4.0, 2655335.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 965, "tag": "div", "text_raw": "Form 10-Q 33", "text": "Form 10-Q 33", "length": 12, "numbers_raw": ["10", "33"], "numbers": [10.0, 33.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 966, "tag": "div", "text_raw": "Form 10-Q 33", "text": "Form 10-Q 33", "length": 12, "numbers_raw": ["10", "33"], "numbers": [10.0, 33.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 967, "tag": "div", "text_raw": "Form 10-Q 33", "text": "Form 10-Q 33", "length": 12, "numbers_raw": ["10", "33"], "numbers": [10.0, 33.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 968, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 969, "tag": "div", "text_raw": "33", "text": "33", "length": 2, "numbers_raw": ["33"], "numbers": [33.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 973, "tag": "div", "text_raw": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan appealed the decision, and in March 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the district court's decision.", "text": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent.", "length": 357, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 973, "tag": "div", "text_raw": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan appealed the decision, and in March 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the district court's decision.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 973, "tag": "div", "text_raw": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan appealed the decision, and in March 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the district court's decision.", "text": "patent is included in one or more cases:", "length": 40, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 973, "tag": "div", "text_raw": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan appealed the decision, and in March 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the district court's decision.", "text": "10,143,693.", "length": 11, "numbers_raw": ["10,143,693"], "numbers": [10143693.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 973, "tag": "div", "text_raw": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan appealed the decision, and in March 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the district court's decision.", "text": "In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid.", "length": 161, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 973, "tag": "div", "text_raw": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan appealed the decision, and in March 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the district court's decision.", "text": "Mylan appealed the decision, and in March 2025, the U.S.", "length": 56, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 973, "tag": "div", "text_raw": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan appealed the decision, and in March 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the district court's decision.", "text": "Court of Appeals for the Federal Circuit affirmed the district court's decision.", "length": 80, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 975, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. In February 2025, Janssen entered into confidential settlement agreements with all defendants, and consent judgments dismissing the cases were entered.", "text": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc.", "length": 117, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 975, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. In February 2025, Janssen entered into confidential settlement agreements with all defendants, and consent judgments dismissing the cases were entered.", "text": "and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents.", "length": 261, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 975, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. In February 2025, Janssen entered into confidential settlement agreements with all defendants, and consent judgments dismissing the cases were entered.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 975, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. In February 2025, Janssen entered into confidential settlement agreements with all defendants, and consent judgments dismissing the cases were entered.", "text": "MSN Laboratories Private Ltd.;", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 975, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. In February 2025, Janssen entered into confidential settlement agreements with all defendants, and consent judgments dismissing the cases were entered.", "text": "MSN Life Sciences Private Ltd.;", "length": 31, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 975, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. In February 2025, Janssen entered into confidential settlement agreements with all defendants, and consent judgments dismissing the cases were entered.", "text": "patents are included in one or more cases:", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 975, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. In February 2025, Janssen entered into confidential settlement agreements with all defendants, and consent judgments dismissing the cases were entered.", "text": "10,039,718 and 10,786,518.", "length": 26, "numbers_raw": ["10,039,718", "10,786,518"], "numbers": [10039718.0, 10786518.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 975, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. In February 2025, Janssen entered into confidential settlement agreements with all defendants, and consent judgments dismissing the cases were entered.", "text": "In February 2025, Janssen entered into confidential settlement agreements with all defendants, and consent judgments dismissing the cases were entered.", "length": 151, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 977, "tag": "div", "text_raw": "In January 2025, Aragon Pharmaceuticals, Inc., Janssen Inc., (collectively, Janssen Inc.) and Sloan-Kettering Institute for Cancer Research (SKI) initiated Statements of Claims under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in response to Sandozs filing of an ANDS seeking approval to market a generic version of ERLEADA before the expiration of CA Patent Nos. 3,008,345 (the 345 patent), 2,875,767 (the 767 patent), 2,885,415 (the 415 patent), and 3,128,331 (the 331 patent). Janssen Inc. and SKI are seeking an order enjoining Sandoz from marketing a generic version of ERLEADA before the expiration of the relevant patents.", "text": "In January 2025, Aragon Pharmaceuticals, Inc., Janssen Inc., (collectively, Janssen Inc.) and Sloan-Kettering Institute for Cancer Research (SKI) initiated Statements of Claims under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc.", "length": 280, "numbers_raw": ["202", "5", "6"], "numbers": [202.0, 5.0, 6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 977, "tag": "div", "text_raw": "In January 2025, Aragon Pharmaceuticals, Inc., Janssen Inc., (collectively, Janssen Inc.) and Sloan-Kettering Institute for Cancer Research (SKI) initiated Statements of Claims under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in response to Sandozs filing of an ANDS seeking approval to market a generic version of ERLEADA before the expiration of CA Patent Nos. 3,008,345 (the 345 patent), 2,875,767 (the 767 patent), 2,885,415 (the 415 patent), and 3,128,331 (the 331 patent). Janssen Inc. and SKI are seeking an order enjoining Sandoz from marketing a generic version of ERLEADA before the expiration of the relevant patents.", "text": "(Sandoz) in response to Sandozs filing of an ANDS seeking approval to market a generic version of ERLEADA before the expiration of CA Patent Nos.", "length": 146, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 977, "tag": "div", "text_raw": "In January 2025, Aragon Pharmaceuticals, Inc., Janssen Inc., (collectively, Janssen Inc.) and Sloan-Kettering Institute for Cancer Research (SKI) initiated Statements of Claims under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in response to Sandozs filing of an ANDS seeking approval to market a generic version of ERLEADA before the expiration of CA Patent Nos. 3,008,345 (the 345 patent), 2,875,767 (the 767 patent), 2,885,415 (the 415 patent), and 3,128,331 (the 331 patent). Janssen Inc. and SKI are seeking an order enjoining Sandoz from marketing a generic version of ERLEADA before the expiration of the relevant patents.", "text": "3,008,345 (the 345 patent), 2,875,767 (the 767 patent), 2,885,415 (the 415 patent), and 3,128,331 (the 331 patent).", "length": 119, "numbers_raw": ["3,008,345", "345", "2,875,767", "767", "2,885,415", "415", "3,128,331", "331"], "numbers": [3008345.0, 345.0, 2875767.0, 767.0, 2885415.0, 415.0, 3128331.0, 331.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 977, "tag": "div", "text_raw": "In January 2025, Aragon Pharmaceuticals, Inc., Janssen Inc., (collectively, Janssen Inc.) and Sloan-Kettering Institute for Cancer Research (SKI) initiated Statements of Claims under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in response to Sandozs filing of an ANDS seeking approval to market a generic version of ERLEADA before the expiration of CA Patent Nos. 3,008,345 (the 345 patent), 2,875,767 (the 767 patent), 2,885,415 (the 415 patent), and 3,128,331 (the 331 patent). Janssen Inc. and SKI are seeking an order enjoining Sandoz from marketing a generic version of ERLEADA before the expiration of the relevant patents.", "text": "and SKI are seeking an order enjoining Sandoz from marketing a generic version of ERLEADA before the expiration of the relevant patents.", "length": 136, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260.", "text": "Beginning in May 2023, Janssen Pharmaceuticals, Inc.", "length": 52, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260.", "text": "and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents.", "length": 260, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260.", "text": "patents are included in one or more cases:", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260.", "text": "10,869,844;", "length": 11, "numbers_raw": ["10,869,844"], "numbers": [10869844.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260.", "text": "11,173,134;", "length": 11, "numbers_raw": ["11,173,134"], "numbers": [11173134.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260.", "text": "11,311,500;", "length": 11, "numbers_raw": ["11,311,500"], "numbers": [11311500.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260.", "text": "and 11,446,260.", "length": 15, "numbers_raw": ["11,446,260"], "numbers": [11446260.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 981, "tag": "div", "text_raw": "Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants: Jamp Pharma Corporation and Apotex Inc. The following Canadian patents are included in one or more cases: 2,534,024 and 2,671,357. Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.", "text": "Beginning in January 2024, Janssen Inc.", "length": 39, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 981, "tag": "div", "text_raw": "Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants: Jamp Pharma Corporation and Apotex Inc. The following Canadian patents are included in one or more cases: 2,534,024 and 2,671,357. Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.", "text": "and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents.", "length": 290, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 981, "tag": "div", "text_raw": "Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants: Jamp Pharma Corporation and Apotex Inc. The following Canadian patents are included in one or more cases: 2,534,024 and 2,671,357. Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 981, "tag": "div", "text_raw": "Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants: Jamp Pharma Corporation and Apotex Inc. The following Canadian patents are included in one or more cases: 2,534,024 and 2,671,357. Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.", "text": "Jamp Pharma Corporation and Apotex Inc.", "length": 39, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 981, "tag": "div", "text_raw": "Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants: Jamp Pharma Corporation and Apotex Inc. The following Canadian patents are included in one or more cases: 2,534,024 and 2,671,357. Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.", "text": "The following Canadian patents are included in one or more cases:", "length": 65, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 981, "tag": "div", "text_raw": "Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants: Jamp Pharma Corporation and Apotex Inc. The following Canadian patents are included in one or more cases: 2,534,024 and 2,671,357. Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.", "text": "2,534,024 and 2,671,357.", "length": 24, "numbers_raw": ["2,534,024", "2,671,357"], "numbers": [2534024.0, 2671357.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 981, "tag": "div", "text_raw": "Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants: Jamp Pharma Corporation and Apotex Inc. The following Canadian patents are included in one or more cases: 2,534,024 and 2,671,357. Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.", "text": "Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.", "length": 120, "numbers_raw": ["202", "5", "202", "5"], "numbers": [202.0, 5.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "Beginning in March 2024, Intra-Cellular Therapies, Inc.", "length": 55, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "(Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents.", "length": 280, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr.", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "Reddys Laboratories Inc., Dr.", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd.", "length": 61, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd.", "length": 131, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "Patents are included in one or more cases:", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "US RE 48,825;", "length": 13, "numbers_raw": ["48,825"], "numbers": [48825.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "RE 48,839;", "length": 10, "numbers_raw": ["48,839"], "numbers": [48839.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "8,648,077;", "length": 10, "numbers_raw": ["8,648,077"], "numbers": [8648077.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "9,168,258;", "length": 10, "numbers_raw": ["9,168,258"], "numbers": [9168258.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "9,199,995;", "length": 10, "numbers_raw": ["9,199,995"], "numbers": [9199995.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "9,616,061;", "length": 10, "numbers_raw": ["9,616,061"], "numbers": [9616061.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "9,956,227;", "length": 10, "numbers_raw": ["9,956,227"], "numbers": [9956227.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "10,117,867;", "length": 11, "numbers_raw": ["10,117,867"], "numbers": [10117867.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "10,464,938;", "length": 11, "numbers_raw": ["10,464,938"], "numbers": [10464938.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "10,960,009;", "length": 11, "numbers_raw": ["10,960,009"], "numbers": [10960009.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "11,026,951;", "length": 11, "numbers_raw": ["11,026,951"], "numbers": [11026951.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "11,753,419;", "length": 11, "numbers_raw": ["11,753,419"], "numbers": [11753419.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "11,980,617;", "length": 11, "numbers_raw": ["11,980,617"], "numbers": [11980617.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "12,070,459;", "length": 11, "numbers_raw": ["12,070,459"], "numbers": [12070459.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "12,090,155;", "length": 11, "numbers_raw": ["12,090,155"], "numbers": [12090155.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "12,122,792;", "length": 11, "numbers_raw": ["12,122,792"], "numbers": [12122792.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "and 12,128,043.", "length": 15, "numbers_raw": ["12,128,043"], "numbers": [12128043.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddys Laboratories Inc., Dr. Reddys Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.", "text": "In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc.", "length": 97, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 985, "tag": "div", "text_raw": "In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the U.S. District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents, including U.S. Patent Nos. 7,022,100 (100 patent); 8,888,728; and 9,327,068. Maquet counterclaimed for infringement of those patents against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. (collectively, Abiomed), and later added claims for", "text": "In March 2016, Abiomed, Inc.", "length": 28, "numbers_raw": ["201", "6"], "numbers": [201.0, 6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 985, "tag": "div", "text_raw": "In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the U.S. District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents, including U.S. Patent Nos. 7,022,100 (100 patent); 8,888,728; and 9,327,068. Maquet counterclaimed for infringement of those patents against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. (collectively, Abiomed), and later added claims for", "text": "filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the U.S.", "length": 90, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 985, "tag": "div", "text_raw": "In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the U.S. District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents, including U.S. Patent Nos. 7,022,100 (100 patent); 8,888,728; and 9,327,068. Maquet counterclaimed for infringement of those patents against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. (collectively, Abiomed), and later added claims for", "text": "District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents, including U.S.", "length": 147, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 985, "tag": "div", "text_raw": "In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the U.S. District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents, including U.S. Patent Nos. 7,022,100 (100 patent); 8,888,728; and 9,327,068. Maquet counterclaimed for infringement of those patents against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. (collectively, Abiomed), and later added claims for", "text": "7,022,100 (100 patent);", "length": 24, "numbers_raw": ["7,022,100", "100"], "numbers": [7022100.0, 100.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 985, "tag": "div", "text_raw": "In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the U.S. District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents, including U.S. Patent Nos. 7,022,100 (100 patent); 8,888,728; and 9,327,068. Maquet counterclaimed for infringement of those patents against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. (collectively, Abiomed), and later added claims for", "text": "8,888,728;", "length": 10, "numbers_raw": ["8,888,728"], "numbers": [8888728.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 985, "tag": "div", "text_raw": "In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the U.S. District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents, including U.S. Patent Nos. 7,022,100 (100 patent); 8,888,728; and 9,327,068. Maquet counterclaimed for infringement of those patents against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. (collectively, Abiomed), and later added claims for", "text": "and 9,327,068.", "length": 14, "numbers_raw": ["9,327,068"], "numbers": [9327068.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 985, "tag": "div", "text_raw": "In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the U.S. District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents, including U.S. Patent Nos. 7,022,100 (100 patent); 8,888,728; and 9,327,068. Maquet counterclaimed for infringement of those patents against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. (collectively, Abiomed), and later added claims for", "text": "Maquet counterclaimed for infringement of those patents against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc.", "length": 121, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": false, "has_percents": false}
{"idx_source": 985, "tag": "div", "text_raw": "In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the U.S. District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents, including U.S. Patent Nos. 7,022,100 (100 patent); 8,888,728; and 9,327,068. Maquet counterclaimed for infringement of those patents against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. (collectively, Abiomed), and later added claims for", "text": "(collectively, Abiomed), and later added claims for", "length": 51, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 986, "tag": "div", "text_raw": "34", "text": "34", "length": 2, "numbers_raw": ["34"], "numbers": [34.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 987, "tag": "div", "text_raw": "34", "text": "34", "length": 2, "numbers_raw": ["34"], "numbers": [34.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 988, "tag": "div", "text_raw": "34", "text": "34", "length": 2, "numbers_raw": ["34"], "numbers": [34.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 989, "tag": "div", "text_raw": "34", "text": "34", "length": 2, "numbers_raw": ["34"], "numbers": [34.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 993, "tag": "div", "text_raw": "infringement of U.S. Patent Nos. 9,545,468; 9,561,314; and 9,597,437. After claim construction, Maquet alleged infringement of only the 100 patent. In September 2021, the court granted Abiomeds motion for summary judgment of non-infringement of the 100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet appealed.", "text": "9,545,468;", "length": 10, "numbers_raw": ["9,545,468"], "numbers": [9545468.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 993, "tag": "div", "text_raw": "infringement of U.S. Patent Nos. 9,545,468; 9,561,314; and 9,597,437. After claim construction, Maquet alleged infringement of only the 100 patent. In September 2021, the court granted Abiomeds motion for summary judgment of non-infringement of the 100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet appealed.", "text": "9,561,314;", "length": 10, "numbers_raw": ["9,561,314"], "numbers": [9561314.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 993, "tag": "div", "text_raw": "infringement of U.S. Patent Nos. 9,545,468; 9,561,314; and 9,597,437. After claim construction, Maquet alleged infringement of only the 100 patent. In September 2021, the court granted Abiomeds motion for summary judgment of non-infringement of the 100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet appealed.", "text": "and 9,597,437.", "length": 14, "numbers_raw": ["9,597,437"], "numbers": [9597437.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 993, "tag": "div", "text_raw": "infringement of U.S. Patent Nos. 9,545,468; 9,561,314; and 9,597,437. After claim construction, Maquet alleged infringement of only the 100 patent. In September 2021, the court granted Abiomeds motion for summary judgment of non-infringement of the 100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet appealed.", "text": "After claim construction, Maquet alleged infringement of only the 100 patent.", "length": 78, "numbers_raw": ["100"], "numbers": [100.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 993, "tag": "div", "text_raw": "infringement of U.S. Patent Nos. 9,545,468; 9,561,314; and 9,597,437. After claim construction, Maquet alleged infringement of only the 100 patent. In September 2021, the court granted Abiomeds motion for summary judgment of non-infringement of the 100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet appealed.", "text": "In September 2021, the court granted Abiomeds motion for summary judgment of non-infringement of the 100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit.", "length": 223, "numbers_raw": ["202", "1", "100", "202", "3"], "numbers": [202.0, 1.0, 100.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 995, "tag": "div", "text_raw": "In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH (collectively, Abiomed) in the U.S. District Court for the District of Massachusetts, alleging that certain Impella products infringe U.S. Patent No. 9,789,238 (238 patent). Maquet subsequently added U.S. Patent No. 10,238,783 (783 patent). After claim construction, the court entered a stipulated judgment of non-infringement of both patents. Maquet appealed. On March 21, 2025, the U.S. Court of Appeals for the Federal Circuit left undisturbed the judgment on non-infringement of the 238 patent, vacated the judgment regarding the 783 patent, and remanded the case to the District Court for further proceedings on the 783 patent.", "text": "In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH (collectively, Abiomed) in the U.S.", "length": 156, "numbers_raw": ["201", "7"], "numbers": [201.0, 7.0], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": true, "has_percents": false}
{"idx_source": 995, "tag": "div", "text_raw": "In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH (collectively, Abiomed) in the U.S. District Court for the District of Massachusetts, alleging that certain Impella products infringe U.S. Patent No. 9,789,238 (238 patent). Maquet subsequently added U.S. Patent No. 10,238,783 (783 patent). After claim construction, the court entered a stipulated judgment of non-infringement of both patents. Maquet appealed. On March 21, 2025, the U.S. Court of Appeals for the Federal Circuit left undisturbed the judgment on non-infringement of the 238 patent, vacated the judgment regarding the 783 patent, and remanded the case to the District Court for further proceedings on the 783 patent.", "text": "District Court for the District of Massachusetts, alleging that certain Impella products infringe U.S.", "length": 102, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 995, "tag": "div", "text_raw": "In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH (collectively, Abiomed) in the U.S. District Court for the District of Massachusetts, alleging that certain Impella products infringe U.S. Patent No. 9,789,238 (238 patent). Maquet subsequently added U.S. Patent No. 10,238,783 (783 patent). After claim construction, the court entered a stipulated judgment of non-infringement of both patents. Maquet appealed. On March 21, 2025, the U.S. Court of Appeals for the Federal Circuit left undisturbed the judgment on non-infringement of the 238 patent, vacated the judgment regarding the 783 patent, and remanded the case to the District Court for further proceedings on the 783 patent.", "text": "9,789,238 (238 patent).", "length": 24, "numbers_raw": ["9,789,238", "238"], "numbers": [9789238.0, 238.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 995, "tag": "div", "text_raw": "In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH (collectively, Abiomed) in the U.S. District Court for the District of Massachusetts, alleging that certain Impella products infringe U.S. Patent No. 9,789,238 (238 patent). Maquet subsequently added U.S. Patent No. 10,238,783 (783 patent). After claim construction, the court entered a stipulated judgment of non-infringement of both patents. Maquet appealed. On March 21, 2025, the U.S. Court of Appeals for the Federal Circuit left undisturbed the judgment on non-infringement of the 238 patent, vacated the judgment regarding the 783 patent, and remanded the case to the District Court for further proceedings on the 783 patent.", "text": "Maquet subsequently added U.S.", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 995, "tag": "div", "text_raw": "In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH (collectively, Abiomed) in the U.S. District Court for the District of Massachusetts, alleging that certain Impella products infringe U.S. Patent No. 9,789,238 (238 patent). Maquet subsequently added U.S. Patent No. 10,238,783 (783 patent). After claim construction, the court entered a stipulated judgment of non-infringement of both patents. Maquet appealed. On March 21, 2025, the U.S. Court of Appeals for the Federal Circuit left undisturbed the judgment on non-infringement of the 238 patent, vacated the judgment regarding the 783 patent, and remanded the case to the District Court for further proceedings on the 783 patent.", "text": "10,238,783 (783 patent).", "length": 25, "numbers_raw": ["10,238,783", "783"], "numbers": [10238783.0, 783.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 995, "tag": "div", "text_raw": "In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH (collectively, Abiomed) in the U.S. District Court for the District of Massachusetts, alleging that certain Impella products infringe U.S. Patent No. 9,789,238 (238 patent). Maquet subsequently added U.S. Patent No. 10,238,783 (783 patent). After claim construction, the court entered a stipulated judgment of non-infringement of both patents. Maquet appealed. On March 21, 2025, the U.S. Court of Appeals for the Federal Circuit left undisturbed the judgment on non-infringement of the 238 patent, vacated the judgment regarding the 783 patent, and remanded the case to the District Court for further proceedings on the 783 patent.", "text": "After claim construction, the court entered a stipulated judgment of non-infringement of both patents.", "length": 102, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 995, "tag": "div", "text_raw": "In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH (collectively, Abiomed) in the U.S. District Court for the District of Massachusetts, alleging that certain Impella products infringe U.S. Patent No. 9,789,238 (238 patent). Maquet subsequently added U.S. Patent No. 10,238,783 (783 patent). After claim construction, the court entered a stipulated judgment of non-infringement of both patents. Maquet appealed. On March 21, 2025, the U.S. Court of Appeals for the Federal Circuit left undisturbed the judgment on non-infringement of the 238 patent, vacated the judgment regarding the 783 patent, and remanded the case to the District Court for further proceedings on the 783 patent.", "text": "On March 21, 2025, the U.S.", "length": 27, "numbers_raw": ["21", "202", "5"], "numbers": [21.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 995, "tag": "div", "text_raw": "In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH (collectively, Abiomed) in the U.S. District Court for the District of Massachusetts, alleging that certain Impella products infringe U.S. Patent No. 9,789,238 (238 patent). Maquet subsequently added U.S. Patent No. 10,238,783 (783 patent). After claim construction, the court entered a stipulated judgment of non-infringement of both patents. Maquet appealed. On March 21, 2025, the U.S. Court of Appeals for the Federal Circuit left undisturbed the judgment on non-infringement of the 238 patent, vacated the judgment regarding the 783 patent, and remanded the case to the District Court for further proceedings on the 783 patent.", "text": "Court of Appeals for the Federal Circuit left undisturbed the judgment on non-infringement of the 238 patent, vacated the judgment regarding the 783 patent, and remanded the case to the District Court for further proceedings on the 783 patent.", "length": 246, "numbers_raw": ["238", "783", "783"], "numbers": [238.0, 783.0, 783.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 998, "tag": "div", "text_raw": "Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.", "text": "Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate.", "length": 272, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 998, "tag": "div", "text_raw": "Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.", "text": "Such regulation has been the basis of government investigations and litigations.", "length": 80, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 998, "tag": "div", "text_raw": "Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.", "text": "The most significant litigation brought by, and investigations conducted by, government agencies are listed below.", "length": 114, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 998, "tag": "div", "text_raw": "Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.", "text": "It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.", "length": 151, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1000, "tag": "div", "text_raw": "In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has provided documents and information responsive to the Civil Investigative Demands and is continuing to cooperate with the DOJ regarding its inquiry.", "text": "In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc.", "length": 153, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1000, "tag": "div", "text_raw": "In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has provided documents and information responsive to the Civil Investigative Demands and is continuing to cooperate with the DOJ regarding its inquiry.", "text": "(collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems.", "length": 226, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1000, "tag": "div", "text_raw": "In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has provided documents and information responsive to the Civil Investigative Demands and is continuing to cooperate with the DOJ regarding its inquiry.", "text": "J&J Vision has provided documents and information responsive to the Civil Investigative Demands and is continuing to cooperate with the DOJ regarding its inquiry.", "length": 162, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1002, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims. On March 28, 2025, the Court granted in part and denied in part Janssens motions and the Company is appealing the verdict and judgments.", "text": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products.", "length": 352, "numbers_raw": ["201", "6"], "numbers": [201.0, 6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1002, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims. On March 28, 2025, the Court granted in part and denied in part Janssens motions and the Company is appealing the verdict and judgments.", "text": "The complaint was filed under seal in December 2012.", "length": 52, "numbers_raw": ["201", "2"], "numbers": [201.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1002, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims. On March 28, 2025, the Court granted in part and denied in part Janssens motions and the Company is appealing the verdict and judgments.", "text": "The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators.", "length": 114, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1002, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims. On March 28, 2025, the Court granted in part and denied in part Janssens motions and the Company is appealing the verdict and judgments.", "text": "The Court denied summary judgment on all claims in December 2021.", "length": 65, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1002, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims. On March 28, 2025, the Court granted in part and denied in part Janssens motions and the Company is appealing the verdict and judgments.", "text": "Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024.", "length": 105, "numbers_raw": ["202", "2", "202", "4"], "numbers": [202.0, 2.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1002, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims. On March 28, 2025, the Court granted in part and denied in part Janssens motions and the Company is appealing the verdict and judgments.", "text": "On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims.", "length": 151, "numbers_raw": ["13", "202", "4"], "numbers": [13.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1002, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims. On March 28, 2025, the Court granted in part and denied in part Janssens motions and the Company is appealing the verdict and judgments.", "text": "The Company is pursuing post-trial briefing challenging the verdict on the off-label claims.", "length": 92, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1002, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims. On March 28, 2025, the Court granted in part and denied in part Janssens motions and the Company is appealing the verdict and judgments.", "text": "On March 28, 2025, the Court granted in part and denied in part Janssens motions and the Company is appealing the verdict and judgments.", "length": 137, "numbers_raw": ["28", "202", "5"], "numbers": [28.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1003, "tag": "div", "text_raw": "In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.", "text": "In March 2017, Janssen Biotech, Inc.", "length": 36, "numbers_raw": ["201", "7"], "numbers": [201.0, 7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1003, "tag": "div", "text_raw": "In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.", "text": "(JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA.", "length": 272, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1003, "tag": "div", "text_raw": "In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.", "text": "In August 2019, the United States Department of Justice notified JBI that it was closing the investigation.", "length": 107, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1003, "tag": "div", "text_raw": "In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.", "text": "Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company.", "length": 160, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1003, "tag": "div", "text_raw": "In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.", "text": "The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019.", "length": 90, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1003, "tag": "div", "text_raw": "In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.", "text": "The Company filed a motion to dismiss, which was granted in part and denied in part.", "length": 84, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1005, "tag": "div", "text_raw": "The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the Companys agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation at such sites.", "text": "The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the Companys agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation at such sites.", "length": 489, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1006, "tag": "div", "text_raw": "In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical", "text": "In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act.", "length": 357, "numbers_raw": ["201", "7"], "numbers": [201.0, 7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1006, "tag": "div", "text_raw": "In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical", "text": "The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical", "length": 155, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1007, "tag": "div", "text_raw": "Form 10-Q 35", "text": "Form 10-Q 35", "length": 12, "numbers_raw": ["10", "35"], "numbers": [10.0, 35.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1008, "tag": "div", "text_raw": "Form 10-Q 35", "text": "Form 10-Q 35", "length": 12, "numbers_raw": ["10", "35"], "numbers": [10.0, 35.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1009, "tag": "div", "text_raw": "Form 10-Q 35", "text": "Form 10-Q 35", "length": 12, "numbers_raw": ["10", "35"], "numbers": [10.0, 35.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1010, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1011, "tag": "div", "text_raw": "35", "text": "35", "length": 2, "numbers_raw": ["35"], "numbers": [35.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1014, "tag": "div", "text_raw": "device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024.", "text": "device contracts with the Iraqi Ministry of Health.", "length": 51, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1014, "tag": "div", "text_raw": "device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024.", "text": "In July 2020, the District Court dismissed the complaint.", "length": 57, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1014, "tag": "div", "text_raw": "device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024.", "text": "In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision.", "length": 128, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1014, "tag": "div", "text_raw": "device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024.", "text": "In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court.", "length": 102, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1014, "tag": "div", "text_raw": "device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024.", "text": "In June 2024, the Supreme Court vacated the D.C.", "length": 48, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1014, "tag": "div", "text_raw": "device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024.", "text": "Circuit's decision and remanded the case to the D.C.", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1014, "tag": "div", "text_raw": "device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024.", "text": "Oral argument was held in November 2024.", "length": 40, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1015, "tag": "div", "text_raw": "In February 2024, a putative class action was filed against the Company and the Pension & Benefits Committee of Johnson & Johnson (Committee) in United States District Court for the District of New Jersey. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Companys prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and denied in part defendants motion to dismiss, with leave to replead. In March 2025, plaintiffs filed a second amended complaint.", "text": "In February 2024, a putative class action was filed against the Company and the Pension & Benefits Committee of Johnson & Johnson (Committee) in United States District Court for the District of New Jersey.", "length": 205, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1015, "tag": "div", "text_raw": "In February 2024, a putative class action was filed against the Company and the Pension & Benefits Committee of Johnson & Johnson (Committee) in United States District Court for the District of New Jersey. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Companys prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and denied in part defendants motion to dismiss, with leave to replead. In March 2025, plaintiffs filed a second amended complaint.", "text": "The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Companys prescription-drug benefits program.", "length": 196, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1015, "tag": "div", "text_raw": "In February 2024, a putative class action was filed against the Company and the Pension & Benefits Committee of Johnson & Johnson (Committee) in United States District Court for the District of New Jersey. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Companys prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and denied in part defendants motion to dismiss, with leave to replead. In March 2025, plaintiffs filed a second amended complaint.", "text": "The complaint seeks damages and other relief.", "length": 45, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1015, "tag": "div", "text_raw": "In February 2024, a putative class action was filed against the Company and the Pension & Benefits Committee of Johnson & Johnson (Committee) in United States District Court for the District of New Jersey. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Companys prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and denied in part defendants motion to dismiss, with leave to replead. In March 2025, plaintiffs filed a second amended complaint.", "text": "In January 2025, the Court granted in part and denied in part defendants motion to dismiss, with leave to replead.", "length": 115, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1015, "tag": "div", "text_raw": "In February 2024, a putative class action was filed against the Company and the Pension & Benefits Committee of Johnson & Johnson (Committee) in United States District Court for the District of New Jersey. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Companys prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and denied in part defendants motion to dismiss, with leave to replead. In March 2025, plaintiffs filed a second amended complaint.", "text": "In March 2025, plaintiffs filed a second amended complaint.", "length": 59, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1017, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.", "text": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc.", "length": 128, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1017, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.", "text": "(Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware.", "length": 177, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1017, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.", "text": "The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019.", "length": 150, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1017, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.", "text": "The complaint seeks damages and other relief.", "length": 45, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1017, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.", "text": "In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action.", "length": 118, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1017, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.", "text": "All claims against the individual defendants were dismissed.", "length": 60, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1017, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.", "text": "The trial occurred in January 2024.", "length": 35, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1017, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.", "text": "In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims.", "length": 122, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1017, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.", "text": "The Company has appealed the decision.", "length": 38, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1018, "tag": "div", "text_raw": "In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc (BWI) in the United States District Court for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. Trial is scheduled for April 2025.", "text": "In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc (BWI) in the United States District Court for the Central District of California.", "length": 169, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1018, "tag": "div", "text_raw": "In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc (BWI) in the United States District Court for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. Trial is scheduled for April 2025.", "text": "The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters.", "length": 259, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1018, "tag": "div", "text_raw": "In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc (BWI) in the United States District Court for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. Trial is scheduled for April 2025.", "text": "Trial is scheduled for April 2025.", "length": 34, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1020, "tag": "div", "text_raw": "In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssens REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.", "text": "In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc.", "length": 139, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1020, "tag": "div", "text_raw": "In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssens REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.", "text": "(collectively, Janssen) in connection with its investigation of whether Janssens REMICADE contracting practices violate federal antitrust laws.", "length": 144, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1020, "tag": "div", "text_raw": "In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssens REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.", "text": "The Company has produced documents and information responsive to the Civil Investigative Demand.", "length": 96, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1020, "tag": "div", "text_raw": "In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssens REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.", "text": "Janssen is in ongoing discussions with the FTC staff regarding its inquiry.", "length": 75, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1021, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc. and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.", "text": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc.", "length": 137, "numbers_raw": ["201", "8"], "numbers": [201.0, 8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1021, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc. and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.", "text": "and Actelion Clinical Research, Inc.", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1021, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc. and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.", "text": "(collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia.", "length": 147, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1021, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc. and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.", "text": "The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER.", "length": 195, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1021, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc. and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.", "text": "TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S.", "length": 85, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1021, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc. and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.", "text": "Food and Drug Administration, which imposes restrictions on distribution of the product.", "length": 88, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1021, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc. and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.", "text": "In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.", "length": 172, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1021, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc. and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.", "text": "In September 2024, the district court granted plaintiff's motion for class certification.", "length": 89, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1021, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc. and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.", "text": "Trial is scheduled for March 2026.", "length": 34, "numbers_raw": ["202", "6"], "numbers": [202.0, 6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1022, "tag": "div", "text_raw": "In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss.", "text": "In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc.", "length": 104, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1022, "tag": "div", "text_raw": "In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss.", "text": "(collectively Janssen) in the United States District Court for the Eastern District of Virginia.", "length": 96, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1022, "tag": "div", "text_raw": "In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss.", "text": "The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA.", "length": 210, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1022, "tag": "div", "text_raw": "In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss.", "text": "The complaint seeks damages and other relief.", "length": 45, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1022, "tag": "div", "text_raw": "In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss.", "text": "In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024.", "length": 102, "numbers_raw": ["202", "4", "202", "4"], "numbers": [202.0, 4.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1022, "tag": "div", "text_raw": "In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss.", "text": "In August 2024, the court granted in part and denied in part Janssen's motion to dismiss.", "length": 89, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1023, "tag": "div", "text_raw": "In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss.", "text": "In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia.", "length": 261, "numbers_raw": ["201", "8"], "numbers": [201.0, 8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1023, "tag": "div", "text_raw": "In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss.", "text": "The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs.", "length": 210, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1023, "tag": "div", "text_raw": "In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss.", "text": "At this time, the federal and state governments have declined to intervene.", "length": 75, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1023, "tag": "div", "text_raw": "In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss.", "text": "In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss.", "length": 117, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1026, "tag": "div", "text_raw": "36", "text": "36", "length": 2, "numbers_raw": ["36"], "numbers": [36.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1027, "tag": "div", "text_raw": "36", "text": "36", "length": 2, "numbers_raw": ["36"], "numbers": [36.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1028, "tag": "div", "text_raw": "36", "text": "36", "length": 2, "numbers_raw": ["36"], "numbers": [36.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1029, "tag": "div", "text_raw": "36", "text": "36", "length": 2, "numbers_raw": ["36"], "numbers": [36.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1034, "tag": "div", "text_raw": "Note 12  Restructuring", "text": "Note 12  Restructuring", "length": 23, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1035, "tag": "div", "text_raw": "In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense in the fiscal first quarter of 2025 primarily included costs related to asset impairments and market and product exits. The pre-tax restructuring expense in the fiscal first quarter of 2024 primarily included costs related to market and product exits. Total project costs of approximately $ 0.5 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $ 0.7 billion - $ 0.8 billion and is expected to be completed by the end of fiscal year 2025.", "text": "In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements.", "length": 224, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1035, "tag": "div", "text_raw": "In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense in the fiscal first quarter of 2025 primarily included costs related to asset impairments and market and product exits. The pre-tax restructuring expense in the fiscal first quarter of 2024 primarily included costs related to market and product exits. Total project costs of approximately $ 0.5 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $ 0.7 billion - $ 0.8 billion and is expected to be completed by the end of fiscal year 2025.", "text": "The pre-tax restructuring expense in the fiscal first quarter of 2025 primarily included costs related to asset impairments and market and product exits.", "length": 153, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1035, "tag": "div", "text_raw": "In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense in the fiscal first quarter of 2025 primarily included costs related to asset impairments and market and product exits. The pre-tax restructuring expense in the fiscal first quarter of 2024 primarily included costs related to market and product exits. Total project costs of approximately $ 0.5 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $ 0.7 billion - $ 0.8 billion and is expected to be completed by the end of fiscal year 2025.", "text": "The pre-tax restructuring expense in the fiscal first quarter of 2024 primarily included costs related to market and product exits.", "length": 131, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1035, "tag": "div", "text_raw": "In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense in the fiscal first quarter of 2025 primarily included costs related to asset impairments and market and product exits. The pre-tax restructuring expense in the fiscal first quarter of 2024 primarily included costs related to market and product exits. Total project costs of approximately $ 0.5 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $ 0.7 billion - $ 0.8 billion and is expected to be completed by the end of fiscal year 2025.", "text": "Total project costs of approximately $ 0.5 billion have been recorded since the restructuring was announced.", "length": 108, "numbers_raw": ["0.5 billion"], "numbers": [500000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1035, "tag": "div", "text_raw": "In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense in the fiscal first quarter of 2025 primarily included costs related to asset impairments and market and product exits. The pre-tax restructuring expense in the fiscal first quarter of 2024 primarily included costs related to market and product exits. Total project costs of approximately $ 0.5 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $ 0.7 billion - $ 0.8 billion and is expected to be completed by the end of fiscal year 2025.", "text": "The estimated costs of the total program are between $ 0.7 billion - $ 0.8 billion and is expected to be completed by the end of fiscal year 2025.", "length": 146, "numbers_raw": ["0.7 billion", "0.8 billion", "202", "5"], "numbers": [700000000.0, 800000000.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1036, "tag": "div", "text_raw": "The following table summarizes the restructuring expenses for 2025 and 2024:", "text": "The following table summarizes the restructuring expenses for 2025 and 2024:", "length": 76, "numbers_raw": ["202", "5", "202", "4"], "numbers": [202.0, 5.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1037, "tag": "div", "text_raw": "(Pre-tax Dollars in Millions) Q1 2025 Q1 2024 MedTech Segment (1) $ 55 27 Innovative Medicine Segment (2) 0 144 Total Programs $ 55 171", "text": "(Pre-tax Dollars in Millions) Q1 2025 Q1 2024 MedTech Segment (1) $ 55 27 Innovative Medicine Segment (2) 0 144 Total Programs $ 55 171", "length": 135, "numbers_raw": ["1", "202", "5", "1", "202", "4 M", "1", "55", "27", "2", "0", "144", "55", "171"], "numbers": [1.0, 202.0, 5.0, 1.0, 202.0, 4000000.0, 1.0, 55.0, 27.0, 2.0, 0.0, 144.0, 55.0, 171.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1038, "tag": "div", "text_raw": "MedTech Segment (1)", "text": "MedTech Segment (1)", "length": 19, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1039, "tag": "div", "text_raw": "Innovative Medicine Segment (2)", "text": "Innovative Medicine Segment (2)", "length": 31, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1040, "tag": "div", "text_raw": "(1) Includes $ 17 million in Restructuring, $ 8 million in Cost of products sold and $ 30 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal first quarter of 2025. Included $ 20 million in Restructuring and $ 7 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal first quarter of 2024.", "text": "(1) Includes $ 17 million in Restructuring, $ 8 million in Cost of products sold and $ 30 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal first quarter of 2025.", "length": 202, "numbers_raw": ["1", "17 million", "8 million", "30 million", "202", "5"], "numbers": [1.0, 17000000.0, 8000000.0, 30000000.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1040, "tag": "div", "text_raw": "(1) Includes $ 17 million in Restructuring, $ 8 million in Cost of products sold and $ 30 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal first quarter of 2025. Included $ 20 million in Restructuring and $ 7 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal first quarter of 2024.", "text": "Included $ 20 million in Restructuring and $ 7 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal first quarter of 2024.", "length": 158, "numbers_raw": ["20 million", "7 million", "202", "4"], "numbers": [20000000.0, 7000000.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1041, "tag": "div", "text_raw": "(2) Included in Restructuring on the Consolidated Statement of Earnings in the fiscal first quarter of 2024. This program was completed in the fiscal fourth quarter of 2024.", "text": "(2) Included in Restructuring on the Consolidated Statement of Earnings in the fiscal first quarter of 2024.", "length": 108, "numbers_raw": ["2", "202", "4"], "numbers": [2.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1041, "tag": "div", "text_raw": "(2) Included in Restructuring on the Consolidated Statement of Earnings in the fiscal first quarter of 2024. This program was completed in the fiscal fourth quarter of 2024.", "text": "This program was completed in the fiscal fourth quarter of 2024.", "length": 64, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1042, "tag": "div", "text_raw": "Restructuring reserves as of March 30, 2025 and December 29, 2024 were insignificant.", "text": "Restructuring reserves as of March 30, 2025 and December 29, 2024 were insignificant.", "length": 85, "numbers_raw": ["30", "202", "5", "29", "202", "4"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1043, "tag": "div", "text_raw": "Form 10-Q 37", "text": "Form 10-Q 37", "length": 12, "numbers_raw": ["10", "37"], "numbers": [10.0, 37.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1044, "tag": "div", "text_raw": "Form 10-Q 37", "text": "Form 10-Q 37", "length": 12, "numbers_raw": ["10", "37"], "numbers": [10.0, 37.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1045, "tag": "div", "text_raw": "Form 10-Q 37", "text": "Form 10-Q 37", "length": 12, "numbers_raw": ["10", "37"], "numbers": [10.0, 37.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1046, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1047, "tag": "div", "text_raw": "37", "text": "37", "length": 2, "numbers_raw": ["37"], "numbers": [37.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1052, "tag": "div", "text_raw": "Item 2  Managements discussion and analysis of financial condition and results of operations", "text": "Item 2  Managements discussion and analysis of financial condition and results of operations", "length": 94, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1055, "tag": "div", "text_raw": "Analysis of consolidated sales", "text": "Analysis of consolidated sales", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1056, "tag": "div", "text_raw": "For the fiscal first quarter of 2025, worldwide sales were $21.9 billion, a total increase of 2.4%, which included operational growth of 4.2% and a negative currency impact of 1.8% as compared to 2024 fiscal first quarter sales of $21.4 billion. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 0.9%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, on the worldwide operational sales was approximately negative 4.7%.", "text": "For the fiscal first quarter of 2025, worldwide sales were $21.9 billion, a total increase of 2.4%, which included operational growth of 4.2% and a negative currency impact of 1.8% as compared to 2024 fiscal first quarter sales of $21.4 billion.", "length": 245, "numbers_raw": ["202", "5", "$21.9 billion", "2.4", "4.2", "1.8", "202", "4", "$21.4 billion"], "numbers": [202.0, 5.0, 21900000000.0, 2.4, 4.2, 1.8, 202.0, 4.0, 21400000000.0], "percents_raw": ["2.4%", "4.2%", "1.8%"], "percents": [0.024, 0.042, 0.018000000000000002], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1056, "tag": "div", "text_raw": "For the fiscal first quarter of 2025, worldwide sales were $21.9 billion, a total increase of 2.4%, which included operational growth of 4.2% and a negative currency impact of 1.8% as compared to 2024 fiscal first quarter sales of $21.4 billion. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 0.9%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, on the worldwide operational sales was approximately negative 4.7%.", "text": "In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 0.9%.", "length": 143, "numbers_raw": ["202", "5", "0.9"], "numbers": [202.0, 5.0, 0.9], "percents_raw": ["0.9%"], "percents": [0.009000000000000001], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1056, "tag": "div", "text_raw": "For the fiscal first quarter of 2025, worldwide sales were $21.9 billion, a total increase of 2.4%, which included operational growth of 4.2% and a negative currency impact of 1.8% as compared to 2024 fiscal first quarter sales of $21.4 billion. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 0.9%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, on the worldwide operational sales was approximately negative 4.7%.", "text": "In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, on the worldwide operational sales was approximately negative 4.7%.", "length": 176, "numbers_raw": ["202", "5", "4.7"], "numbers": [202.0, 5.0, 4.7], "percents_raw": ["4.7%"], "percents": [0.047], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1057, "tag": "div", "text_raw": "Sales by U.S. companies were $12.3 billion in the fiscal first quarter of 2025, which represented an increase of 5.9% as compared to the prior year. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 1.5%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition on the U.S. operational sales was approximately negative 4.9%. Sales by international companies were $9.6 billion, a total decrease of 1.8%, which included operational growth of 2.1% offset by a negative currency impact of 3.9%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on international operational sales growth was a positive 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, on the international operational sales was approximately negative 4.6%.", "text": "companies were $12.3 billion in the fiscal first quarter of 2025, which represented an increase of 5.9% as compared to the prior year.", "length": 134, "numbers_raw": ["$12.3 billion", "202", "5", "5.9"], "numbers": [12300000000.0, 202.0, 5.0, 5.9], "percents_raw": ["5.9%"], "percents": [0.059000000000000004], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1057, "tag": "div", "text_raw": "Sales by U.S. companies were $12.3 billion in the fiscal first quarter of 2025, which represented an increase of 5.9% as compared to the prior year. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 1.5%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition on the U.S. operational sales was approximately negative 4.9%. Sales by international companies were $9.6 billion, a total decrease of 1.8%, which included operational growth of 2.1% offset by a negative currency impact of 3.9%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on international operational sales growth was a positive 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, on the international operational sales was approximately negative 4.6%.", "text": "In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the U.S.", "length": 96, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1057, "tag": "div", "text_raw": "Sales by U.S. companies were $12.3 billion in the fiscal first quarter of 2025, which represented an increase of 5.9% as compared to the prior year. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 1.5%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition on the U.S. operational sales was approximately negative 4.9%. Sales by international companies were $9.6 billion, a total decrease of 1.8%, which included operational growth of 2.1% offset by a negative currency impact of 3.9%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on international operational sales growth was a positive 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, on the international operational sales was approximately negative 4.6%.", "text": "operational sales growth was a positive 1.5%.", "length": 45, "numbers_raw": ["1.5"], "numbers": [1.5], "percents_raw": ["1.5%"], "percents": [0.015], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1057, "tag": "div", "text_raw": "Sales by U.S. companies were $12.3 billion in the fiscal first quarter of 2025, which represented an increase of 5.9% as compared to the prior year. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 1.5%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition on the U.S. operational sales was approximately negative 4.9%. Sales by international companies were $9.6 billion, a total decrease of 1.8%, which included operational growth of 2.1% offset by a negative currency impact of 3.9%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on international operational sales growth was a positive 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, on the international operational sales was approximately negative 4.6%.", "text": "In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition on the U.S.", "length": 119, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1057, "tag": "div", "text_raw": "Sales by U.S. companies were $12.3 billion in the fiscal first quarter of 2025, which represented an increase of 5.9% as compared to the prior year. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 1.5%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition on the U.S. operational sales was approximately negative 4.9%. Sales by international companies were $9.6 billion, a total decrease of 1.8%, which included operational growth of 2.1% offset by a negative currency impact of 3.9%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on international operational sales growth was a positive 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, on the international operational sales was approximately negative 4.6%.", "text": "operational sales was approximately negative 4.9%.", "length": 50, "numbers_raw": ["4.9"], "numbers": [4.9], "percents_raw": ["4.9%"], "percents": [0.049], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1057, "tag": "div", "text_raw": "Sales by U.S. companies were $12.3 billion in the fiscal first quarter of 2025, which represented an increase of 5.9% as compared to the prior year. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 1.5%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition on the U.S. operational sales was approximately negative 4.9%. Sales by international companies were $9.6 billion, a total decrease of 1.8%, which included operational growth of 2.1% offset by a negative currency impact of 3.9%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on international operational sales growth was a positive 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, on the international operational sales was approximately negative 4.6%.", "text": "Sales by international companies were $9.6 billion, a total decrease of 1.8%, which included operational growth of 2.1% offset by a negative currency impact of 3.9%.", "length": 165, "numbers_raw": ["$9.6 billion", "1.8", "2.1", "3.9"], "numbers": [9600000000.0, 1.8, 2.1, 3.9], "percents_raw": ["1.8%", "2.1%", "3.9%"], "percents": [0.018000000000000002, 0.021, 0.039], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1057, "tag": "div", "text_raw": "Sales by U.S. companies were $12.3 billion in the fiscal first quarter of 2025, which represented an increase of 5.9% as compared to the prior year. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 1.5%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition on the U.S. operational sales was approximately negative 4.9%. Sales by international companies were $9.6 billion, a total decrease of 1.8%, which included operational growth of 2.1% offset by a negative currency impact of 3.9%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on international operational sales growth was a positive 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, on the international operational sales was approximately negative 4.6%.", "text": "In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on international operational sales growth was a positive 0.2%.", "length": 147, "numbers_raw": ["202", "5", "0.2"], "numbers": [202.0, 5.0, 0.2], "percents_raw": ["0.2%"], "percents": [0.002], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1057, "tag": "div", "text_raw": "Sales by U.S. companies were $12.3 billion in the fiscal first quarter of 2025, which represented an increase of 5.9% as compared to the prior year. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 1.5%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition on the U.S. operational sales was approximately negative 4.9%. Sales by international companies were $9.6 billion, a total decrease of 1.8%, which included operational growth of 2.1% offset by a negative currency impact of 3.9%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on international operational sales growth was a positive 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, on the international operational sales was approximately negative 4.6%.", "text": "In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, on the international operational sales was approximately negative 4.6%.", "length": 180, "numbers_raw": ["202", "5", "4.6"], "numbers": [202.0, 5.0, 4.6], "percents_raw": ["4.6%"], "percents": [0.046], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1058, "tag": "div", "text_raw": "In the fiscal first quarter of 2025, sales by companies in Europe experienced a sales decline of 1.0%, which included operational growth of 2.2% offset by a negative currency impact of 3.2%. Sales by companies in the Western Hemisphere, excluding the U.S., experienced a sales decline of 2.3%, which included operational growth of 9.2% offset by a negative currency impact of 11.5%. Sales by companies in the Asia-Pacific, Africa region experienced a sales decline of 2.8%, which included an operational decline of 0.6% and a negative currency impact of 2.2%.", "text": "In the fiscal first quarter of 2025, sales by companies in Europe experienced a sales decline of 1.0%, which included operational growth of 2.2% offset by a negative currency impact of 3.2%.", "length": 190, "numbers_raw": ["202", "5", "1.0", "2.2", "3.2"], "numbers": [202.0, 5.0, 1.0, 2.2, 3.2], "percents_raw": ["1.0%", "2.2%", "3.2%"], "percents": [0.01, 0.022000000000000002, 0.032], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 1058, "tag": "div", "text_raw": "In the fiscal first quarter of 2025, sales by companies in Europe experienced a sales decline of 1.0%, which included operational growth of 2.2% offset by a negative currency impact of 3.2%. Sales by companies in the Western Hemisphere, excluding the U.S., experienced a sales decline of 2.3%, which included operational growth of 9.2% offset by a negative currency impact of 11.5%. Sales by companies in the Asia-Pacific, Africa region experienced a sales decline of 2.8%, which included an operational decline of 0.6% and a negative currency impact of 2.2%.", "text": "Sales by companies in the Western Hemisphere, excluding the U.S., experienced a sales decline of 2.3%, which included operational growth of 9.2% offset by a negative currency impact of 11.5%.", "length": 191, "numbers_raw": ["2.3", "9.2", "11.5"], "numbers": [2.3, 9.2, 11.5], "percents_raw": ["2.3%", "9.2%", "11.5%"], "percents": [0.023, 0.092, 0.115], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1058, "tag": "div", "text_raw": "In the fiscal first quarter of 2025, sales by companies in Europe experienced a sales decline of 1.0%, which included operational growth of 2.2% offset by a negative currency impact of 3.2%. Sales by companies in the Western Hemisphere, excluding the U.S., experienced a sales decline of 2.3%, which included operational growth of 9.2% offset by a negative currency impact of 11.5%. Sales by companies in the Asia-Pacific, Africa region experienced a sales decline of 2.8%, which included an operational decline of 0.6% and a negative currency impact of 2.2%.", "text": "Sales by companies in the Asia-Pacific, Africa region experienced a sales decline of 2.8%, which included an operational decline of 0.6% and a negative currency impact of 2.2%.", "length": 176, "numbers_raw": ["2.8", "0.6", "2.2"], "numbers": [2.8, 0.6, 2.2], "percents_raw": ["2.8%", "0.6%", "2.2%"], "percents": [0.027999999999999997, 0.006, 0.022000000000000002], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1059, "tag": "div", "text_raw": "Q1 2025 Sales by Geographic Region (in billions) Q1 2025 Sales by Segment (in billions)", "text": "Q1 2025 Sales by Geographic Region (in billions) Q1 2025 Sales by Segment (in billions)", "length": 87, "numbers_raw": ["1", "202", "5", "1", "202", "5"], "numbers": [1.0, 202.0, 5.0, 1.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1060, "tag": "div", "text_raw": "Q1 2025 Sales by Geographic Region (in billions)", "text": "Q1 2025 Sales by Geographic Region (in billions)", "length": 48, "numbers_raw": ["1", "202", "5"], "numbers": [1.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1061, "tag": "div", "text_raw": "Q1 2025 Sales by Geographic Region (in billions)", "text": "Q1 2025 Sales by Geographic Region (in billions)", "length": 48, "numbers_raw": ["1", "202", "5"], "numbers": [1.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1064, "tag": "div", "text_raw": "Q1 2025 Sales by Segment (in billions)", "text": "Q1 2025 Sales by Segment (in billions)", "length": 38, "numbers_raw": ["1", "202", "5"], "numbers": [1.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1065, "tag": "div", "text_raw": "Q1 2025 Sales by Segment (in billions)", "text": "Q1 2025 Sales by Segment (in billions)", "length": 38, "numbers_raw": ["1", "202", "5"], "numbers": [1.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1069, "tag": "div", "text_raw": "38", "text": "38", "length": 2, "numbers_raw": ["38"], "numbers": [38.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1070, "tag": "div", "text_raw": "38", "text": "38", "length": 2, "numbers_raw": ["38"], "numbers": [38.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1071, "tag": "div", "text_raw": "38", "text": "38", "length": 2, "numbers_raw": ["38"], "numbers": [38.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1072, "tag": "div", "text_raw": "38", "text": "38", "length": 2, "numbers_raw": ["38"], "numbers": [38.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1076, "tag": "div", "text_raw": "Analysis of sales by business segments", "text": "Analysis of sales by business segments", "length": 38, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1077, "tag": "div", "text_raw": "Innovative Medicine Innovative Medicine segment sales in the fiscal first quarter of 2025 were $13.9 billion, an increase of 2.3% as compared to the same period a year ago, including an operational increase of 4.2% and a negative currency impact of 1.9%. U.S. Innovative Medicine sales increased 6.3% as compared to the same period a year ago. International Innovative Medicine sales decreased by 2.9%, including an operational increase of 1.5% offset by a negative currency impact of 4.4%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the worldwide Innovative Medicine segment operational sales growth was a negative 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, was an approximate negative 8.1% on the worldwide, U.S. and international Innovative Medicine segment operational sales.", "text": "Innovative Medicine Innovative Medicine segment sales in the fiscal first quarter of 2025 were $13.9 billion, an increase of 2.3% as compared to the same period a year ago, including an operational increase of 4.2% and a negative currency impact of 1.9%.", "length": 254, "numbers_raw": ["202", "5", "$13.9 billion", "2.3", "4.2", "1.9"], "numbers": [202.0, 5.0, 13900000000.0, 2.3, 4.2, 1.9], "percents_raw": ["2.3%", "4.2%", "1.9%"], "percents": [0.023, 0.042, 0.019], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1077, "tag": "div", "text_raw": "Innovative Medicine Innovative Medicine segment sales in the fiscal first quarter of 2025 were $13.9 billion, an increase of 2.3% as compared to the same period a year ago, including an operational increase of 4.2% and a negative currency impact of 1.9%. U.S. Innovative Medicine sales increased 6.3% as compared to the same period a year ago. International Innovative Medicine sales decreased by 2.9%, including an operational increase of 1.5% offset by a negative currency impact of 4.4%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the worldwide Innovative Medicine segment operational sales growth was a negative 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, was an approximate negative 8.1% on the worldwide, U.S. and international Innovative Medicine segment operational sales.", "text": "Innovative Medicine sales increased 6.3% as compared to the same period a year ago.", "length": 83, "numbers_raw": ["6.3"], "numbers": [6.3], "percents_raw": ["6.3%"], "percents": [0.063], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1077, "tag": "div", "text_raw": "Innovative Medicine Innovative Medicine segment sales in the fiscal first quarter of 2025 were $13.9 billion, an increase of 2.3% as compared to the same period a year ago, including an operational increase of 4.2% and a negative currency impact of 1.9%. U.S. Innovative Medicine sales increased 6.3% as compared to the same period a year ago. International Innovative Medicine sales decreased by 2.9%, including an operational increase of 1.5% offset by a negative currency impact of 4.4%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the worldwide Innovative Medicine segment operational sales growth was a negative 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, was an approximate negative 8.1% on the worldwide, U.S. and international Innovative Medicine segment operational sales.", "text": "International Innovative Medicine sales decreased by 2.9%, including an operational increase of 1.5% offset by a negative currency impact of 4.4%.", "length": 146, "numbers_raw": ["2.9", "1.5", "4.4"], "numbers": [2.9, 1.5, 4.4], "percents_raw": ["2.9%", "1.5%", "4.4%"], "percents": [0.028999999999999998, 0.015, 0.044000000000000004], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1077, "tag": "div", "text_raw": "Innovative Medicine Innovative Medicine segment sales in the fiscal first quarter of 2025 were $13.9 billion, an increase of 2.3% as compared to the same period a year ago, including an operational increase of 4.2% and a negative currency impact of 1.9%. U.S. Innovative Medicine sales increased 6.3% as compared to the same period a year ago. International Innovative Medicine sales decreased by 2.9%, including an operational increase of 1.5% offset by a negative currency impact of 4.4%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the worldwide Innovative Medicine segment operational sales growth was a negative 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, was an approximate negative 8.1% on the worldwide, U.S. and international Innovative Medicine segment operational sales.", "text": "In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the worldwide Innovative Medicine segment operational sales growth was a negative 0.2%.", "length": 175, "numbers_raw": ["202", "5", "0.2"], "numbers": [202.0, 5.0, 0.2], "percents_raw": ["0.2%"], "percents": [0.002], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1077, "tag": "div", "text_raw": "Innovative Medicine Innovative Medicine segment sales in the fiscal first quarter of 2025 were $13.9 billion, an increase of 2.3% as compared to the same period a year ago, including an operational increase of 4.2% and a negative currency impact of 1.9%. U.S. Innovative Medicine sales increased 6.3% as compared to the same period a year ago. International Innovative Medicine sales decreased by 2.9%, including an operational increase of 1.5% offset by a negative currency impact of 4.4%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the worldwide Innovative Medicine segment operational sales growth was a negative 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, was an approximate negative 8.1% on the worldwide, U.S. and international Innovative Medicine segment operational sales.", "text": "In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, was an approximate negative 8.1% on the worldwide, U.S.", "length": 164, "numbers_raw": ["202", "5", "8.1"], "numbers": [202.0, 5.0, 8.1], "percents_raw": ["8.1%"], "percents": [0.081], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1077, "tag": "div", "text_raw": "Innovative Medicine Innovative Medicine segment sales in the fiscal first quarter of 2025 were $13.9 billion, an increase of 2.3% as compared to the same period a year ago, including an operational increase of 4.2% and a negative currency impact of 1.9%. U.S. Innovative Medicine sales increased 6.3% as compared to the same period a year ago. International Innovative Medicine sales decreased by 2.9%, including an operational increase of 1.5% offset by a negative currency impact of 4.4%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the worldwide Innovative Medicine segment operational sales growth was a negative 0.2%. In the fiscal first quarter of 2025, the impact of the Stelara sales decline, due to biosimilar competition, was an approximate negative 8.1% on the worldwide, U.S. and international Innovative Medicine segment operational sales.", "text": "and international Innovative Medicine segment operational sales.", "length": 64, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1078, "tag": "div", "text_raw": "Major Innovative Medicine therapeutic area sales  Fiscal First Quarter Ended", "text": "Major Innovative Medicine therapeutic area sales  Fiscal First Quarter Ended", "length": 77, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1079, "tag": "div", "text_raw": "(Dollars in Millions) March 30, 2025 March 31, 2024 Total Change Operations Change Currency Change Oncology $5,678 $4,814 17.9 % 20.4 % (2.5) % CARVYKTI 369 157 * * * DARZALEX 3,237 2,692 20.3 22.5 (2.2) ERLEADA 771 689 11.9 14.6 (2.7) IMBRUVICA 709 784 (9.5) (6.7) (2.8) RYBREVANT/ LAZCLUZE (1) 141 47 * * * TALVEY (1) 86 58 48.4 50.2 (1.8) TECVAYLI 151 133 13.3 15.0 (1.7) ZYTIGA/ abiraterone acetate 125 181 (30.9) (28.3) (2.6) Other Oncology 89 73 21.7 24.7 (3.0) Immunology 3,707 4,247 (12.7) (10.9) (1.8) REMICADE 467 434 7.5 9.3 (1.8) SIMPONI/ SIMPONI ARIA 659 554 18.9 22.9 (4.0) STELARA 1,625 2,451 (33.7) (32.3) (1.4) TREMFYA 956 808 18.2 20.1 (1.9) Other Immunology 1 0 * *  Neuroscience 1,647 1,803 (8.6) (7.0) (1.6) CONCERTA/ methylphenidate 148 177 (16.3) (13.4) (2.9) INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA 903 1,056 (14.5) (13.5) (1.0) SPRAVATO 320 225 41.9 42.9 (1.0) Other Neuroscience 277 345 (19.6) (16.7) (2.9) Pulmonary Hypertension 1,025 1,049 (2.3) (1.2) (1.1) OPSUMIT/ OPSYNVI (2) 522 524 (0.5) 0.6 (1.1) UPTRAVI 451 468 (3.6) (2.9) (0.7) Other Pulmonary Hypertension 52 56 (7.2) (4.3) (2.9) Infectious Diseases 802 821 (2.2) 0.1 (2.3) EDURANT/rilpivirine 358 323 10.7 14.3 (3.6) PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA 403 418 (3.7) (2.3) (1.4) Other Infectious Diseases (3) 41 78 (47.6) (45.9) (1.7) Cardiovascular / Metabolism / Other 1,013 829 22.3 23.4 (1.1) XARELTO 690 518 33.3 33.3  Other 323 311 3.9 6.7 (2.8) Total Innovative Medicine Sales $13,873 $13,562 2.3 % 4.2 % (1.9) %", "text": "(Dollars in Millions) March 30, 2025 March 31, 2024 Total Change Operations Change Currency Change Oncology $5,678 $4,814 17.9 % 20.4 % (2.5) % CARVYKTI 369 157 * * * DARZALEX 3,237 2,692 20.3 22.5 (2.2) ERLEADA 771 689 11.9 14.6 (2.7) IMBRUVICA 709 784 (9.5) (6.7) (2.8) RYBREVANT/ LAZCLUZE (1) 141 47 * * * TALVEY (1) 86 58 48.4 50.2 (1.8) TECVAYLI 151 133 13.3 15.0 (1.7) ZYTIGA/ abiraterone acetate 125 181 (30.9) (28.3) (2.6) Other Oncology 89 73 21.7 24.7 (3.0) Immunology 3,707 4,247 (12.7) (10.9) (1.8) REMICADE 467 434 7.5 9.3 (1.8) SIMPONI/ SIMPONI ARIA 659 554 18.9 22.9 (4.0) STELARA 1,625 2,451 (33.7) (32.3) (1.4) TREMFYA 956 808 18.2 20.1 (1.9) Other Immunology 1 0 * *  Neuroscience 1,647 1,803 (8.6) (7.0) (1.6) CONCERTA/ methylphenidate 148 177 (16.3) (13.4) (2.9) INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA 903 1,056 (14.5) (13.5) (1.0) SPRAVATO 320 225 41.9 42.9 (1.0) Other Neuroscience 277 345 (19.6) (16.7) (2.9) Pulmonary Hypertension 1,025 1,049 (2.3) (1.2) (1.1) OPSUMIT/ OPSYNVI (2) 522 524 (0.5) 0.6 (1.1) UPTRAVI 451 468 (3.6) (2.9) (0.7) Other Pulmonary Hypertension 52 56 (7.2) (4.3) (2.9) Infectious Diseases 802 821 (2.2) 0.1 (2.3) EDURANT/rilpivirine 358 323 10.7 14.3 (3.6) PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA 403 418 (3.7) (2.3) (1.4) Other Infectious Diseases (3) 41 78 (47.6) (45.9) (1.7) Cardiovascular / Metabolism / Other 1,013 829 22.3 23.4 (1.1) XARELTO 690 518 33.3 33.3  Other 323 311 3.9 6.7 (2.8) Total Innovative Medicine Sales $13,873 $13,562 2.3 % 4.2 % (1.9) %", "length": 1523, "numbers_raw": ["30", "202", "5 M", "31", "202", "4", "$5,678", "$4,814", "17.9", "20.4", "2.5", "369", "157", "3,237", "2,692", "20.3", "22.5", "2.2", "771", "689", "11.9", "14.6", "2.7", "709", "784", "9.5", "6.7", "2.8", "1", "141", "47", "1", "86", "58", "48.4", "50.2", "1.8", "151", "133", "13.3", "15.0", "1.7", "125", "181", "30.9", "28.3", "2.6", "89", "73", "21.7", "24.7", "3.0", "3,707", "4,247", "12.7", "10.9", "1.8", "467", "434", "7.5", "9.3", "1.8", "659", "554", "18.9", "22.9", "4.0", "1,625", "2,451", "33.7", "32.3", "1.4", "956", "808", "18.2", "20.1", "1.9", "1", "0", "1,647", "1,803", "8.6", "7.0", "1.6", "148", "177", "16.3", "13.4", "2.9", "903", "1,056", "14.5", "13.5", "1.0", "320", "225", "41.9", "42.9", "1.0", "277", "345", "19.6", "16.7", "2.9", "1,025", "1,049", "2.3", "1.2", "1.1", "2", "522", "524", "0.5", "0.6", "1.1", "451", "468", "3.6", "2.9", "0.7", "52", "56", "7.2", "4.3", "2.9", "802", "821", "2.2", "0.1", "2.3", "358", "323", "10.7", "14.3", "3.6", "403", "418", "3.7", "2.3", "1.4", "3", "41", "78", "47.6", "45.9", "1.7", "1,013", "829", "22.3", "23.4", "1.1", "690", "518", "33.3", "33.3", "323", "311", "3.9", "6.7", "2.8", "$13,873", "$13,562", "2.3", "4.2", "1.9"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 5678.0, 4814.0, 17.9, 20.4, 2.5, 369.0, 157.0, 3237.0, 2692.0, 20.3, 22.5, 2.2, 771.0, 689.0, 11.9, 14.6, 2.7, 709.0, 784.0, 9.5, 6.7, 2.8, 1.0, 141.0, 47.0, 1.0, 86.0, 58.0, 48.4, 50.2, 1.8, 151.0, 133.0, 13.3, 15.0, 1.7, 125.0, 181.0, 30.9, 28.3, 2.6, 89.0, 73.0, 21.7, 24.7, 3.0, 3707.0, 4247.0, 12.7, 10.9, 1.8, 467.0, 434.0, 7.5, 9.3, 1.8, 659.0, 554.0, 18.9, 22.9, 4.0, 1625.0, 2451.0, 33.7, 32.3, 1.4, 956.0, 808.0, 18.2, 20.1, 1.9, 1.0, 0.0, 1647.0, 1803.0, 8.6, 7.0, 1.6, 148.0, 177.0, 16.3, 13.4, 2.9, 903.0, 1056.0, 14.5, 13.5, 1.0, 320.0, 225.0, 41.9, 42.9, 1.0, 277.0, 345.0, 19.6, 16.7, 2.9, 1025.0, 1049.0, 2.3, 1.2, 1.1, 2.0, 522.0, 524.0, 0.5, 0.6, 1.1, 451.0, 468.0, 3.6, 2.9, 0.7, 52.0, 56.0, 7.2, 4.3, 2.9, 802.0, 821.0, 2.2, 0.1, 2.3, 358.0, 323.0, 10.7, 14.3, 3.6, 403.0, 418.0, 3.7, 2.3, 1.4, 3.0, 41.0, 78.0, 47.6, 45.9, 1.7, 1013.0, 829.0, 22.3, 23.4, 1.1, 690.0, 518.0, 33.3, 33.3, 323.0, 311.0, 3.9, 6.7, 2.8, 13873.0, 13562.0, 2.3, 4.2, 1.9], "percents_raw": ["17.9 %", "20.4 %", "2.3 %", "4.2 %"], "percents": [0.179, 0.204, 0.023, 0.042], "currencies": ["EUR", "USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1080, "tag": "div", "text_raw": "RYBREVANT/ LAZCLUZE (1)", "text": "RYBREVANT/ LAZCLUZE (1)", "length": 23, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1081, "tag": "div", "text_raw": "TALVEY (1)", "text": "TALVEY (1)", "length": 10, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1082, "tag": "div", "text_raw": "INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA", "text": "INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA", "length": 49, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1083, "tag": "div", "text_raw": "OPSUMIT/ OPSYNVI (2)", "text": "OPSUMIT/ OPSYNVI (2)", "length": 20, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1084, "tag": "div", "text_raw": "PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA", "text": "PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA", "length": 38, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1085, "tag": "div", "text_raw": "Other Infectious Diseases (3)", "text": "Other Infectious Diseases (3)", "length": 29, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1086, "tag": "div", "text_raw": "*percentage greater than 100% or not meaningful", "text": "*percentage greater than 100% or not meaningful", "length": 47, "numbers_raw": ["100"], "numbers": [100.0], "percents_raw": ["100%"], "percents": [1.0], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1087, "tag": "div", "text_raw": "Form 10-Q 39", "text": "Form 10-Q 39", "length": 12, "numbers_raw": ["10", "39"], "numbers": [10.0, 39.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1088, "tag": "div", "text_raw": "Form 10-Q 39", "text": "Form 10-Q 39", "length": 12, "numbers_raw": ["10", "39"], "numbers": [10.0, 39.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1089, "tag": "div", "text_raw": "Form 10-Q 39", "text": "Form 10-Q 39", "length": 12, "numbers_raw": ["10", "39"], "numbers": [10.0, 39.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1090, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1091, "tag": "div", "text_raw": "39", "text": "39", "length": 2, "numbers_raw": ["39"], "numbers": [39.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1095, "tag": "div", "text_raw": "(1) Previously in Other Oncology", "text": "(1) Previously in Other Oncology", "length": 32, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1096, "tag": "div", "text_raw": "(2) Opsynvi was previously in Other Pulmonary Hypertension", "text": "(2) Opsynvi was previously in Other Pulmonary Hypertension", "length": 58, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1097, "tag": "div", "text_raw": "(3) Includes the Covid-19 Vaccine in 2024", "text": "(3) Includes the Covid-19 Vaccine in 2024", "length": 41, "numbers_raw": ["3", "19", "202", "4"], "numbers": [3.0, 19.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1098, "tag": "div", "text_raw": "Oncology products achieved operational sales growth of 20.4% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth. Growth of ERLEADA (apalutamide) was due to continued share gains and market growth partially offset by the impact of Medicare Part D redesign (Part D). Increased sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains and capacity expansion. Additionally, sales from the ongoing launches of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab)/LAZCLUZE (lazertinib) contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) declines due to competitive pressures and the impact of Part D.", "text": "Oncology products achieved operational sales growth of 20.4% as compared to the same period a year ago.", "length": 103, "numbers_raw": ["20.4"], "numbers": [20.4], "percents_raw": ["20.4%"], "percents": [0.204], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1098, "tag": "div", "text_raw": "Oncology products achieved operational sales growth of 20.4% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth. Growth of ERLEADA (apalutamide) was due to continued share gains and market growth partially offset by the impact of Medicare Part D redesign (Part D). Increased sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains and capacity expansion. Additionally, sales from the ongoing launches of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab)/LAZCLUZE (lazertinib) contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) declines due to competitive pressures and the impact of Part D.", "text": "Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth.", "length": 94, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1098, "tag": "div", "text_raw": "Oncology products achieved operational sales growth of 20.4% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth. Growth of ERLEADA (apalutamide) was due to continued share gains and market growth partially offset by the impact of Medicare Part D redesign (Part D). Increased sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains and capacity expansion. Additionally, sales from the ongoing launches of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab)/LAZCLUZE (lazertinib) contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) declines due to competitive pressures and the impact of Part D.", "text": "Growth of ERLEADA (apalutamide) was due to continued share gains and market growth partially offset by the impact of Medicare Part D redesign (Part D).", "length": 151, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1098, "tag": "div", "text_raw": "Oncology products achieved operational sales growth of 20.4% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth. Growth of ERLEADA (apalutamide) was due to continued share gains and market growth partially offset by the impact of Medicare Part D redesign (Part D). Increased sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains and capacity expansion. Additionally, sales from the ongoing launches of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab)/LAZCLUZE (lazertinib) contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) declines due to competitive pressures and the impact of Part D.", "text": "Increased sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains and capacity expansion.", "length": 116, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1098, "tag": "div", "text_raw": "Oncology products achieved operational sales growth of 20.4% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth. Growth of ERLEADA (apalutamide) was due to continued share gains and market growth partially offset by the impact of Medicare Part D redesign (Part D). Increased sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains and capacity expansion. Additionally, sales from the ongoing launches of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab)/LAZCLUZE (lazertinib) contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) declines due to competitive pressures and the impact of Part D.", "text": "Additionally, sales from the ongoing launches of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab)/LAZCLUZE (lazertinib) contributed to the growth.", "length": 180, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1098, "tag": "div", "text_raw": "Oncology products achieved operational sales growth of 20.4% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth. Growth of ERLEADA (apalutamide) was due to continued share gains and market growth partially offset by the impact of Medicare Part D redesign (Part D). Increased sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains and capacity expansion. Additionally, sales from the ongoing launches of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab)/LAZCLUZE (lazertinib) contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) declines due to competitive pressures and the impact of Part D.", "text": "Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) declines due to competitive pressures and the impact of Part D.", "length": 176, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1099, "tag": "div", "text_raw": "Immunology products experienced an operational decline of 10.9% as compared to the same period a year ago primarily due to the decline of STELARA (ustekinumab) sales driven by the impact of biosimilar competition and Part D. The growth of TREMFYA (guselkumab) was due to share gains and market growth partially offset by the impact of Part D. The SIMPONI/SIMPONI ARIA sales increase was primarily driven by the Merck, Sharp & Dohme return of rights in Europe in the fiscal fourth quarter of 2024. The REMICADE (infliximab) sales increase was due to a one-time favorable patient mix, market growth, and the Merck, Sharp & Dohme return of rights in Europe, partially offset biosimilar competition.", "text": "Immunology products experienced an operational decline of 10.9% as compared to the same period a year ago primarily due to the decline of STELARA (ustekinumab) sales driven by the impact of biosimilar competition and Part D.", "length": 224, "numbers_raw": ["10.9"], "numbers": [10.9], "percents_raw": ["10.9%"], "percents": [0.109], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1099, "tag": "div", "text_raw": "Immunology products experienced an operational decline of 10.9% as compared to the same period a year ago primarily due to the decline of STELARA (ustekinumab) sales driven by the impact of biosimilar competition and Part D. The growth of TREMFYA (guselkumab) was due to share gains and market growth partially offset by the impact of Part D. The SIMPONI/SIMPONI ARIA sales increase was primarily driven by the Merck, Sharp & Dohme return of rights in Europe in the fiscal fourth quarter of 2024. The REMICADE (infliximab) sales increase was due to a one-time favorable patient mix, market growth, and the Merck, Sharp & Dohme return of rights in Europe, partially offset biosimilar competition.", "text": "The growth of TREMFYA (guselkumab) was due to share gains and market growth partially offset by the impact of Part D.", "length": 117, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1099, "tag": "div", "text_raw": "Immunology products experienced an operational decline of 10.9% as compared to the same period a year ago primarily due to the decline of STELARA (ustekinumab) sales driven by the impact of biosimilar competition and Part D. The growth of TREMFYA (guselkumab) was due to share gains and market growth partially offset by the impact of Part D. The SIMPONI/SIMPONI ARIA sales increase was primarily driven by the Merck, Sharp & Dohme return of rights in Europe in the fiscal fourth quarter of 2024. The REMICADE (infliximab) sales increase was due to a one-time favorable patient mix, market growth, and the Merck, Sharp & Dohme return of rights in Europe, partially offset biosimilar competition.", "text": "The SIMPONI/SIMPONI ARIA sales increase was primarily driven by the Merck, Sharp & Dohme return of rights in Europe in the fiscal fourth quarter of 2024.", "length": 153, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": true, "has_percents": false}
{"idx_source": 1099, "tag": "div", "text_raw": "Immunology products experienced an operational decline of 10.9% as compared to the same period a year ago primarily due to the decline of STELARA (ustekinumab) sales driven by the impact of biosimilar competition and Part D. The growth of TREMFYA (guselkumab) was due to share gains and market growth partially offset by the impact of Part D. The SIMPONI/SIMPONI ARIA sales increase was primarily driven by the Merck, Sharp & Dohme return of rights in Europe in the fiscal fourth quarter of 2024. The REMICADE (infliximab) sales increase was due to a one-time favorable patient mix, market growth, and the Merck, Sharp & Dohme return of rights in Europe, partially offset biosimilar competition.", "text": "The REMICADE (infliximab) sales increase was due to a one-time favorable patient mix, market growth, and the Merck, Sharp & Dohme return of rights in Europe, partially offset biosimilar competition.", "length": 198, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": false, "has_percents": false}
{"idx_source": 1100, "tag": "div", "text_raw": "Sales of STELARA in the United States were approximately $6.7 billion in fiscal 2024. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. The Company has settled certain litigation under the Biosimilar Price Competition and Innovation Act of 2009. According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025 which will impact the Companys sales of STELARA.", "text": "Sales of STELARA in the United States were approximately $6.7 billion in fiscal 2024.", "length": 85, "numbers_raw": ["$6.7 billion", "202", "4"], "numbers": [6700000000.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1100, "tag": "div", "text_raw": "Sales of STELARA in the United States were approximately $6.7 billion in fiscal 2024. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. The Company has settled certain litigation under the Biosimilar Price Competition and Innovation Act of 2009. According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025 which will impact the Companys sales of STELARA.", "text": "Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA.", "length": 139, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1100, "tag": "div", "text_raw": "Sales of STELARA in the United States were approximately $6.7 billion in fiscal 2024. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. The Company has settled certain litigation under the Biosimilar Price Competition and Innovation Act of 2009. According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025 which will impact the Companys sales of STELARA.", "text": "The Company has settled certain litigation under the Biosimilar Price Competition and Innovation Act of 2009.", "length": 109, "numbers_raw": ["200", "9"], "numbers": [200.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1100, "tag": "div", "text_raw": "Sales of STELARA in the United States were approximately $6.7 billion in fiscal 2024. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. The Company has settled certain litigation under the Biosimilar Price Competition and Innovation Act of 2009. According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025 which will impact the Companys sales of STELARA.", "text": "According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025 which will impact the Companys sales of STELARA.", "length": 217, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": true, "has_percents": false}
{"idx_source": 1101, "tag": "div", "text_raw": "Neuroscience products experienced an operational decline of 7.0% as compared to the same period a year ago. The decline was driven by INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA primarily due to the impact of Part D and Other Neuroscience primarily due to RISPERDAL/RISPERDAL CONSTA and the PONVORY divestiture. The decline was partially offset by the growth of SPRAVATO (esketamine) driven by the ongoing launch and increased physician and patient demand.", "text": "Neuroscience products experienced an operational decline of 7.0% as compared to the same period a year ago.", "length": 107, "numbers_raw": ["7.0"], "numbers": [7.0], "percents_raw": ["7.0%"], "percents": [0.07], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 1101, "tag": "div", "text_raw": "Neuroscience products experienced an operational decline of 7.0% as compared to the same period a year ago. The decline was driven by INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA primarily due to the impact of Part D and Other Neuroscience primarily due to RISPERDAL/RISPERDAL CONSTA and the PONVORY divestiture. The decline was partially offset by the growth of SPRAVATO (esketamine) driven by the ongoing launch and increased physician and patient demand.", "text": "The decline was driven by INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA primarily due to the impact of Part D and Other Neuroscience primarily due to RISPERDAL/RISPERDAL CONSTA and the PONVORY divestiture.", "length": 212, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": false, "has_percents": false}
{"idx_source": 1101, "tag": "div", "text_raw": "Neuroscience products experienced an operational decline of 7.0% as compared to the same period a year ago. The decline was driven by INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA primarily due to the impact of Part D and Other Neuroscience primarily due to RISPERDAL/RISPERDAL CONSTA and the PONVORY divestiture. The decline was partially offset by the growth of SPRAVATO (esketamine) driven by the ongoing launch and increased physician and patient demand.", "text": "The decline was partially offset by the growth of SPRAVATO (esketamine) driven by the ongoing launch and increased physician and patient demand.", "length": 144, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1102, "tag": "div", "text_raw": "Pulmonary Hypertension products experienced an operational decline of 1.2% as compared to the same period a year ago. Sales growth of OPSUMIT (macitentan)/ OPSYNVI (macitentan/tadalafil) were driven by share gains and market growth partially offset by the impact of Part D redesign. The sales decline of UPTRAVI (selexipag) was driven by the impact of Part D partially offset by market growth.", "text": "Pulmonary Hypertension products experienced an operational decline of 1.2% as compared to the same period a year ago.", "length": 117, "numbers_raw": ["1.2"], "numbers": [1.2], "percents_raw": ["1.2%"], "percents": [0.012], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1102, "tag": "div", "text_raw": "Pulmonary Hypertension products experienced an operational decline of 1.2% as compared to the same period a year ago. Sales growth of OPSUMIT (macitentan)/ OPSYNVI (macitentan/tadalafil) were driven by share gains and market growth partially offset by the impact of Part D redesign. The sales decline of UPTRAVI (selexipag) was driven by the impact of Part D partially offset by market growth.", "text": "Sales growth of OPSUMIT (macitentan)/ OPSYNVI (macitentan/tadalafil) were driven by share gains and market growth partially offset by the impact of Part D redesign.", "length": 164, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1102, "tag": "div", "text_raw": "Pulmonary Hypertension products experienced an operational decline of 1.2% as compared to the same period a year ago. Sales growth of OPSUMIT (macitentan)/ OPSYNVI (macitentan/tadalafil) were driven by share gains and market growth partially offset by the impact of Part D redesign. The sales decline of UPTRAVI (selexipag) was driven by the impact of Part D partially offset by market growth.", "text": "The sales decline of UPTRAVI (selexipag) was driven by the impact of Part D partially offset by market growth.", "length": 110, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1103, "tag": "div", "text_raw": "Infectious disease products achieved operational sales growth of 0.1% as compared to the same period a year ago primarily driven by EDURANT/rilpivirine partially offset by declines across the portfolio including COVID-19 vaccine revenue in Other Infectious Diseases.", "text": "Infectious disease products achieved operational sales growth of 0.1% as compared to the same period a year ago primarily driven by EDURANT/rilpivirine partially offset by declines across the portfolio including COVID-19 vaccine revenue in Other Infectious Diseases.", "length": 266, "numbers_raw": ["0.1", "19"], "numbers": [0.1, 19.0], "percents_raw": ["0.1%"], "percents": [0.001], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1104, "tag": "div", "text_raw": "Cardiovascular / Metabolism / Other products achieved operational growth of 23.4% as compared to the same period a year ago. The growth of XARELTO (rivaroxaban) sales was primarily driven by one-time favorable patient mix and the impact of Part D.", "text": "Cardiovascular / Metabolism / Other products achieved operational growth of 23.4% as compared to the same period a year ago.", "length": 124, "numbers_raw": ["23.4"], "numbers": [23.4], "percents_raw": ["23.4%"], "percents": [0.23399999999999999], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1104, "tag": "div", "text_raw": "Cardiovascular / Metabolism / Other products achieved operational growth of 23.4% as compared to the same period a year ago. The growth of XARELTO (rivaroxaban) sales was primarily driven by one-time favorable patient mix and the impact of Part D.", "text": "The growth of XARELTO (rivaroxaban) sales was primarily driven by one-time favorable patient mix and the impact of Part D.", "length": 122, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1105, "tag": "div", "text_raw": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.", "text": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location.", "length": 143, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1105, "tag": "div", "text_raw": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.", "text": "This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions.", "length": 159, "numbers_raw": ["340"], "numbers": [340.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1105, "tag": "div", "text_raw": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.", "text": "Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions.", "length": 122, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1105, "tag": "div", "text_raw": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.", "text": "The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute.", "length": 266, "numbers_raw": ["340", "340"], "numbers": [340.0, 340.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1105, "tag": "div", "text_raw": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.", "text": "The 340B Drug Pricing Program is a U.S.", "length": 39, "numbers_raw": ["340"], "numbers": [340.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1105, "tag": "div", "text_raw": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.", "text": "federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.", "length": 137, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1107, "tag": "div", "text_raw": "40", "text": "40", "length": 2, "numbers_raw": ["40"], "numbers": [40.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1108, "tag": "div", "text_raw": "40", "text": "40", "length": 2, "numbers_raw": ["40"], "numbers": [40.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1109, "tag": "div", "text_raw": "40", "text": "40", "length": 2, "numbers_raw": ["40"], "numbers": [40.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1110, "tag": "div", "text_raw": "40", "text": "40", "length": 2, "numbers_raw": ["40"], "numbers": [40.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1115, "tag": "div", "text_raw": "MedTech segment sales in the fiscal first quarter of 2025 were $8.0 billion, an increase of 2.5% as compared to the same period a year ago, which included operational growth of 4.1% and a negative currency impact of 1.6%. U.S. MedTech sales increased 5.1%. International MedTech sales decreased by 0.2%, including operational growth of 3.0% offset by a negative currency impact of 3.2%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 2.8%, primarily related to the Shockwave acquisition.", "text": "MedTech segment sales in the fiscal first quarter of 2025 were $8.0 billion, an increase of 2.5% as compared to the same period a year ago, which included operational growth of 4.1% and a negative currency impact of 1.6%.", "length": 221, "numbers_raw": ["202", "5", "$8.0 billion", "2.5", "4.1", "1.6"], "numbers": [202.0, 5.0, 8000000000.0, 2.5, 4.1, 1.6], "percents_raw": ["2.5%", "4.1%", "1.6%"], "percents": [0.025, 0.040999999999999995, 0.016], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1115, "tag": "div", "text_raw": "MedTech segment sales in the fiscal first quarter of 2025 were $8.0 billion, an increase of 2.5% as compared to the same period a year ago, which included operational growth of 4.1% and a negative currency impact of 1.6%. U.S. MedTech sales increased 5.1%. International MedTech sales decreased by 0.2%, including operational growth of 3.0% offset by a negative currency impact of 3.2%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 2.8%, primarily related to the Shockwave acquisition.", "text": "MedTech sales increased 5.1%.", "length": 29, "numbers_raw": ["5.1"], "numbers": [5.1], "percents_raw": ["5.1%"], "percents": [0.051], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1115, "tag": "div", "text_raw": "MedTech segment sales in the fiscal first quarter of 2025 were $8.0 billion, an increase of 2.5% as compared to the same period a year ago, which included operational growth of 4.1% and a negative currency impact of 1.6%. U.S. MedTech sales increased 5.1%. International MedTech sales decreased by 0.2%, including operational growth of 3.0% offset by a negative currency impact of 3.2%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 2.8%, primarily related to the Shockwave acquisition.", "text": "International MedTech sales decreased by 0.2%, including operational growth of 3.0% offset by a negative currency impact of 3.2%.", "length": 129, "numbers_raw": ["0.2", "3.0", "3.2"], "numbers": [0.2, 3.0, 3.2], "percents_raw": ["0.2%", "3.0%", "3.2%"], "percents": [0.002, 0.03, 0.032], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1115, "tag": "div", "text_raw": "MedTech segment sales in the fiscal first quarter of 2025 were $8.0 billion, an increase of 2.5% as compared to the same period a year ago, which included operational growth of 4.1% and a negative currency impact of 1.6%. U.S. MedTech sales increased 5.1%. International MedTech sales decreased by 0.2%, including operational growth of 3.0% offset by a negative currency impact of 3.2%. In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 2.8%, primarily related to the Shockwave acquisition.", "text": "In the fiscal first quarter of 2025, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 2.8%, primarily related to the Shockwave acquisition.", "length": 201, "numbers_raw": ["202", "5", "2.8"], "numbers": [202.0, 5.0, 2.8], "percents_raw": ["2.8%"], "percents": [0.027999999999999997], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1116, "tag": "div", "text_raw": "Major MedTech franchise sales  Fiscal First Quarter Ended", "text": "Major MedTech franchise sales  Fiscal First Quarter Ended", "length": 58, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1117, "tag": "div", "text_raw": "(Dollars in Millions) March 30, 2025 March 31, 2024 Total Change Operations Change Currency Change Surgery $2,396 $2,416 (0.8) % 1.1 % (1.9) % Advanced 1,073 1,087 (1.2) 0.5 (1.7) General 1,323 1,330 (0.5) 1.6 (2.1) Orthopaedics 2,241 2,340 (4.2) (3.1) (1.1) Hips 409 422 (3.1) (1.9) (1.2) Knees 389 401 (3.0) (1.7) (1.3) Trauma 772 765 0.9 2.1 (1.2) Spine, Sports & Other 671 752 (10.8) (9.7) (1.1) Cardiovascular 2,103 1,806 16.4 17.7 (1.3) Electrophysiology 1,323 1,344 (1.6) (0.2) (1.4) Abiomed 420 371 13.3 14.0 (0.7) Shockwave (1) 258  * *  Other Cardiovascular 103 92 12.5 14.1 (1.6) Vision 1,279 1,258 1.7 3.7 (2.0) Contact Lenses/Other 919 910 1.0 2.7 (1.7) Surgical 361 348 3.7 6.2 (2.5) Total MedTech Sales $8,020 $7,821 2.5 % 4.1 % (1.6) %", "text": "(Dollars in Millions) March 30, 2025 March 31, 2024 Total Change Operations Change Currency Change Surgery $2,396 $2,416 (0.8) % 1.1 % (1.9) % Advanced 1,073 1,087 (1.2) 0.5 (1.7) General 1,323 1,330 (0.5) 1.6 (2.1) Orthopaedics 2,241 2,340 (4.2) (3.1) (1.1) Hips 409 422 (3.1) (1.9) (1.2) Knees 389 401 (3.0) (1.7) (1.3) Trauma 772 765 0.9 2.1 (1.2) Spine, Sports & Other 671 752 (10.8) (9.7) (1.1) Cardiovascular 2,103 1,806 16.4 17.7 (1.3) Electrophysiology 1,323 1,344 (1.6) (0.2) (1.4) Abiomed 420 371 13.3 14.0 (0.7) Shockwave (1) 258  * *  Other Cardiovascular 103 92 12.5 14.1 (1.6) Vision 1,279 1,258 1.7 3.7 (2.0) Contact Lenses/Other 919 910 1.0 2.7 (1.7) Surgical 361 348 3.7 6.2 (2.5) Total MedTech Sales $8,020 $7,821 2.5 % 4.1 % (1.6) %", "length": 753, "numbers_raw": ["30", "202", "5 M", "31", "202", "4", "$2,396", "$2,416", "0.8", "1.1", "1.9", "1,073", "1,087", "1.2", "0.5", "1.7", "1,323", "1,330", "0.5", "1.6", "2.1", "2,241", "2,340", "4.2", "3.1", "1.1", "409", "422", "3.1", "1.9", "1.2", "389", "401", "3.0", "1.7", "1.3", "772", "765", "0.9", "2.1", "1.2", "671", "752", "10.8", "9.7", "1.1", "2,103", "1,806", "16.4", "17.7", "1.3", "1,323", "1,344", "1.6", "0.2", "1.4", "420", "371", "13.3", "14.0", "0.7", "1", "258", "103", "92", "12.5", "14.1", "1.6", "1,279", "1,258", "1.7", "3.7", "2.0", "919", "910", "1.0", "2.7", "1.7", "361", "348", "3.7", "6.2", "2.5", "$8,020", "$7,821", "2.5", "4.1", "1.6"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 2396.0, 2416.0, 0.8, 1.1, 1.9, 1073.0, 1087.0, 1.2, 0.5, 1.7, 1323.0, 1330.0, 0.5, 1.6, 2.1, 2241.0, 2340.0, 4.2, 3.1, 1.1, 409.0, 422.0, 3.1, 1.9, 1.2, 389.0, 401.0, 3.0, 1.7, 1.3, 772.0, 765.0, 0.9, 2.1, 1.2, 671.0, 752.0, 10.8, 9.7, 1.1, 2103.0, 1806.0, 16.4, 17.7, 1.3, 1323.0, 1344.0, 1.6, 0.2, 1.4, 420.0, 371.0, 13.3, 14.0, 0.7, 1.0, 258.0, 103.0, 92.0, 12.5, 14.1, 1.6, 1279.0, 1258.0, 1.7, 3.7, 2.0, 919.0, 910.0, 1.0, 2.7, 1.7, 361.0, 348.0, 3.7, 6.2, 2.5, 8020.0, 7821.0, 2.5, 4.1, 1.6], "percents_raw": ["1.1 %", "2.5 %", "4.1 %"], "percents": [0.011000000000000001, 0.025, 0.040999999999999995], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1118, "tag": "div", "text_raw": "Shockwave (1)", "text": "Shockwave (1)", "length": 13, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1119, "tag": "div", "text_raw": "(1) Acquired on May 31, 2024", "text": "(1) Acquired on May 31, 2024", "length": 28, "numbers_raw": ["1", "31", "202", "4"], "numbers": [1.0, 31.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1120, "tag": "div", "text_raw": "*Percentage greater than 100% or not meaningful", "text": "*Percentage greater than 100% or not meaningful", "length": 47, "numbers_raw": ["100"], "numbers": [100.0], "percents_raw": ["100%"], "percents": [1.0], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1121, "tag": "div", "text_raw": "The Surgery franchise achieved operational sales growth of 1.1% as compared to the prior year fiscal first quarter. The operational growth in Advanced Surgery was primarily due to the strength of the portfolio and recovery from U.S. supply challenges in Biosurgery as well as commercial execution in Biosurgery and Endocutters and strategic price actions in Endocutters. The growth was partially offset by competitive pressures in Energy and Endocutters as well as the negative impact of China volume-based procurement. The operational growth in General Surgery was primarily driven by technology penetration and upgrades within the differentiated Wound Closure portfolio and tender timing outside the U.S. The growth was partially offset by the impact from divestitures.", "text": "The Surgery franchise achieved operational sales growth of 1.1% as compared to the prior year fiscal first quarter.", "length": 115, "numbers_raw": ["1.1"], "numbers": [1.1], "percents_raw": ["1.1%"], "percents": [0.011000000000000001], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1121, "tag": "div", "text_raw": "The Surgery franchise achieved operational sales growth of 1.1% as compared to the prior year fiscal first quarter. The operational growth in Advanced Surgery was primarily due to the strength of the portfolio and recovery from U.S. supply challenges in Biosurgery as well as commercial execution in Biosurgery and Endocutters and strategic price actions in Endocutters. The growth was partially offset by competitive pressures in Energy and Endocutters as well as the negative impact of China volume-based procurement. The operational growth in General Surgery was primarily driven by technology penetration and upgrades within the differentiated Wound Closure portfolio and tender timing outside the U.S. The growth was partially offset by the impact from divestitures.", "text": "The operational growth in Advanced Surgery was primarily due to the strength of the portfolio and recovery from U.S.", "length": 116, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1121, "tag": "div", "text_raw": "The Surgery franchise achieved operational sales growth of 1.1% as compared to the prior year fiscal first quarter. The operational growth in Advanced Surgery was primarily due to the strength of the portfolio and recovery from U.S. supply challenges in Biosurgery as well as commercial execution in Biosurgery and Endocutters and strategic price actions in Endocutters. The growth was partially offset by competitive pressures in Energy and Endocutters as well as the negative impact of China volume-based procurement. The operational growth in General Surgery was primarily driven by technology penetration and upgrades within the differentiated Wound Closure portfolio and tender timing outside the U.S. The growth was partially offset by the impact from divestitures.", "text": "supply challenges in Biosurgery as well as commercial execution in Biosurgery and Endocutters and strategic price actions in Endocutters.", "length": 137, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1121, "tag": "div", "text_raw": "The Surgery franchise achieved operational sales growth of 1.1% as compared to the prior year fiscal first quarter. The operational growth in Advanced Surgery was primarily due to the strength of the portfolio and recovery from U.S. supply challenges in Biosurgery as well as commercial execution in Biosurgery and Endocutters and strategic price actions in Endocutters. The growth was partially offset by competitive pressures in Energy and Endocutters as well as the negative impact of China volume-based procurement. The operational growth in General Surgery was primarily driven by technology penetration and upgrades within the differentiated Wound Closure portfolio and tender timing outside the U.S. The growth was partially offset by the impact from divestitures.", "text": "The growth was partially offset by competitive pressures in Energy and Endocutters as well as the negative impact of China volume-based procurement.", "length": 148, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1121, "tag": "div", "text_raw": "The Surgery franchise achieved operational sales growth of 1.1% as compared to the prior year fiscal first quarter. The operational growth in Advanced Surgery was primarily due to the strength of the portfolio and recovery from U.S. supply challenges in Biosurgery as well as commercial execution in Biosurgery and Endocutters and strategic price actions in Endocutters. The growth was partially offset by competitive pressures in Energy and Endocutters as well as the negative impact of China volume-based procurement. The operational growth in General Surgery was primarily driven by technology penetration and upgrades within the differentiated Wound Closure portfolio and tender timing outside the U.S. The growth was partially offset by the impact from divestitures.", "text": "The operational growth in General Surgery was primarily driven by technology penetration and upgrades within the differentiated Wound Closure portfolio and tender timing outside the U.S.", "length": 186, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1121, "tag": "div", "text_raw": "The Surgery franchise achieved operational sales growth of 1.1% as compared to the prior year fiscal first quarter. The operational growth in Advanced Surgery was primarily due to the strength of the portfolio and recovery from U.S. supply challenges in Biosurgery as well as commercial execution in Biosurgery and Endocutters and strategic price actions in Endocutters. The growth was partially offset by competitive pressures in Energy and Endocutters as well as the negative impact of China volume-based procurement. The operational growth in General Surgery was primarily driven by technology penetration and upgrades within the differentiated Wound Closure portfolio and tender timing outside the U.S. The growth was partially offset by the impact from divestitures.", "text": "The growth was partially offset by the impact from divestitures.", "length": 64, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1122, "tag": "div", "text_raw": "The Orthopaedics franchise experienced an operational sales decline of 3.1% as compared to the prior year fiscal first quarter. All platforms were impacted by one-time events: the lapping of the prior year one-time revenue recognition timing change related to certain products in the U.S., fewer selling days, and revenue disruption from the previously announced Orthopaedics restructuring. The operational decline in Hips reflects the aforementioned one-time events partially offset by the continued strength of the portfolio. The operational decline in Knees was driven by the aforementioned one-time events and tender timing outside the U.S. partially offset by procedure growth, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. The operational growth in Trauma was primarily driven by the continued adoption of recently launched products, procedure growth, and commercial execution, partially offset by the aforementioned one-time events. The operational sales decline in Spine, Sports & Other reflects the aforementioned one-time events, competitive pressures, price pressures in the U.S. Early Interventional segment, and China volume-based procurement partially offset by growth in Shoulders.", "text": "The Orthopaedics franchise experienced an operational sales decline of 3.1% as compared to the prior year fiscal first quarter.", "length": 127, "numbers_raw": ["3.1"], "numbers": [3.1], "percents_raw": ["3.1%"], "percents": [0.031], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1122, "tag": "div", "text_raw": "The Orthopaedics franchise experienced an operational sales decline of 3.1% as compared to the prior year fiscal first quarter. All platforms were impacted by one-time events: the lapping of the prior year one-time revenue recognition timing change related to certain products in the U.S., fewer selling days, and revenue disruption from the previously announced Orthopaedics restructuring. The operational decline in Hips reflects the aforementioned one-time events partially offset by the continued strength of the portfolio. The operational decline in Knees was driven by the aforementioned one-time events and tender timing outside the U.S. partially offset by procedure growth, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. The operational growth in Trauma was primarily driven by the continued adoption of recently launched products, procedure growth, and commercial execution, partially offset by the aforementioned one-time events. The operational sales decline in Spine, Sports & Other reflects the aforementioned one-time events, competitive pressures, price pressures in the U.S. Early Interventional segment, and China volume-based procurement partially offset by growth in Shoulders.", "text": "All platforms were impacted by one-time events:", "length": 47, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1122, "tag": "div", "text_raw": "The Orthopaedics franchise experienced an operational sales decline of 3.1% as compared to the prior year fiscal first quarter. All platforms were impacted by one-time events: the lapping of the prior year one-time revenue recognition timing change related to certain products in the U.S., fewer selling days, and revenue disruption from the previously announced Orthopaedics restructuring. The operational decline in Hips reflects the aforementioned one-time events partially offset by the continued strength of the portfolio. The operational decline in Knees was driven by the aforementioned one-time events and tender timing outside the U.S. partially offset by procedure growth, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. The operational growth in Trauma was primarily driven by the continued adoption of recently launched products, procedure growth, and commercial execution, partially offset by the aforementioned one-time events. The operational sales decline in Spine, Sports & Other reflects the aforementioned one-time events, competitive pressures, price pressures in the U.S. Early Interventional segment, and China volume-based procurement partially offset by growth in Shoulders.", "text": "the lapping of the prior year one-time revenue recognition timing change related to certain products in the U.S., fewer selling days, and revenue disruption from the previously announced Orthopaedics restructuring.", "length": 214, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1122, "tag": "div", "text_raw": "The Orthopaedics franchise experienced an operational sales decline of 3.1% as compared to the prior year fiscal first quarter. All platforms were impacted by one-time events: the lapping of the prior year one-time revenue recognition timing change related to certain products in the U.S., fewer selling days, and revenue disruption from the previously announced Orthopaedics restructuring. The operational decline in Hips reflects the aforementioned one-time events partially offset by the continued strength of the portfolio. The operational decline in Knees was driven by the aforementioned one-time events and tender timing outside the U.S. partially offset by procedure growth, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. The operational growth in Trauma was primarily driven by the continued adoption of recently launched products, procedure growth, and commercial execution, partially offset by the aforementioned one-time events. The operational sales decline in Spine, Sports & Other reflects the aforementioned one-time events, competitive pressures, price pressures in the U.S. Early Interventional segment, and China volume-based procurement partially offset by growth in Shoulders.", "text": "The operational decline in Hips reflects the aforementioned one-time events partially offset by the continued strength of the portfolio.", "length": 136, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1122, "tag": "div", "text_raw": "The Orthopaedics franchise experienced an operational sales decline of 3.1% as compared to the prior year fiscal first quarter. All platforms were impacted by one-time events: the lapping of the prior year one-time revenue recognition timing change related to certain products in the U.S., fewer selling days, and revenue disruption from the previously announced Orthopaedics restructuring. The operational decline in Hips reflects the aforementioned one-time events partially offset by the continued strength of the portfolio. The operational decline in Knees was driven by the aforementioned one-time events and tender timing outside the U.S. partially offset by procedure growth, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. The operational growth in Trauma was primarily driven by the continued adoption of recently launched products, procedure growth, and commercial execution, partially offset by the aforementioned one-time events. The operational sales decline in Spine, Sports & Other reflects the aforementioned one-time events, competitive pressures, price pressures in the U.S. Early Interventional segment, and China volume-based procurement partially offset by growth in Shoulders.", "text": "The operational decline in Knees was driven by the aforementioned one-time events and tender timing outside the U.S.", "length": 116, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1122, "tag": "div", "text_raw": "The Orthopaedics franchise experienced an operational sales decline of 3.1% as compared to the prior year fiscal first quarter. All platforms were impacted by one-time events: the lapping of the prior year one-time revenue recognition timing change related to certain products in the U.S., fewer selling days, and revenue disruption from the previously announced Orthopaedics restructuring. The operational decline in Hips reflects the aforementioned one-time events partially offset by the continued strength of the portfolio. The operational decline in Knees was driven by the aforementioned one-time events and tender timing outside the U.S. partially offset by procedure growth, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. The operational growth in Trauma was primarily driven by the continued adoption of recently launched products, procedure growth, and commercial execution, partially offset by the aforementioned one-time events. The operational sales decline in Spine, Sports & Other reflects the aforementioned one-time events, competitive pressures, price pressures in the U.S. Early Interventional segment, and China volume-based procurement partially offset by growth in Shoulders.", "text": "partially offset by procedure growth, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution.", "length": 135, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1122, "tag": "div", "text_raw": "The Orthopaedics franchise experienced an operational sales decline of 3.1% as compared to the prior year fiscal first quarter. All platforms were impacted by one-time events: the lapping of the prior year one-time revenue recognition timing change related to certain products in the U.S., fewer selling days, and revenue disruption from the previously announced Orthopaedics restructuring. The operational decline in Hips reflects the aforementioned one-time events partially offset by the continued strength of the portfolio. The operational decline in Knees was driven by the aforementioned one-time events and tender timing outside the U.S. partially offset by procedure growth, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. The operational growth in Trauma was primarily driven by the continued adoption of recently launched products, procedure growth, and commercial execution, partially offset by the aforementioned one-time events. The operational sales decline in Spine, Sports & Other reflects the aforementioned one-time events, competitive pressures, price pressures in the U.S. Early Interventional segment, and China volume-based procurement partially offset by growth in Shoulders.", "text": "The operational growth in Trauma was primarily driven by the continued adoption of recently launched products, procedure growth, and commercial execution, partially offset by the aforementioned one-time events.", "length": 210, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1122, "tag": "div", "text_raw": "The Orthopaedics franchise experienced an operational sales decline of 3.1% as compared to the prior year fiscal first quarter. All platforms were impacted by one-time events: the lapping of the prior year one-time revenue recognition timing change related to certain products in the U.S., fewer selling days, and revenue disruption from the previously announced Orthopaedics restructuring. The operational decline in Hips reflects the aforementioned one-time events partially offset by the continued strength of the portfolio. The operational decline in Knees was driven by the aforementioned one-time events and tender timing outside the U.S. partially offset by procedure growth, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. The operational growth in Trauma was primarily driven by the continued adoption of recently launched products, procedure growth, and commercial execution, partially offset by the aforementioned one-time events. The operational sales decline in Spine, Sports & Other reflects the aforementioned one-time events, competitive pressures, price pressures in the U.S. Early Interventional segment, and China volume-based procurement partially offset by growth in Shoulders.", "text": "The operational sales decline in Spine, Sports & Other reflects the aforementioned one-time events, competitive pressures, price pressures in the U.S.", "length": 150, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1122, "tag": "div", "text_raw": "The Orthopaedics franchise experienced an operational sales decline of 3.1% as compared to the prior year fiscal first quarter. All platforms were impacted by one-time events: the lapping of the prior year one-time revenue recognition timing change related to certain products in the U.S., fewer selling days, and revenue disruption from the previously announced Orthopaedics restructuring. The operational decline in Hips reflects the aforementioned one-time events partially offset by the continued strength of the portfolio. The operational decline in Knees was driven by the aforementioned one-time events and tender timing outside the U.S. partially offset by procedure growth, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. The operational growth in Trauma was primarily driven by the continued adoption of recently launched products, procedure growth, and commercial execution, partially offset by the aforementioned one-time events. The operational sales decline in Spine, Sports & Other reflects the aforementioned one-time events, competitive pressures, price pressures in the U.S. Early Interventional segment, and China volume-based procurement partially offset by growth in Shoulders.", "text": "Early Interventional segment, and China volume-based procurement partially offset by growth in Shoulders.", "length": 105, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1123, "tag": "div", "text_raw": "The Cardiovascular franchise, which includes sales from Shockwave Medical (Shockwave) acquired on May 31, 2024, achieved operational sales growth of 17.7% as compared to the prior year fiscal first quarter. Abiomed sales growth was driven by the continued strong adoption of Impella 5.5 and Impella CP. Electrophysiology sales declined due to competitive pressures in Pulsed", "text": "The Cardiovascular franchise, which includes sales from Shockwave Medical (Shockwave) acquired on May 31, 2024, achieved operational sales growth of 17.7% as compared to the prior year fiscal first quarter.", "length": 206, "numbers_raw": ["31", "202", "4", "17.7"], "numbers": [31.0, 202.0, 4.0, 17.7], "percents_raw": ["17.7%"], "percents": [0.177], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1123, "tag": "div", "text_raw": "The Cardiovascular franchise, which includes sales from Shockwave Medical (Shockwave) acquired on May 31, 2024, achieved operational sales growth of 17.7% as compared to the prior year fiscal first quarter. Abiomed sales growth was driven by the continued strong adoption of Impella 5.5 and Impella CP. Electrophysiology sales declined due to competitive pressures in Pulsed", "text": "Abiomed sales growth was driven by the continued strong adoption of Impella 5.5 and Impella CP.", "length": 95, "numbers_raw": ["5.5"], "numbers": [5.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1123, "tag": "div", "text_raw": "The Cardiovascular franchise, which includes sales from Shockwave Medical (Shockwave) acquired on May 31, 2024, achieved operational sales growth of 17.7% as compared to the prior year fiscal first quarter. Abiomed sales growth was driven by the continued strong adoption of Impella 5.5 and Impella CP. Electrophysiology sales declined due to competitive pressures in Pulsed", "text": "Electrophysiology sales declined due to competitive pressures in Pulsed", "length": 71, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1124, "tag": "div", "text_raw": "Form 10-Q 41", "text": "Form 10-Q 41", "length": 12, "numbers_raw": ["10", "41"], "numbers": [10.0, 41.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1125, "tag": "div", "text_raw": "Form 10-Q 41", "text": "Form 10-Q 41", "length": 12, "numbers_raw": ["10", "41"], "numbers": [10.0, 41.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1126, "tag": "div", "text_raw": "Form 10-Q 41", "text": "Form 10-Q 41", "length": 12, "numbers_raw": ["10", "41"], "numbers": [10.0, 41.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1127, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1128, "tag": "div", "text_raw": "41", "text": "41", "length": 2, "numbers_raw": ["41"], "numbers": [41.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1131, "tag": "div", "text_raw": "Field Ablation catheters and lapping of prior year inventory build in Asia. The decline was mostly offset by global procedure growth, new products and commercial execution.", "text": "Field Ablation catheters and lapping of prior year inventory build in Asia.", "length": 75, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1131, "tag": "div", "text_raw": "Field Ablation catheters and lapping of prior year inventory build in Asia. The decline was mostly offset by global procedure growth, new products and commercial execution.", "text": "The decline was mostly offset by global procedure growth, new products and commercial execution.", "length": 96, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1132, "tag": "div", "text_raw": "The Vision franchise achieved operational sales growth of 3.7% as compared to the prior year fiscal first quarter. The Contact Lenses/Other operational growth was driven by price actions and continued strong performance in the ACUVUE OASYS 1-Day family of products (including recent launches). The Surgical operational growth was primarily driven by the continued strength of recent innovations and commercial execution partially offset by competitive pressures in the U.S.", "text": "The Vision franchise achieved operational sales growth of 3.7% as compared to the prior year fiscal first quarter.", "length": 114, "numbers_raw": ["3.7"], "numbers": [3.7], "percents_raw": ["3.7%"], "percents": [0.037000000000000005], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1132, "tag": "div", "text_raw": "The Vision franchise achieved operational sales growth of 3.7% as compared to the prior year fiscal first quarter. The Contact Lenses/Other operational growth was driven by price actions and continued strong performance in the ACUVUE OASYS 1-Day family of products (including recent launches). The Surgical operational growth was primarily driven by the continued strength of recent innovations and commercial execution partially offset by competitive pressures in the U.S.", "text": "The Contact Lenses/Other operational growth was driven by price actions and continued strong performance in the ACUVUE OASYS 1-Day family of products (including recent launches).", "length": 178, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1132, "tag": "div", "text_raw": "The Vision franchise achieved operational sales growth of 3.7% as compared to the prior year fiscal first quarter. The Contact Lenses/Other operational growth was driven by price actions and continued strong performance in the ACUVUE OASYS 1-Day family of products (including recent launches). The Surgical operational growth was primarily driven by the continued strength of recent innovations and commercial execution partially offset by competitive pressures in the U.S.", "text": "The Surgical operational growth was primarily driven by the continued strength of recent innovations and commercial execution partially offset by competitive pressures in the U.S.", "length": 179, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1133, "tag": "div", "text_raw": "Analysis of consolidated earnings before provision for taxes on income", "text": "Analysis of consolidated earnings before provision for taxes on income", "length": 70, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1134, "tag": "div", "text_raw": "Consolidated earnings before provision for taxes on income for the fiscal first quarter of 2025 was $13.6 billion representing 62.3% of sales as compared to $3.7 billion in the fiscal first quarter of 2024, representing 17.4% of sales. The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of approximately $2.7 billion.", "text": "Consolidated earnings before provision for taxes on income for the fiscal first quarter of 2025 was $13.6 billion representing 62.3% of sales as compared to $3.7 billion in the fiscal first quarter of 2024, representing 17.4% of sales.", "length": 235, "numbers_raw": ["202", "5", "$13.6 billion", "62.3", "$3.7 billion", "202", "4", "17.4"], "numbers": [202.0, 5.0, 13600000000.0, 62.3, 3700000000.0, 202.0, 4.0, 17.4], "percents_raw": ["62.3%", "17.4%"], "percents": [0.623, 0.174], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1134, "tag": "div", "text_raw": "Consolidated earnings before provision for taxes on income for the fiscal first quarter of 2025 was $13.6 billion representing 62.3% of sales as compared to $3.7 billion in the fiscal first quarter of 2024, representing 17.4% of sales. The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of approximately $2.7 billion.", "text": "The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve.", "length": 147, "numbers_raw": ["202", "5", "$7.0 billion"], "numbers": [202.0, 5.0, 7000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1134, "tag": "div", "text_raw": "Consolidated earnings before provision for taxes on income for the fiscal first quarter of 2025 was $13.6 billion representing 62.3% of sales as compared to $3.7 billion in the fiscal first quarter of 2024, representing 17.4% of sales. The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of approximately $2.7 billion.", "text": "The fiscal first quarter of 2024 includes charges for talc matters of approximately $2.7 billion.", "length": 97, "numbers_raw": ["202", "4", "$2.7 billion"], "numbers": [202.0, 4.0, 2700000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1137, "tag": "div", "text_raw": "(Dollars in billions. Percentages in chart are as a percent to total sales)", "text": "Percentages in chart are as a percent to total sales)", "length": 53, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1138, "tag": "div", "text_raw": "Q1 2025 versus Q1 2024", "text": "Q1 2025 versus Q1 2024", "length": 22, "numbers_raw": ["1", "202", "5", "1", "202", "4"], "numbers": [1.0, 202.0, 5.0, 1.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1139, "tag": "div", "text_raw": "Cost of products sold increased as a percent to sales primarily driven by:", "text": "Cost of products sold increased as a percent to sales primarily driven by:", "length": 74, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1140, "tag": "div", "text_raw": " Unfavorable currency and product mix in the Innovative Medicine business", "text": " Unfavorable currency and product mix in the Innovative Medicine business", "length": 74, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1141, "tag": "div", "text_raw": " The fair value inventory step-up and amortization related to Shockwave", "text": " The fair value inventory step-up and amortization related to Shockwave", "length": 72, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1143, "tag": "div", "text_raw": "The intangible asset amortization expense included in cost of products sold for both the fiscal first quarters of 2025 and 2024 was $1.1 billion.", "text": "The intangible asset amortization expense included in cost of products sold for both the fiscal first quarters of 2025 and 2024 was $1.1 billion.", "length": 145, "numbers_raw": ["202", "5", "202", "4", "$1.1 billion"], "numbers": [202.0, 5.0, 202.0, 4.0, 1100000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1144, "tag": "div", "text_raw": "Selling, marketing and administrative expenses", "text": "Selling, marketing and administrative expenses", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1146, "tag": "div", "text_raw": "(Dollars in billions. Percentages in chart are as a percent to total sales)", "text": "Percentages in chart are as a percent to total sales)", "length": 53, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1147, "tag": "div", "text_raw": "42", "text": "42", "length": 2, "numbers_raw": ["42"], "numbers": [42.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1148, "tag": "div", "text_raw": "42", "text": "42", "length": 2, "numbers_raw": ["42"], "numbers": [42.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1149, "tag": "div", "text_raw": "42", "text": "42", "length": 2, "numbers_raw": ["42"], "numbers": [42.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1150, "tag": "div", "text_raw": "42", "text": "42", "length": 2, "numbers_raw": ["42"], "numbers": [42.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1155, "tag": "div", "text_raw": "Q1 2025 versus Q1 2024", "text": "Q1 2025 versus Q1 2024", "length": 22, "numbers_raw": ["1", "202", "5", "1", "202", "4"], "numbers": [1.0, 202.0, 5.0, 1.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1156, "tag": "div", "text_raw": "Selling, Marketing and Administrative Expenses decreased as a percent to sales primarily driven by:", "text": "Selling, Marketing and Administrative Expenses decreased as a percent to sales primarily driven by:", "length": 99, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1157, "tag": "div", "text_raw": " Planned leverage and phasing of investments in the Innovative Medicine business.", "text": " Planned leverage and phasing of investments in the Innovative Medicine business.", "length": 82, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1158, "tag": "div", "text_raw": "Research and development expense", "text": "Research and development expense", "length": 32, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1159, "tag": "div", "text_raw": "Research and development expense by segment of business was as follows: Fiscal First Quarter Ended 2025 2024 (Dollars in Millions) Amount % of Sales* Amount % of Sales* Innovative Medicine $2,548 18.4 % $2,896 21.4 % MedTech 677 8.4 646 8.3 Total research and development expense $3,225 14.7 % $3,542 16.6 % Percent increase/(decrease) over the prior year (8.9 %) *As a percent to segment sales", "text": "Research and development expense by segment of business was as follows:", "length": 71, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1159, "tag": "div", "text_raw": "Research and development expense by segment of business was as follows: Fiscal First Quarter Ended 2025 2024 (Dollars in Millions) Amount % of Sales* Amount % of Sales* Innovative Medicine $2,548 18.4 % $2,896 21.4 % MedTech 677 8.4 646 8.3 Total research and development expense $3,225 14.7 % $3,542 16.6 % Percent increase/(decrease) over the prior year (8.9 %) *As a percent to segment sales", "text": "Fiscal First Quarter Ended 2025 2024 (Dollars in Millions) Amount % of Sales* Amount % of Sales* Innovative Medicine $2,548 18.4 % $2,896 21.4 % MedTech 677 8.4 646 8.3 Total research and development expense $3,225 14.7 % $3,542 16.6 % Percent increase/(decrease) over the prior year (8.9 %) *As a percent to segment sales", "length": 322, "numbers_raw": ["202", "5", "202", "4", "$2,548", "18.4", "$2,896", "21.4", "677", "8.4", "646", "8.3", "$3,225", "14.7", "$3,542", "16.6", "8.9"], "numbers": [202.0, 5.0, 202.0, 4.0, 2548.0, 18.4, 2896.0, 21.4, 677.0, 8.4, 646.0, 8.3, 3225.0, 14.7, 3542.0, 16.6, 8.9], "percents_raw": ["18.4 %", "21.4 %", "14.7 %", "16.6 %", "8.9 %"], "percents": [0.184, 0.214, 0.147, 0.166, 0.08900000000000001], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1160, "tag": "div", "text_raw": "Q1 2025 versus Q1 2024", "text": "Q1 2025 versus Q1 2024", "length": 22, "numbers_raw": ["1", "202", "5", "1", "202", "4"], "numbers": [1.0, 202.0, 5.0, 1.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1161, "tag": "div", "text_raw": "Research and Development decreased as a percent to sales driven by:", "text": "Research and Development decreased as a percent to sales driven by:", "length": 67, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1162, "tag": "div", "text_raw": " Reduced spending and phasing of investments in the Innovative Medicine business", "text": " Reduced spending and phasing of investments in the Innovative Medicine business", "length": 81, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1164, "tag": "div", "text_raw": " Investments associated with Shockwave and V-Wave in the MedTech business", "text": " Investments associated with Shockwave and V-Wave in the MedTech business", "length": 74, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1166, "tag": "div", "text_raw": "Interest (income) expense in the fiscal first quarter of 2025 was net income of $128 million as compared to net income of $209 million in the fiscal first quarter of 2024. Interest income in the fiscal first quarter of 2025 decreased slightly as compared to the prior year driven by lower interest rates earned on cash balances. Interest expense was slightly higher due to a higher average debt balance at higher interest rates. The balance of cash, cash equivalents and current marketable securities was $38.8 billion at the end of the fiscal first quarter of 2025 as compared to $26.2 billion at the end of the fiscal first quarter of 2024. The Companys debt position was $52.3 billion as of March 30, 2025, as compared to $33.6 billion the same period a year ago.", "text": "Interest (income) expense in the fiscal first quarter of 2025 was net income of $128 million as compared to net income of $209 million in the fiscal first quarter of 2024.", "length": 171, "numbers_raw": ["202", "5", "$128 million", "$209 million", "202", "4"], "numbers": [202.0, 5.0, 128000000.0, 209000000.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1166, "tag": "div", "text_raw": "Interest (income) expense in the fiscal first quarter of 2025 was net income of $128 million as compared to net income of $209 million in the fiscal first quarter of 2024. Interest income in the fiscal first quarter of 2025 decreased slightly as compared to the prior year driven by lower interest rates earned on cash balances. Interest expense was slightly higher due to a higher average debt balance at higher interest rates. The balance of cash, cash equivalents and current marketable securities was $38.8 billion at the end of the fiscal first quarter of 2025 as compared to $26.2 billion at the end of the fiscal first quarter of 2024. The Companys debt position was $52.3 billion as of March 30, 2025, as compared to $33.6 billion the same period a year ago.", "text": "Interest income in the fiscal first quarter of 2025 decreased slightly as compared to the prior year driven by lower interest rates earned on cash balances.", "length": 156, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1166, "tag": "div", "text_raw": "Interest (income) expense in the fiscal first quarter of 2025 was net income of $128 million as compared to net income of $209 million in the fiscal first quarter of 2024. Interest income in the fiscal first quarter of 2025 decreased slightly as compared to the prior year driven by lower interest rates earned on cash balances. Interest expense was slightly higher due to a higher average debt balance at higher interest rates. The balance of cash, cash equivalents and current marketable securities was $38.8 billion at the end of the fiscal first quarter of 2025 as compared to $26.2 billion at the end of the fiscal first quarter of 2024. The Companys debt position was $52.3 billion as of March 30, 2025, as compared to $33.6 billion the same period a year ago.", "text": "Interest expense was slightly higher due to a higher average debt balance at higher interest rates.", "length": 99, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1166, "tag": "div", "text_raw": "Interest (income) expense in the fiscal first quarter of 2025 was net income of $128 million as compared to net income of $209 million in the fiscal first quarter of 2024. Interest income in the fiscal first quarter of 2025 decreased slightly as compared to the prior year driven by lower interest rates earned on cash balances. Interest expense was slightly higher due to a higher average debt balance at higher interest rates. The balance of cash, cash equivalents and current marketable securities was $38.8 billion at the end of the fiscal first quarter of 2025 as compared to $26.2 billion at the end of the fiscal first quarter of 2024. The Companys debt position was $52.3 billion as of March 30, 2025, as compared to $33.6 billion the same period a year ago.", "text": "The balance of cash, cash equivalents and current marketable securities was $38.8 billion at the end of the fiscal first quarter of 2025 as compared to $26.2 billion at the end of the fiscal first quarter of 2024.", "length": 213, "numbers_raw": ["$38.8 billion", "202", "5", "$26.2 billion", "202", "4"], "numbers": [38800000000.0, 202.0, 5.0, 26200000000.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1166, "tag": "div", "text_raw": "Interest (income) expense in the fiscal first quarter of 2025 was net income of $128 million as compared to net income of $209 million in the fiscal first quarter of 2024. Interest income in the fiscal first quarter of 2025 decreased slightly as compared to the prior year driven by lower interest rates earned on cash balances. Interest expense was slightly higher due to a higher average debt balance at higher interest rates. The balance of cash, cash equivalents and current marketable securities was $38.8 billion at the end of the fiscal first quarter of 2025 as compared to $26.2 billion at the end of the fiscal first quarter of 2024. The Companys debt position was $52.3 billion as of March 30, 2025, as compared to $33.6 billion the same period a year ago.", "text": "The Companys debt position was $52.3 billion as of March 30, 2025, as compared to $33.6 billion the same period a year ago.", "length": 124, "numbers_raw": ["$52.3 billion", "30", "202", "5", "$33.6 billion"], "numbers": [52300000000.0, 30.0, 202.0, 5.0, 33600000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1168, "tag": "div", "text_raw": "Q1 2025 versus Q1 2024", "text": "Q1 2025 versus Q1 2024", "length": 22, "numbers_raw": ["1", "202", "5", "1", "202", "4"], "numbers": [1.0, 202.0, 5.0, 1.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1169, "tag": "div", "text_raw": "Other (income) expense, net for the fiscal first quarter of 2025 reflected an increase in income of $9.7 billion as compared to the prior year primarily due to the following:", "text": "Other (income) expense, net for the fiscal first quarter of 2025 reflected an increase in income of $9.7 billion as compared to the prior year primarily due to the following:", "length": 174, "numbers_raw": ["202", "5", "$9.7 billion"], "numbers": [202.0, 5.0, 9700000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1170, "tag": "div", "text_raw": "Fiscal First Quarter (Dollars in Billions)(Income)/Expense March 30, 2025 March 31, 2024 Change Litigation related (1) $ (7.0) 2.7 (9.7) Acquisition, Integration and Divestiture related 0.1 0.1  Employee benefit plan related (0.1) (0.2) 0.1 Other (0.3) (0.2) (0.1) Total Other (Income) Expense, Net $ (7.3) 2.4 (9.7)", "text": "Fiscal First Quarter (Dollars in Billions)(Income)/Expense March 30, 2025 March 31, 2024 Change Litigation related (1) $ (7.0) 2.7 (9.7) Acquisition, Integration and Divestiture related 0.1 0.1  Employee benefit plan related (0.1) (0.2) 0.1 Other (0.3) (0.2) (0.1) Total Other (Income) Expense, Net $ (7.3) 2.4 (9.7)", "length": 317, "numbers_raw": ["30", "202", "5 M", "31", "202", "4", "1", "7.0", "2.7", "9.7", "0.1", "0.1", "0.1", "0.2", "0.1", "0.3", "0.2", "0.1", "7.3", "2.4", "9.7"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 1.0, 7.0, 2.7, 9.7, 0.1, 0.1, 0.1, 0.2, 0.1, 0.3, 0.2, 0.1, 7.3, 2.4, 9.7], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1171, "tag": "div", "text_raw": "Litigation related (1)", "text": "Litigation related (1)", "length": 22, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1172, "tag": "div", "text_raw": "Form 10-Q 43", "text": "Form 10-Q 43", "length": 12, "numbers_raw": ["10", "43"], "numbers": [10.0, 43.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1173, "tag": "div", "text_raw": "Form 10-Q 43", "text": "Form 10-Q 43", "length": 12, "numbers_raw": ["10", "43"], "numbers": [10.0, 43.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1174, "tag": "div", "text_raw": "Form 10-Q 43", "text": "Form 10-Q 43", "length": 12, "numbers_raw": ["10", "43"], "numbers": [10.0, 43.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1175, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1176, "tag": "div", "text_raw": "43", "text": "43", "length": 2, "numbers_raw": ["43"], "numbers": [43.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1179, "tag": "div", "text_raw": "(1) The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "text": "(1) The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve.", "length": 151, "numbers_raw": ["1", "202", "5", "$7.0 billion"], "numbers": [1.0, 202.0, 5.0, 7000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1179, "tag": "div", "text_raw": "(1) The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "text": "The fiscal first quarter of 2024 includes charges for talc matters.", "length": 67, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1179, "tag": "div", "text_raw": "(1) The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "text": "For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "length": 97, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1180, "tag": "div", "text_raw": "*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, gains and losses on divestitures, gains and losses on sale of assets, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.", "text": "*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc.", "length": 215, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1180, "tag": "div", "text_raw": "*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, gains and losses on divestitures, gains and losses on sale of assets, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.", "text": "(JJDC), changes in the fair value of securities, gains and losses on divestitures, gains and losses on sale of assets, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.", "length": 318, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1182, "tag": "div", "text_raw": "Income (loss) before tax by segment of business for the fiscal first quarters were as follows:", "text": "Income (loss) before tax by segment of business for the fiscal first quarters were as follows:", "length": 94, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1183, "tag": "div", "text_raw": "Income Before Tax Segment Sales Percent of Segment Sales (Dollars in Millions) March 30, 2025 March 31, 2024 March 30, 2025 March 31, 2024 March 30, 2025 March 31, 2024 Innovative Medicine $5,210 $4,969 $13,873 $13,562 37.6 % 36.6 % MedTech 1,421 1,520 8,020 7,821 17.7 19.4 Segment total 6,631 6,489 21,893 21,383 30.3 30.3 (Income) Expenses not allocated to segments (1) (7,000) 2,775 Earnings before provision for taxes on income $13,631 $3,714 $21,893 $21,383 62.3 % 17.4 %", "text": "Income Before Tax Segment Sales Percent of Segment Sales (Dollars in Millions) March 30, 2025 March 31, 2024 March 30, 2025 March 31, 2024 March 30, 2025 March 31, 2024 Innovative Medicine $5,210 $4,969 $13,873 $13,562 37.6 % 36.6 % MedTech 1,421 1,520 8,020 7,821 17.7 19.4 Segment total 6,631 6,489 21,893 21,383 30.3 30.3 (Income) Expenses not allocated to segments (1) (7,000) 2,775 Earnings before provision for taxes on income $13,631 $3,714 $21,893 $21,383 62.3 % 17.4 %", "length": 477, "numbers_raw": ["30", "202", "5 M", "31", "202", "4 M", "30", "202", "5 M", "31", "202", "4 M", "30", "202", "5 M", "31", "202", "4", "$5,210", "$4,969", "$13,873", "$13,562", "37.6", "36.6", "1,421", "1,520", "8,020", "7,821", "17.7", "19.4", "6,631", "6,489", "21,893", "21,383", "30.3", "30.3", "1", "7,000", "2,775", "$13,631", "$3,714", "$21,893", "$21,383", "62.3", "17.4"], "numbers": [30.0, 202.0, 5000000.0, 31.0, 202.0, 4000000.0, 30.0, 202.0, 5000000.0, 31.0, 202.0, 4000000.0, 30.0, 202.0, 5000000.0, 31.0, 202.0, 4.0, 5210.0, 4969.0, 13873.0, 13562.0, 37.6, 36.6, 1421.0, 1520.0, 8020.0, 7821.0, 17.7, 19.4, 6631.0, 6489.0, 21893.0, 21383.0, 30.3, 30.3, 1.0, 7000.0, 2775.0, 13631.0, 3714.0, 21893.0, 21383.0, 62.3, 17.4], "percents_raw": ["37.6 %", "36.6 %", "62.3 %", "17.4 %"], "percents": [0.376, 0.366, 0.623, 0.174], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1184, "tag": "div", "text_raw": "(Income) Expenses not allocated to segments (1)", "text": "(Income) Expenses not allocated to segments (1)", "length": 47, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1185, "tag": "div", "text_raw": "(1) Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense. The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of $2.7 billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "text": "(1) Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense.", "length": 140, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1185, "tag": "div", "text_raw": "(1) Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense. The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of $2.7 billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "text": "The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve.", "length": 147, "numbers_raw": ["202", "5", "$7.0 billion"], "numbers": [202.0, 5.0, 7000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1185, "tag": "div", "text_raw": "(1) Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense. The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of $2.7 billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "text": "The fiscal first quarter of 2024 includes charges for talc matters of $2.7 billion.", "length": 83, "numbers_raw": ["202", "4", "$2.7 billion"], "numbers": [202.0, 4.0, 2700000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1185, "tag": "div", "text_raw": "(1) Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense. The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of $2.7 billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "text": "For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.", "length": 97, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1187, "tag": "div", "text_raw": "The Innovative Medicine segment income before tax as a percent of sales in the fiscal first quarter of 2025 was 37.6% versus 36.6% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal first quarter of 2025 as compared to the prior year was primarily driven by the following:", "text": "The Innovative Medicine segment income before tax as a percent of sales in the fiscal first quarter of 2025 was 37.6% versus 36.6% for the same period a year ago.", "length": 162, "numbers_raw": ["202", "5", "37.6", "36.6"], "numbers": [202.0, 5.0, 37.6, 36.6], "percents_raw": ["37.6%", "36.6%"], "percents": [0.376, 0.366], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1187, "tag": "div", "text_raw": "The Innovative Medicine segment income before tax as a percent of sales in the fiscal first quarter of 2025 was 37.6% versus 36.6% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal first quarter of 2025 as compared to the prior year was primarily driven by the following:", "text": "The increase in the income before tax as a percent of sales for the fiscal first quarter of 2025 as compared to the prior year was primarily driven by the following:", "length": 165, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1188, "tag": "div", "text_raw": " Lower restructuring related costs and amortization expense of $0.6 billion in 2025 versus $0.8 billion in 2024", "text": " Lower restructuring related costs and amortization expense of $0.6 billion in 2025 versus $0.8 billion in 2024", "length": 112, "numbers_raw": ["$0.6 billion", "202", "5", "$0.8 billion", "202", "4"], "numbers": [600000000.0, 202.0, 5.0, 800000000.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1189, "tag": "div", "text_raw": " Planned leverage and phasing of investments in Selling, Marketing and Administrative Expenses", "text": " Planned leverage and phasing of investments in Selling, Marketing and Administrative Expenses", "length": 95, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1190, "tag": "div", "text_raw": " Reduced spending and phasing of investments in Research & Development", "text": " Reduced spending and phasing of investments in Research & Development", "length": 71, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1192, "tag": "div", "text_raw": " Unfavorable currency in Cost of products sold", "text": " Unfavorable currency in Cost of products sold", "length": 47, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1196, "tag": "div", "text_raw": "The MedTech segment income before tax as a percent of sales in the fiscal first quarter of 2025 was 17.7% versus 19.4% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal first quarter of 2025 as compared to the prior year was primarily driven by the following:", "text": "The MedTech segment income before tax as a percent of sales in the fiscal first quarter of 2025 was 17.7% versus 19.4% for the same period a year ago.", "length": 150, "numbers_raw": ["202", "5", "17.7", "19.4"], "numbers": [202.0, 5.0, 17.7, 19.4], "percents_raw": ["17.7%", "19.4%"], "percents": [0.177, 0.19399999999999998], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1196, "tag": "div", "text_raw": "The MedTech segment income before tax as a percent of sales in the fiscal first quarter of 2025 was 17.7% versus 19.4% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal first quarter of 2025 as compared to the prior year was primarily driven by the following:", "text": "The decrease in the income before tax as a percent of sales for the fiscal first quarter of 2025 as compared to the prior year was primarily driven by the following:", "length": 165, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1197, "tag": "div", "text_raw": " The fair value inventory step-up and amortization related to Shockwave of $0.1 billion in 2025", "text": " The fair value inventory step-up and amortization related to Shockwave of $0.1 billion in 2025", "length": 96, "numbers_raw": ["$0.1 billion", "202", "5"], "numbers": [100000000.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1198, "tag": "div", "text_raw": " Increased investments in Research & Development associated with Shockwave and V-Wave", "text": " Increased investments in Research & Development associated with Shockwave and V-Wave", "length": 86, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1200, "tag": "div", "text_raw": "In the fiscal year 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense was $55 million in the fiscal first quarter of 2025, of which $17 million was recorded in Restructuring, $8 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings primarily for costs related to asset impairments and market and product exits. The pre-tax restructuring expense was $27 million in the fiscal first quarter of 2024, of which $20 million was recorded in Restructuring and $7 million was recorded in Cost of products sold on the Consolidated Statement of Earnings. Total project costs of approximately $0.5 billion have been recorded since the restructuring was announced.", "text": "In the fiscal year 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements.", "length": 233, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1200, "tag": "div", "text_raw": "In the fiscal year 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense was $55 million in the fiscal first quarter of 2025, of which $17 million was recorded in Restructuring, $8 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings primarily for costs related to asset impairments and market and product exits. The pre-tax restructuring expense was $27 million in the fiscal first quarter of 2024, of which $20 million was recorded in Restructuring and $7 million was recorded in Cost of products sold on the Consolidated Statement of Earnings. Total project costs of approximately $0.5 billion have been recorded since the restructuring was announced.", "text": "The pre-tax restructuring expense was $55 million in the fiscal first quarter of 2025, of which $17 million was recorded in Restructuring, $8 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings primarily for costs related to asset impairments and market and product exits.", "length": 337, "numbers_raw": ["$55 million", "202", "5", "$17 million", "$8 million", "$30 million"], "numbers": [55000000.0, 202.0, 5.0, 17000000.0, 8000000.0, 30000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1200, "tag": "div", "text_raw": "In the fiscal year 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense was $55 million in the fiscal first quarter of 2025, of which $17 million was recorded in Restructuring, $8 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings primarily for costs related to asset impairments and market and product exits. The pre-tax restructuring expense was $27 million in the fiscal first quarter of 2024, of which $20 million was recorded in Restructuring and $7 million was recorded in Cost of products sold on the Consolidated Statement of Earnings. Total project costs of approximately $0.5 billion have been recorded since the restructuring was announced.", "text": "The pre-tax restructuring expense was $27 million in the fiscal first quarter of 2024, of which $20 million was recorded in Restructuring and $7 million was recorded in Cost of products sold on the Consolidated Statement of Earnings.", "length": 233, "numbers_raw": ["$27 million", "202", "4", "$20 million", "$7 million"], "numbers": [27000000.0, 202.0, 4.0, 20000000.0, 7000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1200, "tag": "div", "text_raw": "In the fiscal year 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense was $55 million in the fiscal first quarter of 2025, of which $17 million was recorded in Restructuring, $8 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings primarily for costs related to asset impairments and market and product exits. The pre-tax restructuring expense was $27 million in the fiscal first quarter of 2024, of which $20 million was recorded in Restructuring and $7 million was recorded in Cost of products sold on the Consolidated Statement of Earnings. Total project costs of approximately $0.5 billion have been recorded since the restructuring was announced.", "text": "Total project costs of approximately $0.5 billion have been recorded since the restructuring was announced.", "length": 107, "numbers_raw": ["$0.5 billion"], "numbers": [500000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1201, "tag": "div", "text_raw": "44", "text": "44", "length": 2, "numbers_raw": ["44"], "numbers": [44.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1202, "tag": "div", "text_raw": "44", "text": "44", "length": 2, "numbers_raw": ["44"], "numbers": [44.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1203, "tag": "div", "text_raw": "44", "text": "44", "length": 2, "numbers_raw": ["44"], "numbers": [44.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1204, "tag": "div", "text_raw": "44", "text": "44", "length": 2, "numbers_raw": ["44"], "numbers": [44.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1208, "tag": "div", "text_raw": "In the fiscal year 2023, the Company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. The pre-tax restructuring charge of approximately $0.1 billion in the fiscal first quarter of 2024 included the termination of partnered and non-partnered program costs and asset impairments. The program was completed in the fiscal fourth quarter of 2024.", "text": "In the fiscal year 2023, the Company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients.", "length": 231, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1208, "tag": "div", "text_raw": "In the fiscal year 2023, the Company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. The pre-tax restructuring charge of approximately $0.1 billion in the fiscal first quarter of 2024 included the termination of partnered and non-partnered program costs and asset impairments. The program was completed in the fiscal fourth quarter of 2024.", "text": "The pre-tax restructuring charge of approximately $0.1 billion in the fiscal first quarter of 2024 included the termination of partnered and non-partnered program costs and asset impairments.", "length": 191, "numbers_raw": ["$0.1 billion", "202", "4"], "numbers": [100000000.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1208, "tag": "div", "text_raw": "In the fiscal year 2023, the Company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. The pre-tax restructuring charge of approximately $0.1 billion in the fiscal first quarter of 2024 included the termination of partnered and non-partnered program costs and asset impairments. The program was completed in the fiscal fourth quarter of 2024.", "text": "The program was completed in the fiscal fourth quarter of 2024.", "length": 63, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1209, "tag": "div", "text_raw": "For further details related to the restructuring refer to Note 12 to the Consolidated Financial Statements.", "text": "For further details related to the restructuring refer to Note 12 to the Consolidated Financial Statements.", "length": 107, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1211, "tag": "div", "text_raw": "The worldwide effective income tax rate for the fiscal three months was 19.3% in 2025 and 12.4% in 2024.", "text": "The worldwide effective income tax rate for the fiscal three months was 19.3% in 2025 and 12.4% in 2024.", "length": 104, "numbers_raw": ["19.3", "202", "5", "12.4", "202", "4"], "numbers": [19.3, 202.0, 5.0, 12.4, 202.0, 4.0], "percents_raw": ["19.3%", "12.4%"], "percents": [0.193, 0.124], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1212, "tag": "div", "text_raw": "On December 15, 2022, the European Union (EU) Member States formally adopted the EUs Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. Several EU and non-EU countries have enacted Pillar Two legislation with an initial effective date of January 1, 2024, with other aspects of the law effective in 2025 or later. While countries continue to enact new provisions or issue new regulations this could have an impact to the Companys effective tax rate.", "text": "On December 15, 2022, the European Union (EU) Member States formally adopted the EUs Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide.", "length": 330, "numbers_raw": ["15", "202", "2", "15", "130"], "numbers": [15.0, 202.0, 2.0, 15.0, 130.0], "percents_raw": ["15%"], "percents": [0.15], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 1212, "tag": "div", "text_raw": "On December 15, 2022, the European Union (EU) Member States formally adopted the EUs Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. Several EU and non-EU countries have enacted Pillar Two legislation with an initial effective date of January 1, 2024, with other aspects of the law effective in 2025 or later. While countries continue to enact new provisions or issue new regulations this could have an impact to the Companys effective tax rate.", "text": "Several EU and non-EU countries have enacted Pillar Two legislation with an initial effective date of January 1, 2024, with other aspects of the law effective in 2025 or later.", "length": 176, "numbers_raw": ["1", "202", "4", "202", "5"], "numbers": [1.0, 202.0, 4.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1212, "tag": "div", "text_raw": "On December 15, 2022, the European Union (EU) Member States formally adopted the EUs Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. Several EU and non-EU countries have enacted Pillar Two legislation with an initial effective date of January 1, 2024, with other aspects of the law effective in 2025 or later. While countries continue to enact new provisions or issue new regulations this could have an impact to the Companys effective tax rate.", "text": "While countries continue to enact new provisions or issue new regulations this could have an impact to the Companys effective tax rate.", "length": 136, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1213, "tag": "div", "text_raw": "For further details related to the fiscal 2025 provision for taxes refer to Note 5 to the Consolidated Financial Statements.", "text": "For further details related to the fiscal 2025 provision for taxes refer to Note 5 to the Consolidated Financial Statements.", "length": 124, "numbers_raw": ["202", "5", "5"], "numbers": [202.0, 5.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1214, "tag": "div", "text_raw": "Liquidity and capital resources", "text": "Liquidity and capital resources", "length": 31, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1215, "tag": "div", "text_raw": "Acquisitions (net of cash acquired) Proceeds from the disposal of assets/businesses, net Dividends to shareholders", "text": "Acquisitions (net of cash acquired) Proceeds from the disposal of assets/businesses, net Dividends to shareholders", "length": 114, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1216, "tag": "div", "text_raw": "Acquisitions (net of cash acquired)", "text": "Acquisitions (net of cash acquired)", "length": 35, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1217, "tag": "div", "text_raw": "Acquisitions (net of cash acquired)", "text": "Acquisitions (net of cash acquired)", "length": 35, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1220, "tag": "div", "text_raw": "Proceeds from the disposal of assets/businesses, net", "text": "Proceeds from the disposal of assets/businesses, net", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1221, "tag": "div", "text_raw": "Proceeds from the disposal of assets/businesses, net", "text": "Proceeds from the disposal of assets/businesses, net", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1228, "tag": "div", "text_raw": "Cash and cash equivalents were $38.5 billion at the end of the fiscal first quarter of 2025 as compared with $24.1 billion at the end of fiscal year 2024. The primary sources and uses of cash that contributed to the $14.4 billion increase were:", "text": "Cash and cash equivalents were $38.5 billion at the end of the fiscal first quarter of 2025 as compared with $24.1 billion at the end of fiscal year 2024.", "length": 154, "numbers_raw": ["$38.5 billion", "202", "5", "$24.1 billion", "202", "4"], "numbers": [38500000000.0, 202.0, 5.0, 24100000000.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1228, "tag": "div", "text_raw": "Cash and cash equivalents were $38.5 billion at the end of the fiscal first quarter of 2025 as compared with $24.1 billion at the end of fiscal year 2024. The primary sources and uses of cash that contributed to the $14.4 billion increase were:", "text": "The primary sources and uses of cash that contributed to the $14.4 billion increase were:", "length": 89, "numbers_raw": ["$14.4 billion"], "numbers": [14400000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1229, "tag": "div", "text_raw": "(Dollars In Billions) 24.1 Q4 2024 Cash and cash equivalents balance 4.2 net cash generated from operating activities (0.3) net cash used by investing activities 10.4 net cash from financing activities 0.1 effect of exchange rate changes on cash and cash equivalents $ 38.5 Q1 2025 Cash and cash equivalents", "text": "(Dollars In Billions) 24.1 Q4 2024 Cash and cash equivalents balance 4.2 net cash generated from operating activities (0.3) net cash used by investing activities 10.4 net cash from financing activities 0.1 effect of exchange rate changes on cash and cash equivalents $ 38.5 Q1 2025 Cash and cash equivalents", "length": 307, "numbers_raw": ["24.1", "4", "202", "4", "4.2", "0.3", "10.4", "0.1", "38.5", "1", "202", "5"], "numbers": [24.1, 4.0, 202.0, 4.0, 4.2, 0.3, 10.4, 0.1, 38.5, 1.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1230, "tag": "div", "text_raw": "In addition, the Company had $0.3 billion in marketable securities at the end of the fiscal first quarter of 2025 and $0.4 billion at the end of fiscal year 2024.", "text": "In addition, the Company had $0.3 billion in marketable securities at the end of the fiscal first quarter of 2025 and $0.4 billion at the end of fiscal year 2024.", "length": 162, "numbers_raw": ["$0.3 billion", "202", "5", "$0.4 billion", "202", "4"], "numbers": [300000000.0, 202.0, 5.0, 400000000.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1232, "tag": "div", "text_raw": "Form 10-Q 45", "text": "Form 10-Q 45", "length": 12, "numbers_raw": ["10", "45"], "numbers": [10.0, 45.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1233, "tag": "div", "text_raw": "Form 10-Q 45", "text": "Form 10-Q 45", "length": 12, "numbers_raw": ["10", "45"], "numbers": [10.0, 45.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1234, "tag": "div", "text_raw": "Form 10-Q 45", "text": "Form 10-Q 45", "length": 12, "numbers_raw": ["10", "45"], "numbers": [10.0, 45.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1235, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1236, "tag": "div", "text_raw": "45", "text": "45", "length": 2, "numbers_raw": ["45"], "numbers": [45.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1239, "tag": "div", "text_raw": "Cash flow from operations of $4.2 billion was the result of:", "text": "Cash flow from operations of $4.2 billion was the result of:", "length": 60, "numbers_raw": ["$4.2 billion"], "numbers": [4200000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1240, "tag": "div", "text_raw": "(Dollars In Billions) $ 11.0 Net earnings 4.2 non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, deferred tax provision, charge for in-process research and development assets and asset write-downs partially offset by the net gain on sale of assets/businesses (1.1) an increase in accounts receivable and inventories (2.1) a decrease in accounts payable and accrued liabilities (1.3) an increase in other current and non-current assets (6.5) a decrease in other current and non-current liabilities $ 4.2 Net cash flows from operations", "text": "(Dollars In Billions) $ 11.0 Net earnings 4.2 non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, deferred tax provision, charge for in-process research and development assets and asset write-downs partially offset by the net gain on sale of assets/businesses (1.1) an increase in accounts receivable and inventories (2.1) a decrease in accounts payable and accrued liabilities (1.3) an increase in other current and non-current assets (6.5) a decrease in other current and non-current liabilities $ 4.2 Net cash flows from operations", "length": 593, "numbers_raw": ["11.0", "4.2", "1.1", "2.1", "1.3", "6.5", "4.2"], "numbers": [11.0, 4.2, 1.1, 2.1, 1.3, 6.5, 4.2], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1241, "tag": "div", "text_raw": "Cash flow used by investing activities of $0.3 billion was primarily from:", "text": "Cash flow used by investing activities of $0.3 billion was primarily from:", "length": 74, "numbers_raw": ["$0.3 billion"], "numbers": [300000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1242, "tag": "div", "text_raw": "(Dollars In Billions) $ (0.8) additions to property, plant and equipment 0.3 proceeds from the disposal of assets/businesses, net 0.3 credit support agreements activity, net (0.1) Other (primarily capitalized licenses and milestones) and rounding $ (0.3) Net cash used by investing activities", "text": "(Dollars In Billions) $ (0.8) additions to property, plant and equipment 0.3 proceeds from the disposal of assets/businesses, net 0.3 credit support agreements activity, net (0.1) Other (primarily capitalized licenses and milestones) and rounding $ (0.3) Net cash used by investing activities", "length": 292, "numbers_raw": ["0.8", "0.3", "0.3", "0.1", "0.3"], "numbers": [0.8, 0.3, 0.3, 0.1, 0.3], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1243, "tag": "div", "text_raw": "Cash flow from financing activities of $10.4 billion was primarily from:", "text": "Cash flow from financing activities of $10.4 billion was primarily from:", "length": 72, "numbers_raw": ["$10.4 billion"], "numbers": [10400000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1244, "tag": "div", "text_raw": "(Dollars In Billions) $ (3.0) dividends to shareholders (2.1) repurchase of common stock 15.1 net proceeds from short and long term debt 0.5 proceeds from stock options exercised/employee withholding tax on stock awards, net (0.1) Other and rounding $ 10.4 Net cash from financing activities", "text": "(Dollars In Billions) $ (3.0) dividends to shareholders (2.1) repurchase of common stock 15.1 net proceeds from short and long term debt 0.5 proceeds from stock options exercised/employee withholding tax on stock awards, net (0.1) Other and rounding $ 10.4 Net cash from financing activities", "length": 291, "numbers_raw": ["3.0", "2.1", "15.1", "0.5", "0.1", "10.4"], "numbers": [3.0, 2.1, 15.1, 0.5, 0.1, 10.4], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1245, "tag": "div", "text_raw": "The Company has access to substantial sources of funds at numerous banks worldwide and has the ability to issue up to $20 billion in Commercial Paper. Furthermore, in June 2024, the Company secured a new 364-day Credit Facility of $10 billion (expiration on June 25, 2025) which may be used for general corporate purposes including to support our commercial paper borrowings. Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.", "text": "The Company has access to substantial sources of funds at numerous banks worldwide and has the ability to issue up to $20 billion in Commercial Paper.", "length": 150, "numbers_raw": ["$20 billion"], "numbers": [20000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1245, "tag": "div", "text_raw": "The Company has access to substantial sources of funds at numerous banks worldwide and has the ability to issue up to $20 billion in Commercial Paper. Furthermore, in June 2024, the Company secured a new 364-day Credit Facility of $10 billion (expiration on June 25, 2025) which may be used for general corporate purposes including to support our commercial paper borrowings. Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.", "text": "Furthermore, in June 2024, the Company secured a new 364-day Credit Facility of $10 billion (expiration on June 25, 2025) which may be used for general corporate purposes including to support our commercial paper borrowings.", "length": 224, "numbers_raw": ["202", "4", "364", "$10 billion", "25", "202", "5"], "numbers": [202.0, 4.0, 364.0, 10000000000.0, 25.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1245, "tag": "div", "text_raw": "The Company has access to substantial sources of funds at numerous banks worldwide and has the ability to issue up to $20 billion in Commercial Paper. Furthermore, in June 2024, the Company secured a new 364-day Credit Facility of $10 billion (expiration on June 25, 2025) which may be used for general corporate purposes including to support our commercial paper borrowings. Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.", "text": "Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins.", "length": 204, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1245, "tag": "div", "text_raw": "The Company has access to substantial sources of funds at numerous banks worldwide and has the ability to issue up to $20 billion in Commercial Paper. Furthermore, in June 2024, the Company secured a new 364-day Credit Facility of $10 billion (expiration on June 25, 2025) which may be used for general corporate purposes including to support our commercial paper borrowings. Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.", "text": "Commitment fees under the agreement are not material.", "length": 53, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1246, "tag": "div", "text_raw": "As of March 30, 2025, the Company had cash, cash equivalents and marketable securities of approximately $38.8 billion and had approximately $52.3 billion of notes payable and long-term debt for a net debt position of $13.5 billion as compared to the prior year fiscal first quarter net debt position of $7.4 billion. In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. For additional details on borrowings, see Note 4 to the Consolidated Financial Statements. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.6 billion which closed subsequent to the quarter on April 2, 2025, and for general corporate purposes. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Companys remaining balance of approximately $4.2 billion related to talc matters and the remaining approximately $1.5 billion to settle opioid litigation (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.", "text": "As of March 30, 2025, the Company had cash, cash equivalents and marketable securities of approximately $38.8 billion and had approximately $52.3 billion of notes payable and long-term debt for a net debt position of $13.5 billion as compared to the prior year fiscal first quarter net debt position of $7.4 billion.", "length": 316, "numbers_raw": ["30", "202", "5", "$38.8 billion", "$52.3 billion", "$13.5 billion", "$7.4 billion"], "numbers": [30.0, 202.0, 5.0, 38800000000.0, 52300000000.0, 13500000000.0, 7400000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1246, "tag": "div", "text_raw": "As of March 30, 2025, the Company had cash, cash equivalents and marketable securities of approximately $38.8 billion and had approximately $52.3 billion of notes payable and long-term debt for a net debt position of $13.5 billion as compared to the prior year fiscal first quarter net debt position of $7.4 billion. In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. For additional details on borrowings, see Note 4 to the Consolidated Financial Statements. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.6 billion which closed subsequent to the quarter on April 2, 2025, and for general corporate purposes. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Companys remaining balance of approximately $4.2 billion related to talc matters and the remaining approximately $1.5 billion to settle opioid litigation (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.", "text": "In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion.", "length": 110, "numbers_raw": ["202", "5", "$9.2 billion"], "numbers": [202.0, 5.0, 9200000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1246, "tag": "div", "text_raw": "As of March 30, 2025, the Company had cash, cash equivalents and marketable securities of approximately $38.8 billion and had approximately $52.3 billion of notes payable and long-term debt for a net debt position of $13.5 billion as compared to the prior year fiscal first quarter net debt position of $7.4 billion. In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. For additional details on borrowings, see Note 4 to the Consolidated Financial Statements. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.6 billion which closed subsequent to the quarter on April 2, 2025, and for general corporate purposes. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Companys remaining balance of approximately $4.2 billion related to talc matters and the remaining approximately $1.5 billion to settle opioid litigation (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.", "text": "For additional details on borrowings, see Note 4 to the Consolidated Financial Statements.", "length": 90, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1246, "tag": "div", "text_raw": "As of March 30, 2025, the Company had cash, cash equivalents and marketable securities of approximately $38.8 billion and had approximately $52.3 billion of notes payable and long-term debt for a net debt position of $13.5 billion as compared to the prior year fiscal first quarter net debt position of $7.4 billion. In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. For additional details on borrowings, see Note 4 to the Consolidated Financial Statements. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.6 billion which closed subsequent to the quarter on April 2, 2025, and for general corporate purposes. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Companys remaining balance of approximately $4.2 billion related to talc matters and the remaining approximately $1.5 billion to settle opioid litigation (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.", "text": "The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc.", "length": 88, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1246, "tag": "div", "text_raw": "As of March 30, 2025, the Company had cash, cash equivalents and marketable securities of approximately $38.8 billion and had approximately $52.3 billion of notes payable and long-term debt for a net debt position of $13.5 billion as compared to the prior year fiscal first quarter net debt position of $7.4 billion. In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. For additional details on borrowings, see Note 4 to the Consolidated Financial Statements. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.6 billion which closed subsequent to the quarter on April 2, 2025, and for general corporate purposes. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Companys remaining balance of approximately $4.2 billion related to talc matters and the remaining approximately $1.5 billion to settle opioid litigation (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.", "text": "acquisition for approximately $14.6 billion which closed subsequent to the quarter on April 2, 2025, and for general corporate purposes.", "length": 136, "numbers_raw": ["$14.6 billion", "2", "202", "5"], "numbers": [14600000000.0, 2.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1246, "tag": "div", "text_raw": "As of March 30, 2025, the Company had cash, cash equivalents and marketable securities of approximately $38.8 billion and had approximately $52.3 billion of notes payable and long-term debt for a net debt position of $13.5 billion as compared to the prior year fiscal first quarter net debt position of $7.4 billion. In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. For additional details on borrowings, see Note 4 to the Consolidated Financial Statements. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.6 billion which closed subsequent to the quarter on April 2, 2025, and for general corporate purposes. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Companys remaining balance of approximately $4.2 billion related to talc matters and the remaining approximately $1.5 billion to settle opioid litigation (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.", "text": "The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Companys remaining balance of approximately $4.2 billion related to talc matters and the remaining approximately $1.5 billion to settle opioid litigation (See Note 11 to the Consolidated Financial Statements for additional details).", "length": 523, "numbers_raw": ["$4.2 billion", "$1.5 billion", "11"], "numbers": [4200000000.0, 1500000000.0, 11.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1246, "tag": "div", "text_raw": "As of March 30, 2025, the Company had cash, cash equivalents and marketable securities of approximately $38.8 billion and had approximately $52.3 billion of notes payable and long-term debt for a net debt position of $13.5 billion as compared to the prior year fiscal first quarter net debt position of $7.4 billion. In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. For additional details on borrowings, see Note 4 to the Consolidated Financial Statements. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.6 billion which closed subsequent to the quarter on April 2, 2025, and for general corporate purposes. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Companys remaining balance of approximately $4.2 billion related to talc matters and the remaining approximately $1.5 billion to settle opioid litigation (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.", "text": "In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.", "length": 158, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1247, "tag": "div", "text_raw": "Subsequent to March 30, 2025, the Company paid approximately $3.0 billion to the U.S. Treasury, including $2.5 billion related to the final installment due on foreign undistributed earnings as part of the TCJA charge (see Note 1 to the Consolidated Financial Statements in the Companys Annual Report on Form 10-K for the fiscal year ended December 29, 2024) and $0.5 billion primarily", "text": "Subsequent to March 30, 2025, the Company paid approximately $3.0 billion to the U.S.", "length": 85, "numbers_raw": ["30", "202", "5", "$3.0 billion"], "numbers": [30.0, 202.0, 5.0, 3000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1247, "tag": "div", "text_raw": "Subsequent to March 30, 2025, the Company paid approximately $3.0 billion to the U.S. Treasury, including $2.5 billion related to the final installment due on foreign undistributed earnings as part of the TCJA charge (see Note 1 to the Consolidated Financial Statements in the Companys Annual Report on Form 10-K for the fiscal year ended December 29, 2024) and $0.5 billion primarily", "text": "Treasury, including $2.5 billion related to the final installment due on foreign undistributed earnings as part of the TCJA charge (see Note 1 to the Consolidated Financial Statements in the Companys Annual Report on Form 10-K for the fiscal year ended December 29, 2024) and $0.5 billion primarily", "length": 299, "numbers_raw": ["$2.5 billion", "1", "10", "29", "202", "4", "$0.5 billion"], "numbers": [2500000000.0, 1.0, 10.0, 29.0, 202.0, 4.0, 500000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1248, "tag": "div", "text_raw": "46", "text": "46", "length": 2, "numbers_raw": ["46"], "numbers": [46.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1249, "tag": "div", "text_raw": "46", "text": "46", "length": 2, "numbers_raw": ["46"], "numbers": [46.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1250, "tag": "div", "text_raw": "46", "text": "46", "length": 2, "numbers_raw": ["46"], "numbers": [46.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1251, "tag": "div", "text_raw": "46", "text": "46", "length": 2, "numbers_raw": ["46"], "numbers": [46.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1255, "tag": "div", "text_raw": "related to the normal estimated payment for the fiscal first quarter of 2025. Additionally, the Company has paid $0.6 billion in income related taxes net of refunds in foreign jurisdictions in the first three months of fiscal 2025.", "text": "related to the normal estimated payment for the fiscal first quarter of 2025.", "length": 77, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1255, "tag": "div", "text_raw": "related to the normal estimated payment for the fiscal first quarter of 2025. Additionally, the Company has paid $0.6 billion in income related taxes net of refunds in foreign jurisdictions in the first three months of fiscal 2025.", "text": "Additionally, the Company has paid $0.6 billion in income related taxes net of refunds in foreign jurisdictions in the first three months of fiscal 2025.", "length": 153, "numbers_raw": ["$0.6 billion", "202", "5"], "numbers": [600000000.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1257, "tag": "div", "text_raw": "On January 2, 2025, the Board of Directors declared a regular cash dividend of $1.24 per share, payable on March 4, 2025, to shareholders of record as of February 18, 2025.", "text": "On January 2, 2025, the Board of Directors declared a regular cash dividend of $1.24 per share, payable on March 4, 2025, to shareholders of record as of February 18, 2025.", "length": 172, "numbers_raw": ["2", "202", "5", "$1.24", "4", "202", "5", "18", "202", "5"], "numbers": [2.0, 202.0, 5.0, 1.24, 4.0, 202.0, 5.0, 18.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1258, "tag": "div", "text_raw": "On April 15, 2025, the Board of Directors declared a regular cash dividend of $1.30 per share, payable on June 10, 2025, to shareholders of record as of May 27, 2025. The Company expects to continue the practice of paying regular quarterly cash dividends.", "text": "On April 15, 2025, the Board of Directors declared a regular cash dividend of $1.30 per share, payable on June 10, 2025, to shareholders of record as of May 27, 2025.", "length": 166, "numbers_raw": ["15", "202", "5", "$1.30", "10", "202", "5", "27", "202", "5"], "numbers": [15.0, 202.0, 5.0, 1.3, 10.0, 202.0, 5.0, 27.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1258, "tag": "div", "text_raw": "On April 15, 2025, the Board of Directors declared a regular cash dividend of $1.30 per share, payable on June 10, 2025, to shareholders of record as of May 27, 2025. The Company expects to continue the practice of paying regular quarterly cash dividends.", "text": "The Company expects to continue the practice of paying regular quarterly cash dividends.", "length": 88, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1261, "tag": "div", "text_raw": "Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.", "text": "Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.", "length": 91, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1263, "tag": "div", "text_raw": "In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssens rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRAs mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In April 2024, Janssen appealed the district courts denial of its summary judgment motion to the Third Circuit.", "text": "In July 2023, Janssen Pharmaceuticals, Inc.", "length": 43, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1263, "tag": "div", "text_raw": "In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssens rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRAs mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In April 2024, Janssen appealed the district courts denial of its summary judgment motion to the Third Circuit.", "text": "(Janssen) filed litigation against the U.S.", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1263, "tag": "div", "text_raw": "In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssens rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRAs mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In April 2024, Janssen appealed the district courts denial of its summary judgment motion to the Third Circuit.", "text": "Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program.", "length": 185, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1263, "tag": "div", "text_raw": "In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssens rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRAs mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In April 2024, Janssen appealed the district courts denial of its summary judgment motion to the Third Circuit.", "text": "The litigation requests a declaration that the IRA violates Janssens rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRAs mandatory pricing scheme.", "length": 227, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1263, "tag": "div", "text_raw": "In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssens rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRAs mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In April 2024, Janssen appealed the district courts denial of its summary judgment motion to the Third Circuit.", "text": "The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress.", "length": 322, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1263, "tag": "div", "text_raw": "In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssens rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRAs mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In April 2024, Janssen appealed the district courts denial of its summary judgment motion to the Third Circuit.", "text": "In April 2024, Janssen appealed the district courts denial of its summary judgment motion to the Third Circuit.", "length": 112, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1265, "tag": "div", "text_raw": "Although the long-term implications of Russias invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal first quarter of 2025, including accounts receivable or inventory reserves, was not material. As of the fiscal three months ending March 30, 2025, and the fiscal year ending December 29, 2024, the business of the Companys Russian subsidiaries represented less than 1% of the Companys consolidated assets and represented approximately 1% of revenues. The Company does not maintain Ukrainian subsidiaries.", "text": "Although the long-term implications of Russias invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal first quarter of 2025, including accounts receivable or inventory reserves, was not material.", "length": 251, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1265, "tag": "div", "text_raw": "Although the long-term implications of Russias invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal first quarter of 2025, including accounts receivable or inventory reserves, was not material. As of the fiscal three months ending March 30, 2025, and the fiscal year ending December 29, 2024, the business of the Companys Russian subsidiaries represented less than 1% of the Companys consolidated assets and represented approximately 1% of revenues. The Company does not maintain Ukrainian subsidiaries.", "text": "As of the fiscal three months ending March 30, 2025, and the fiscal year ending December 29, 2024, the business of the Companys Russian subsidiaries represented less than 1% of the Companys consolidated assets and represented approximately 1% of revenues.", "length": 257, "numbers_raw": ["30", "202", "5", "29", "202", "4", "1", "1"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4.0, 1.0, 1.0], "percents_raw": ["1%", "1%"], "percents": [0.01, 0.01], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1265, "tag": "div", "text_raw": "Although the long-term implications of Russias invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal first quarter of 2025, including accounts receivable or inventory reserves, was not material. As of the fiscal three months ending March 30, 2025, and the fiscal year ending December 29, 2024, the business of the Companys Russian subsidiaries represented less than 1% of the Companys consolidated assets and represented approximately 1% of revenues. The Company does not maintain Ukrainian subsidiaries.", "text": "The Company does not maintain Ukrainian subsidiaries.", "length": 53, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1266, "tag": "div", "text_raw": "In March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. The Company continues to supply products relied upon by patients for healthcare purposes.", "text": "In March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia.", "length": 140, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1266, "tag": "div", "text_raw": "In March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. The Company continues to supply products relied upon by patients for healthcare purposes.", "text": "The Company continues to supply products relied upon by patients for healthcare purposes.", "length": 89, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1268, "tag": "div", "text_raw": "Although the long-term implications of the conflict in the Middle East are difficult to predict at this time, the financial impact of the conflict in the fiscal first quarter of 2025, including accounts receivable or inventory reserves, was not material. As of the fiscal three months ending March 30, 2025, and the fiscal year ending December 29, 2024, the business of the Companys Israel subsidiaries represented less than 1% of both Companys consolidated assets and revenues.", "text": "Although the long-term implications of the conflict in the Middle East are difficult to predict at this time, the financial impact of the conflict in the fiscal first quarter of 2025, including accounts receivable or inventory reserves, was not material.", "length": 254, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1268, "tag": "div", "text_raw": "Although the long-term implications of the conflict in the Middle East are difficult to predict at this time, the financial impact of the conflict in the fiscal first quarter of 2025, including accounts receivable or inventory reserves, was not material. As of the fiscal three months ending March 30, 2025, and the fiscal year ending December 29, 2024, the business of the Companys Israel subsidiaries represented less than 1% of both Companys consolidated assets and revenues.", "text": "As of the fiscal three months ending March 30, 2025, and the fiscal year ending December 29, 2024, the business of the Companys Israel subsidiaries represented less than 1% of both Companys consolidated assets and revenues.", "length": 225, "numbers_raw": ["30", "202", "5", "29", "202", "4", "1"], "numbers": [30.0, 202.0, 5.0, 29.0, 202.0, 4.0, 1.0], "percents_raw": ["1%"], "percents": [0.01], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1269, "tag": "div", "text_raw": "Other Macroeconomic Considerations", "text": "Other Macroeconomic Considerations", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1270, "tag": "div", "text_raw": "The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela, Argentina, Turkey and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.", "text": "The Company operates in certain countries where the economic conditions continue to present significant challenges.", "length": 115, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1270, "tag": "div", "text_raw": "The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela, Argentina, Turkey and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.", "text": "The Company continues to monitor these situations and take appropriate actions.", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1270, "tag": "div", "text_raw": "The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela, Argentina, Turkey and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.", "text": "Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates.", "length": 145, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1270, "tag": "div", "text_raw": "The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela, Argentina, Turkey and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.", "text": "The Company has accounted for operations in Venezuela, Argentina, Turkey and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%.", "length": 221, "numbers_raw": ["202", "4", "100"], "numbers": [202.0, 4.0, 100.0], "percents_raw": ["100%"], "percents": [1.0], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1270, "tag": "div", "text_raw": "The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela, Argentina, Turkey and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.", "text": "In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.", "length": 172, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1271, "tag": "div", "text_raw": "Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries.", "text": "Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates.", "length": 157, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1271, "tag": "div", "text_raw": "Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries.", "text": "In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries.", "length": 232, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1272, "tag": "div", "text_raw": "Form 10-Q 47", "text": "Form 10-Q 47", "length": 12, "numbers_raw": ["10", "47"], "numbers": [10.0, 47.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1273, "tag": "div", "text_raw": "Form 10-Q 47", "text": "Form 10-Q 47", "length": 12, "numbers_raw": ["10", "47"], "numbers": [10.0, 47.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1274, "tag": "div", "text_raw": "Form 10-Q 47", "text": "Form 10-Q 47", "length": 12, "numbers_raw": ["10", "47"], "numbers": [10.0, 47.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1275, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1276, "tag": "div", "text_raw": "47", "text": "47", "length": 2, "numbers_raw": ["47"], "numbers": [47.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1279, "tag": "div", "text_raw": "A change in statutory tax rate in any country would result in the revaluation of the Companys deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Companys Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.", "text": "A change in statutory tax rate in any country would result in the revaluation of the Companys deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted.", "length": 221, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1279, "tag": "div", "text_raw": "A change in statutory tax rate in any country would result in the revaluation of the Companys deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Companys Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.", "text": "This change would result in an expense or benefit recorded to the Companys Consolidated Statement of Earnings.", "length": 111, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1279, "tag": "div", "text_raw": "A change in statutory tax rate in any country would result in the revaluation of the Companys deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Companys Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.", "text": "The Company closely monitors these proposals as they arise in the countries where it operates.", "length": 94, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1279, "tag": "div", "text_raw": "A change in statutory tax rate in any country would result in the revaluation of the Companys deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Companys Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.", "text": "Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.", "length": 183, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1280, "tag": "div", "text_raw": "The Company may be further impacted by the imposition of tariffs, trade protection measures or other policies adopted by any jurisdiction that favor domestic companies and technologies over foreign competitors.", "text": "The Company may be further impacted by the imposition of tariffs, trade protection measures or other policies adopted by any jurisdiction that favor domestic companies and technologies over foreign competitors.", "length": 210, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1281, "tag": "div", "text_raw": "The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.", "text": "The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.", "length": 246, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1282, "tag": "div", "text_raw": "Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage, may continue to impact the Companys businesses.", "text": "Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage, may continue to impact the Companys businesses.", "length": 308, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1283, "tag": "div", "text_raw": "The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers, seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the applicable patents. These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with the FDA or otherwise challenged the coverage and/or validity of the Companys patents. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.", "text": "The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers, seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the applicable patents.", "length": 274, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1283, "tag": "div", "text_raw": "The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers, seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the applicable patents. These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with the FDA or otherwise challenged the coverage and/or validity of the Companys patents. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.", "text": "These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with the FDA or otherwise challenged the coverage and/or validity of the Companys patents.", "length": 194, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1283, "tag": "div", "text_raw": "The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers, seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the applicable patents. These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with the FDA or otherwise challenged the coverage and/or validity of the Companys patents. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.", "text": "In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset.", "length": 384, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1283, "tag": "div", "text_raw": "The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers, seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the applicable patents. These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with the FDA or otherwise challenged the coverage and/or validity of the Companys patents. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.", "text": "There is also risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.", "length": 198, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1285, "tag": "div", "text_raw": "Item 3  Quantitative and qualitative disclosures about market risk", "text": "Item 3  Quantitative and qualitative disclosures about market risk", "length": 67, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1286, "tag": "div", "text_raw": "There has been no material change in the Companys assessment of its sensitivity to market risk since its presentation set forth in Item 7A, Quantitative and Qualitative Disclosures About Market Risk, in its Annual Report on Form 10-K for the fiscal year ended December 29, 2024.", "text": "There has been no material change in the Companys assessment of its sensitivity to market risk since its presentation set forth in Item 7A, Quantitative and Qualitative Disclosures About Market Risk, in its Annual Report on Form 10-K for the fiscal year ended December 29, 2024.", "length": 281, "numbers_raw": ["7", "10", "29", "202", "4"], "numbers": [7.0, 10.0, 29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1288, "tag": "div", "text_raw": "Item 4  Controls and procedures", "text": "Item 4  Controls and procedures", "length": 32, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1289, "tag": "div", "text_raw": "Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "Disclosure controls and procedures.", "length": 35, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1289, "tag": "div", "text_raw": "Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures.", "length": 159, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1289, "tag": "div", "text_raw": "Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms.", "length": 315, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1289, "tag": "div", "text_raw": "Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.", "length": 480, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1289, "tag": "div", "text_raw": "Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "Joaquin Duato, Chief Executive Officer;", "length": 39, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1289, "tag": "div", "text_raw": "Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "Chairman, Executive Committee and Joseph J.", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1289, "tag": "div", "text_raw": "Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation.", "length": 102, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1289, "tag": "div", "text_raw": "Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "Based on this evaluation, Messrs.", "length": 33, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1289, "tag": "div", "text_raw": "Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "length": 147, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1290, "tag": "div", "text_raw": "Internal control. During the period covered by this report, there were no changes in the Companys internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Companys internal control over financial reporting. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures.", "text": "During the period covered by this report, there were no changes in the Companys internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Companys internal control over financial reporting.", "length": 257, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1290, "tag": "div", "text_raw": "Internal control. During the period covered by this report, there were no changes in the Companys internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Companys internal control over financial reporting. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures.", "text": "The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures.", "length": 132, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1291, "tag": "div", "text_raw": "The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems for the human resources, information technology, procurement, supply chain and finance functions. These are enhancements to support the growth of the Companys financial shared service capabilities and standardize financial systems. This initiative is not in response to any identified deficiency or weakness in the Companys internal control over financial reporting. In response to this initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.", "text": "The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems for the human resources, information technology, procurement, supply chain and finance functions.", "length": 227, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1291, "tag": "div", "text_raw": "The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems for the human resources, information technology, procurement, supply chain and finance functions. These are enhancements to support the growth of the Companys financial shared service capabilities and standardize financial systems. This initiative is not in response to any identified deficiency or weakness in the Companys internal control over financial reporting. In response to this initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.", "text": "These are enhancements to support the growth of the Companys financial shared service capabilities and standardize financial systems.", "length": 134, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1291, "tag": "div", "text_raw": "The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems for the human resources, information technology, procurement, supply chain and finance functions. These are enhancements to support the growth of the Companys financial shared service capabilities and standardize financial systems. This initiative is not in response to any identified deficiency or weakness in the Companys internal control over financial reporting. In response to this initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.", "text": "This initiative is not in response to any identified deficiency or weakness in the Companys internal control over financial reporting.", "length": 135, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1291, "tag": "div", "text_raw": "The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems for the human resources, information technology, procurement, supply chain and finance functions. These are enhancements to support the growth of the Companys financial shared service capabilities and standardize financial systems. This initiative is not in response to any identified deficiency or weakness in the Companys internal control over financial reporting. In response to this initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.", "text": "In response to this initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.", "length": 152, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1292, "tag": "div", "text_raw": "48", "text": "48", "length": 2, "numbers_raw": ["48"], "numbers": [48.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1293, "tag": "div", "text_raw": "48", "text": "48", "length": 2, "numbers_raw": ["48"], "numbers": [48.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1294, "tag": "div", "text_raw": "48", "text": "48", "length": 2, "numbers_raw": ["48"], "numbers": [48.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1295, "tag": "div", "text_raw": "48", "text": "48", "length": 2, "numbers_raw": ["48"], "numbers": [48.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1302, "tag": "div", "text_raw": "Item 1  Legal proceedings", "text": "Item 1  Legal proceedings", "length": 26, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1303, "tag": "div", "text_raw": "The information called for by this item is incorporated herein by reference to Note 11 included in Part I, Item 1, Financial Statements (unaudited)  Notes to Consolidated Financial Statements.", "text": "The information called for by this item is incorporated herein by reference to Note 11 included in Part I, Item 1, Financial Statements (unaudited)  Notes to Consolidated Financial Statements.", "length": 193, "numbers_raw": ["11", "1"], "numbers": [11.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1305, "tag": "div", "text_raw": "Item 2  Unregistered sales of equity securities and use of proceeds", "text": "Item 2  Unregistered sales of equity securities and use of proceeds", "length": 68, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1306, "tag": "div", "text_raw": "(c) Purchases of Equity Securities by the Issuer and Affiliated Purchasers.", "text": "(c) Purchases of Equity Securities by the Issuer and Affiliated Purchasers.", "length": 75, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1307, "tag": "div", "text_raw": "The following table provides information with respect to Common Stock purchases by the Company during the fiscal first quarter of 2025. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal first quarter.", "text": "The following table provides information with respect to Common Stock purchases by the Company during the fiscal first quarter of 2025.", "length": 135, "numbers_raw": ["202", "5"], "numbers": [202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1307, "tag": "div", "text_raw": "The following table provides information with respect to Common Stock purchases by the Company during the fiscal first quarter of 2025. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal first quarter.", "text": "Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs.", "length": 137, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1307, "tag": "div", "text_raw": "The following table provides information with respect to Common Stock purchases by the Company during the fiscal first quarter of 2025. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal first quarter.", "text": "The repurchases below also include the stock-for-stock option exercises that settled in the fiscal first quarter.", "length": 113, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1308, "tag": "div", "text_raw": "Fiscal Month Period Total Number of Shares Purchased (1) Avg. Price Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs December 30, 2024 through January 26, 2025 359,317 146.70   January 27, 2025 through February 23, 2025 6,291,084 153.52   February 24, 2025 through March 30, 2025 6,729,499 164.80   Total 13,379,900 159.01  ", "text": "Fiscal Month Period Total Number of Shares Purchased (1) Avg.", "length": 61, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1308, "tag": "div", "text_raw": "Fiscal Month Period Total Number of Shares Purchased (1) Avg. Price Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs December 30, 2024 through January 26, 2025 359,317 146.70   January 27, 2025 through February 23, 2025 6,291,084 153.52   February 24, 2025 through March 30, 2025 6,729,499 164.80   Total 13,379,900 159.01  ", "text": "Price Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs December 30, 2024 through January 26, 2025 359,317 146.70   January 27, 2025 through February 23, 2025 6,291,084 153.52   February 24, 2025 through March 30, 2025 6,729,499 164.80   Total 13,379,900 159.01  ", "length": 391, "numbers_raw": ["30", "202", "4", "26", "202", "5", "359,317", "146.70", "27", "202", "5", "23", "202", "5", "6,291,084", "153.52", "24", "202", "5", "30", "202", "5", "6,729,499", "164.80", "13,379,900", "159.01"], "numbers": [30.0, 202.0, 4.0, 26.0, 202.0, 5.0, 359317.0, 146.7, 27.0, 202.0, 5.0, 23.0, 202.0, 5.0, 6291084.0, 153.52, 24.0, 202.0, 5.0, 30.0, 202.0, 5.0, 6729499.0, 164.8, 13379900.0, 159.01], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1311, "tag": "div", "text_raw": "Purchased (1)", "text": "Purchased (1)", "length": 13, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1322, "tag": "div", "text_raw": "(1) During the fiscal first quarter of 2025, the Company repurchased an aggregate of 13,379,900 shares of Johnson & Johnson Common Stock in open-market transactions, all of which were purchased as part of a systematic plan to meet the needs of the Companys compensation programs.", "text": "(1) During the fiscal first quarter of 2025, the Company repurchased an aggregate of 13,379,900 shares of Johnson & Johnson Common Stock in open-market transactions, all of which were purchased as part of a systematic plan to meet the needs of the Companys compensation programs.", "length": 280, "numbers_raw": ["1", "202", "5", "13,379,900"], "numbers": [1.0, 202.0, 5.0, 13379900.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1324, "tag": "div", "text_raw": "Form 10-Q 49", "text": "Form 10-Q 49", "length": 12, "numbers_raw": ["10", "49"], "numbers": [10.0, 49.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1325, "tag": "div", "text_raw": "Form 10-Q 49", "text": "Form 10-Q 49", "length": 12, "numbers_raw": ["10", "49"], "numbers": [10.0, 49.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1326, "tag": "div", "text_raw": "Form 10-Q 49", "text": "Form 10-Q 49", "length": 12, "numbers_raw": ["10", "49"], "numbers": [10.0, 49.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1327, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1328, "tag": "div", "text_raw": "49", "text": "49", "length": 2, "numbers_raw": ["49"], "numbers": [49.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1332, "tag": "div", "text_raw": "Item 5  Other information", "text": "Item 5  Other information", "length": 26, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1333, "tag": "div", "text_raw": "Securities trading plans of Directors and Executive Officers . During the fiscal first quarter of 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) informed us of the adoption or termination of a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, each as defined in Item 408 of Regulation S-K.", "text": "Securities trading plans of Directors and Executive Officers .", "length": 62, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1333, "tag": "div", "text_raw": "Securities trading plans of Directors and Executive Officers . During the fiscal first quarter of 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) informed us of the adoption or termination of a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, each as defined in Item 408 of Regulation S-K.", "text": "During the fiscal first quarter of 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) informed us of the adoption or termination of a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, each as defined in Item 408 of Regulation S-K.", "length": 295, "numbers_raw": ["202", "5", "16", "1", "10", "5", "1", "10", "5", "1", "408"], "numbers": [202.0, 5.0, 16.0, 1.0, 10.0, 5.0, 1.0, 10.0, 5.0, 1.0, 408.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1336, "tag": "div", "text_raw": "Item 6  Exhibits", "text": "Item 6  Exhibits", "length": 17, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1337, "tag": "div", "text_raw": "Exhibit 31.1 Certification of Chief Executive Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  Filed with this document.", "text": "Exhibit 31.1 Certification of Chief Executive Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  Filed with this document.", "length": 191, "numbers_raw": ["31.1", "13", "14", "302", "200", "2"], "numbers": [31.1, 13.0, 14.0, 302.0, 200.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1338, "tag": "div", "text_raw": "Exhibit 31.2 Certification of Chief Financial Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  Filed with this document.", "text": "Exhibit 31.2 Certification of Chief Financial Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  Filed with this document.", "length": 191, "numbers_raw": ["31.2", "13", "14", "302", "200", "2"], "numbers": [31.2, 13.0, 14.0, 302.0, 200.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1339, "tag": "div", "text_raw": "Exhibit 32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  Furnished with this document.", "text": "Exhibit 32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  Furnished with this document.", "length": 143, "numbers_raw": ["32.1", "906", "200", "2"], "numbers": [32.1, 906.0, 200.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1340, "tag": "div", "text_raw": "Exhibit 32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  Furnished with this document.", "text": "Exhibit 32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  Furnished with this document.", "length": 143, "numbers_raw": ["32.2", "906", "200", "2"], "numbers": [32.2, 906.0, 200.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1341, "tag": "div", "text_raw": "Exhibit 101:", "text": "Exhibit 101:", "length": 12, "numbers_raw": ["101"], "numbers": [101.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1342, "tag": "div", "text_raw": "EX-101.INS Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document EX-101.SCH Inline XBRL Taxonomy Extension Schema EX-101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase EX-101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase EX-101.DEF Inline XBRL Taxonomy Extension Definition Document Exhibit 104: Cover Page Interactive Data Filethe cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.", "text": "EX-101.INS Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document EX-101.SCH Inline XBRL Taxonomy Extension Schema EX-101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase EX-101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase EX-101.DEF Inline XBRL Taxonomy Extension Definition Document Exhibit 104:", "length": 472, "numbers_raw": ["101", "101", "101", "101", "101", "101", "104"], "numbers": [101.0, 101.0, 101.0, 101.0, 101.0, 101.0, 104.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1342, "tag": "div", "text_raw": "EX-101.INS Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document EX-101.SCH Inline XBRL Taxonomy Extension Schema EX-101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase EX-101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase EX-101.DEF Inline XBRL Taxonomy Extension Definition Document Exhibit 104: Cover Page Interactive Data Filethe cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.", "text": "Cover Page Interactive Data Filethe cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.", "length": 183, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1343, "tag": "div", "text_raw": "Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document", "text": "Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document", "length": 153, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1345, "tag": "div", "text_raw": "50", "text": "50", "length": 2, "numbers_raw": ["50"], "numbers": [50.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1346, "tag": "div", "text_raw": "50", "text": "50", "length": 2, "numbers_raw": ["50"], "numbers": [50.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1347, "tag": "div", "text_raw": "50", "text": "50", "length": 2, "numbers_raw": ["50"], "numbers": [50.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1348, "tag": "div", "text_raw": "50", "text": "50", "length": 2, "numbers_raw": ["50"], "numbers": [50.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1354, "tag": "div", "text_raw": "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.", "text": "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.", "length": 184, "numbers_raw": ["193", "4"], "numbers": [193.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1355, "tag": "div", "text_raw": "Date: April 23, 2025 Date: April 23, 2025 JOHNSON & JOHNSON (Registrant) By /s/ J. J. Wolk J. J. Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer) By /s/ R. J. Decker Jr. R. J. Decker Jr. , Controller (Principal Accounting Officer)", "text": "April 23, 2025 Date:", "length": 20, "numbers_raw": ["23", "202", "5"], "numbers": [23.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1355, "tag": "div", "text_raw": "Date: April 23, 2025 Date: April 23, 2025 JOHNSON & JOHNSON (Registrant) By /s/ J. J. Wolk J. J. Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer) By /s/ R. J. Decker Jr. R. J. Decker Jr. , Controller (Principal Accounting Officer)", "text": "April 23, 2025 JOHNSON & JOHNSON (Registrant) By /s/ J.", "length": 55, "numbers_raw": ["23", "202", "5"], "numbers": [23.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1355, "tag": "div", "text_raw": "Date: April 23, 2025 Date: April 23, 2025 JOHNSON & JOHNSON (Registrant) By /s/ J. J. Wolk J. J. Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer) By /s/ R. J. Decker Jr. R. J. Decker Jr. , Controller (Principal Accounting Officer)", "text": "Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer) By /s/ R.", "length": 96, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1355, "tag": "div", "text_raw": "Date: April 23, 2025 Date: April 23, 2025 JOHNSON & JOHNSON (Registrant) By /s/ J. J. Wolk J. J. Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer) By /s/ R. J. Decker Jr. R. J. Decker Jr. , Controller (Principal Accounting Officer)", "text": ", Controller (Principal Accounting Officer)", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1356, "tag": "div", "text_raw": "Date: April 23, 2025 Date: April 23, 2025", "text": "April 23, 2025 Date:", "length": 20, "numbers_raw": ["23", "202", "5"], "numbers": [23.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1356, "tag": "div", "text_raw": "Date: April 23, 2025 Date: April 23, 2025", "text": "April 23, 2025", "length": 14, "numbers_raw": ["23", "202", "5"], "numbers": [23.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1357, "tag": "div", "text_raw": "Date: April 23, 2025", "text": "April 23, 2025", "length": 14, "numbers_raw": ["23", "202", "5"], "numbers": [23.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1358, "tag": "div", "text_raw": "Date: April 23, 2025", "text": "April 23, 2025", "length": 14, "numbers_raw": ["23", "202", "5"], "numbers": [23.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1359, "tag": "div", "text_raw": "Date: April 23, 2025", "text": "April 23, 2025", "length": 14, "numbers_raw": ["23", "202", "5"], "numbers": [23.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1360, "tag": "div", "text_raw": "Date: April 23, 2025", "text": "April 23, 2025", "length": 14, "numbers_raw": ["23", "202", "5"], "numbers": [23.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1362, "tag": "div", "text_raw": "JOHNSON & JOHNSON (Registrant) By /s/ J. J. Wolk J. J. Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer) By /s/ R. J. Decker Jr. R. J. Decker Jr. , Controller (Principal Accounting Officer)", "text": "JOHNSON & JOHNSON (Registrant) By /s/ J.", "length": 40, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1362, "tag": "div", "text_raw": "JOHNSON & JOHNSON (Registrant) By /s/ J. J. Wolk J. J. Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer) By /s/ R. J. Decker Jr. R. J. Decker Jr. , Controller (Principal Accounting Officer)", "text": "Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer) By /s/ R.", "length": 96, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1362, "tag": "div", "text_raw": "JOHNSON & JOHNSON (Registrant) By /s/ J. J. Wolk J. J. Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer) By /s/ R. J. Decker Jr. R. J. Decker Jr. , Controller (Principal Accounting Officer)", "text": ", Controller (Principal Accounting Officer)", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1363, "tag": "div", "text_raw": "JOHNSON & JOHNSON (Registrant)", "text": "JOHNSON & JOHNSON (Registrant)", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1364, "tag": "div", "text_raw": "By /s/ J. J. Wolk J. J. Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer)", "text": "Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer)", "length": 86, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1366, "tag": "div", "text_raw": "J. J. Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer)", "text": "Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer)", "length": 86, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1367, "tag": "div", "text_raw": "By /s/ R. J. Decker Jr. R. J. Decker Jr. , Controller (Principal Accounting Officer)", "text": ", Controller (Principal Accounting Officer)", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1369, "tag": "div", "text_raw": "R. J. Decker Jr. , Controller (Principal Accounting Officer)", "text": ", Controller (Principal Accounting Officer)", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1370, "tag": "div", "text_raw": "Form 10-Q 51", "text": "Form 10-Q 51", "length": 12, "numbers_raw": ["10", "51"], "numbers": [10.0, 51.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1371, "tag": "div", "text_raw": "Form 10-Q 51", "text": "Form 10-Q 51", "length": 12, "numbers_raw": ["10", "51"], "numbers": [10.0, 51.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1372, "tag": "div", "text_raw": "Form 10-Q 51", "text": "Form 10-Q 51", "length": 12, "numbers_raw": ["10", "51"], "numbers": [10.0, 51.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1373, "tag": "div", "text_raw": "Form 10-Q", "text": "Form 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1374, "tag": "div", "text_raw": "51", "text": "51", "length": 2, "numbers_raw": ["51"], "numbers": [51.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
